0000950170-24-11910010-Q Larimar Therapeutics, Inc. 20241030202410301703261703261703261

product candidateâ€™s manufacturing process and to manufacture sufficient quantities of clinical supplies, and, if approved, commercial supplies of nomlabofusp or any other product candidates that we may develop in the future and our ability to maintain our relationships and contracts with our key vendors and to identify and contract with alternate or secondary key vendors; â€¢our ability to realize any value from nomlabofusp and/or any other product candidates we may develop in the future in light of inherent risks and difficulties involved in successfully bringing product candidates to market and the risk that the product candidates, if approved, will not achieve broad market acceptance; Â Â â€¢our ability to comply with regulatory requirements applicable to our business and other regulatory developments in the United States and other countries; â€¢the size and growth of the potential markets for nomlabofusp, if approved, or any other product candidates that we may develop in the future, the rate and degree of market acceptance of nomlabofusp or any other product candidate, if approved, that we may develop in the future and our ability to serve those markets; â€¢given both approved and competing therapies and products for the treatment of FA, our ability to obtain and maintain designations or eligibility for expedited regulatory programs, and to commercialize current and future product candidates, if approved, (including the impact of potential barriers to entry if competitors are able to establish a strong market position before we are able to commercialize our products); â€¢our ability to obtain and maintain patent protection and defend our intellectual property rights against third parties; â€¢the performance and compliance with the rules and regulations of the FDA (and all other regulatory authorities) of third parties upon which we depend, including third-party contract research organizations ("CROs"), consultants, and third-party suppliers, manufacturers, distributors, and logistics providers; â€¢our ability to recruit and retain key scientific, technical, commercial, and management personnel and to retain our executive officers; â€¢our ability to maintain proper functionality and security of our internal computer and information systems and prevent or avoid cyber-attacks, malicious intrusion, breakdown, destruction, loss of data privacy or other significant disruption; â€¢the extent to which geopolitical tensions, including regional conflicts around the world, adverse macroeconomic events, including those due to inflationary pressures, rising interest rates, banking instability, monetary policy changes, economic slowdowns or recessions, health epidemics, unforeseen emergencies and other outbreaks of communicable diseases could disrupt our operations, the operations of third parties on which we rely or the operations of regulatory agencies we interact with in the development of nomlabofusp and any other product candidates that we may develop; â€¢the potential impact of healthcare reform in the United States, including the Inflation Reduction Act of 2022, and measures being taken worldwide designed to reduce healthcare costs and limit the overall level of government expenditures. These forward-looking statements are based on managementâ€™s current expectations, estimates, forecasts and projections about our business and the industry in which we operate, and managementâ€™s beliefs and assumptions are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. Although we believe the expectations reflected in the forward-looking statements are reasonable, the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements may not be achieved or occur at all. The factors that could cause or contribute to such differences include, but are not limited to, those discussed in our Annual Report on Form 10-K filed on March 14, 2024 and our Quarterly Reports on Form 10-Q filed on May 9, 2024 and August 8, 2024. All forward-looking statements are applicable only as of the date on which they were made and, except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this Quarterly Report on Form 10-Q or to reflect the occurrence of any unanticipated events. Comparisons of results for current and any prior periods are not intended to express any future trends or indications of future performance, unless expressed as such, and should only be viewed as historical data. Â Â Larimar Therapeutics, Inc. INDEX Â Â Â Page Â Â Â PART I - FINANCIAL INFORMATION Â Â Â Â Â Item 1 Â Financial Statements (unaudited) Â 3 Â Â Â Â Â Â Â Condensed Consolidated Balance Sheets as of September 30, 2024 and December 31, 2023 Â 3 Â Â Â Â Â Â Â Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and nine months ended September 30, 2024 and 2023 Â 4 Â Â Â Â Â Â Â Condensed Consolidated Statements of Changes in Stockholders' Equity for the three and nine months ended September 30, 2024 and 2023 Â 5 Â Â Â Â Â Â Â Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2024 and 2023 Â 7 Â Â Â Â Â Â Notes to Condensed Consolidated Financial Statements Â 8 Â Â Â Â Â Item 2. Â Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations Â 22 Â Â Â Â Â Item 3. Â Quantitative and Qualitative Disclosures About Market Risk Â 31 Â Â Â Â Â Item 4. Â Controls and Procedures Â 31 Â Â Â Â Â PART II - OTHER INFORMATION Â Â Â Â Â Item 1. Â Legal Proceedings Â 32 Â Â Â Â Â Item 1A. Â Risk Factors Â 32 Â Â Â Â Â Item 2. Â Unregistered Sales of Equity Securities and Use of Proceeds Â 32 Â Â Â Â Â Item 3. Defaults Upon Senior Securities Â 32 Â Â Â Â Â Item 4. Mine Safety Disclosures Â 32 Â Â Â Â Â Item 5. Â Other Information Â 32 Â Â Â Â Â Item 6. Â Exhibits Â 33 Â Â Â Â Â Signatures Â 34 Â 2 Â PART I-FINANCIAL INFORMATION Item 1. Financial Statements LARIMAR THERAPEUTICS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except share and per share data) (Unaudited) Â Â Â September 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Assets Â Â Â Â Â Â Current assets: Â Â Â Â Â Â Cash and cash equivalents Â $ 35,067 Â Â $ 26,749 Â Short-term marketable securities Â Â 168,640 Â Â Â 60,041 Â Prepaid expenses and other current assets Â Â 9,549 Â Â Â 3,385 Â Total current assets Â Â 213,256 Â Â Â 90,175 Â Property and equipment, net Â Â 779 Â Â Â 684 Â Operating lease right-of-use assets Â Â 3,026 Â Â Â 3,078 Â Restricted cash Â Â 1,339 Â Â Â 1,339 Â Other assets Â Â 621 Â Â Â 659 Â Total assets Â $ 219,021 Â Â $ 95,935 Â Liabilities and Stockholdersâ€™ Equity Â Â Â Â Â Â Current liabilities: Â Â Â Â Â Â Accounts payable Â $ 1,686 Â Â $ 1,283 Â Accrued expenses Â Â 13,573 Â Â Â 7,386 Â Operating lease liabilities, current Â Â 1,026 Â Â Â 837 Â Total current liabilities Â Â 16,285 Â Â Â 9,506 Â Operating lease liabilities Â Â 4,336 Â Â Â 4,709 Â Total liabilities Â Â 20,621 Â Â Â 14,215 Â Commitments and contingencies (See Note 8) Â Â Â Â Â Â Stockholdersâ€™ equity: Â Â Â Â Â Â Preferred stock; $0.001Â par value per share; 5,000,000Â shares authorizedÂ Â Â as of September 30, 2024 and December 31, 2023; noÂ shares issued andÂ Â Â outstanding as of September 30, 2024 and December 31, 2023 Â Â â€” Â Â Â â€” Â Common stock, $0.001Â par value per share; 115,000,000Â sharesÂ Â Â authorized as of September 30, 2024 and December 31, 2023; Â Â Â 63,806,628Â and 43,909,069Â shares issued and outstanding as of Â Â Â September 30, 2024 and December 31, 2023, respectively Â Â 64 Â Â Â 43 Â Additional paid-in capital Â Â 438,312 Â Â Â 270,150 Â Accumulated deficit Â Â (240,334) Â Â (188,554) Accumulated other comprehensive gain Â Â 358 Â Â Â 81 Â Total stockholdersâ€™ equity Â Â 198,400 Â Â Â 81,720 Â Total liabilities and stockholdersâ€™ equity Â $ 219,021 Â Â $ 95,935 Â Â The accompanying notes are an integral part of these condensed consolidated financial statements. 3 Â LARIMAR THERAPEUTICS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (In thousands, except share and per share data) (Unaudited) Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Operating expenses: Â Â Â Â Â Â Â Â Â Â Â Â Research and development Â $ 13,919 Â Â $ 6,585 Â Â $ 46,540 Â Â $ 17,022 Â General and administrative Â Â 4,345 Â Â Â 3,754 Â Â Â 13,057 Â Â Â 10,574 Â Total operating expenses Â Â 18,264 Â Â Â 10,339 Â Â Â 59,597 Â Â Â 27,596 Â Loss from operations Â Â (18,264) Â Â (10,339) Â Â (59,597) Â Â (27,596) Other income, net Â Â 2,765 Â Â Â 1,275 Â Â Â 7,817 Â Â Â 3,640 Â Net loss Â $ (15,499) Â $ (9,064) Â $ (51,780) Â $ (23,956) Net loss per share, basic and diluted Â $ (0.24) Â $ (0.21) Â $ (0.86) Â $ (0.55) Weighted average common shares outstanding, basic and diluted Â Â 63,806,158 Â Â Â 43,903,738 Â Â Â 60,399,697 Â Â Â 43,899,670 Â Comprehensive loss: Â Â Â Â Â Â Â Â Â Â Â Â Net loss Â $ (15,499) Â $ (9,064) Â $ (51,780) Â $ (23,956) Other comprehensive gain (loss): Â Â Â Â Â Â Â Â Â Â Â Â Unrealized gain (loss) on marketable securities Â Â 508 Â Â Â (5) Â Â 277 Â Â Â 38 Â Total other comprehensive gain (loss) Â Â 508 Â Â Â (5) Â Â 277 Â Â Â 38 Â Total comprehensive loss Â $ (14,991) Â $ (9,069) Â $ (51,503) Â $ (23,918) Â The accompanying notes are an integral part of these condensed consolidated financial statements. 4 Â LARIMAR THERAPEUTICS, INC. CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERSâ€™ EQUITY (In thousands, except share data) (Unaudited) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Accumulated Â Â Â Â Â Â Â Â Â Â Â Â Additional Â Â Â Â Â Other Â Â Total Â Â Â Common Stock Â Â Paid-in Â Â Accumulated Â Â Comprehensive Â Â Stockholdersâ€™ Â Â Â Shares Â Â Par Value Â Â Capital Â Â Deficit Â Â Gain (Loss) Â Â Equity Â Balances as of December 31, 2023 Â Â 43,909,069 Â Â $ 43 Â Â $ 270,150 Â Â $ (188,554) Â $ 81 Â Â $ 81,720 Â Issuance of common stock, net Â Â 19,736,842 Â Â Â 20 Â Â Â 161,736 Â Â Â â€” Â Â Â â€” Â Â Â 161,756 Â Vesting of restricted stock units Â Â 153,750 Â Â Â 1 Â Â Â (1) Â Â â€” Â Â Â â€” Â Â Â â€” Â Exercise of stock options Â Â 356 Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Stock-based compensation expense Â Â â€” Â Â Â â€” Â Â Â 2,128 Â Â Â â€” Â Â Â â€” Â Â Â 2,128 Â Unrealized loss on marketable securities Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (106) Â Â (106) Net loss Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (14,654) Â Â â€” Â Â Â (14,654) Balances as of March 31, 2024 Â Â 63,800,017 Â Â $ 64 Â Â $ 434,013 Â Â $ (203,208) Â $ (25) Â $ 230,844 Â Stock-based compensation expense Â Â â€” Â Â Â â€” Â Â Â 2,301 Â Â Â â€” Â Â Â â€” Â Â Â 2,301 Â Exercise of stock options Â Â 2,500 Â Â Â â€” Â Â Â 11 Â Â Â â€” Â Â Â â€” Â Â Â 11 Â Unrealized loss on marketable debt securities Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (125) Â Â (125) Net loss Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (21,627) Â Â â€” Â Â Â (21,627) Balances as of June 30, 2024 Â Â 63,802,517 Â Â $ 64 Â Â $ 436,325 Â Â $ (224,835) Â $ (150) Â $ 211,404 Â Stock-based compensation expense Â Â â€” Â Â Â â€” Â Â Â 1,957 Â Â Â â€” Â Â Â â€” Â Â Â 1,957 Â Exercise of stock options Â Â 4,111 Â Â Â â€” Â Â Â 30 Â Â Â â€” Â Â Â â€” Â Â Â 30 Â Unrealized gain on marketable debt securities Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â 508 Â Â Â 508 Â Net loss Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (15,499) Â Â â€” Â Â Â (15,499) Balances as of September 30, 2024 Â Â 63,806,628 Â Â $ 64 Â Â $ 438,312 Â Â $ (240,334) Â $ 358 Â Â $ 198,400 Â Â 5 Â LARIMAR THERAPEUTICS, INC. CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERSâ€™ EQUITY (In thousands, except share data) (Unaudited) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Accumulated Â Â Â Â Â Â Â Â Â Â Â Â Additional Â Â Â Â Â Other Â Â Total Â Â Â Common Stock Â Â Paid-in Â Â Accumulated Â Â Comprehensive Â Â Stockholdersâ€™ Â Â Â Shares Â Â Par Value Â Â Capital Â Â Deficit Â Â Gain (Loss) Â Â Equity Â Balances as of December 31, 2022 Â Â 43,269,200 Â Â $ 43 Â Â $ 262,496 Â Â $ (151,605) Â $ (31) Â $ 110,903 Â Stock-based compensation expense Â Â â€” Â Â Â â€” Â Â Â 1,833 Â Â Â â€” Â Â Â â€” Â Â Â 1,833 Â Unrealized gain on marketable securities Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â 31 Â Â Â 31 Â Net loss Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (6,526) Â Â â€” Â Â Â (6,526) Balances as of March 31, 2023 Â Â 43,269,200 Â Â $ 43 Â Â $ 264,329 Â Â $ (158,131) Â $ â€” Â Â $ 106,241 Â Stock-based compensation expense Â Â â€” Â Â Â â€” Â Â Â 2,043 Â Â Â â€” Â Â Â â€” Â Â Â 2,043 Â Unrealized gain on marketable debt securities Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â 12 Â Â Â 12 Â Net loss Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (8,366) Â Â â€” Â Â Â (8,366) Balances as of June 30, 2023 Â Â 43,269,200 Â Â $ 43 Â Â $ 266,372 Â Â $ (166,497) Â $ 12 Â Â $ 99,930 Â Stock-based compensation expense Â Â â€” Â Â Â â€” Â Â Â 1,821 Â Â Â â€” Â Â Â â€” Â Â Â 1,821 Â Exercise of stock options Â Â 8,300 Â Â Â â€” Â Â Â 24 Â Â Â â€” Â Â Â â€” Â Â Â 24 Â Exercise of warrants Â Â 628,403 Â Â Â â€” Â Â Â 6 Â Â Â â€” Â Â Â â€” Â Â Â 6 Â Unrealized loss on marketable securities Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (5) Â Â (5) Net loss Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (9,064) Â Â â€” Â Â Â (9,064) Balances as of September 30, 2023 Â Â 43,905,903 Â Â $ 43 Â Â $ 268,223 Â Â $ (175,561) Â $ 7 Â Â $ 92,712 Â Â The accompanying notes are an integral part of these condensed consolidated financial statements. 6 Â LARIMAR THERAPEUTICS, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands) (Unaudited) Â Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Cash flows from operating activities: Â Â Â Â Â Net loss Â $ (51,780) Â $ (23,956) Adjustments to reconcile net loss to net cash used in operating activities: Â Â Â Â Â Â Stock-based compensation expense Â Â 6,386 Â Â Â 5,697 Â Lease expense Â Â (132) Â Â (58) Depreciation expense Â Â 241 Â Â Â 230 Â Amortization of premium on marketable securities Â Â (4,074) Â Â (1,210) Changes in operating assets and liabilities: Â Â Â Â Â Â Prepaid expenses and other current assets Â Â (6,164) Â Â (579) Accounts payable Â Â 403 Â Â Â (930) Accrued expenses Â Â 6,137 Â Â Â (3,314) Other assets Â Â 38 Â Â Â 4 Â Net cash used in operating activities: Â Â (48,945) Â Â (24,116) Cash flows from investing activities: Â Â Â Â Â Purchases of property and equipment Â Â (336) Â Â â€” Â Purchases of marketable securities Â Â (189,248) Â Â (66,268) Maturities and sales of marketable securities Â Â 85,000 Â Â Â 102,250 Â Net cash provided by (used in) investing activities Â Â (104,584) Â Â 35,982 Â Cash flows from financing activities: Â Â Â Â Â Â Proceeds from issuance of equity securities, net of issuance costs Â Â 161,806 Â Â Â â€” Â Proceeds from exercise of stock options and warrants Â Â 41 Â Â Â 30 Â Net cash provided by financing activities Â Â 161,847 Â Â Â 30 Â Net increase in cash, cash equivalents and restricted cash Â Â 8,318 Â Â Â 11,896 Â Cash, cash equivalents and restricted cash at beginning of period Â Â 28,088 Â Â Â 28,164 Â Cash, cash equivalents and restricted cash at end of period Â $ 36,406 Â Â $ 40,060 Â Supplemental disclosure of non-cash investing and financing activities: Â Â Â Â Â Â Offering costs included in accrued expense Â $ 50 Â Â $ â€” Â Leased assets obtained in exchange for new operating lease liabilities Â $ 465 Â Â $ 452 Â Â The accompanying notes are an integral part of these condensed consolidated financial statements. 7 Â LARIMAR THERAPEUTICS, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) 1.Description of Business and Basis of Presentation Larimar Therapeutics, Inc., together with its subsidiary (the â€œCompanyâ€ or â€œLarimarâ€), is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Larimar's lead product candidate, nomlabofusp (nomlabofusp is the International Nonproprietary Name and the United States Adopted Name for CTI-1601), is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin ("FXN"), an essential protein, to the mitochondria of patients with Friedreichâ€™s ataxia ("FA"). FA is a rare, progressive and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. The Company has completed two phase 1 studies of nomlabofusp, a Phase 2 dose exploration study, and initiated an open label extension study (â€œOLEâ€) in patients with FA in January, 2024. This OLE study is ongoing and continues to enroll patients. In May 2021, after reporting positive top-line data from the Companyâ€™s Phase 1 FA program, the U.S. Food and Drug Administration (â€œFDAâ€) placed a clinical hold on the Companyâ€™s nomlabofusp clinical program after the Company notified the FDA of mortalities at the highest dose levels of a 26-week non-human primate toxicology study that was designed to support extended dosing of patients with nomlabofusp. In September 2022, the FDA lifted its full clinical hold on the nomlabofusp program and imposed a partial clinical hold. In May 2023, the Company announced top-line data from its completed 25 mg cohort of a Phase 2, four-week, dose exploration trial of nomlabofusp in patients with FA and provided a complete response to the FDA in June 2023, which included unblinded safety, pharmacokinetic ("PK"), and pharmacodynamic ("PD") data from the Phase 2 trialâ€™s completed 25 mg cohort.In June 2023, the Company met with the FDA. Following that meeting, the Company submitted a complete response to the FDAâ€™s partial clinical hold that included unblinded safety, PK and frataxin data from the Phase 2 trialâ€™s completed 25 mg cohort. In July 2023, following the FDAâ€™s review of the Company's complete response to the partial clinical hold, the FDA cleared initiation of a second cohort at 50 mg of our four-week, placebo-controlled, Phase 2 dose exploration trial and initiation of an OLE study with daily dosing of 25 mg. In February 2024, the Company reported positive top-line data and successful completion of their four-week, placebo-controlled Phase 2 dose exploration study of nomlabofusp in participants with FA. Nomlabofusp was generally well tolerated throughout the four-week treatment periods, had a predictable pharmacokinetic profile and led to dose dependent increases in FXN levels in all evaluated tissues (skin and buccal cells) after daily dosing of 14 days followed by every other day dosing until day 28 in the 25 mg and 50 mg cohorts. Participants in the 25 mg (n=13) and 50 mg (n=15) cohorts were randomized 2:1 to receive subcutaneous injections of nomlabofusp or placebo. In May 2024 the FDA removed the partial clinical hold on the development of nomlabofusp. Patients who completed treatment in the Company's Phase 2 dose exploration study or who previously completed a prior clinical trial of nomlabofusp are eligible to screen and possibly participate in the OLE study. Current patients in the OLE study either participated in the Phase 2 dose exploration study and/or a previous clinical trial.In March 2024, the Company dosed the first patient in its OLE trial discussed above, evaluating daily subcutaneous injections of 25 mg of nomlabofusp self-administered or administered by a caregiver. This study is ongoing with seven sites activated and additional patients are continuing to be enrolled and dosed. Participants who completed treatment in the Phase 2 dose exploration study, or who previously completed a prior clinical trial of nomlabofusp, are potentially eligible to screen for the OLE study. The OLE study will evaluate the safety and tolerability, pharmacokinetics, and frataxin levels in peripheral tissues as well as other exploratory pharmacodynamic markers (lipid profiles and gene expression data) following long-term subcutaneous administration of nomlabofusp. In addition, following the completion of enrollment, as well as at least one participant completing one year of dosing, clinical assessments collected during the study will be compared to data from a matched control arm derived from participants in the Friedreichâ€™s Ataxia Clinical Outcome Measures Study ("FACOMS") database. Dose escalation to the 50 mg dose in the OLE study is currently planned following further characterization of the frataxin PD at the 25 mg dose. The Company currently expects to provide a nomlabofusp development program update in mid-December 2024 that will include available safety, pharmacokinetic and frataxin data as well as available clinical outcome observations from patients currently receiving the daily 25 mg dose of nomlabofusp for approximately 30 to 180 days in the ongoing OLE study. An update on enrollment and plans on the OLE study will also be provided. 8 Â Separately, the Company has had discussions with the FDA regarding the use of tissue FXN levels as a novel surrogate endpoint. The FDA acknowledged that

frataxin deficiency appears to be critical to the pathogenic mechanism of FA, and that there continues to be an unmet need for treatments for FA patients that address the underlying disease pathophysiology. The Company intends to pursue an accelerated approval using FXN levels, supportive PD and clinical information, and safety data from the OLE study, along with additional non-clinical pharmacology information needed to support the novel surrogate endpoint approach. The Company is on track to expand the nomlabofusp clinical program into adolescent (12-17 years old) and pediatric (2-11 years old) patients with FA. The Company expects to initiate a PK run-in study in adolescents by the end of this year and expects to transition these study participants into the ongoing OLE study after assessment of safety and exposure data in the adolescent cohort. The run-in-study will enroll 12-15 adolescent patients and 12-15 pediatric patients who will be randomized 2:1 to receive either nomlabofusp or placebo daily. The Company is also planning the initiation of a global confirmatory/registration study by mid-2025 with potential sites in the U.S., Europe, the U.K., Canada and Australia. The Biologics License Application ("BLA") filing is targeted in the second half of 2025 to support potential accelerated approval. On May 30, 2024, the Company announced that the FDA's Center for Drug Evaluation and Research ("CDER") had selected nomlabofusp as one of a few programs for participation in the Support for Clinical Trials Advancing Rare Disease Therapeutics ("START") Pilot Program. The objective of the program is to accelerate the development of drugs for rare diseases that lead to significant disability or death by facilitating frequent advice and regular communication with the FDA staff to expedite the review process of biologics and drugs. In September 2024, the Company received the Medicines and Healthcare Regulatory Agency ("MHRA") Innovative Licensing and Access Pathway ("ILAP") aimed at potentially accelerating access and reducing the time to market in the United Kingdom.The Company is subject to risks and uncertainties common to pre-commercial companies in the biotechnology industry, including, but not limited to, development and commercialization by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with governmental regulations, failure to secure regulatory approval for its drug candidates or any other product candidates and the ability to secure additional capital to fund its operations. Product candidates under development will require extensive non-clinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel, infrastructure and extensive compliance-reporting capabilities. Even if the Company's drug development efforts are successful, it is uncertain when, if ever, it will realize significant revenue from product sales.Basis of PresentationThe condensed consolidated financial statements include the accounts of Larimar and its wholly owned subsidiary. All intercompany balances and transactions have been eliminated. The accompanying condensed consolidated financial statements have been prepared in conformity with Generally Accepted Accounting Principles ("GAAP").The condensed consolidated balance sheet as of December 31, 2023 was derived from the Companyâ€™s audited financial statements but does not include all disclosures required by GAAP. The accompanying unaudited condensed consolidated financial statements as of September 30, 2024 and for the three and nine months ended September 30, 2024 and 2023, have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (â€œSECâ€) for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. However, the Company believes that the disclosures are adequate to make the information presented not misleading. These condensed consolidated financial statements should be read in conjunction with the Companyâ€™s audited consolidated financial statements and the notes thereto for the year ended December 31, 2023 included in the Companyâ€™s Annual Report on Form 10-K filed with the SEC on March 14, 2024 and the Company's Quarterly Reports on Form 10-Q filed with the SEC on May 9, 2024 and August 8, 2024.In the opinion of management, all adjustments, consisting only of normal recurring adjustments necessary for a fair statement of the Companyâ€™s condensed consolidated financial position as of September 30, 2024, condensed consolidated results of operations for the three and nine months ended September 30, 2024 and condensed consolidated statement of cash flows for the nine months ended September 30, 2024 have been made. The results of operations for the three and nine months ended September 30, 2024 are not necessarily indicative of the results of operations that may be expected for the year ending December 31, 2024. 9 Â Liquidity and Capital ResourcesThe Companyâ€™s condensed consolidated financial statements have been presented on the basis that it will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business.Since its inception, the Company has incurred significant recurring operating losses and negative cash flows from operations. The Company has incurred net losses of $51.8 million and $24.0 million for the nine months ended September 30, 2024 and 2023, respectively. In addition, as of September 30, 2024, the Company had an accumulated deficit of $240.3 million. The Company expects to continue to generate operating losses for the foreseeable future. As of September 30, 2024, the Company had approximately $203.7 million of cash, cash equivalents and marketable securities available for use to fund its operations and capital requirements.The Company has funded its operations to date primarily with proceeds from sales of common stock and proceeds from the sale of prefunded warrants for the purchase of common stock, the acquisition in 2020 of cash, cash equivalents and marketable securities upon the merger with Zafgen, Inc. ("Zafgen") and, prior to the 2020 merger with Zafgen, capital contributions from Chondrial Holdings, LLC. In February 2024, the Company completed an underwritten public offering in which the Company issued and sold 19,736,842 shares of its common stock at a public offering price of $8.74 per share. The Company received net proceeds of approximately $161.8 million after deducting underwriting discounts, commissions and other offering expenses.In accordance with Accounting Standards Update (â€œASUâ€) No. 2014-15, "Disclosure of Uncertainties about an Entityâ€™s Ability to Continue as a Going Concern", the Company has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the Companyâ€™s ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are issued. As of the issuance date of these condensed consolidated financial statements, the Company expects its cash, cash equivalents and marketable securities will be sufficient to fund its forecasted operating expenses and capital expenditure requirements into 2026. If the timing of the Company's clinical assumptions are delayed, or if there are other forecasted assumption changes that negatively impact its operating plan, the Company could reduce expenditures in order to further extend cash resources. The Company has not yet commercialized any products and does not expect to generate revenue from the commercial sale of any products for several years, if at all. The Company expects that its research and development and general and administrative expenses will continue to increase, that sales and marketing expenses will become significant and, as a result, that it will need additional capital to fund its future operating and capital requirements. Unless and until the Company can generate substantial revenue, management continuously evaluates different strategies to obtain the required funding for future operations. These strategies include seeking additional funding through a combination of public or private equity offerings, debt or royalty financings, collaborations and licensing arrangements, strategic partnerships with pharmaceutical and/or larger biotechnology companies, or other sources. The incurrence of indebtedness would result in increased fixed payment obligations and the Company may be required to agree to certain restrictive covenants, such as limitations on its ability to incur additional debt, limitations on its ability to acquire, sell or license intellectual property rights, minimum required cash balances and other operating restrictions that could adversely impact the Company's ability to conduct its business. Any additional fundraising efforts may divert the Company's management from their day-to-day activities, which may adversely affect its ability to develop and commercialize its product candidates. There can be no assurance that the Company will be able to raise sufficient additional capital on acceptable terms, if at all. If such additional financing is not available on satisfactory terms, or is not available in sufficient amounts, or if the Company does not have sufficient authorized shares, the Company may be required to delay, limit, or eliminate the development of business opportunities and its ability to achieve its business objectives, its competitiveness, and its business, financial condition, and results of operations will be materially adversely affected. The Company could also be required to seek funds through arrangements with collaborative partners or otherwise at an earlier stage than otherwise would be desirable and it may be required to relinquish rights to some of its technologies or product candidates or otherwise agree to terms unfavorable to it, any of which may have a material adverse effect on the Company's business, operating results and prospects. In addition, geopolitical tensions, volatility of capital markets, and other adverse macroeconomic events, including those due to inflationary pressures, rising interest rates, banking instability, monetary policy changes and the ability of the U.S. government to manage 10 Â federal debt limits as well as the potential impact of other health crises on the global financial markets may reduce the Company's ability to access capital, which could negatively affect its liquidity and ability to continue as a going concern. If the Company is unable to obtain sufficient funding when needed and/or on acceptable terms, the Company may be required to significantly curtail, delay or discontinue one or more of its research and development programs, the manufacture of clinical and commercial supplies, product portfolio expansion, pre commercialization efforts and/or commercial operations, which could adversely affect its business prospects, or the Company may be unable to continue operations. 2.Summary of Significant Accounting PoliciesUse of EstimatesThe preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. This process involves reviewing open contracts and purchase orders, communicating with our personnel and outside vendors to identify services that have been performed on our behalf and estimating the level of service performed and the associated costs incurred for the services when we have not yet been invoiced or otherwise notified of the actual costs. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual of research and development expense, the recording as prepaid expense of payments made in advance of the actual provision of goods or services, valuation of stock-based awards and valuation of leases. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions.Research and Development CostsCosts associated with internal research and development and external research and development services, including drug development, clinical studies and non-clinical studies, are expensed as incurred. Research and development expenses include costs for salaries, employee benefits, subcontractors, facility-related expenses, depreciation, non-cash stock-based compensation, third-party license fees, laboratory supplies, and external costs of outside vendors engaged to conduct discovery, non-clinical and clinical development activities and clinical trials as well as to manufacture clinical trial materials, and other costs. The Company recognizes external research and development costs based on an evaluation of the progress to completion of specific tasks using information provided to the Company by its key service providers.Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. Such prepaid expenses are recognized as an expense when the goods have been delivered or the related services have been performed, or when it is no longer expected that the goods will be delivered, or the services rendered.Upfront payments, milestone payments and annual maintenance fees under license agreements are currently expensed in the period in which they are incurred.Patent CostsAll patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses. 11 Â Stock-Based CompensationThe Company measures all stock-based awards granted to employees and directors based on the fair value on the date of grant using the Black-Scholes option-pricing model. Compensation expense of those awards is recognized over the requisite service period, which is the vesting period of the respective award. Typically, the Company issues awards with only service-based vesting conditions and records the expense for these awards using the straight-line method. The Company accounts for forfeitures as they occur.The Company classifies stock-based compensation expense in its condensed consolidated statements of operations and comprehensive loss in the same manner in which the award recipientâ€™s payroll costs are classified or in which the award recipientâ€™s service payments are classified.Prior to May 28, 2020, the Company had been a private company and lacked company-specific historical and implied volatility information for its common stock. Prior to January 1, 2023, the Company estimated its expected common stock price volatility solely based on the historical volatility of publicly traded peer companies. Beginning on January 1, 2023, based on the availability of sufficient historical trading data of the Company's own common stock on the Nasdaq Global Market to calculate accurately its volatility, the Company began blending its volatility starting from June 2020 (following its merger with Zafgen in 2020) to the date of each stock-based award, and weighing the volatility of its peer group for the amount of time from May 31, 2020 backwards so that the blended volatility equals the expected term of the related stock-based award. The expected term of the Companyâ€™s stock options has been determined utilizing the â€œsimplifiedâ€ method for awards that qualify as â€œplain-vanillaâ€ options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected dividend yield considers the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future.Net Loss Per ShareBasic net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period. Prior to August 11, 2023, basic shares outstanding includes the weighted average effect of the Companyâ€™s prefunded warrants issued in June 2020, the exercise of which requires little or no consideration for the delivery of shares of common stock. These prefunded warrants were exercised on August 11, 2023 and the Company received cash proceeds of less than $0.1 million. Accordingly, the 628,403 shares were issued upon the exercise of these warrants and are included in issued and outstanding common stock. Diluted net loss per share attributable to common stockholders is computed by dividing the diluted net loss attributable to common stockholders by the weighted average number of common shares, including potentially dilutive common stock equivalents assuming the dilutive effect of outstanding stock options, outstanding restricted stock units, and unvested restricted common shares, as determined using the treasury stock method. For periods in which the Company has reported net losses (all periods since inception), diluted net loss per common share attributable to common stockholders is the same as basic net loss per common share attributable to common stockholders, since dilutive common stock equivalents are not assumed to have been issued if their effect is antidilutive.The Company excluded 6,990,827 and 5,100,997 common stock equivalents outstanding as of September 30, 2024 and 2023, respectively, from the computation of diluted net loss per share for the three and nine months ended September 30, 2024 and 2023 because they had an anti-dilutive impact due to the net loss incurred for the periods presented. Recently Issued and Adopted Accounting Pronouncements From time to time, new accounting guidance is issued by the FASB or other standard setting bodies that is adopted by us as of the effective date or, in some cases where early adoption is permitted, in advance of the effective date. We have assessed the recently issued guidance that is not yet effective and believe the new guidance will not have a material impact on the condensed consolidated results of operations, cash flows or financial position.In November 2023, the FASB issued new guidance designed to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant expenses per segment. The new standard must be adopted on a retrospective basis. We intend to adopt the new guidance for the fiscal year ending December 31, 2024, and subsequent interim periods. Given that the accounting standard update affects disclosures exclusively, we do not anticipate that its adoption will have a material impact on our consolidated financial statements. 12 Â In December 2023, the FASB issued new guidance designed to improve income tax disclosure requirements primarily through increased disaggregation disclosures within the effective tax rate reconciliation as well as enhanced disclosures on income taxes paid. The guidance is effective for all fiscal years beginning after December 15, 2024. The new standard can be adopted on a prospective basis with an option for it to be adopted retrospectively and early adoption is permitted. We are currently evaluating this guidance to determine its impact on our consolidated financial statements. 3.Fair Value Measurements and Marketable SecuritiesFair Value MeasurementsThe Companyâ€™s assets and liabilities that are measured at fair value on a recurring basis as of September 30, 2024 and December 31, 2023 are measured in accordance with the standards of ASC 820, "Fair Value Measurements and Disclosures", which establishes a three-level valuation hierarchy for measuring fair value and expands financial statement disclosures about fair value measurements. The valuation hierarchy is based on the transparency of inputs to the valuation of an asset or liability as of the measurement date. The three levels are defined as follows: Â Level â€“ 1 Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. Â Â Level â€“ 2 Inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. Â Â Level â€“ 3 Inputs to the valuation methodology are unobservable and significant to the fair value measurement. The Companyâ€™s financial instruments consist primarily of cash, cash equivalents, marketable securities, accounts payable and accrued liabilities. For accounts payable and accrued liabilities, the carrying amounts of these financial instruments as of September 30, 2024 and December 31, 2023 were considered representative of their fair values due to their short term to maturity. 13 Â The following tables summarize the Companyâ€™s cash equivalents and marketable securities as of September 30, 2024 and December 31, 2023:Â Â Â Total Â Â QuotedPrices inActiveMarkets (Level 1) Â Â SignificantOtherObservableInputs (Level 2) Â Â SignificantUnobservableInputs (Level 3) Â Â Â (in thousands) Â September 30, 2024 Â Â Â Â Â Â Â Â Â Â Â Â Cash equivalents: Â Â Â Â Â Â Â Â Â Â Â Â Money market funds invested in government securities Â $ 31,338 Â Â $ 31,338 Â Â $ â€” Â Â $ â€” Â Total cash equivalents Â Â 31,338 Â Â Â 31,338 Â Â Â â€” Â Â Â Â Â Â Â Â Â Â Â Â Marketable securities: Â Â Â Â Â Â Â Â Â Â Â Â U.S. Treasury Bills Â Â 10,944 Â Â Â 10,944 Â Â Â Â â€” Â Â Â â€” Â U.S. Government securities Â Â 157,696 Â Â Â â€” Â Â Â 157,696 Â Â Â â€” Â Total marketable securities Â Â 168,640 Â Â Â 10,944 Â Â Â 157,696

Â Â Â â€” Â Total cash equivalents and marketable securities Â $ 199,978 Â Â $ 42,282 Â Â $ 157,696 Â Â $ â€” Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â December 31, 2023 Â Â Â Â Â Â Â Â Â Â Â Â Cash equivalents: Â Â Â Â Â Â Â Â Â Â Â Â Money market funds invested in government securities Â $ 24,701 Â Â $ 24,701 Â Â $ â€” Â Â $ â€” Â Total cash equivalents Â Â 24,701 Â Â Â 24,701 Â Â Â â€” Â Â Â â€” Â Â Â Â Â Â Â Â Â Â Â Â Marketable securities: Â Â Â Â Â Â Â Â Â Â Â Â U.S. Treasury Bills Â Â 17,334 Â Â Â 17,334 Â Â Â â€” Â Â Â â€” Â U.S. Government securities Â Â 35,719 Â Â Â â€” Â Â Â 35,719 Â Â Â â€” Â Corporate bonds Â Â 6,988 Â Â Â â€” Â Â Â 6,988 Â Â Â â€” Â Total marketable securities Â Â 60,041 Â Â Â 17,334 Â Â Â 42,707 Â Â Â â€” Â Total cash equivalents and marketable securities Â $ 84,742 Â Â $ 42,035 Â Â $ 42,707 Â Â $ â€” Â The accrued interest receivable related to the Companyâ€™s investments was $0.9 million and $0.3 million as of September 30, 2024 and December 31, 2023, respectively, and is included in prepaid expenses and other current assets on the condensed consolidated balance sheet. The Company classifies its money market funds and U.S. treasury bills, which are valued based on quoted market prices in active markets with no valuation adjustment, as Level 1 assets within the fair value hierarchy. 14 Â The Company classifies its investments in U.S. government and agency securities, corporate commercial paper, and corporate bonds, if any, as Level 2 assets within the fair value hierarchy. The fair values of these investments are estimated by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income- and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data and other observable inputs.As of September 30, 2024 and December 31, 2023, no allowances for credit losses for the Companyâ€™s investments were recorded. During the three and nine months ended September 30, 2024 and 2023, the Company did not recognize any impairment losses related to investments.Marketable securitiesThe following table summarizes the Company's marketable securities as of September 30, 2024 and December 31, 2023. Â Â Â AmortizedCost Â Â GrossUnrealizedGains Â Â GrossUnrealized Losses Â Â Fair Value Â Â Â (in thousands) Â September 30, 2024 Â Â Â Â Â Â Â Â Â Â Â Assets: Â Â Â Â Â Â Â Â Â Â Â Â U.S. Treasury Bills Â $ 10,937 Â Â $ 7 Â Â $ â€” Â Â $ 10,944 Â U.S. Government securities Â Â 157,345 Â Â Â 351 Â Â Â â€” Â Â Â 157,696 Â Total marketable securities Â $ 168,282 Â Â $ 358 Â Â $ â€” Â Â $ 168,640 Â Â Â Â Â Â Â Â Â Â Â Â December 31, 2023 Â Â Â Â Â Â Â Â Â Â Â Assets: Â Â Â Â Â Â Â Â Â Â Â Â U.S. Treasury Bills Â $ 17,330 Â Â $ 4 Â Â $ â€” Â Â $ 17,334 Â U.S. Government securities Â Â 35,653 Â Â Â 66 Â Â Â â€” Â Â Â 35,719 Â Corporate bonds Â Â 6,977 Â Â Â 11 Â Â Â â€” Â Â Â 6,988 Â Total marketable securities Â $ 59,960 Â Â $ 81 Â Â $ â€” Â Â $ 60,041 Â Â 4.Prepaid Expenses and Other Current AssetsPrepaid expenses and other current assets consisted of the following: Â Â Â September 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Â Â (in thousands) Â Prepaid research and development expenses Â $ 8,192 Â Â $ 1,994 Â Interest receivable Â Â 943 Â Â Â 332 Â Prepaid insurance Â Â 43 Â Â Â 682 Â Other prepaid expenses and other assets Â Â 371 Â Â Â 377 Â Â $ 9,549 Â Â $ 3,385 Â Â 15 Â 5.Fixed AssetsFixed assets, net consisted of the following:Â Â Â Â Â September 30, Â Â December 31, Â Â Â Useful Life Â 2024 Â Â 2023 Â Â Â Â Â (in thousands) Â Computer equipment Â 5 years Â $ 117 Â Â $ 117 Â Lab equipment Â 5 years Â Â 1,528 Â Â Â 1,192 Â Furniture and fixtures Â 7 years Â Â 555 Â Â Â 555 Â Leasehold improvements Â lease term Â Â 45 Â Â Â 45 Â Â Â Â Â 2,245 Â Â Â 1,909 Â Less: Accumulated depreciation Â Â Â Â (1,466) Â Â (1,225) Â Â Â $ 779 Â Â $ 684 Â Â Depreciation expense was $0.1 million and $0.2 million for the three and nine months ended September 30, 2024, respectively. Depreciation expense was $0.1 million and $0.2 million for the three and nine months ended September 30, 2023, respectively. In addition, for the three and nine months ended September 30, 2024, there was less than $0.1 million of depreciation in each period related to sublet assets recorded as other expense. For the three and nine months ended September 30, 2023, there was less than $0.1 million and $0.1 million, respectively, of depreciation related to sublet assets recorded as other expense. 6.Accrued ExpensesAccrued expenses consisted of the following: Â Â Â September 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Â Â (in thousands) Â Accrued research and development expenses Â $ 10,329 Â Â $ 4,594 Â Accrued payroll and related expenses Â Â 2,377 Â Â Â 2,365 Â Accrued other Â Â 867 Â Â Â 427 Â Â $ 13,573 Â Â $ 7,386 Â Â 7.Stockholdersâ€™ Equity and Stock OptionsCommon Stock and Prefunded WarrantsOn May 28, 2020, the Company entered into a securities purchase agreement with certain accredited investors (the â€œPurchasersâ€) for the sale by the Company in a private placement of 6,105,359 shares of the Companyâ€™s common stock and prefunded warrants to purchase an aggregate of 628,403 shares of the Companyâ€™s common stock, for a price of $11.88 per share of the common stock and $11.87 per prefunded warrant. The prefunded warrants were exercisable at an exercise price of $0.01 and were exercisable indefinitely. In August 2023, the 628,403 shares of prefunded warrants were exercised and the Company received cash proceeds of six thousand two hundred and eighty-four dollars. The private placement closed on June 1, 2020. The aggregate gross proceeds for the issuance and sale of the common stock and prefunded warrants were $80.0 million, transaction costs totaled $4.6 million and resulted in net proceeds of $75.4 million. The Companyâ€™s Registration Statement on Form S-3, filed with the SEC on June 26, 2020, registered the resale of 6,105,359 shares of common stock sold and the 628,403 shares of common stock underlying the prefunded warrants. MTS Health Partners served as placement agent to the Company in connection with the private placement. As partial compensation for these services, the Company issued MTS Health Partners 35,260 shares of common stock. As of September 30, 2024, the Companyâ€™s Ninth Amended and Restated Certificate of Incorporation, as amended, authorized the Company to issue up to 115,000,000 shares of common stock, par value $0.001 per share, of which 63,806,628 shares were issued and outstanding, and up to 5,000,000 shares of undesignated preferred stock, par value $0.001 per share, of which no shares were issued or outstanding. The voting, dividend and liquidation rights of the holders of the Companyâ€™s common stock are subject to and qualified by the rights, powers and preferences of the holders of the preferred stock. Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Companyâ€™s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the board of directors of the Company (the â€œBoardâ€), if any. No cash dividends have been declared or paid to date. 16 Â In February 2024, the Company completed an underwritten public offering in which the Company issued and sold 19,736,842 shares of its common stock at a public offering price of $8.74 per share. The Company received net proceeds of approximately $161.8 million after deducting underwriting discounts, commissions and other offering expenses.ATM AgreementIn November 2022, the Company entered into a Sales Agreement (the "2022 ATM Agreement") with Guggenheim Securities, LLC as a sales agent in connection with the establishment of an â€œat-the-marketâ€ offering program under which the Company could sell up to an aggregate of $50 million of shares of common stock (the â€œ2022 ATM Sharesâ€) from time to time. In February 2024, in connection with the underwritten public offering described above, the Company terminated the 2022 ATM Agreement. No ATM Shares were ever sold pursuant to the 2022 ATM Agreement.In May 2024, the Company entered into a sales agreement (the "ATM Agreement") with Guggenheim Securities, LLC in connection with the establishment of an â€œat-the-marketâ€ offering program under which the Company could sell up to an aggregate of $100 million of shares of common stock (the â€œATM Sharesâ€) from time to time. To date, no sales of common stock have been made under this ATM Agreement.2020 Equity Incentive PlanThe Board adopted the 2020 Equity Incentive Plan (the "2020 Plan") on July 16, 2020 and the stockholders of the Company approved the 2020 Plan on September 29, 2020. The 2020 Plan replaced the predecessor plans (the "Prior Plans") that the Company assumed following its merger with Zafgen in May 2020. Options outstanding under the Prior Plans will remain outstanding, unchanged, and subject to the terms of the Prior Plans and the respective award agreements, and no further awards will be made under the Prior Plans. However, if any award previously granted under the Prior Plans, expires, terminates, is canceled, or is forfeited for any reason after the approval of the 2020 Plan, the shares subject to that award will be added to the 2020 Plan share pool so that they can be utilized for new grants under the 2020 Plan.The 2020 Plan provides for the grant of incentive stock options (â€œISOsâ€), nonstatutory stock options (â€œNSOsâ€), stock appreciation rights, restricted stock awards, restricted stock unit awards, and cash or other stock-based awards. ISOs may be granted only to the Companyâ€™s employees, including the Companyâ€™s officers, and the employees of the Companyâ€™s affiliates. All other awards may be granted to the Companyâ€™s employees, including the Companyâ€™s officers, the Companyâ€™s non-employee directors and consultants, and the employees and consultants of the Companyâ€™s affiliates.The maximum number of shares that may be issued in respect of any awards under the 2020 Plan is the sum of: (i) 1,700,000 shares plus (ii) an annual increase on January 1, 2021 and each anniversary of such date thereafter through January 1, 2030, equal to the lesser of (A) 4% of the shares issued and outstanding on the last day of the immediately preceding fiscal year, or (B) such smaller number of shares as determined by the Board (collectively, the â€œPlan Limitâ€). The maximum aggregate number of shares that may be issued under the 2020 Plan is 8,000,000 over the ten-year term of the 2020 Plan. As permitted by the 2020 Plan, the Company added 1,756,363 and 1,730,768 shares available for grant to the 2020 Plan on January 1, 2024 and January 1, 2023, respectively. As of September 30, 2024, 779,926 shares of common stock were available for grant under the 2020 Plan.During the twelve months ended December 31, 2023, options to purchase 224,437 shares issued under the Prior Plans were cancelled and became available for grant under the 2020 Plan. During the nine months ended September 30, 2024, options to purchase 1,242 shares issued under the Prior Plans were cancelled and became available for grant under the 2020 Plan. At September 30, 2024, 344,683 options under the Prior Plans remained outstanding at prices ranging from $11.88 to $445.80, and, if unexercised, will return to the 2020 Plan no later than July 15, 2030. 17 Â Stock Option ValuationThe following table presents, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted to employees:Â Â Â September 30, Â Â 2024 Risk-free interest rate Â 4.12% Expected term (in years) Â 6.22 Expected volatility Â 96% Dividend yield Â 0.00% Stock OptionsThe following table summarizes the Companyâ€™s stock option activity for the nine months ended September 30, 2024 (amounts in millions, except for share, contractual term, and per share data):Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Weighted Â Â Weighted Average Â Â Aggregate Â Â Â Â Â Â Average Â Â Remaining Â Â Intrinsic Â Â Â Number of Â Â Exercise Â Â Contractual Â Â Value (a) Â Â Â Shares Â Â Price Â Â Term (in years) Â Â (in millions) Â Outstanding as of December 31, 2023 Â Â 4,273,502 Â Â $ 9.06 Â Â Â 7.8 Â Â Â Â Options granted Â Â 2,082,377 Â Â Â 5.22 Â Â Â Â Â Â Â Options exercised Â Â (6,967) Â Â 5.92 Â Â Â Â Â Â Â Options forfeited/expired Â Â (57,088) Â Â 10.08 Â Â Â Â Â Â Â Outstanding as of September 30, 2024 Â Â 6,291,824 Â Â $ 7.79 Â Â Â 7.8 Â Â $ 7.4 Â Exercisable as of September 30, 2024 Â Â 2,921,508 Â Â $ 10.63 Â Â Â 6.5 Â Â $ 1.7 Â Vested and expected to vest as of September 30, 2024 Â Â 6,291,824 Â Â $ 7.79 Â Â Â 7.8 Â Â $ 7.4 Â (a)The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of the common stock for the options that were "in the money" at September 30, 2024.Option GrantsDuring the nine months ended September 30, 2024, the Company granted options to purchase 2,082,377 shares of common stock to employees and directors under the 2020 Plan. The options have an exercise price equal to the closing stock price as of the grant date. Of the 2,082,377 options granted, 1,987,377 were granted to employees and vest over four years, with 25% vesting on the first anniversary of the grant and the remainder vesting in equal monthly installments thereafter. The remaining 95,000 options were annual grants to the Company's directors and vest one year from the grant date. The weighted-average grant date fair value of options granted under the 2020 Plan during the nine months ended September 30, 2024 was $4.15.As of September 30, 2024, total unrecognized compensation expense related to unvested stock options granted under the 2020 Plan was $11.8 million, which is expected to be recognized over a weighted average period of 2.56 years.Inducement Stock Option GrantThere were no inducement awards granted in the nine months ended September 30, 2024.As of September 30, 2024, total unrecognized compensation expense related to unvested inducement options granted was $0.8 million, which is expected to be recognized over a weighted average period of 2.53 years.Restricted Stock UnitsIn January 2024, RSUs were granted under the 2020 Plan to certain of the Company's employees in order to maintain retention of key employees. The value of an RSU award is based on the Company's stock price on the date of grant. The shares underlying the RSUs are not issued until the RSUs vest. 18 Â Activity with respect to the Company's RSUs during the nine months ended September 30, 2024 was as follows (in millions, except share, contractual term, and per share data):Â Â Â Â Â Â Weighted Â Â Weighted Average Â Â Aggregate Â Â Â Â Â Â Average Â Â Remaining Â Â Intrinsic Â Â Â Number of Â Â Grant Date Â Â Contractual Â Â Value (a) Â Â Â Shares Â Â Fair Value Â Â Term (in years) Â Â (in millions) Â Outstanding as of December 31, 2023 Â Â 615,000 Â Â $ 4.94 Â Â Â 1.6 Â Â Â Â Restricted stock units granted Â Â 245,372 Â Â Â 4.21 Â Â Â Â Â Â Â Restricted stock units vested Â Â (153,750) Â Â 4.94 Â Â Â Â Â Â Â Restricted stock units forfeited Â Â (7,619) Â Â 4.64 Â Â Â Â Â Â Â Outstanding as of September 30, 2024 Â Â 699,003 Â Â $ 4.69 Â Â Â 1.5 Â Â $ 4.6 Â Unvested and expected to vest as of September 30, 2024 Â Â 699,003 Â Â $ 4.69 Â Â Â 1.5 Â Â $ 4.6 Â Restricted Stock Unit GrantsDuring the nine months ended September 30, 2024, the Company granted 245,372 shares of RSUs to employees under the 2020 Plan. The RSUs vest annually over four years and have a weighted-average grant date fair value of $4.21 per unit. As of September 30, 2024, total unrecognized compensation expense for RSUs was $2.6 million, which is expected to be recognized over a weighted-average period of 2.65 years.Stock-Based CompensationStock-based compensation expense was classified in the condensed consolidated statements of operations as follows:Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Research and development Â $ 918 Â Â $ 697 Â Â $ 2,816 Â Â $ 2,304 Â General and administrative Â Â 1,039 Â Â Â 1,124 Â Â Â 3,570 Â Â Â 3,393 Â Â $ 1,957 Â Â $ 1,821 Â Â $ 6,386 Â Â $ 5,697 Â Â 8.Commitments and ContingenciesIntellectual Property Licenses The Company is party to an exclusive License Agreement (the â€œWFUHS Licenseâ€), dated November 30, 2016, as amended, with Wake Forest University Health Sciences (â€œWFUHSâ€) and an exclusive License Agreement (the â€œIU Licenseâ€), dated November 30, 2016, as amended, with Indiana University (â€œIUâ€). Such agreements provide for a transferable, worldwide license to certain patent rights regarding technology used by the Company with respect to the development of nomlabofusp. Both agreements continue from their effective date through the last to date of expiration of the licensed patents, unless earlier terminated by either party in accordance with their terms.In partial consideration for the right and license granted under these agreements, the Company will pay each of WFUHS and IU a royalty of a low single digit percentage of net sales of licensed products depending on whether there is a valid patent covering such products. As additional consideration for these agreements, the Company is obligated to pay each of WFUHS and IU certain milestone payments of up to $2.6 million in the aggregate upon the achievement of certain developmental milestones, which commenced with the enrollment of the first patient in a Phase 1 clinical trial. The Company enrolled the first patient in its SAD trial on December 11, 2019 and paid WFUHS and IU less than $0.1 million. The Company will also pay each of WFUHS and IU sublicensing fees ranging from a high-single digit to a low double-digit percentage of sublicense consideration depending on the Companyâ€™s achievement of certain regulatory milestones as of the time of receipt of the sublicense consideration. The Company is also obligated to reimburse WFUHS and IU for patent-related expenses. In the event that the Company disputes the validity of any of the licensed patents, the royalty rate would be tripled during such dispute. The Company is also obligated to pay to IU a minimum annual royalty of less than $0.1 million per annum. 19 Â In the event that the Company is required to pay IU consideration, then the Company may deduct 20% of such IU consideration on a dollar-for-dollar basis from the consideration due to WFUHS. In the event that the Company is required to pay WFUHS consideration, then the Company may deduct 60% of such WFUHS consideration on a dollar-for-dollar basis from the consideration due to IU.In October 2022, the Company initiated dosing of a Phase 2 study. Pursuant to the terms of both the WFUHS License and the IU License, the company recognized milestone expense of $0.3 million within research and development expenses. Both agreements continue from their effective date through the last date of expiration of the licensed patents, unless earlier terminated by either party in accordance with their terms.LeasesBala Cynwyd Office SpaceOn August 8, 2019, the Company entered into an operating lease for office space in Bala Cynwyd, Pennsylvania, effective as of December 15, 2019, for a period of three years and six months with an option to extend the lease for three additional years. Due to required tenant improvements to be completed by the landlord, the Company did not take immediate possession of the leased property and the lease term commenced on February 15, 2020. On March 9, 2023, the Company executed a lease extension agreement on its original 4,642 square footage of office space in Bala Cynwyd, Pennsylvania (which was set to expire in August 2023) and agreed to lease an additional 3,462 square feet of office space from the same landlord.The lease extension on the original 4,642 square footage commenced on September 1, 2023 and the Company recorded a right of use asset and lease liability of $0.5 million as of that date.The new lease on 3,462 additional square footage commenced on October 1, 2023 and the Company recorded a right of use asset and lease liability of $0.3 million as of that date.The right of use assets and lease liabilities with both these leases are reflected in the financial statements as of September 30, 2024 as are the right of use asset and lease liability of the Company's Boston office space discussed below.Boston Office LeaseIn connection with the Company's 2020 merger with Zafgen described in footnote 1, on May 28, 2020, the Company acquired a non-cancellable operating lease for approximately 17,705 square feet of office space (the â€œPremisesâ€). The lease expires on October 30, 2029. As part of the agreement, the Company is required to maintain a letter of credit, which upon signing was $1.3 million and was later reduced to $0.6 million in October 2024, and is classified as restricted cash within the condensed consolidated financial statements. In addition to the base rent, the Company is also responsible for its share of operating expenses, electricity and real estate taxes, which costs are not included in the determination of the leasesâ€™ right-of-use assets or lease liabilities. The right-of-use asset is being amortized to other income/(expense) over the remaining lease term as a result of the sublease described below. On October 27, 2020, the Company entered into a sublease

agreement (the â€œSubleaseâ€) with Massachusetts Municipal Association, Inc. (the â€œSubtenantâ€), whereby the Company sublet the entire Premises to the Subtenant. The initial term of the Sublease commenced on December 4, 2020 and continues until October 30, 2029. In connection with the Sublease, the Company evaluated the need for impairment under ASC 360 "Impairment Testing: Long-Lived Assets Classified as Held and Used," and determined there was no impairment.The Sublease provided for an initial annual base rent of $0.8 million, which increases annually up to a maximum annual base rent of $1.0 million. The Subtenant also is responsible for paying to the Company future increases in operating costs (commencing on January 1, 2022), future increases in annual tax costs (commencing July 1, 2021) and all utility costs (commencing March 1, 2021) attributable to the Premises during the term of the Sublease. As part of the Sublease, the subtenant deposited a letter of credit in the amount of $0.8 million to assure their performance under the sublease. If there are no uncured events of default under the sublease, the amount of this security deposit decreases over time to $0.4 million on the sixth anniversary of the Sublease. The Company records sublease income on this sublease on a straight-line basis as a component of other income/(expense). 20 Â Lab SpaceOn November 5, 2018, the Company entered into an operating lease for office and lab space in Philadelphia, Pennsylvania, effective as of January 1, 2019, and expiring on December 31, 2020 with an option to extend the lease for two additional years. On August 4, 2020, the Company executed the first option to extend the lease for an additional year, expiring on December 31, 2021. On August 9, 2021, the Company executed the remaining option to extend the lease for an additional year, expiring on December 31, 2022. In September 2023, the Company extended this lease for an additional year with the option to terminate with four months' notice. On March 28, 2024, the Company gave the requisite notice and vacated the property in May 2024.On October 16, 2023, the Company entered into an operating lease for lab space in King of Prussia, Pennsylvania for a period of four years. Due to required tenant improvements to be completed by the landlord, the Company did not take immediate possession of the leased property. The actual lease term commenced on May 10, 2024. Upon commencement of the lease term, the Company recorded a right of use asset and lease liability of $0.5 million which are reflected in these condensed consolidated financial statements.Lease ExpenseExpense arising from operating leases was $0.1 million and $0.4 million during the three and nine months ended September 30, 2024, respectively. Expense arising from operating leases was $0.1 million and $0.2 million during the three and nine months ended September 30, 2023, respectively. For operating leases, the weighted-average remaining lease term for leases at September 30, 2024 and December 31, 2023 was 4.7 and 5.5 years, respectively. For operating leases, the weighted average discount rate for leases at September 30, 2024 and December 31, 2023 was 11.0%. The Company has not entered into any financing leases. Maturities of lease liabilities due under these lease agreements as of September 30, 2024 are as follows: Â Â Â Operating Â (in thousands) Leases Â Three months ending December 31, 2024 Â $ 383 Â Year ended December 31, 2025 Â Â 1,543 Â Year ended December 31, 2026 Â Â 1,473 Â Year ended December 31, 2027 Â Â 1,267 Â Year ended December 31, 2028 Â Â 1,189 Â Thereafter Â Â 959 Â Total lease payments Â Â 6,814 Â Less: imputed interest Â Â (1,452) Present value of lease liabilities Â $ 5,362 Â Â Legal ProceedingsThe Company is not currently a party to any litigation, nor is management aware of any pending or threatened litigation against the Company, that it believes would materially affect the Company's business, operating results, financial condition or cash flows. Â 9.Related PartyÂ In May 2024, the Company entered into an agreement with the Friedreichâ€™s Ataxia Research Alliance (FARA) to join the TRACK-FA Neuroimaging Consortium that includes pharmaceutical, biotechnology, academic and clinical partners. The consortium will conduct a natural history study designed to establish disease-specific neuroimaging biomarkers to track disease progression in the brain and spinal cord and provide a basis for utilizing these biomarkers in clinical trials. As an industry partner, the Company will help fund the study and contribute to the study design, research activities, and analysis. The Company will have access to all study data for use in its regulatory filings, as appropriate. During the three and nine months ended September 30, 2024, the Company incurred less than $0.1 million and $0.8 million of costs related to the Track-FA program and will fund future costs going forward. One of the Companyâ€™s Directors is also a director of FARA. 21 Â Item 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our condensed consolidated financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q (â€œQuarterly Reportâ€), and the audited consolidated financial statements and notes thereto and managementâ€™s discussion and analysis of financial condition and results of operations for the year ended December 31, 2023 included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (â€œSECâ€) on March 14, 2024 (the "2023 Annual Report"). Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks, uncertainties, and assumptions. These statements are based on our beliefs and expectations about future outcomes and are subject to risks and uncertainties that could cause our actual results to differ materially from anticipated results. We undertake no obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise. You should read the â€œRisk Factorsâ€ section included in our 2023 Annual Report, in addition to the "Risk Factors" and â€œCautionary Note Regarding Forward-Looking Statementsâ€ sections of this Quarterly Report for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. Overview We are a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using our novel cell penetrating peptide ("CPP") technology platform. Our lead product candidate, nomlabofusp (nomlabofusp is the International Nonproprietary Name and the United States Adopted Name for CTI-1601), is a subcutaneously administered, recombinant fusion protein intended to deliver tissue frataxin ("FXN"), an essential protein, to the mitochondria of patients with Friedreich's ataxia (â€œFAâ€). FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. Currently, there are no treatment options that address the core deficit of FA, low levels of FXN. Nomlabofusp represents the first potential therapy designed to increase FXN levels in patients with FA. We believe that our CPP platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, has the potential to enable the treatment of other rare and orphan diseases. We intend to use our proprietary platform to target additional orphan indications characterized by deficiencies in or alterations of intracellular content or activity. Since our inception, we have devoted substantially all of our resources to developing nomlabofusp, building our intellectual property portfolio, developing third-party manufacturing capabilities, business planning, raising capital, and providing general and administrative support for such operations. Nomlabofusp Program Update Clinical Trials We have completed two Phase 1 clinical trials, a Phase 2 dose exploration trial, and recently initiated an open label extension study (â€œOLEâ€) in patients with FA. This OLE study is ongoing. In May 2021, after reporting positive top-line data from our Phase 1 FA program, the U.S. Food and Drug Administration (â€œFDAâ€) placed a clinical hold on our nomlabofusp clinical program after we notified the FDA of mortalities at the highest dose levels of a 26-week non-human primate toxicology study that was designed to support extended dosing of patients with nomlabofusp. In September 2022, the FDA lifted its full clinical hold on the nomlabofusp program and imposed a partial clinical hold. In May 2023, we announced top-line data from our completed 25 mg cohort of a Phase 2, four-week, dose exploration trial of nomlabofusp in patients with FA and provided a complete response to the FDA in June 2023, which included unblinded safety, pharmacokinetic ("PK"), and pharmacodynamic ("PD") data from the Phase 2 trialâ€™s completed 25 mg cohort. In June 2023, we met with the FDA. Following that meeting, we submitted a complete response to the FDAâ€™s partial clinical hold that included unblinded safety, PK and frataxin data from the Phase 2 trialâ€™s completed 25 mg cohort. 22 Â In July 2023, following the FDAâ€™s review of the complete response to the partial clinical hold, the FDA cleared initiation of a second cohort at 50 mg of our four-week, placebo-controlled, Phase 2 dose exploration trial and initiation of an OLE study with daily dosing of 25 mg. In February 2024, we reported positive top-line data and successful completion of their four-week, placebo-controlled Phase 2 dose exploration study of nomlabofusp in participants with FA. Nomlabofusp was generally well tolerated throughout the four-week treatment periods, had a predictable pharmacokinetic profile and led to dose dependent increases in FXN levels in all evaluated tissues (skin and buccal cells) after daily dosing of 14 days followed by every other day dosing until day 28 in the 25 mg and 50 mg cohorts. Participants in the 25 mg (n=13) and 50 mg (n=15) cohorts were randomized 2:1 to receive subcutaneous injections of nomlabofusp or placebo. In May 2024 the FDA removed the partial clinical hold on the development of nomlabofusp. Patients who completed treatment in our Phase 2 dose exploration study or who previously completed a prior clinical trial of nomlabofusp are eligible to screen and possibly participate in the OLE study. Current patients in the OLE study either participated in the Phase 2 dose exploration study and/or a previous clinical trial. In March 2024, we dosed the first patient in our OLE trial discussed above, evaluating daily subcutaneous injections of 25 mg of nomlabofusp self-administered or administered by a caregiver. This study is ongoing with seven sites activated and additional patients are continuing to be enrolled and dosed. Participants who completed treatment in the Phase 2 dose exploration study, or who previously completed a prior clinical trial of nomlabofusp, are potentially eligible to screen for the OLE study. The OLE study will evaluate the safety and tolerability, pharmacokinetics, and frataxin levels in peripheral tissues as well as other exploratory pharmacodynamic markers (lipid profiles and gene expression data) following long-term subcutaneous administration of nomlabofusp. In addition, clinical assessments collected during the study will be compared to data from a matched control arm derived from participants in the Friedreichâ€™s Ataxia Clinical Outcome Measures Study ("FACOMS") database. Dose escalation to the 50 mg dose in the OLE study is currently planned following further characterization of the frataxin pharmacodynamics ("PD") at the 25 mg dose. We currently expect to provide a nomlabofusp development program update in mid-December 2024 that will include available safety, pharmacokinetic and frataxin data as well as available clinical outcome observations from patients currently receiving the daily 25 mg dose of nomlabofusp for approximately 30 to 180 days in the ongoing OLE study. An update on enrollment in the OLE study will also be provided. Separately, we have had discussions with the FDA regarding the use of tissue FXN levels as a novel surrogate endpoint. The FDA acknowledged that frataxin deficiency appears to be critical to the pathogenic mechanism of FA, and that there continues to be an unmet need for treatments for FA patients that address the underlying disease pathophysiology. We intend to pursue an accelerated approval using FXN levels, supportive PD and clinical information, and safety data from the OLE study, along with additional non-clinical pharmacology information needed to support the novel surrogate endpoint approach. We are on track to expand the nomlabofusp clinical program into adolescent (12-17 years old) and pediatric (2-11 years old) patients with FA. We expect to initiate a PK run-in study in adolescents by the end of this year and expect to transition these study participants into the ongoing OLE study after assessment of safety and exposure data in the adolescent cohort. The run-in-study will enroll 12-15 adolescent patients and 12-15 pediatric patients who will be randomized 2:1 to receive either nomlabofusp or placebo daily. We are also planning the initiation of a global confirmatory/registration study by mid-2025 with potential sites in the U.S., Europe, the U.K., Canada and Australia. The Biologics License Application ("BLA") filing is targeted in the second half of 2025 to support potential accelerated approval. On May 30, 2024, we announced that the FDA's Center for Drug Evaluation and Research ("CDER") had selected nomlabofusp as one of a few programs for participation in the Support for Clinical Trials Advancing Rare Disease Therapeutics ("START") Pilot Program. The objective of the program is to accelerate the development of drugs for rare diseases that lead to significant disability or death by facilitating frequent advice and regular communication with the FDA staff to expedite the review process of biologics and drugs. In September 2024, we received the Medicines and Healthcare Regulatory Agency ("MHRA") Innovative Licensing and Access Pathway ("ILAP")for the treatment of adults and children with FA aimed to facilitate patient access to novel treatments by accelerating time to market through opportunities for enhanced engagements with UK regulatory authorities and other stakeholders. Along with the receipt of the ILAP designation, nomlabofusp has already been granted orphan drug designations in the U.S. and the European Union (EU), Fast Track and Rare Pediatric Disease designations in the U.S., PRIME designation in the EU, and selected to be in the START pilot program by the FDA. We are subject to risks and uncertainties common to pre-commercial companies in the biotechnology industry, including, but not limited to, development and commercialization by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with governmental regulations, 23 Â failure to secure regulatory approval for our drug candidates or any other product candidates and the ability to secure additional capital to fund our operations. Product candidates under development will require extensive non-clinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel, infrastructure and extensive compliance-reporting capabilities. Even if our drug development efforts are successful, it is uncertain when, if ever, it will realize significant revenue from product sales. Financing Activities, including Recent Material Financings We have funded our operations to date primarily with proceeds from sales of common stock, proceeds from the sale of prefunded warrants for the purchase of common stock, the acquisition in 2020 of cash, cash equivalents, marketable securities and restricted cash upon the merger with Zafgen, Inc. ("Zafgen") and, prior to the 2020 merger with Zafgen, capital contributions from Chondrial Holdings, LLC. In February 2024, we completed an underwritten public offering in which we issued and sold 19,736,842 shares of our common stock at a public offering price of $8.74 per share. We received net proceeds of approximately $161.8 million after deducting underwriting discounts, commissions and other offering expenses. In May 2024, we entered into a Sales Agreement (the "ATM Agreement") with Guggenheim Securities, LLC in connection with the establishment of an â€œat-the-marketâ€ offering program providing for the sale of up to an aggregate of $100 million of shares of our common stock from time to time. To date, we have made no sales under this ATM agreement. Â Critical Accounting Policies and Significant Judgments and Estimates Our condensed consolidated financial statements are prepared in accordance with GAAP. The preparation of our condensed consolidated financial statements and related disclosures requires us to make estimates and assumptions that affect the reported amount of assets, liabilities, costs and expenses, and related disclosures. We believe that the estimates and assumptions involved in the accounting policies described below may have the greatest potential impact on our condensed consolidated financial statements and, therefore, consider these to be our critical accounting policies. We evaluate these estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions and conditions. Research and Development Expense Costs for certain research and development activities, such as manufacturing, non-clinical studies and clinical trials are generally recognized based on the evaluation of the progress of completion of specific tasks using information and data provided by our vendors and collaborators, and accordingly, are considered an area of significant judgment and managementâ€™s review of manufacturing, non-clinical and clinical expenses. This process involves reviewing open contracts and purchase orders, communicating with our personnel and outside vendors to identify services that have been performed on our behalf and estimating the level of service performed and the associated costs incurred for the services when we have not yet been invoiced or otherwise notified of the actual costs. We work with vendors and suppliers to ensure that our estimates of our research and development expenses are reasonable. We expect to increase our investment in research and development in order to advance nomlabofusp through additional clinical trials. As a result, we expect that our research and development expenses will increase in the foreseeable future as we pursue clinical development of nomlabofusp and/or any other product candidates we develop. Stock Compensation Expense We measure all stock-based awards granted to employees and directors based on the fair value on the date of grant using the Black-Scholes option-pricing model. The Black-Scholes option-pricing model requires the use of highly subjective assumptions which determine the fair value of stock-based awards. The assumptions used in our option-pricing model represent managementâ€™s best estimates. These estimates are complex, involve a number of variables, uncertainties and assumptions and the application of managementâ€™s judgment, and thus are inherently subjective. If factors change and different assumptions are used, our stock-based compensation expense could be materially different in the future. Prior to May 28, 2020, we were a private company and lacked company-specific historical and implied volatility information for our common stock. Prior to January 1, 2023, we estimated our expected common stock price volatility solely based on the historical volatility of publicly traded peer companies with comparable characteristics including enterprise value, risk profiles and position within the industry. Beginning on January 1, 24 Â 2023, we began blending our historical data starting in June 2020 (following our merger with Zafgen in 2020) with our historical peer group. We regularly evaluate our peer group to assess changes in circumstances where identified companies may no longer be similar to us, in which case, more suitable companies whose share prices are publicly available would be utilized in the calculation. We expect to continue to do so until we have full historical data regarding the volatility of our own traded stock price. The expected term of our stock options has been determined utilizing the â€œsimplifiedâ€ method for awards that qualify as â€œplain-vanillaâ€ options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected dividend yield considers the fact that we have never paid cash dividends on common stock and do not expect to pay any cash dividends in the foreseeable future. Compensation expense of those awards is recognized over the requisite service period, which is generally the vesting period of the respective award. Typically, we issue awards with only service-based vesting conditions and record the expense for these awards using the straight-line method. We account for forfeitures as they occur. We classify stock-based compensation expense in our consolidated statements of operations and comprehensive loss in the same manner in which the award recipientâ€™s payroll costs are classified or in which the award recipientâ€™s service payments are classified. Financial Operations Overview Revenue To date, we have not generated any revenue from product sales, and do not expect to generate any revenue from the sale of products in the foreseeable future. If our development efforts result in clinical success and regulatory approval or collaboration agreements with third parties for

our product candidates, we may generate revenue from those product candidates or collaborations. Operating Expenses The majority of our operating expenses since inception have consisted primarily of research and development activities, and general and administrative costs. Research and Development Expenses Research and development expenses, which consist primarily of costs associated with our product research and development efforts, are expensed as incurred. Research and development expenses consist primarily of: â€¢third-party contract costs relating to research, formulation, manufacturing, non-clinical studies and clinical trial activities; â€¢employee related costs, including salaries, benefits and stock-based compensation expenses for employees engaged in scientific research and development functions; â€¢external costs of outside consultants and vendors; â€¢payments made under our third-party licensing agreements; â€¢sponsored research agreements; â€¢laboratory consumables; and â€¢allocated facility-related costs. At this time, we cannot reasonably estimate or know the nature, timing and estimated costs of the efforts that will be necessary to complete the clinical and commercial development of nomlabofusp, or any other product candidates we develop. We are also unable to predict when, if ever, material net cash inflows will commence from sales of our product candidates. The duration, costs, and timing of clinical trials and development of nomlabofusp or any other product candidates we develop will depend on a variety of factors, including: â€¢the scope, rate of progress and expense of clinical trials and other research and development activities; â€¢clinical trial results; 25 Â â€¢uncertainties in clinical trial enrollment rate or design; â€¢significant and changing government regulation; â€¢the timing and receipt of any regulatory approvals; â€¢the influence of the FDA or other regulatory authorities on our clinical trial design and timing; â€¢establishing manufacturing capabilities or making arrangements with third-party manufacturers and risk involved with development of manufacturing processes, FDA pre-approval inspection practices and successful completion of manufacturing batches for clinical development and other regulatory purposes; â€¢our ability to obtain and maintain patent and trade secret protection and regulatory exclusivity for our product candidates; and â€¢our ability to recruit and retain key research and development personnel. A change in the outcome of one or more of these variables with respect to the development of a product candidate could significantly change the costs, timing and viability associated with the development of that product candidate. For example, if the FDA or another regulatory authority were to require us to conduct additional non-clinical or clinical trials beyond those that we currently anticipate will be required for the completion of clinical development of a product candidate, or if we experience significant delays in enrollment in any of our clinical trials, we could be required to expend significant additional financial resources and time on the completion of clinical development. General and Administrative Expenses General and administrative expenses consist primarily of personnel costs, consisting of salaries, related benefits and stock-based compensation, costs related to our executive, finance, information technology, and costs related to other administrative functions. General and administrative expenses also include insurance expenses and professional fees for auditing, tax, and legal services, including legal expenses to pursue patent protection for our intellectual property. We expect that our general and administrative expenses will increase in the foreseeable future as we hire additional employees to implement, improve and scale our operational, financial, commercial and management systems. Results of Operations Comparison of three months ended September 30, 2024 and 2023 The following table summarizes our results of operations for the three months ended September 30, 2024 and 2023: Â Â Â Three Months Ended September 30, Â Â Â Â Â Â Â Â Â Â Increase Â Â Â 2024 Â Â 2023 Â Â (Decrease) Â Â Â (in thousands) Â Statement of Operations Data: Â Â Â Â Â Â Â Â Â Operating expenses: Â Â Â Â Â Â Â Â Â Â Research and development Â $ 13,919 Â Â $ 6,585 Â Â $ 7,334 Â General and administrative Â Â 4,345 Â Â Â 3,754 Â Â Â 591 Â Total operating expenses Â Â 18,264 Â Â Â 10,339 Â Â Â 7,925 Â Loss from operations Â Â (18,264) Â Â (10,339) Â Â (7,925) Other income (expense), net Â Â 2,765 Â Â Â 1,275 Â Â Â 1,490 Â Net loss Â $ (15,499) Â $ (9,064) Â $ (6,435) Research and development expenses Research and development expenses for the three months ended September 30, 2024 increased $7.3 million compared to the three months ended September 30, 2023. The increase in research and development expenses was primarily driven by an increase of $3.8 million in nomlabofusp manufacturing costs including lyophilization development, production scaling costs and manufacturing costs related to producing doses to be used in ongoing and planned clinical trials, an increase of $1.1 million in personnel expense due to increased headcount, an increase of 26 Â $0.9 million in assay development costs, an increase of $0.6 million in clinical costs primarily associated with the OLE study which began dosing patients in the first quarter of 2024, an increase of $0.3 million of professional fees related to consulting costs, an increase of $0.2 million in stock compensation costs associated with 2024 grants and an increase of $0.2 million in internal lab costs. General and administrative expenses General and administrative expenses for the three months ended September 30, 2024 increased $0.6 million compared to the three months ended September 30, 2023. The increase in general and administrative expenses was primarily driven by an increase of $0.4 million in personnel expense and an increase of $0.2 million in professional fees primarily related to consulting costs related to commercial activity and other public company related expenses. Other income (expense), net Other income (expense), net was $2.8 million income in the three months ended September 30, 2024 compared to $1.3 million income in the three months ended September 30, 2023. The increase primarily relates to interest income earned on a higher investment base. Comparison of nine months ended September 30, 2024 and 2023 The following table summarizes our results of operations for the nine months ended September 30, 2024 and 2023: Â Â Â Nine Months Ended September 30, Â Â Â Â Â Â Â Â Â Increase Â Â Â 2024 Â Â 2023 Â Â (Decrease) Â Â Â (in thousands) Â Statement of Operations Data: Â Â Â Â Â Â Â Â Â Operating expenses: Â Â Â Â Â Â Â Â Â Research and development Â $ 46,540 Â Â $ 17,022 Â Â $ 29,518 Â General and administrative Â Â 13,057 Â Â Â 10,574 Â Â Â 2,483 Â Total operating expenses Â Â 59,597 Â Â Â 27,596 Â Â Â 32,001 Â Loss from operations Â Â (59,597) Â Â (27,596) Â Â (32,001) Other income (expense), net Â Â 7,817 Â Â Â 3,640 Â Â Â 4,177 Â Net loss Â $ (51,780) Â $ (23,956) Â $ (27,824) Research and development expenses Research and development expenses for the nine months ended September 30, 2024 increased $29.5 million compared to the nine months ended September 30, 2023. The increase in research and development expenses was primarily driven by an increase of $20.2 million in nomlabofusp manufacturing costs including lyophilization development, production scaling costs and manufacturing costs related to producing doses to be used in ongoing and planned clinical trials, an increase of $3.2 million in personnel expense due to increased headcount, an increase of $2.9 million in clinical costs primarily associated with the OLE study which began dosing patients in the first quarter of 2024, an increase of $0.9 million in assay development costs, an increase of $0.8 million related to the Track-FA program discussed above, an increase of $0.5 million in stock compensation costs associated with 2024 grants, an increase of $0.5 million in internal lab costs and an increase of $0.3 million of professional fees related to consulting costs. General and administrative expenses General and administrative expenses for the nine months ended September 30, 2024 increased $2.5 million compared to the nine months ended September 30, 2023. The increase in general and administrative expenses was primarily driven by an increase of $1.0 million in personnel expense, an increase of $1.0 million in professional fees primarily related to consulting costs related to commercial activity and other public company related expenses, an increase of $0.3 million of other expense related to computer software, information technology services and recruiting and an increase of $0.2 million in stock compensation costs associated with 2024 grants. 27 Â Other income (expense), net Other income (expense), net was $7.8 million income in the nine months ended September 30, 2024 compared to $3.6 million income in the nine months ended September 30, 2023. The increase primarily relates to interest income earned on a higher investment base. Â Liquidity and Capital Resources Since our inception, we have not generated any revenue from any sources, including from product sales, and have incurred significant operating losses and negative cash flows from our operations. We have devoted substantially all of our resources to developing nomlabofusp, building our intellectual property portfolio, developing third-party manufacturing capabilities, business planning, capital raising, and providing general and administrative support for such operations. Cash Flows The following table summarizes our sources and uses of cash for each of the periods presented below: Â Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â Â (in thousands) Â Net cash used in operating activities Â $ (48,945) Â $ (24,116) Net cash provided by (used in) investing activities Â Â (104,584) Â Â 35,982 Â Net cash provided by financing activities Â Â 161,847 Â Â Â 30 Â Net increase in cash, cash equivalents and restricted cash Â $ 8,318 Â Â $ 11,896 Â Net cash used in operating activities During the nine months ended September 30, 2024, operating activities used $48.9 million of cash, resulting from our net loss of $51.8 million, adjusted for noncash expenses of $2.4 million and changes in our operating assets and liabilities resulting in a source of cash of $0.4 million. Our net loss was primarily attributed to research and development activities related to our nomlabofusp program and our general and administrative expenses as described above. Noncash expenses primarily relate to stock-based compensation expenses. The change in operating assets and liabilities was primarily due to an increase in accrued expenses and accounts payable driven primarily by the increase in R&D activities discussed as well as an increase in prepaid expense. During the nine months ended September 30, 2023, operating activities used $24.1 million of cash, resulting from our net loss of $24.0 million, adjusted for noncash expenses of $4.7 million and changes in our operating assets and liabilities resulting in a source of cash of $4.8 million. Our net loss was primarily attributed to research and development activities related to our nomlabofusp program and our general and administrative expenses as described above. Noncash expenses are primarily stock-based compensation expense. Net cash provided by (used in) investing activities During the nine months ended September 30, 2024, investing activities used $104.6 million of cash to purchase $189.2 million of marketable securities, partially offset by $85 million of cash provided by maturities of marketable securities. During the nine months ended September 30, 2023, investing activities provided $36.0 million of cash, including $102.3 million from maturities of marketable securities partially offset by $66.3 million in purchases of marketable securities. Net cash provided by financing activities During the nine months ended September 30, 2024, financing activities provided $161.8 million of cash flows primarily from an offering of common stock. During the nine months ended September 30, 2023, financing activities provided less than $0.1 million of cash from the exercise of stock options and warrants. 28 Â Operating Capital Requirements We have not yet commercialized any products and do not expect to generate revenue from the commercial sale of any products for several years, if at all. We have to date incurred net losses. We incurred net losses of approximately $51.8 million and $24.0 million for the nine months ended September 30, 2024 and 2023, respectively. As of September 30, 2024, we had an accumulated deficit of $240.3 million and cash, cash equivalents and marketable securities of $203.7 million, excluding restricted cash of $1.3 million. Losses have resulted principally from costs incurred in connection with research and development activities, and general and administrative costs associated with the development of nomlabofusp and our operations. We expect to incur significant expenses and operating losses for the foreseeable future as we expect to continue to incur expenses in connection with our ongoing activities, if and as we: â€¢continue to advance the development of nomlabofusp through additional clinical trials, including related manufacturing costs; â€¢seek to identify and advance development of additional product candidates into clinical development and identify additional indications for our product candidates; â€¢seek to obtain regulatory approvals for nomlabofusp and other potential product candidates; â€¢identify, acquire or in-license other product candidates and technologies; â€¢maintain, leverage and expand our intellectual property portfolio; and â€¢expand our operational, financial, commercial and management systems and personnel, including personnel to support our clinical development and commercialization efforts and our operations as a public company. In February 2024, we completed an underwritten public offering in which we issued and sold 19,736,842 shares of our common stock and received net proceeds of approximately $161.8 million after deducting underwriting discounts, commissions and other offering expenses. We anticipate that our current cash, cash equivalents and marketable securities will fund operations into 2026. If we encounter unexpected delays in our clinical trials or if there are other unanticipated changes to our operating plan from our current assumptions that negatively impact our operations, we may reduce expenditures in order to further extend our existing cash resources. Until we can generate substantial revenue, if ever, we expect to seek additional funding through a combination of public or private equity offerings, debt/royalty financings, collaborations, strategic alliances and licensing arrangements or other sources. The incurrence of indebtedness would result in increased fixed payment obligations and we may be required to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, minimum cash balances, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. Any additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our product candidates. There can be no assurance that we will be able to raise sufficient additional capital on acceptable terms, if at all. If such additional financing is not available on satisfactory terms, or is not available in sufficient amounts, or we do not have sufficient authorized shares, we may be required to delay, limit, or eliminate the development of business opportunities and our ability to achieve our business objectives, our competitiveness, and our business, financial condition, and results of operations will be materially adversely affected. We could also be required to seek funds through arrangements with collaborative partners, strategic alliances or otherwise at an earlier stage than otherwise would be desirable and we may be required to relinquish rights to some of our technologies or product candidates or otherwise agree to terms unfavorable to us, any of which may have a material adverse effect on our business, operating results and prospects. In addition, geopolitical tensions, volatility of capital markets, and other adverse macroeconomic events, including those due to inflationary pressures, rising interest rates, banking instability, monetary policy changes and the ability of the U.S. government to manage federal debt limits, as well as the potential impact of health crises on the global financial markets may reduce our ability to access capital, which could negatively affect our liquidity and ability to continue as a going concern. 29 Â If we are unable to obtain sufficient funding when needed and/or on acceptable terms, we may be required to significantly curtail, delay or discontinue one or more of our research and development programs, the manufacture of clinical and commercial supplies, product portfolio expansion and/or pre commercialization efforts, which could adversely affect our business prospects, or we may be unable to continue operations. Certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. Any additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our product candidates. Off-Balance Sheet Arrangements During the periods presented we did not have, and we currently do not have, any off-balance sheet arrangements, as defined under applicable SEC rules, such as relationships with unconsolidated entities or financial partnerships, which are often referred to as structured finance or special purpose entities, established for the purpose of facilitating financing transactions that are not required to be reflected on our balance sheets. Recently Issued Accounting Pronouncements Please read Note 2 to our condensed consolidated financial statements included in Part I of Item 1 of this Quarterly Report on Form 10-Q for a description of recent accounting pronouncements applicable to our business, if any. Other Company Information None. 30 Â Item 3. Quantitative and Qualitative Disclosures about Market Risk We are a "smaller reporting company" as defined by Rule 12b-2 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") and are not required to provide the information under this item. Item 4. Controls and Procedures We maintain â€œdisclosure controls and procedures,â€ as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, that are designed to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and our Chief Financial Officer, to allow timely decisions regarding required disclosure. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. With respect to the quarter ended September 30, 2024, under the supervision and with the participation of our management, we conducted an evaluation of the effectiveness of the design and operations of our disclosure controls and procedures. Based upon this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures are effective. Management does not expect that our internal control over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control systems are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in a cost-effective control system, no evaluation of internal control over financial reporting can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been or will be detected. Changes in Internal Control Over Financial Reporting There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the fiscal quarter ended September 30, 2024 which have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. 31 Â PART II - OTHER INFORMATION Item 1. Legal Proceedings From time to time, we are subject to claims in legal proceedings arising in the normal course of business. To our knowledge, during the nine months ended September 30, 2024, there were no, and as of the date of this Quarterly Report, there are no, threatened or pending legal actions that could reasonably be expected to have a material adverse effect on our business, financial condition, results of operations or cash flows. Item 1A. Risk Factors You should carefully consider the risk factors described in our 2023 Annual Report under the caption â€œItem 1A. Risk Factors.â€ The risks described in our 2023 Annual Report are not the only risks facing our company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition or future results. There have been no material changes in our risk factors disclosed in our 2023 Annual Report and Quarterly Reports on Form

10-Q filed on May 9, 2024 and August 8, 2024. Â Â Item 2. Unregistered Sales of Equity Securities and Use of Proceeds None. Item 3. Defaults Upon Senior Securities None. Item 4. Mine Safety Disclosures Not applicable. Item 5. Other Information None. 32 Â Item 6. Exhibits The exhibits filed as part of this Quarterly Report are set forth on the Exhibit Index, which is incorporated herein by reference. EXHIBIT INDEX Â Exhibit No. Â Description Â Â Â 31.1* Â Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. Â Â Â 31.2* Â Certification of Principal Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. Â Â Â 32.1** Â Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. Â Â Â 101.INS* Â Inline XBRL Instance Document- the instance document does not appear in the Interactive Data File because its XBRL tag re embedded within the Inline XBRL document Â Â Â 101.SCH* Â Inline XBRL Taxonomy Extension Schema Document. Â Â Â 104 Â Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101) Â * Filed herewith. ** Furnished herewith. 33 Â SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Â Â Â LARIMAR THERAPEUTICS, INC. Â Â Â Date: October 30, 2024 Â By: Â /s/ Carole S. Ben-Maimon, M.D. Â Â Â Â Carole S. Ben-Maimon, M.D. Â Â Â Â President and Chief Executive Officer(Principal Executive Officer) Â Â Â Â Â Â Date: October 30, 2024 Â Â By: Â /s/ Michael Celano Â Â Â Â Michael Celano Â Â Â Â Chief Financial Officer(Principal Financial and Accounting Officer) Â 34 EX-31.1 2 lrmr-ex31_1.htm EX-31.1 EX-31.1 Exhibit 31.1 CERTIFICATION I, Carole S. Ben-Maimon, M.D., certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of Larimar Therapeutics, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4. The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: 1.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; 2.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; 3.Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and 4.Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and 5. The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): 1.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and 2.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Date: October 30, 2024 /s/ Carole S. Ben-Maimon, M.D. Carole S. Ben-Maimon, M.D.President and Chief Executive Officer(Principal Executive Officer) Â EX-31.2 3 lrmr-ex31_2.htm EX-31.2 EX-31.2 Exhibit 31.2 CERTIFICATION I, Michael Celano, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of Larimar Therapeutics, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4. The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: 1.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; 2.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; 3.Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and 4.Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and 5. The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): 1.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and 2.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Date: October 30, 2024 /s/ Michael Celano Michael CelanoChief Financial Officer(Principal Financial Officer and Accounting Officer) Â EX-32.1 4 lrmr-ex32_1.htm EX-32.1 EX-32.1 Â Exhibit 32.1 CERTIFICATION Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) Â Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Larimar Therapeutics, Inc. (the â€œCompanyâ€), does hereby certify, to the best of such officerâ€™s knowledge, that: (1)The Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 (the â€œReportâ€) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and (2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Date: October 30, 2024 Â Â Â Â Â /s/ Carole S. Ben-Maimon, M.D. Â Â Â Â Â Â Carole S. Ben-Maimon, M.D. Â Â Â Â Â Â Â President and Chief Executive Officer Â Â Â Â Â Â Â (Principal Executive Officer) Â Â Â Â Â Â Date: October 30, 2024 Â Â Â Â Â Â /s/ Michael Celano Â Â Â Â Â Â Michael Celano Â Â Â Â Â Â Â Chief Financial Officer Â Â Â Â Â Â Â (Principal Financial and Accounting Officer) Â Â EX-101.SCH 5 lrmr-20240930.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 100010 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 100020 - Disclosure - Commitments and Contingencies - Schedule of Maturities of Lease Liabilities Due Under Lease Agreements (Detail) 2 link:presentationLink link:calculationLink link:definitionLink 100030 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 100040 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss 2 link:presentationLink link:calculationLink link:definitionLink 100050 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 100060 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 100070 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 995455 - Disclosure - Description of Business and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 995465 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 995475 - Disclosure - Fair Value Measurements and Marketable Securities link:presentationLink link:calculationLink link:definitionLink 995485 - Disclosure - Prepaid Expenses and Other Current Assets link:presentationLink link:calculationLink link:definitionLink 995495 - Disclosure - Fixed Assets link:presentationLink link:calculationLink link:definitionLink 995505 - Disclosure - Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 995515 - Disclosure - Stockholders' Equity and Stock Options link:presentationLink link:calculationLink link:definitionLink 995525 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 995535 - Disclosure - Related Party link:presentationLink link:calculationLink link:definitionLink 995545 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 995555 - Disclosure - Fair Value Measurements and Marketable Securities (Tables) link:presentationLink link:calculationLink link:definitionLink 995565 - Disclosure - Prepaid Expenses and Other Current Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 995575 - Disclosure - Fixed Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 995585 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 995595 - Disclosure - Stockholders' Equity and Stock Options (Tables) link:presentationLink link:calculationLink link:definitionLink 995605 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 995615 - Disclosure - Description of Business and Basis of Presentation - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995625 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995635 - Disclosure - Fair Value Measurements and Marketable Securities - Summary of Cash Equivalents and Marketable Securities (Detail) link:presentationLink link:calculationLink link:definitionLink 995645 - Disclosure - Fair Value Measurements and Marketable Securities - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995655 - Disclosure - Fair Value Measurements and Marketable Securities - Summary of Marketable Debt Securities (Details) link:presentationLink link:calculationLink link:definitionLink 995665 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Detail) link:presentationLink link:calculationLink link:definitionLink 995675 - Disclosure - Fixed Assets - Schedule of Fixed Assets, Net (Detail) link:presentationLink link:calculationLink link:definitionLink 995685 - Disclosure - Fixed Assets - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995695 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail) link:presentationLink link:calculationLink link:definitionLink 995705 - Disclosure - Stockholders Equity and Stock Options - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995715 - Disclosure - Stockholders Equity and Stock Options - Assumptions used to Determine Fair Value of Stock Options Granted (Detail) link:presentationLink link:calculationLink link:definitionLink 995725 - Disclosure - Stockholders Equity and Stock Options - Summary of Stock Option Activity (Detail) link:presentationLink link:calculationLink link:definitionLink 995735 - Disclosure - Stockholders Equity and Stock Options - Summary of Restricted Stock Units (Details) link:presentationLink link:calculationLink link:definitionLink 995745 - Disclosure - Stockholders Equity and Stock Options - Summary of Stock-Based Compensation Expense (Detail) link:presentationLink link:calculationLink link:definitionLink 995755 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995765 - Disclosure - Commitments and Contingencies - Schedule of Maturities of Lease Liabilities Due Under Lease Agreements (Detail) link:presentationLink link:calculationLink link:definitionLink 995775 - Disclosure - Related Party - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink Maturities and sales of marketable securities Proceeds from Sale and Maturity of Debt Securities, Available-for-sale, Total Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale Statement [Line Items] Statement [Line Items] Stock option outstanding exercise price lower range limit Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit Plan Name [Domain] Lab Space [Member] Lab Space [Member] Lab space. Entity Address, Postal Zip Code Entity Address, Postal Zip Code Fair Value, Recurring and Nonrecurring [Table] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Entity Incorporation, State or Country Code Entity Incorporation State Country Code Other comprehensive gain (loss): Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Amount of payment due upon reaching milestone. Milestone Payment Amount Milestone payments Lease term commencement date. Lease Term Commencement Date Lease term commencement date Weighted average exercise price, Exercisable as of September 30, 2024 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Vesting of restricted stock units Stock Issued During Period, Value, Restricted Stock Award, Gross Shares, Outstanding Ending balance, shares Beginning balance, shares Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV Fair Value, Inputs, Level 2 [Member] Significant Other Observable Inputs (Level 2) [Member] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Employees and directors. Employees and Directors [Member] Employees and Directors [Member] Three months ending December 31, 2024 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Vest over four years, Vest Over Four Years [Member] Vest Over 4 Years [Member] Security Deposit Liability Lease security deposits letters of credit Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage Stock option vesting percentage Award vesting Related Party Transaction [Line Items] Equity [Text Block] Stockholders' Equity and Stock Options Title and Position [Axis] Amount of asset related to consideration paid in advance for costs related to research and development. Prepaid Research And Development Expenses Prepaid research and development expenses Sale of Stock [Domain] Sale of Stock The value of marketable securities with remaining maturities greater than two years, as of the balance sheet date. Marketable Securities With Remaining Maturities Greater Than Two Years Marketable securities with remaining maturities greater than two years Other Commitments [Line Items] Other Commitments [Line Items] Entity Central Index Key Entity Central Index Key Debt Securities, Available-for-Sale [Line Items] Schedule Of Available For Sale Securities [Line Items] Weighted average grant date fair value, Unvested and expected to vest as of September 30, 2024 Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options Unvested And Expected To Vest, Weighted Average Grant Date Fair Value Per share or unit weighted-average fair value of awards that are unvested and expected to vest under share-based payment arrangement. Excludes share and unit options. Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Common Stock, Shares, Issued, Total Common Stock, Shares, Issued Common stock, shares issued Common stock, shares issued Increase (Decrease) in Prepaid Expense and Other Assets, Total Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other current assets Business Description and Basis of Presentation [Text Block] Description of Business and Basis of Presentation Income Statement [Abstract] Entity Address, State or Province Entity Address, State or Province Area of office space. Area Of Office Space Area of office space Marketable securities Marketable Securities, Total Marketable Securities Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized Increase in shares reserved for future issuance Aggregate intrinsic value, exercisable as of September 30, 2024 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value First Anniversary [Member] First Anniversary [Member] First anniversary. Cover [Abstract] The entire disclosure for prepaid expenses and other current assets. Prepaid Expenses And Other Current Assets [Text Block] Prepaid Expenses and Other Current Assets Earnings Per Share, Basic, Total Earnings Per Share, Basic Net loss per share, basic Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Gross Unrealized Gains Operating Expenses [Abstract] Operating expenses: Share-Based Payment Arrangement, Expense Total stock-based compensation expense Summary of significant accounting policies. Summary Of Significant Accounting Policies [Line Items] Summary Of Significant Accounting Policies [Line Items] Retained Earnings (Accumulated Deficit), Ending Balance Retained Earnings (Accumulated Deficit), Beginning Balance Retained Earnings (Accumulated Deficit), Total Retained Earnings (Accumulated Deficit) Accumulated deficit Plan Name [Axis] Plan Name Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Number of shares, Outstanding Number of shares, Outstanding Assets, Current [Abstract] Current assets: Per unit amount of prefunded warrant issued. Warrants Issued Price Per Share Warrants price per share Investment Type [Axis] Investment Type Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities: Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value

Weighted average grant date fair value, Restricted stock units forfeited Option Indexed to Issuer's Equity [Axis] Accumulated other comprehensive gain Accumulated Other Comprehensive Income (Loss), Net of Tax, Total Accumulated Other Comprehensive Income (Loss), Net of Tax Lessee, Operating Lease, Term of Contract Operating lease term Weighted average remaining contractual term, Outstanding as of September 30, 2024 Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms Property, Plant and Equipment, Net, Beginning Balance Property, Plant and Equipment, Net, Ending Balance Property, Plant and Equipment, Net Property and equipment, net Fixed assets, net Year ended December 31, 2028 Lessee, Operating Lease, Liability, to be Paid, Year Four Net Cash Provided by (Used in) Operating Activities [Abstract] Cash flows from operating activities: Vesting [Axis] Vesting Common Stock, Par or Stated Value Per Share Common stock, par value per share Common stock, par value Comprehensive loss: Statement of Cash Flows [Abstract] Real Estate [Domain] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name Class of Warrant or Right, Number of Securities Called by Warrants or Rights Issuance of warrants Warrants issued Annual base rent Sublease Annual Base Rent Sublease annual base rent. Restricted Stock [Member] Restricted Stock [Member] Equity Components [Axis] Equity Components Entity Address, Address Line One Entity Address, Address Line One Employee-related Liabilities, Current, Total Employee-related Liabilities, Current Accrued payroll and related expenses Related Party Transaction [Table] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Number of shares, Restricted stock units granted Additional Office [Member] Additional Office [Member] Additional office. Computer Equipment [Member] Computer Equipment [Member] Subsequent Event Type [Axis] Other income net Nonoperating Income (Expense), Total Nonoperating Income (Expense) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk-free interest rate Legal Entity of Counterparty, Type [Axis] Legal Entity of Counterparty, Type Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Number of shares, Outstanding Number of shares, Outstanding Amendment Flag Amendment Flag Operating Lease, Liability, Noncurrent Operating lease liabilities Additional Paid in Capital, Common Stock, Ending Balance Additional Paid in Capital, Common Stock, Beginning Balance Additional Paid in Capital, Common Stock Additional paid-in capital Long-term marketable securities Debt Securities, Available-for-Sale, Noncurrent Net loss Net loss Net loss Exercise of stock options, shares Number of shares, Exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Vest one year. Vest One Year [Member] Vest One Year [Member] Operating Costs and Expenses, Total Operating Costs and Expenses Cost related to Track-FA program Number of shares, Exercisable as of September 30, 2024 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Research and Development Expense [Member] Research and Development [Member] Research and Development Expenses [Member] Description of sales agreement.. Sales Agreement Description Sales agreement, description Equity Component [Domain] Equity Component Statistical Measurement [Domain] Statistical Measurement General and Administrative Expense, Total General and Administrative Expense General and administrative Unrealized gain (loss) on marketable securities Unrealized gain (loss) on marketable securities Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent, Total Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent Unrealized gain (loss) on marketable debt securities Furniture and Fixtures [Member] Furniture and Fixtures [Member] Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Undesignated preferred stock, shares issued Preferred Stock, Shares Issued, Total Preferred Stock, Shares Issued Preferred stock, shares issued U.S. Government and Agency Securities [Member] US Government Corporations and Agencies Securities [Member] U.S Government and Agency Securities (due within 1 year) [Member] Offering costs included in accounts payable and accrued expense Offering Costs Included In Accounts Payable And Accrued Expense The amount of offering costs that were incurred, but not yet paid, during the period. Payables and Accruals [Abstract] 2020 Equity Incentive Plan [Member] Two Thousand Twenty Equity Incentive Plan [Member] Two thousand twenty equity incentive plan. Minimum level of maximum number of shares allowed to be issued The minimum threshold number of shares used to determine the maximum number of shares that may be issued under the Plan. Share Based Compensation Arrangement By Share Based Payment Award Threshold Number Of Shares Allowed To Issue Operating Lease, Expense Lease expenses Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Total prepaid expenses and other current assets Restricted Cash, Noncurrent Restricted cash Liability Reserve Estimate, Policy [Policy Text Block] Liquidity and Capital Resources Comprehensive Income (Loss), Net of Tax, Attributable to Parent Total comprehensive loss Common Stock, Shares, Outstanding, Ending Balance Common Stock, Shares, Outstanding, Beginning Balance Common Stock, Shares, Outstanding Common stock, shares outstanding Common stock outstanding MTS Health Partners. M T S Health Partners [Member] MTS Health Partners [Member] Payments to Acquire Debt Securities, Available-for-Sale Purchases of marketable securities Undesignated preferred stock, par value Preferred Stock, Par or Stated Value Per Share Preferred stock, par value per share Preferred stock, par value Carrying value as of the balance sheet date of obligations incurred through that date and payable for expenses related to research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Accrued Research And Development Expense Current Accrued research and development expenses Antidilutive Securities [Axis] Antidilutive Securities Corporate Bond Securities [Member] Corporate Bonds [Member] Exercise of warrants, shares Stock Issued During Period Shares Exercise of Warrants Number of shares of issued as a result of the exercise of warrants. Proceeds from issuance of equity securities, net of issuance costs Proceeds from Issuance or Sale of Equity Proceeds from Issuance or Sale of Equity, Total MOROCCO Massachusetts [Member] Entity Interactive Data Current Entity Interactive Data Current Amount of payment due for milestones that have been achieved Milestone Liability Milestone payments due Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block] Summary of Cash Equivalents and Marketable Securities Lease Expiration Date Lease term expiration date Legal Entity Type of Counterparty [Domain] Legal Entity Type of Counterparty Document Quarterly Report Document Quarterly Report Weighted average grant date fair value, Restricted stock units vested Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Related Party Transaction [Domain] Related Party Transactions Disclosure [Text Block] Related Party Statistical Measurement [Axis] Statistical Measurement U.S. Government Securities [Member] U.S. Government Securities [Member] U.S. Government securities. Assets, Fair Value Disclosure Total cash equivalents and marketable securities Related and Nonrelated Parties [Domain] Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Schedule of Maturities of Lease Liabilities Due Under Lease Agreements Directors [Member] Director [Member] Commercial Paper [Member] Commercial Paper [Member] Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Summary of Restricted Stock Units Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Shares available for grant Weighted average grant date fair value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted average grant date fair value, Restricted stock units granted Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Unrecognized compensation expense recognized period Proceeds from Issuance of Private Placement Gross proceeds Research and Development Expense, Policy [Policy Text Block] Research and Development Costs Statement of Income Location, Balance [Axis] Income Statement Location Assets Total assets Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Expected term (in years) Number of shares, Restricted stock units vested Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Dividends Payable Dividend paid New Accounting Pronouncements, Policy [Policy Text Block] Recently Issued and Adopted Accounting Pronouncements Entity Address, City or Town Entity Address, City or Town AOCI Attributable to Parent [Member] Accumulated Other Comprehensive Gain (Loss) [Member] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Number of shares, Restricted stock units forfeited Prior ATM Agreement At The Market Equity Distribution Agreement [Member] At the market equity distribution agreement. The amount that may be deducted from consideration due to Licensor 2 as a percentage of consideration paid to Licensor 1, whereby Licensor 1 is the identified party. License Agreement Consideration Deduction Percentage License agreement consideration deduction percentage Depreciation, Total Depreciation Depreciation expense Private Placement [Member] Private Placement [Member] Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Maximum number of shares that may be issued under stock option incentive plan Operating Lease, Weighted Average Discount Rate, Percent Weighted average discount rate Fair Value Disclosures [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Weighted average exercise price, Forfeited/Expired Weighted average exercise price, Options forfeited/expired Issuance of common stock, net Stock Issued During Period, Value, New Issues Exercise of stock options Stock Issued During Period, Value, Stock Options Exercised The fee for services as a percentage of gross proceeds resulting from the sale of shares of common stock under a sales agreement. Percentage Of Compensation For Services Equal To Gross Proceeds Percentage of compensation for services equal to gross proceeds Liabilities, Current [Abstract] Current liabilities: Wake forest university health sciences and indiana university research and technology corporation. Wake Forest University Health Sciences And Indiana University Research And Technology Corporation [Member] WFUHS and IU [Member] Intangible Assets, Finite-Lived, Policy [Policy Text Block] Patent Costs Lease Contractual Term [Axis] Lease Contractual Term Sixth sublease year member Sixth Sublease Year [Member] Sixth Sublease Year Aggregate intrinsic value, Unvested and expected to vest as of September 30, 2024 Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options Unvested And Expected To Vest, Aggregate Intrinsic Value Intrinsic value of awards that are unvested and expected to vest under share-based payment arrangement. Excludes share and unit options. Document Type Document Type Asset Impairment Charges, Total Asset Impairment Charges Impairment losses on investment Title of 12(b) Security Title of 12(b) Security Cash and Cash Equivalents, at Carrying Value, Ending Balance Cash and Cash Equivalents, at Carrying Value, Beginning Balance Cash and Cash Equivalents, at Carrying Value, Total Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Statement of Stockholders' Equity [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Research and Development Expense, Total Research and Development Expense Research and development Research and development expense 2022 Equity Distribution Agreement [Member] Two Thousand Twenty Two Equity Distribution Agreement [Member] Two thousand twenty two equity distribution agreement member. Options to purchase shares of common stock granted Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Number of shares, Options granted Property, Plant and Equipment, Gross, Ending Balance Property, Plant and Equipment, Gross, Beginning Balance Property, Plant and Equipment, Gross, Total Property, Plant and Equipment, Gross Fixed assets, gross Subsequent Event Type [Domain] Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Assumptions used to Determine Fair Value of Stock Options Granted Investments in continuous loss position for 12 months or longer Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer Class of Warrant or Right, Exercise Price of Warrants or Rights Warrants exercise price Financial Instruments [Domain] Sale of Stock [Axis] Sale of Stock Net Cash Provided by (Used in) Investing Activities [Abstract] Cash flows from investing activities: Investments [Domain] Investments Other Commitments [Table] Other Commitments [Table] Short-Term Debt, Type [Axis] Short-term Debt, Type Debt Securities, Available-for-Sale [Table] Short-Term Debt, Type [Domain] Short-term Debt, Type Other Accrued Liabilities, Current Accrued other Increase (Decrease) in Accounts Payable, Total Increase (Decrease) in Accounts Payable Accounts payable Entity Address, Address Line Two Entity Address, Address Line Two Liabilities and Equity [Abstract] Liabilities and Stockholdersâ€™ Equity Document Period End Date Document Period End Date Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Net cash provided by financing activities Prepaid Expense and Other Assets [Abstract] Stockholders' Equity Note [Abstract] Vesting of restricted stock units, shares Stock Issued During Period, Shares, Restricted Stock Award, Gross Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Total potentially dilutive shares APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Stock-based compensation expense Proceeds net of issuance costs Sale of Stock, Consideration Received on Transaction Accrued Liabilities, Current Accrued expenses Total accrued expenses Exercise of warrants Stock Issued During Period Value Exercise of Warrants Value of stock issued as a result of the exercise of warrants. First sublease year member. First Sublease Year [Member] First Sublease Year [Member] Trading Symbol Trading Symbol Equity, Attributable to Parent Ending balance Beginning balance Total stockholdersâ€™ equity Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset Share-Based Payment Arrangement [Policy Text Block] Stock-Based Compensation Restricted Stock Units (RSUs) [Member] Restricted Stock Units (RSUs) Restricted Stock Units [Member] Related Party Transactions [Abstract] From Exercise of Warrants [Member] From Exercise of Warrants [Member] From exercise of warrants. Option Indexed to Issuer's Equity, Type [Domain] Option Indexed to Issuer's Equity, Type Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Unrecognized compensation expense The minimum annual royalty payment that is required under a contractual arrangement. Minimum Annual Royalty Obligation Annual royalty pay obligation Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Summary of Stock-Based Compensation Expense Wake Forest University Health Sciences (WFUHS) [Member] Wake Forest University Health Sciences [Member] WFUHS [Member] Geographical [Axis] Geographical The maximum number of shares that may be added annually to the threshold number of shares issued under the Plan, as a percentage of the shares issued and outstanding on the last day of the immediately preceding fiscal year. Share Based Compensation Arrangement By Share Based Payment Award Additional Shares Percentage Of Outstanding Stock Percentage of outstanding shares Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Gross Unrealized Losses Gross Unrealized Losses Leases [Abstract] Equipment [Member] Lab Equipment [Member] Use of Estimates, Policy [Policy Text Block] Use of Estimates Stock option outstanding exercise price upper range limit Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit Scenario [Axis] Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Dividend yield Security Exchange Name Security Exchange Name Tabular disclosure of the carrying amounts of prepaid expenses and other current assets. Schedule Of Prepaid Expenses And Other Current Assets Table [Text Block] Schedule of Prepaid Expenses and Other Current Assets Summary of Marketable Securities Schedule of Available-for-Sale Securities Reconciliation [Table Text Block] Operating Expenses Total operating expenses Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Less: Accumulated depreciation Fair Value Measurements and Marketable Securities Fair Value Disclosures [Text Block] Year ended December 31, 2027 Lessee, Operating Lease, Liability, to be Paid, Year Three Weighted-average grant date fair value of options granted Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Interest receivable Interest Receivable, Current Subsequent Event [Member] Maximum [Member] Maximum [Member] Liabilities and Equity Total liabilities and stockholdersâ€™ equity Operating Lease, Right-of-Use Asset Operating lease right-of-use assets Common Stock Equivalents. Common Stock Equivalents [Member] Common Stock Equivalents [Member] Net loss per share, diluted Earnings Per Share, Diluted, Total Earnings Per Share, Diluted Leasehold Improvements [Member] Leasehold Improvements [Member] Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, not separately disclosed. Other Prepaid Expense And Other Current Assets Other prepaid expenses and other assets Liabilities Total liabilities Common Stock, Voting Rights Common stock voting rights Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV Assets, Current Total current assets Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities Forecast [Member] Forecast [Member] Issuance of common stock, net, shares Issuance of common stock Stock Issued During Period, Shares, New Issues Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Vesting period of stock option Number of stock options remained outstanding under the plan Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding, Ending Balance Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding, Beginning Balance Entity Filer Category Entity Filer Category At-the-market equity offering program. At The Market Equity Offering Program [Member] ATM Offering Program [Member] Current Fiscal Year End Date Current Fiscal Year End Date Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Lessee, Operating Lease, Liability, Undiscounted Excess Amount Less: imputed interest The amount of depreciation expenses recognized in the period, excluding depreciation for leased assets as part of a sublease agreement. Depreciation Expense Excluding Leased Assets Depreciation expense Share-based Payment Arrangement, Noncash Expense, Total Share-Based Payment Arrangement, Noncash Expense Stock-

based compensation expense Related Party Transaction [Axis] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Aggregate intrinsic value, outstanding Aggregate intrinsic value of outstanding options granted Related and Nonrelated Parties [Axis] Entity Registrant Name Entity Registrant Name Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Entity Emerging Growth Company Entity Emerging Growth Company Real Estate, Type of Property [Axis] Real Estate, Type of Property Money Market Funds [Member] Money Market Funds [Member] Weighted Average Number of Shares Outstanding, Basic, Total Weighted Average Number of Shares Outstanding, Basic Weighted average common shares outstanding, basic Vesting [Domain] Vesting Common Stock, Shares Authorized Common stock, shares authorized Property, Plant and Equipment, Useful Life Property Plant And Equipment Useful Life Fixed assets, useful life Incentive stock options member. Incentive Stock Options [Member] Incentive Stock Options [Member] Fair Value, Inputs, Level 1 [Member] Quoted Prices in Active Markets, (Level 1) [Member] Weighted average exercise price, Vested and expected to vest as of September 30, 2024 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Weighted average exercise price, Options granted Financial Instrument [Axis] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Weighted average remaining contractual term, outstanding Net Loss Per Share Earnings Per Share, Policy [Policy Text Block] General and Administrative Expense [Member] General and Administrative [Member] Fair Value Marketable securities Debt Securities, Available-for-Sale Debt Securities, Available-for-Sale, Total Accounting Policies [Abstract] Share-Based Payment Arrangement, Option, Activity [Table Text Block] Summary of Stock Option Activity Equity, Attributable to Parent [Abstract] Stockholdersâ€™ equity: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Supplemental disclosure of non-cash investing and financing activities: Statement [Table] Statement [Table] Property, Plant and Equipment [Table Text Block] Schedule of Fixed Assets, Net Weighted average remaining contractual term, Vested and expected to vest as of September 30, 2024 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Payment for license agreements. Payment for license agreements Undesignated preferred stock, shares authorized Preferred Stock, Shares Authorized Preferred stock, shares authorized Entity File Number Entity File Number Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net increase in cash, cash equivalents and restricted cash Interest Receivable Accrued interest receivable Disclosure of accounting policy for the assessment of the ability to continue as a going concern. Going Concern Policy [Text Block] Going Concern Assessment Proceeds From Stock Options And Warrant Exercises Proceeds from exercise of stock options and warrants The cash inflow from the exercise of options under share-based payment arrangements and from holders exercising their stock warrants. Lease Contractual Term [Domain] Lease Contractual Term Statement of Financial Position [Abstract] Public Offering [Member] Operating Income (Loss) Loss from operations Shares Issued, Price Per Share Share price per share Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected volatility Letter of Credit [Member] Letter of Credit Entity Shell Company Entity Shell Company Entity Tax Identification Number Entity Tax Identification Number Assets [Abstract] Assets Employees. Employees [Member] Employees [Member] Entity Current Reporting Status Entity Current Reporting Status Lease expense Cash and Non Cash Operating Lease Expense The amount of lease expense, both cash and non-cash, related to operating leases. Weighted average remaining contractual term, Unvested and expected to vest as of September 30, 2024 Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options Unvested And Expected To Vest, Weighted Average Remaining Contractual Terms Weighted average remaining contractual term for equity-based awards excluding options that are unvested and expected to vest, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Weighted average remaining contractual term, Exercisable as of September 30, 2024 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Property, Plant and Equipment Disclosure [Text Block] Fixed Assets Geographical [Domain] Geographical Document Fiscal Year Focus Document Fiscal Year Focus Cash and cash equivalents Cash, Cash Equivalents, and Short-Term Investments Cash, Cash Equivalents, and Short-Term Investments, Total Preferred stock; $0.001 par value per share; 5,000,000 shares authorized as of September 30, 2024 and December 31, 2023; no shares issued and outstanding as of September 30, 2024 and December 31, 2023 Preferred Stock, Value, Issued, Ending Balance Preferred Stock, Value, Issued, Beginning Balance Preferred Stock, Value, Issued, Total Preferred Stock, Value, Issued Number of shares, Forfeited/Expired Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Total Number of shares, Options forfeited/expired Capital Expenditures Incurred but Not yet Paid Purchases of property and equipment included in accounts payable and accrued expenses Cash, cash equivalents and restricted cash at end of period Cash, cash equivalents and restricted cash at beginning of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total From Prior Plans [Member] From Prior Plans [Member] From Prior Plans [Member] City Area Code City Area Code Liabilities, Current Total current liabilities Office [Member] Office [Member] Office. Term of plan The term of the plan. Share Based Compensation Arrangement By Share Based Payment Award Duration Track-FA program. Track F A Program [Member] Track-FA program [Member] Organization, Consolidation and Presentation of Financial Statements [Abstract] Local Phone Number Local Phone Number Undesignated preferred stock, shares outstanding Preferred Stock, Shares Outstanding, Ending Balance Preferred Stock, Shares Outstanding, Beginning Balance Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Office and Lab [Member] Office And Lab [Member] Office and Lab. Cash proceeds from exercises of warrants Proceeds from Warrant Exercises Commitments and Contingencies Disclosure [Abstract] Number of shares, Unvested and expected to vest as of September 30, 2024 Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Unvested And Expected To Vest Outstanding Number The number of equity-based payment instruments, excluding stock (or unit) options, that are unvested and expected to vest as of the balance sheet date. Debt Securities, Available-for-Sale, Amortized Cost Amortized Cost Amortized Cost Operating Lease, Liability, Current Operating lease liabilities, current The amount of expense recognized during the period related to milestones. Such amount may include, but is not limited to, amounts due for attainment of milestones as well as deductions granted as part of a license agreement. Milestone Expenses Milestone expenses Indiana University Research and Technology Corporation. Indiana University Research And Technology Corporation [Member] IU [Member] Retained Earnings [Member] Accumulated Deficit [Member] Underwritten Public Offering [Member] Over-Allotment Option [Member] Payments to Acquire Property, Plant, and Equipment, Total Payments to Acquire Property, Plant, and Equipment Purchase of property and equipment Purchase of property and equipment Document Transition Report Document Transition Report Year ended December 31, 2026 Lessee, Operating Lease, Liability, to be Paid, Year Two Weighted average exercise price, Exercised Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Minimum [Member] Minimum [Member] Common Stock [Member] Common Stock [Member] Restricted Cash, Total Restricted Cash Letter of credit Aggregate intrinsic value, Vested and expected to vest as of September 30, 2024 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Weighted average grant date fair value, balance Weighted average grant date fair value, balance Increase (Decrease) in Other Noncurrent Assets Other assets Additional Paid-in Capital [Member] Additional Paid-in Capital [Member] Short-term marketable securities Debt Securities, Available-for-Sale, Current Fair Value Inducement Stock. Inducement Stock [Member] Inducement Stock [Member] Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: The potential aggregate gross sales proceeds available under a sales agreement to sell shares of the Company's common stock. Aggregate Gross Sales Proceeds Under Sales Agreement Aggregate sale of shares of our common stock Aggregate sale of shares of our common stock Statement of Income Location, Balance [Domain] Income Statement Location Year ended December 31, 2025 Lessee, Operating Lease, Liability, to be Paid, Year One Other Assets, Noncurrent, Total Other Assets, Noncurrent Other assets Amount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Lessee Operating Lease Liability Payments Due After Year Four Thereafter Final sublease year Final Sublease Year [Member] Final Sublease Year [Member] Debt Securities, Available-for-Sale, Unrealized Gain (Loss), Total Debt Securities, Available-for-Sale, Unrealized Gain (Loss) Unrealized gains or losses related to available-for-sale investments Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration] At the market offering member. At The Market Offering [Member] ATM Offering [Member] The amount of depreciation expense recognized in the period related to leased assets as part of a sublease agreement. Depreciation Expenses Related to Sublet Assets Depreciation expenses related to sublet assets Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Scenario [Domain] Title and Position [Domain] Allowance for credit loss Debt Securities, Available-for-Sale, Allowance for Credit Loss Debt Securities, Available-for-Sale, Allowance for Credit Loss, Ending Balance Debt Securities, Available-for-Sale, Allowance for Credit Loss, Beginning Balance Debt Securities, Available-for-Sale, Allowance for Credit Loss, Total Common stock, $0.001 par value per share; 115,000,000 shares authorized as of September 30, 2024 and December 31, 2023; 63,806,628 and 43,909,069 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively Common Stock, Value, Issued, Ending Balance Common Stock, Value, Issued, Beginning Balance Common Stock, Value, Issued, Total Common Stock, Value, Issued Prepaid Insurance Prepaid insurance Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Operating Lease, Liability, Total Operating Lease, Liability Operating lease liability Present value of lease liabilities Schedule of Accrued Liabilities [Table Text Block] Schedule of Accrued Expenses Commitments and contingencies (See Note 8) Commitments and Contingencies Proceeds from issuance of common stock and prefunded warrants to purchase common stock, net of offering costs. Proceeds From Issuance Common Stock And Warrants Net Offering Costs Proceeds from issuance common stock and warrants net offering costs Friedreich's Ataxia Research Alliances. Friedreich's Ataxia Research Alliances [Member] Friedreich's Ataxia Research Alliances [Member] Weighted average common shares outstanding, diluted Weighted Average Number of Shares Outstanding, Diluted, Total Weighted Average Number of Shares Outstanding, Diluted Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies Costs incurred during the period related to the issuance of stock and warrants. Stock And Warrant Issuance Transaction Costs Transaction cost Lessee, Operating Lease, Renewal Term Lease extension period Number of shares, Vested and expected to vest as of September 30, 2024 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Lessee, Operating Lease, Liability, to be Paid Total lease payments Office Sublease [Member] Office Sublease [Member] Office Sublease Entity Small Business Entity Small Business Share-Based Compensation Arrangement by Share-Based Payment Award, Terms of Award Share-based compensation arrangement by share-based payment award, description US Treasury Bills [Member] US Treasury Securities [Member] Summary of significant accounting policies. Summary Of Significant Accounting Policies [Table] Summary Of Significant Accounting Policies [Table] Net Cash Provided by (Used in) Financing Activities [Abstract] Cash flows from financing activities: Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Weighted average exercise price, balance Weighted average exercise price, balance Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] Accrued Expenses Amortization of Debt Discount (Premium) Amortization of premium on marketable securities PENNSYLVANIA Pennsylvania [Member] Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Leased assets obtained in exchange for new operating lease liabilities Aggregate intrinsic value, Outstanding as of September 30, 2024 Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding Total other comprehensive gain (loss) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Fair Value, Inputs, Level 3 [Member] Significant Unobservable Inputs (Level 3) [Member] Operating Lease, Weighted Average Remaining Lease Term Weighted average remaining lease term in years Accounts Payable, Current, Total Accounts Payable, Current Accounts payable Increase (Decrease) in Accrued Liabilities, Total Increase (Decrease) in Accrued Liabilities Accrued expenses Accounts Receivable, Allowance for Credit Loss, Beginning Balance Accounts Receivable, Allowance for Credit Loss, Ending Balance Accounts Receivable, Allowance for Credit Loss Allowance for credit loss XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.3 Document and Entity Information - shares 9 Months Ended Sep. 30, 2024 Oct. 28, 2024 Cover [Abstract] Â Â Document Type 10-Q Â Amendment Flag false Â Document Period End Date Sep. 30, 2024 Â Document Fiscal Year Focus 2024 Â Document Fiscal Period Focus Q3 Â Trading Symbol LRMR Â Entity Registrant Name LARIMAR THERAPEUTICS, INC. Â Entity Central Index Key 0001374690 Â Current Fiscal Year End Date --12-31 Â Entity Filer Category Non-accelerated Filer Â Entity Small Business true Â Entity Emerging Growth Company false Â Entity Common Stock, Shares Outstanding Â 63,806,628 Entity Current Reporting Status Yes Â Entity Shell Company false Â Entity File Number 001-36510 Â Entity Tax Identification Number 20-3857670 Â Entity Address, Address Line One Three Bala Plaza East Â Entity Address, Address Line Two Suite 506 Â Entity Address, City or Town Bala Cynwyd Â Entity Address, State or Province PA Â Entity Address, Postal Zip Code 19004 Â City Area Code 844 Â Local Phone Number 511-9056 Â Title of 12(b) Security Common Stock, par value $0.001 per share Â Security Exchange Name NASDAQ Â Entity Interactive Data Current Yes Â Document Quarterly Report true Â Document Transition Report false Â Entity Incorporation State Country Code DE Â X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCover page. + ReferencesNo definition available. + Details Name: dei_CoverAbstract Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 2 such as Street or Suite number + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine2 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration

X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 8 R2.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Balance Sheets - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Current assets: Â Â Cash and cash equivalents $ 35,067 $ 26,749 Short-term marketable securities 168,640 60,041 Prepaid expenses and other current assets 9,549 3,385 Total current assets 213,256 90,175 Property and equipment, net 779 684 Operating lease right-of-use assets 3,026 3,078 Restricted cash 1,339 1,339 Other assets 621 659 Total assets 219,021 95,935 Current liabilities: Â Â Accounts payable 1,686 1,283 Accrued expenses 13,573 7,386 Operating lease liabilities, current 1,026 837 Total current liabilities 16,285 9,506 Operating lease liabilities 4,336 4,709 Total liabilities 20,621 14,215 Commitments and contingencies (See Note 8) Stockholdersâ€™ equity: Â Â Common stock, $0.001 par value per share; 115,000,000 shares authorized as of September 30, 2024 and December 31, 2023; 63,806,628 and 43,909,069 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively 64 43 Additional paid-in capital 438,312 270,150 Accumulated deficit (240,334) (188,554) Accumulated other comprehensive gain 358 81 Total stockholdersâ€™ equity 198,400 81,720 Total liabilities and stockholdersâ€™ equity $ 219,021 $ 95,935 X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionValue received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapitalCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -

Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommitmentsAndContingencies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9:

http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 5 -SubTopic 210 -Topic 954 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8 + Details Name: us-gaap_RestrictedCashNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 9 R3.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares Sep. 30, 2024 Dec. 31, 2023 Statement of Financial Position [Abstract] Â Â Preferred stock, par value per share $ 0.001 $ 0.001 Preferred stock, shares authorized 5,000,000 5,000,000 Preferred stock, shares issued 0 0 Preferred stock, shares outstanding 0 0 Common stock, par value per share $ 0.001 $ 0.001 Common stock, shares authorized 115,000,000 115,000,000 Common stock, shares issued 63,806,628 43,909,069 Common stock, shares outstanding 63,806,628 43,909,069 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfFinancialPositionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 10 R4.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Operating expenses: Â Â Â Â Research and development $ 13,919 $ 6,585 $ 46,540 $ 17,022 General and administrative 4,345 3,754 13,057 10,574 Total operating expenses 18,264 10,339 59,597 27,596 Loss from operations (18,264) (10,339) (59,597) (27,596) Other income net 2,765 1,275 7,817 3,640 Net loss $ (15,499) $ (9,064) $ (51,780) $ (23,956) Net loss per share, basic $ (0.24) $ (0.21) $ (0.86) $ (0.55) Net loss per share, diluted $ (0.24) $ (0.21) $ (0.86) $ (0.55) Weighted average common shares outstanding, basic 63,806,158 43,903,738 60,399,697 43,899,670 Weighted average common shares outstanding, diluted 63,806,158 43,903,738 60,399,697 43,899,670 Comprehensive loss: Â Â Â Â Net Income (Loss) $ (15,499) $ (9,064) $ (51,780) $ (23,956) Other comprehensive gain (loss): Â Â Â Â Unrealized gain (loss) on marketable securities 508 (5) 277 38 Total other comprehensive gain (loss) 508 (5) 277 38 Total comprehensive loss $ (14,991) $ (9,069) $ (51,503) $ (23,918) X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5 + Details Name: us-gaap_ComprehensiveIncomeNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_ComprehensiveIncomeNetOfTaxAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_GeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting

Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_NonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(3) -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of other comprehensive income (loss) attributable to parent entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(3) -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 11 R5.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Changes in Stockholders' Equity - USD ($) $ in Thousands Total Common Stock [Member] Additional Paid-in Capital [Member] Accumulated Deficit [Member] Accumulated Other Comprehensive Gain (Loss) [Member] Beginning balance at Dec. 31, 2022 $ 110,903 $ 43 $ 262,496 $ (151,605) $ (31) Beginning balance, shares at Dec. 31, 2022 Â 43,269,200 Â Â Â Stock-based compensation expense 1,833 Â 1,833 Â Â Unrealized gain (loss) on marketable securities 31 Â Â Â Â 31 Net loss (6,526) Â Â (6,526) Â Ending balance at Mar. 31, 2023 106,241 $ 43 264,329 (158,131) Â Ending balance, shares at Mar. 31, 2023 Â 43,269,200 Â Â Â Beginning balance at Dec. 31, 2022 110,903 $ 43 262,496 (151,605) (31) Beginning balance, shares at Dec. 31, 2022 Â 43,269,200 Â Â Â Unrealized gain (loss) on marketable securities 38 Â Â Â Â Net loss (23,956) Â Â Â Â Ending balance at Sep. 30, 2023 92,712 $ 43 268,223 (175,561) 7 Ending balance, shares at Sep. 30, 2023 Â 43,905,903 Â Â Â Beginning balance at Mar. 31, 2023 106,241 $ 43 264,329 (158,131) Â Beginning balance, shares at Mar. 31, 2023 Â 43,269,200 Â Â Â Stock-based compensation expense 2,043 Â 2,043 Â Â Unrealized gain (loss) on marketable securities 12 Â Â Â 12 Net loss (8,366) Â Â (8,366) Â Ending balance at Jun. 30, 2023 99,930 $ 43 266,372 (166,497) 12 Ending balance, shares at Jun. 30, 2023 Â 43,269,200 Â Â Â Exercise of stock options 24 Â 24 Â Â Exercise of stock options, shares Â 8,300 Â Â Â Stock-based compensation expense 1,821 Â 1,821 Â Â Exercise of warrants 6 Â 6 Â Â Exercise of warrants, shares Â 628,403 Â Â Â Unrealized gain (loss) on marketable securities (5) Â Â Â (5) Net loss (9,064) Â Â (9,064) Â Ending balance at Sep. 30, 2023 92,712 $ 43 268,223 (175,561) 7 Ending balance, shares at Sep. 30, 2023 Â 43,905,903 Â Â Â Beginning balance at Dec. 31, 2023 81,720 $ 43 270,150 (188,554) 81 Beginning balance, shares at Dec. 31, 2023 Â 43,909,069 Â Â Â Issuance of common stock, net 161,756 $ 20 161,736 Â Â Issuance of common stock, net, shares Â 19,736,842 Â Â Â Vesting of restricted stock units Â $ 1 (1) Â Â Vesting of restricted stock units, shares Â 153,750 Â Â Â Exercise of stock options, shares Â 356 Â Â Â Stock-based compensation expense 2,128 Â 2,128 Â Â Unrealized gain (loss) on marketable securities (106) Â Â Â (106) Net loss (14,654) Â Â (14,654) Â Ending balance at Mar. 31, 2024 230,844 $ 64 434,013 (203,208) (25) Ending balance, shares at Mar. 31, 2024 Â 63,800,017 Â Â Â Beginning balance at Dec. 31, 2023 $ 81,720 $ 43 270,150 (188,554) 81 Beginning balance, shares at Dec. 31, 2023 Â 43,909,069 Â Â Â Exercise of stock options, shares 6,967 Â Â Â Â Unrealized gain (loss) on marketable securities $ 277 Â Â Â Â Net loss (51,780) Â Â Â Â Ending balance at Sep. 30, 2024 198,400 $ 64 $ 438,312 (240,334) 358 Ending balance, shares at Sep. 30, 2024 Â 63,806,628 Â Â Â Beginning balance at Mar. 31, 2024 230,844 $ 64 434,013 (203,208) (25) Beginning balance, shares at Mar. 31, 2024 Â 63,800,017 Â Â Â Exercise of stock options 11 Â 11 Â Â Exercise of stock options, shares Â 2,500 Â Â Â Stock-based compensation expense 2,301 Â 2,301 Â Â Unrealized gain (loss) on marketable securities (125) Â Â Â (125) Net loss (21,627) Â Â (21,627) Â Ending balance at Jun. 30, 2024 211,404 $ 64 436,325 (224,835) (150) Ending balance, shares at Jun. 30, 2024 Â 63,802,517 Â Â Â Exercise of stock options 30 Â 30 Â Â Exercise of stock options, shares Â 4,111 Â Â Â Stock-based compensation expense 1,957 Â 1,957 Â Â Unrealized gain (loss) on marketable securities 508 Â Â Â Â 508 Net loss (15,499) Â Â (15,499) Â Ending balance at Sep. 30, 2024 $ 198,400 $ 64 $ 438,312 $ (240,334) $ 358 Ending balance, shares at Sep. 30, 2024 Â 63,806,628 Â Â Â Â X - DefinitionNumber of shares of issued as a result of the exercise of warrants. + ReferencesNo definition available. + Details Name: lrmr_StockIssuedDuringPeriodSharesExerciseOfWarrants Namespace Prefix: lrmr_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionValue of stock issued as a result of the exercise of warrants. + ReferencesNo definition available. + Details Name: lrmr_StockIssuedDuringPeriodValueExerciseOfWarrants Namespace Prefix: lrmr_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(3) -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued which are neither cancelled nor held in the treasury. + ReferencesNo definition available. + Details Name: us-gaap_SharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionTotal number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAggregate value of stock related to Restricted Stock Awards issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock issued as a result of the exercise of stock options. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -

URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 12 R6.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Cash flows from operating activities: Â Â Net loss $ (51,780) $ (23,956) Adjustments to reconcile net loss to net cash used in operating activities: Â Â Stock-based compensation expense 6,386 5,697 Lease expense (132) (58) Depreciation expense 241 230 Amortization of premium on marketable securities (4,074) (1,210) Changes in operating assets and liabilities: Â Â Prepaid expenses and other current assets (6,164) (579) Accounts payable 403 (930) Accrued expenses 6,137 (3,314) Other assets 38 4 Net cash used in operating activities: (48,945) (24,116) Cash flows from investing activities: Â Â Purchase of property and equipment (336) Â Purchases of marketable securities (189,248) (66,268) Maturities and sales of marketable securities 85,000 102,250 Net cash provided by (used in) investing activities (104,584) 35,982 Cash flows from financing activities: Â Â Proceeds from issuance of equity securities, net of issuance costs 161,806 Â Proceeds from exercise of stock options and warrants 41 30 Net cash provided by financing activities 161,847 30 Net increase in cash, cash equivalents and restricted cash 8,318 11,896 Cash, cash equivalents and restricted cash at beginning of period 28,088 28,164 Cash, cash equivalents and restricted cash at end of period 36,406 40,060 Supplemental disclosure of non-cash investing and financing activities: Â Â Offering costs included in accounts payable and accrued expense 50 Â Leased assets obtained in exchange for new operating lease liabilities $ 465 $ 452 X - DefinitionThe amount of lease expense, both cash and non-cash, related to operating leases. + ReferencesNo definition available. + Details Name: lrmr_CashAndNonCashOperatingLeaseExpense Namespace Prefix: lrmr_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of offering costs that were incurred, but not yet paid, during the period. + ReferencesNo definition available. + Details Name: lrmr_OfferingCostsIncludedInAccountsPayableAndAccruedExpense Namespace Prefix: lrmr_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from the exercise of options under share-based payment arrangements and from holders exercising their stock warrants. + ReferencesNo definition available. + Details Name: lrmr_ProceedsFromStockOptionsAndWarrantExercises Namespace Prefix: lrmr_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3 + Details Name: us-gaap_AmortizationOfDebtDiscountPremium Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_Depreciation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInOtherNoncurrentAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11 + Details Name: us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_ProceedsFromIssuanceOrSaleOfEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10:

http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase in right-of-use asset obtained in exchange for operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 13 R7.htm IDEA: XBRL DOCUMENT v3.24.3 Pay vs Performance Disclosure - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Jun. 30, 2024 Mar. 31, 2024 Sep. 30, 2023 Jun. 30, 2023 Mar. 31, 2023 Sep. 30, 2024 Sep. 30, 2023 Pay vs Performance Disclosure Â Â Â Â Â Â Â Â Â Net Income (Loss) $ (15,499) $ (21,627) $ (14,654) $ (9,064) $ (8,366) $ (6,526) $ (51,780) $ (23,956) X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details Name: ecd_PvpTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 14 R8.htm IDEA: XBRL DOCUMENT v3.24.3 Insider Trading Arrangements 3 Months Ended Sep. 30, 2024 Trading Arrangements, by Individual Â Rule 10b5-1 Arrangement Adopted false Non-Rule 10b5-1 Arrangement Adopted false Rule 10b5-1 Arrangement Terminated false Non-Rule 10b5-1 Arrangement Terminated false X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TradingArrByIndTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 15 R9.htm IDEA: XBRL DOCUMENT v3.24.3 Description of Business and Basis of Presentation 9 Months Ended Sep. 30, 2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â Description of Business and Basis of Presentation 1.Description of Business and Basis of Presentation Larimar Therapeutics, Inc., together with its subsidiary (the â€œCompanyâ€ or â€œLarimarâ€), is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Larimar's lead product candidate, nomlabofusp (nomlabofusp is the International Nonproprietary Name and the United States Adopted Name for CTI-1601), is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin ("FXN"), an essential protein, to the mitochondria of patients with Friedreichâ€™s ataxia ("FA"). FA is a rare, progressive and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. The Company has completed two phase 1 studies of nomlabofusp, a Phase 2 dose exploration study, and initiated an open label extension study (â€œOLEâ€) in patients with FA in January, 2024.

This OLE study is ongoing and continues to enroll patients. In May 2021, after reporting positive top-line data from the Companyâ€™s Phase 1 FA program, the U.S. Food and Drug Administration (â€œFDAâ€) placed a clinical hold on the Companyâ€™s nomlabofusp clinical program after the Company notified the FDA of mortalities at the highest dose levels of a 26-week non-human primate toxicology study that was designed to support extended dosing of patients with nomlabofusp. In September 2022, the FDA lifted its full clinical hold on the nomlabofusp program and imposed a partial clinical hold. In May 2023, the Company announced top-line data from its completed 25 mg cohort of a Phase 2, four-week, dose exploration trial of nomlabofusp in patients with FA and provided a complete response to the FDA in June 2023, which included unblinded safety, pharmacokinetic ("PK"), and pharmacodynamic ("PD") data from the Phase 2 trialâ€™s completed 25 mg cohort.In June 2023, the Company met with the FDA. Following that meeting, the Company submitted a complete response to the FDAâ€™s partial clinical hold that included unblinded safety, PK and frataxin data from the Phase 2 trialâ€™s completed 25 mg cohort. In July 2023, following the FDAâ€™s review of the Company's complete response to the partial clinical hold, the FDA cleared initiation of a second cohort at 50 mg of our four-week, placebo-controlled, Phase 2 dose exploration trial and initiation of an OLE study with daily dosing of 25 mg. In February 2024, the Company reported positive top-line data and successful completion of their four-week, placebo-controlled Phase 2 dose exploration study of nomlabofusp in participants with FA. Nomlabofusp was generally well tolerated throughout the four-week treatment periods, had a predictable pharmacokinetic profile and led to dose dependent increases in FXN levels in all evaluated tissues (skin and buccal cells) after daily dosing of 14 days followed by every other day dosing until day 28 in the 25 mg and 50 mg cohorts. Participants in the 25 mg (n=13) and 50 mg (n=15) cohorts were randomized 2:1 to receive subcutaneous injections of nomlabofusp or placebo. In May 2024 the FDA removed the partial clinical hold on the development of nomlabofusp. Patients who completed treatment in the Company's Phase 2 dose exploration study or who previously completed a prior clinical trial of nomlabofusp are eligible to screen and possibly participate in the OLE study. Current patients in the OLE study either participated in the Phase 2 dose exploration study and/or a previous clinical trial.In March 2024, the Company dosed the first patient in its OLE trial discussed above, evaluating daily subcutaneous injections of 25 mg of nomlabofusp self-administered or administered by a caregiver. This study is ongoing with seven sites activated and additional patients are continuing to be enrolled and dosed. Participants who completed treatment in the Phase 2 dose exploration study, or who previously completed a prior clinical trial of nomlabofusp, are potentially eligible to screen for the OLE study. The OLE study will evaluate the safety and tolerability, pharmacokinetics, and frataxin levels in peripheral tissues as well as other exploratory pharmacodynamic markers (lipid profiles and gene expression data) following long-term subcutaneous administration of nomlabofusp. In addition, following the completion of enrollment, as well as at least one participant completing one year of dosing, clinical assessments collected during the study will be compared to data from a matched control arm derived from participants in the Friedreichâ€™s Ataxia Clinical Outcome Measures Study ("FACOMS") database. Dose escalation to the 50 mg dose in the OLE study is currently planned following further characterization of the frataxin PD at the 25 mg dose. The Company currently expects to provide a nomlabofusp development program update in mid-December 2024 that will include available safety, pharmacokinetic and frataxin data as well as available clinical outcome observations from patients currently receiving the daily 25 mg dose of nomlabofusp for approximately 30 to 180 days in the ongoing OLE study. An update on enrollment and plans on the OLE study will also be provided.Separately, the Company has had discussions with the FDA regarding the use of tissue FXN levels as a novel surrogate endpoint. The FDA acknowledged that frataxin deficiency appears to be critical to the pathogenic mechanism of FA, and that there continues to be an unmet need for treatments for FA patients that address the underlying disease pathophysiology. The Company intends to pursue an accelerated approval using FXN levels, supportive PD and clinical information, and safety data from the OLE study, along with additional non-clinical pharmacology information needed to support the novel surrogate endpoint approach. The Company is on track to expand the nomlabofusp clinical program into adolescent (12-17 years old) and pediatric (2-11 years old) patients with FA. The Company expects to initiate a PK run-in study in adolescents by the end of this year and expects to transition these study participants into the ongoing OLE study after assessment of safety and exposure data in the adolescent cohort. The run-in-study will enroll 12-15 adolescent patients and 12-15 pediatric patients who will be randomized 2:1 to receive either nomlabofusp or placebo daily. The Company is also planning the initiation of a global confirmatory/registration study by mid-2025 with potential sites in the U.S., Europe, the U.K., Canada and Australia. The Biologics License Application ("BLA") filing is targeted in the second half of 2025 to support potential accelerated approval. On May 30, 2024, the Company announced that the FDA's Center for Drug Evaluation and Research ("CDER") had selected nomlabofusp as one of a few programs for participation in the Support for Clinical Trials Advancing Rare Disease Therapeutics ("START") Pilot Program. The objective of the program is to accelerate the development of drugs for rare diseases that lead to significant disability or death by facilitating frequent advice and regular communication with the FDA staff to expedite the review process of biologics and drugs. In September 2024, the Company received the Medicines and Healthcare Regulatory Agency ("MHRA") Innovative Licensing and Access Pathway ("ILAP") aimed at potentially accelerating access and reducing the time to market in the United Kingdom.The Company is subject to risks and uncertainties common to pre-commercial companies in the biotechnology industry, including, but not limited to, development and commercialization by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with governmental regulations, failure to secure regulatory approval for its drug candidates or any other product candidates and the ability to secure additional capital to fund its operations. Product candidates under development will require extensive non-clinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel, infrastructure and extensive compliance-reporting capabilities. Even if the Company's drug development efforts are successful, it is uncertain when, if ever, it will realize significant revenue from product sales.Basis of PresentationThe condensed consolidated financial statements include the accounts of Larimar and its wholly owned subsidiary. All intercompany balances and transactions have been eliminated. The accompanying condensed consolidated financial statements have been prepared in conformity with Generally Accepted Accounting Principles ("GAAP").The condensed consolidated balance sheet as of December 31, 2023 was derived from the Companyâ€™s audited financial statements but does not include all disclosures required by GAAP. The accompanying unaudited condensed consolidated financial statements as of September 30, 2024 and for the three and nine months ended September 30, 2024 and 2023, have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (â€œSECâ€) for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. However, the Company believes that the disclosures are adequate to make the information presented not misleading. These condensed consolidated financial statements should be read in conjunction with the Companyâ€™s audited consolidated financial statements and the notes thereto for the year ended December 31, 2023 included in the Companyâ€™s Annual Report on Form 10-K filed with the SEC on March 14, 2024 and the Company's Quarterly Reports on Form 10-Q filed with the SEC on May 9, 2024 and August 8, 2024.In the opinion of management, all adjustments, consisting only of normal recurring adjustments necessary for a fair statement of the Companyâ€™s condensed consolidated financial position as of September 30, 2024, condensed consolidated results of operations for the three and nine months ended September 30, 2024 and condensed consolidated statement of cash flows for the nine months ended September 30, 2024 have been made. The results of operations for the three and nine months ended September 30, 2024 are not necessarily indicative of the results of operations that may be expected for the year ending December 31, 2024.Liquidity and Capital ResourcesThe Companyâ€™s condensed consolidated financial statements have been presented on the basis that it will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business.Since its inception, the Company has incurred significant recurring operating losses and negative cash flows from operations. The Company has incurred net losses of $51.8 million and $24.0 million for the nine months ended September 30, 2024 and 2023, respectively. In addition, as of September 30, 2024, the Company had an accumulated deficit of $240.3 million. The Company expects to continue to generate operating losses for the foreseeable future. As of September 30, 2024, the Company had approximately $203.7 million of cash, cash equivalents and marketable securities available for use to fund its operations and capital requirements.The Company has funded its operations to date primarily with proceeds from sales of common stock and proceeds from the sale of prefunded warrants for the purchase of common stock, the acquisition in 2020 of cash, cash equivalents and marketable securities upon the merger with Zafgen, Inc. ("Zafgen") and, prior to the 2020 merger with Zafgen, capital contributions from Chondrial Holdings, LLC. In February 2024, the Company completed an underwritten public offering in which the Company issued and sold 19,736,842 shares of its common stock at a public offering price of $8.74 per share. The Company received net proceeds of approximately $161.8 million after deducting underwriting discounts, commissions and other offering expenses.In accordance with Accounting Standards Update (â€œASUâ€) No. 2014-15, "Disclosure of Uncertainties about an Entityâ€™s Ability to Continue as a Going Concern", the Company has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the Companyâ€™s ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are issued. As of the issuance date of these condensed consolidated financial statements, the Company expects its cash, cash equivalents and marketable securities will be sufficient to fund its forecasted operating expenses and capital expenditure requirements into 2026. If the timing of the Company's clinical assumptions are delayed, or if there are other forecasted assumption changes that negatively impact its operating plan, the Company could reduce expenditures in order to further extend cash resources. The Company has not yet commercialized any products and does not expect to generate revenue from the commercial sale of any products for several years, if at all. The Company expects that its research and development and general and administrative expenses will continue to increase, that sales and marketing expenses will become significant and, as a result, that it will need additional capital to fund its future operating and capital requirements. Unless and until the Company can generate substantial revenue, management continuously evaluates different strategies to obtain the required funding for future operations. These strategies include seeking additional funding through a combination of public or private equity offerings, debt or royalty financings, collaborations and licensing arrangements, strategic partnerships with pharmaceutical and/or larger biotechnology companies, or other sources. The incurrence of indebtedness would result in increased fixed payment obligations and the Company may be required to agree to certain restrictive covenants, such as limitations on its ability to incur additional debt, limitations on its ability to acquire, sell or license intellectual property rights, minimum required cash balances and other operating restrictions that could adversely impact the Company's ability to conduct its business. Any additional fundraising efforts may divert the Company's management from their day-to-day activities, which may adversely affect its ability to develop and commercialize its product candidates. There can be no assurance that the Company will be able to raise sufficient additional capital on acceptable terms, if at all. If such additional financing is not available on satisfactory terms, or is not available in sufficient amounts, or if the Company does not have sufficient authorized shares, the Company may be required to delay, limit, or eliminate the development of business opportunities and its ability to achieve its business objectives, its competitiveness, and its business, financial condition, and results of operations will be materially adversely affected. The Company could also be required to seek funds through arrangements with collaborative partners or otherwise at an earlier stage than otherwise would be desirable and it may be required to relinquish rights to some of its technologies or product candidates or otherwise agree to terms unfavorable to it, any of which may have a material adverse effect on the Company's business, operating results and prospects. In addition, geopolitical tensions, volatility of capital markets, and other adverse macroeconomic events, including those due to inflationary pressures, rising interest rates, banking instability, monetary policy changes and the ability of the U.S. government to manage federal debt limits as well as the potential impact of other health crises on the global financial markets may reduce the Company's ability to access capital, which could negatively affect its liquidity and ability to continue as a going concern. If the Company is unable to obtain sufficient funding when needed and/or on acceptable terms, the Company may be required to significantly curtail, delay or discontinue one or more of its research and development programs, the manufacture of clinical and commercial supplies, product portfolio expansion, pre commercialization efforts and/or commercial operations, which could adversely affect its business prospects, or the Company may be unable to continue operations. X - DefinitionThe entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContentReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 275 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/275/tableOfContentReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205/tableOfContent + Details Name: us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 16 R10.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies 9 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] Â Summary of Significant Accounting Policies 2.Summary of Significant Accounting PoliciesUse of EstimatesThe preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. This process involves reviewing open contracts and purchase orders, communicating with our personnel and outside vendors to identify services that have been performed on our behalf and estimating the level of service performed and the associated costs incurred for the services when we have not yet been invoiced or otherwise notified of the actual costs. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual of research and development expense, the recording as prepaid expense of payments made in advance of the actual provision of goods or services, valuation of stock-based awards and valuation of leases. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions.Research and Development CostsCosts associated with internal research and development and external research and development services, including drug development, clinical studies and non-clinical studies, are expensed as incurred. Research and development expenses include costs for salaries, employee benefits, subcontractors, facility-related expenses, depreciation, non-cash stock-based compensation, third-party license fees, laboratory supplies, and external costs of outside vendors engaged to conduct discovery, non-clinical and clinical development activities and clinical trials as well as to manufacture clinical trial materials, and other costs. The Company recognizes external research and development costs based on an evaluation of the progress to completion of specific tasks using information provided to the Company by its key service providers.Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. Such prepaid expenses are recognized as an expense when the goods have been delivered or the related services have been performed, or when it is no longer expected that the goods will be delivered, or the services rendered.Upfront payments, milestone payments and annual maintenance fees under license agreements are currently expensed in the period in which they are incurred.Patent CostsAll patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.Stock-Based CompensationThe Company measures all stock-based awards granted to employees and directors based on the fair value on the date of grant using the Black-Scholes option-pricing model. Compensation expense of those awards is recognized over the requisite service period, which is the vesting period of the respective award. Typically, the Company issues awards with only service-based vesting conditions and records the expense for these awards using the straight-line method. The Company accounts for forfeitures as they occur.The Company classifies stock-based compensation expense in its condensed consolidated statements of operations and comprehensive loss in the same manner in which the award recipientâ€™s payroll costs are classified or in which the award recipientâ€™s service payments are classified.Prior to May 28, 2020, the Company had been a private company and lacked company-specific historical and implied volatility information for its common stock. Prior to January 1, 2023, the Company estimated its expected common stock price volatility solely based on the historical volatility of publicly traded peer companies. Beginning on January 1, 2023, based on the availability of sufficient historical trading data of the Company's own common stock on the Nasdaq Global Market to calculate accurately its volatility, the Company began blending its volatility starting from June 2020 (following its merger with Zafgen in 2020) to the date of each stock-based award, and weighing the volatility of its peer group for the amount of time from May 31, 2020 backwards so that the blended volatility equals the expected term of the related stock-based award. The expected term of the Companyâ€™s stock options has been determined utilizing the â€œsimplifiedâ€ method for awards that qualify as â€œplain-vanillaâ€ options. The risk-

free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected dividend yield considers the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future.Net Loss Per ShareBasic net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period. Prior to August 11, 2023, basic shares outstanding includes the weighted average effect of the Companyâ€™s prefunded warrants issued in June 2020, the exercise of which requires little or no consideration for the delivery of shares of common stock. These prefunded warrants were exercised on August 11, 2023 and the Company received cash proceeds of less than $0.1 million. Accordingly, the 628,403 shares were issued upon the exercise of these warrants and are included in issued and outstanding common stock. Diluted net loss per share attributable to common stockholders is computed by dividing the diluted net loss attributable to common stockholders by the weighted average number of common shares, including potentially dilutive common stock equivalents assuming the dilutive effect of outstanding stock options, outstanding restricted stock units, and unvested restricted common shares, as determined using the treasury stock method. For periods in which the Company has reported net losses (all periods since inception), diluted net loss per common share attributable to common stockholders is the same as basic net loss per common share attributable to common stockholders, since dilutive common stock equivalents are not assumed to have been issued if their effect is antidilutive.The Company excluded 6,990,827 and 5,100,997 common stock equivalents outstanding as of September 30, 2024 and 2023, respectively, from the computation of diluted net loss per share for the three and nine months ended September 30, 2024 and 2023 because they had an anti-dilutive impact due to the net loss incurred for the periods presented. Recently Issued and Adopted Accounting Pronouncements From time to time, new accounting guidance is issued by the FASB or other standard setting bodies that is adopted by us as of the effective date or, in some cases where early adoption is permitted, in advance of the effective date. We have assessed the recently issued guidance that is not yet effective and believe the new guidance will not have a material impact on the condensed consolidated results of operations, cash flows or financial position.In November 2023, the FASB issued new guidance designed to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant expenses per segment. The new standard must be adopted on a retrospective basis. We intend to adopt the new guidance for the fiscal year ending December 31, 2024, and subsequent interim periods. Given that the accounting standard update affects disclosures exclusively, we do not anticipate that its adoption will have a material impact on our consolidated financial statements.In December 2023, the FASB issued new guidance designed to improve income tax disclosure requirements primarily through increased disaggregation disclosures within the effective tax rate reconciliation as well as enhanced disclosures on income taxes paid. The guidance is effective for all fiscal years beginning after December 15, 2024. The new standard can be adopted on a prospective basis with an option for it to be adopted retrospectively and early adoption is permitted. We are currently evaluating this guidance to determine its impact on our consolidated financial statements. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for all significant accounting policies of the reporting entity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent + Details Name: us-gaap_SignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 17 R11.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value Measurements and Marketable Securities 9 Months Ended Sep. 30, 2024 Fair Value Disclosures [Abstract] Â Fair Value Measurements and Marketable Securities 3.Fair Value Measurements and Marketable SecuritiesFair Value MeasurementsThe Companyâ€™s assets and liabilities that are measured at fair value on a recurring basis as of September 30, 2024 and December 31, 2023 are measured in accordance with the standards of ASC 820, "Fair Value Measurements and Disclosures", which establishes a three-level valuation hierarchy for measuring fair value and expands financial statement disclosures about fair value measurements. The valuation hierarchy is based on the transparency of inputs to the valuation of an asset or liability as of the measurement date. The three levels are defined as follows: Â Level â€“ 1 Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. Â Â Level â€“ 2 Inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. Â Â Level â€“ 3 Inputs to the valuation methodology are unobservable and significant to the fair value measurement. The Companyâ€™s financial instruments consist primarily of cash, cash equivalents, marketable securities, accounts payable and accrued liabilities. For accounts payable and accrued liabilities, the carrying amounts of these financial instruments as of September 30, 2024 and December 31, 2023 were considered representative of their fair values due to their short term to maturity. The following tables summarize the Companyâ€™s cash equivalents and marketable securities as of September 30, 2024 and December 31, 2023:Â Â Â Total Â Â QuotedPrices inActiveMarkets (Level 1) Â Â SignificantOtherObservableInputs (Level 2) Â Â SignificantUnobservableInputs (Level 3) Â Â Â (in thousands) Â September 30, 2024 Â Â Â Â Â Â Â Â Â Â Â Â Cash equivalents: Â Â Â Â Â Â Â Â Â Â Â Â Money market funds invested in government securities Â $ 31,338 Â Â $ 31,338 Â Â $ â€” Â Â $ â€” Â Total cash equivalents Â Â 31,338 Â Â Â 31,338 Â Â Â â€” Â Â Â â€” Â Â Â Â Â Â Â Â Â Â Â Â Marketable securities: Â Â Â Â Â Â Â Â Â Â Â Â U.S. Treasury Bills Â Â 10,944 Â Â Â 10,944 Â Â Â â€” Â Â Â â€” Â U.S. Government securities Â Â 157,696 Â Â Â â€” Â Â Â 157,696 Â Â Â â€” Â Total marketable securities Â Â 168,640 Â Â Â 10,944 Â Â Â 157,696 Â Â Â â€” Â Total cash equivalents and marketable securities Â $ 199,978 Â Â $ 42,282 Â Â $ 157,696 Â Â $ â€” Â Â Â Â Â Â Â Â Â Â Â Â December 31, 2023 Â Â Â Â Â Â Â Â Â Â Â Â Cash equivalents: Â Â Â Â Â Â Â Â Â Â Â Â Money market funds invested in government securities Â $ 24,701 Â Â $ 24,701 Â Â $ â€” Â Â $ â€” Â Total cash equivalents Â Â 24,701 Â Â Â 24,701 Â Â Â â€” Â Â Â â€” Â Â Â Â Â Â Â Â Â Â Â Â Marketable securities: Â Â Â Â Â Â Â Â Â Â Â Â U.S. Treasury Bills Â Â 17,334 Â Â Â 17,334 Â Â Â â€” Â Â Â â€” Â U.S. Government securities Â Â 35,719 Â Â Â â€” Â Â Â 35,719 Â Â Â â€” Â Corporate bonds Â Â 6,988 Â Â Â â€” Â Â Â 6,988 Â Â Â â€” Â Total marketable securities Â Â 60,041 Â Â Â 17,334 Â Â Â 42,707 Â Â Â â€” Â Total cash equivalents and marketable securities Â $ 84,742 Â Â $ 42,035 Â Â $ 42,707 Â Â $ â€” Â The accrued interest receivable related to the Companyâ€™s investments was $0.9 million and $0.3 million as of September 30, 2024 and December 31, 2023, respectively, and is included in prepaid expenses and other current assets on the condensed consolidated balance sheet. The Company classifies its money market funds and U.S. treasury bills, which are valued based on quoted market prices in active markets with no valuation adjustment, as Level 1 assets within the fair value hierarchy.The Company classifies its investments in U.S. government and agency securities, corporate commercial paper, and corporate bonds, if any, as Level 2 assets within the fair value hierarchy. The fair values of these investments are estimated by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income- and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data and other observable inputs.As of September 30, 2024 and December 31, 2023, no allowances for credit losses for the Companyâ€™s investments were recorded. During the three and nine months ended September 30, 2024 and 2023, the Company did not recognize any impairment losses related to investments.Marketable securitiesThe following table summarizes the Company's marketable securities as of September 30, 2024 and December 31, 2023. Â Â Â AmortizedCost Â Â GrossUnrealizedGains Â Â GrossUnrealized Losses Â Â Fair Value Â Â Â (in thousands) Â September 30, 2024 Â Â Â Â Â Â Â Â Â Â Â Â Assets: Â Â Â Â Â Â Â Â Â Â Â Â U.S. Treasury Bills Â $ 10,937 Â Â $ 7 Â Â $ â€” Â Â $ 10,944 Â U.S. Government securities Â Â 157,345 Â Â Â 351 Â Â Â â€” Â Â Â 157,696 Â Total marketable securities Â $ 168,282 Â Â $ 358 Â Â $ â€” Â Â $ 168,640 Â Â Â Â Â Â Â Â Â Â Â Â December 31, 2023 Â Â Â Â Â Â Â Â Â Â Â Â Assets: Â Â Â Â Â Â Â Â Â Â Â Â U.S. Treasury Bills Â $ 17,330 Â Â $ 4 Â Â $ â€” Â Â $ 17,334 Â U.S. Government securities Â Â 35,653 Â Â Â 66 Â Â Â â€” Â Â Â 35,719 Â Corporate bonds Â Â 6,977 Â Â Â 11 Â Â Â â€” Â Â Â 6,988 Â Total marketable securities Â $ 59,960 Â Â $ 81 Â Â $ â€” Â Â $ 60,041 Â X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 107 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 940 -SubTopic 820 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1 + Details Name: us-gaap_FairValueDisclosuresTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 18 R12.htm IDEA: XBRL DOCUMENT v3.24.3 Prepaid Expenses and Other Current Assets 9 Months Ended Sep. 30, 2024 Prepaid Expense and Other Assets [Abstract] Â Prepaid Expenses and Other Current Assets 4.Prepaid Expenses and Other Current AssetsPrepaid expenses and other current assets consisted of the following: Â Â Â September 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Â Â (in thousands) Â Prepaid research and development expenses Â $ 8,192 Â Â $ 1,994 Â Interest receivable Â Â 943 Â Â Â 332 Â Prepaid insurance Â Â 43 Â Â Â 682 Â Other prepaid expenses and other assets Â Â 371 Â Â Â 377 Â Â $ 9,549 Â Â $ 3,385 Â X - DefinitionThe entire disclosure for prepaid expenses and other current assets. + ReferencesNo definition available. + Details Name: lrmr_PrepaidExpensesAndOtherCurrentAssetsTextBlock Namespace Prefix: lrmr_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 19 R13.htm IDEA: XBRL DOCUMENT v3.24.3 Fixed Assets 9 Months Ended Sep. 30, 2024 Assets [Abstract] Â Fixed Assets 5.Fixed AssetsFixed assets, net consisted of the following:Â Â Â Â Â September 30, Â Â December 31, Â Â Â Useful Life Â 2024 Â Â 2023 Â Â Â Â Â (in thousands) Â Computer equipment Â 5 years Â Â $ 117 Â Â $ 117 Â Lab equipment Â 5 years Â Â 1,528 Â Â Â 1,192 Â Furniture and fixtures Â 7 years Â Â 555 Â Â Â 555 Â Leasehold improvements Â lease term Â Â 45 Â Â Â 45 Â Â Â Â Â 2,245 Â Â Â 1,909 Â Less: Accumulated depreciation Â Â Â Â (1,466) Â Â (1,225) Â Â Â $ 779 Â Â $ 684 Â Depreciation expense was $0.1 million and $0.2 million for the three and nine months ended September 30, 2024, respectively. Depreciation expense was $0.1 million and $0.2 million for the three and nine months ended September 30, 2023, respectively. In addition, for the three and nine months ended September 30, 2024, there was less than $0.1 million of depreciation in each period related to sublet assets recorded as other expense. For the three and nine months ended September 30, 2023, there was less than $0.1 million and $0.1 million, respectively, of depreciation related to sublet assets recorded as other expense. X - ReferencesNo definition available. + Details Name: us-gaap_AssetsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/360/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 6 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 7 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7 + Details Name: us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 20 R14.htm IDEA: XBRL DOCUMENT v3.24.3 Accrued Expenses 9 Months Ended Sep. 30, 2024 Payables and Accruals [Abstract] Â Accrued Expenses 6.Accrued ExpensesAccrued expenses consisted of the following: Â Â Â September 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Â Â (in thousands) Â Accrued research and development expenses Â $ 10,329 Â Â $ 4,594 Â Accrued payroll and related expenses Â Â 2,377 Â Â Â 2,365 Â Accrued other Â Â 867 Â Â Â 427 Â Â $ 13,573 Â Â $ 7,386 Â X - DefinitionThe entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 720 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1 + Details Name: us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 21 R15.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Equity and Stock Options 9 Months Ended Sep. 30, 2024 Stockholders' Equity Note [Abstract] Â Stockholders' Equity and Stock Options 7.Stockholdersâ€™ Equity and Stock OptionsCommon Stock and Prefunded WarrantsOn May 28, 2020, the Company entered into a securities purchase agreement with certain accredited investors (the â€œPurchasersâ€) for the sale by the Company in a private placement of 6,105,359 shares of the Companyâ€™s common stock and prefunded warrants to purchase an aggregate of 628,403 shares of the Companyâ€™s common stock, for a price of $11.88 per share of the common stock and $11.87 per prefunded warrant. The prefunded warrants were exercisable at an exercise price of $0.01 and were exercisable indefinitely. In August 2023, the 628,403 shares of prefunded warrants were exercised and the Company received cash proceeds of six thousand two hundred and eighty-four dollars. The private placement closed on June 1, 2020. The aggregate gross proceeds for the issuance and sale of the common stock and

prefunded warrants were $80.0 million, transaction costs totaled $4.6 million and resulted in net proceeds of $75.4 million. The Companyâ€™s Registration Statement on Form S-3, filed with the SEC on June 26, 2020, registered the resale of 6,105,359 shares of common stock sold and the 628,403 shares of common stock underlying the prefunded warrants. MTS Health Partners served as placement agent to the Company in connection with the private placement. As partial compensation for these services, the Company issued MTS Health Partners 35,260 shares of common stock. As of September 30, 2024, the Companyâ€™s Ninth Amended and Restated Certificate of Incorporation, as amended, authorized the Company to issue up to 115,000,000 shares of common stock, par value $0.001 per share, of which 63,806,628 shares were issued and outstanding, and up to 5,000,000 shares of undesignated preferred stock, par value $0.001 per share, of which no shares were issued or outstanding. The voting, dividend and liquidation rights of the holders of the Companyâ€™s common stock are subject to and qualified by the rights, powers and preferences of the holders of the preferred stock. Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Companyâ€™s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the board of directors of the Company (the â€œBoardâ€), if any. No cash dividends have been declared or paid to date.In February 2024, the Company completed an underwritten public offering in which the Company issued and sold 19,736,842 shares of its common stock at a public offering price of $8.74 per share. The Company received net proceeds of approximately $161.8 million after deducting underwriting discounts, commissions and other offering expenses.ATM AgreementIn November 2022, the Company entered into a Sales Agreement (the "2022 ATM Agreement") with Guggenheim Securities, LLC as a sales agent in connection with the establishment of an â€œat-the-marketâ€ offering program under which the Company could sell up to an aggregate of $50 million of shares of common stock (the â€œ2022 ATM Sharesâ€) from time to time. In February 2024, in connection with the underwritten public offering described above, the Company terminated the 2022 ATM Agreement. No ATM Shares were ever sold pursuant to the 2022 ATM Agreement.In May 2024, the Company entered into a sales agreement (the "ATM Agreement") with Guggenheim Securities, LLC in connection with the establishment of an â€œat-the-marketâ€ offering program under which the Company could sell up to an aggregate of $100 million of shares of common stock (the â€œATM Sharesâ€) from time to time. To date, no sales of common stock have been made under this ATM Agreement.2020 Equity Incentive PlanThe Board adopted the 2020 Equity Incentive Plan (the "2020 Plan") on July 16, 2020 and the stockholders of the Company approved the 2020 Plan on September 29, 2020. The 2020 Plan replaced the predecessor plans (the "Prior Plans") that the Company assumed following its merger with Zafgen in May 2020. Options outstanding under the Prior Plans will remain outstanding, unchanged, and subject to the terms of the Prior Plans and the respective award agreements, and no further awards will be made under the Prior Plans. However, if any award previously granted under the Prior Plans, expires, terminates, is canceled, or is forfeited for any reason after the approval of the 2020 Plan, the shares subject to that award will be added to the 2020 Plan share pool so that they can be utilized for new grants under the 2020 Plan.The 2020 Plan provides for the grant of incentive stock options (â€œISOsâ€), nonstatutory stock options (â€œNSOsâ€), stock appreciation rights, restricted stock awards, restricted stock unit awards, and cash or other stock-based awards. ISOs may be granted only to the Companyâ€™s employees, including the Companyâ€™s officers, and the employees of the Companyâ€™s affiliates. All other awards may be granted to the Companyâ€™s employees, including the Companyâ€™s officers, the Companyâ€™s non-employee directors and consultants, and the employees and consultants of the Companyâ€™s affiliates.The maximum number of shares that may be issued in respect of any awards under the 2020 Plan is the sum of: (i) 1,700,000 shares plus (ii) an annual increase on January 1, 2021 and each anniversary of such date thereafter through January 1, 2030, equal to the lesser of (A) 4% of the shares issued and outstanding on the last day of the immediately preceding fiscal year, or (B) such smaller number of shares as determined by the Board (collectively, the â€œPlan Limitâ€). The maximum aggregate number of shares that may be issued under the 2020 Plan is 8,000,000 over the ten-year term of the 2020 Plan. As permitted by the 2020 Plan, the Company added 1,756,363 and 1,730,768 shares available for grant to the 2020 Plan on January 1, 2024 and January 1, 2023, respectively. As of September 30, 2024, 779,926 shares of common stock were available for grant under the 2020 Plan.During the twelve months ended December 31, 2023, options to purchase 224,437 shares issued under the Prior Plans were cancelled and became available for grant under the 2020 Plan. During the nine months ended September 30, 2024, options to purchase 1,242 shares issued under the Prior Plans were cancelled and became available for grant under the 2020 Plan. At September 30, 2024, 344,683 options under the Prior Plans remained outstanding at prices ranging from $11.88 to $445.80, and, if unexercised, will return to the 2020 Plan no later than July 15, 2030.Stock Option ValuationThe following table presents, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted to employees:Â Â Â September 30, Â Â 2024 Risk-free interest rate Â 4.12% Expected term (in years) Â 6.22 Expected volatility Â 96% Dividend yield Â 0.00% Stock OptionsThe following table summarizes the Companyâ€™s stock option activity for the nine months ended September 30, 2024 (amounts in millions, except for share, contractual term, and per share data):Â Â Â

assure their performance under the sublease. If there are no uncured events of default under the sublease, the amount of this security deposit decreases over time to $0.4 million on the sixth anniversary of the Sublease. The Company records sublease income on this sublease on a straight-line basis as a component of other income/(expense).Lab SpaceOn November 5, 2018, the Company entered into an operating lease for office and lab space in Philadelphia, Pennsylvania, effective as of January 1, 2019, and expiring on December 31, 2020 with an option to extend the lease for two additional years. On August 4, 2020, the Company executed the first option to extend the lease for an additional year, expiring on December 31, 2021. On August 9, 2021, the Company executed the remaining option to extend the lease for an additional year, expiring on December 31, 2022. In September 2023, the Company extended this lease for an additional year with the option to terminate with four months' notice. On March 28, 2024, the Company gave the requisite notice and vacated the property in May 2024.On October 16, 2023, the Company entered into an operating lease for lab space in King of Prussia, Pennsylvania for a period of four years. Due to required tenant improvements to be completed by the landlord, the Company did not take immediate possession of the leased property. The actual lease term commenced on May 10, 2024. Upon commencement of the lease term, the Company recorded a right of use asset and lease liability of $0.5 million which are reflected in these condensed consolidated financial statements.Lease ExpenseExpense arising from operating leases was $0.1 million and $0.4 million during the three and nine months ended September 30, 2024, respectively. Expense arising from operating leases was $0.1 million and $0.2 million during the three and nine months ended September 30, 2023, respectively. For operating leases, the weighted-average remaining lease term for leases at September 30, 2024 and December 31, 2023 was 4.7 and 5.5 years, respectively. For operating leases, the weighted average discount rate for leases at September 30, 2024 and December 31, 2023 was 11.0%. The Company has not entered into any financing leases. Maturities of lease liabilities due under these lease agreements as of September 30, 2024 are as follows: Â Â Â Operating Â (in thousands) Leases Â Three months ending December 31, 2024 Â $ 383 Â Year ended December 31, 2025 Â Â 1,543 Â Year ended December 31, 2026 Â Â 1,473 Â Year ended December 31, 2027 Â Â 1,267 Â Year ended December 31, 2028 Â Â 1,189 Â Thereafter Â Â 959 Â Total lease payments Â Â 6,814 Â Less: imputed interest Â Â (1,452) Present value of lease liabilities Â $ 5,362 Â Â Legal ProceedingsThe Company is not currently a party to any litigation, nor is management aware of any pending or threatened litigation against the Company, that it believes would materially affect the Company's business, operating results, financial condition or cash flows. X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 23 R17.htm IDEA: XBRL DOCUMENT v3.24.3 Related Party 9 Months Ended Sep. 30, 2024 Related Party Transactions [Abstract] Â Related Party 9.Related PartyÂ In May 2024, the Company entered into an agreement with the Friedreichâ€™s Ataxia Research Alliance (FARA) to join the TRACK-FA Neuroimaging Consortium that includes pharmaceutical, biotechnology, academic and clinical partners. The consortium will conduct a natural history study designed to establish disease-specific neuroimaging biomarkers to track disease progression in the brain and spinal cord and provide a basis for utilizing these biomarkers in clinical trials. As an industry partner, the Company will help fund the study and contribute to the study design, research activities, and analysis. The Company will have access to all study data for use in its regulatory filings, as appropriate. During the three and nine months ended September 30, 2024, the Company incurred less than $0.1 million and $0.8 million of costs related to the Track-FA program and will fund future costs going forward. One of the Companyâ€™s Directors is also a director of FARA. X - ReferencesNo definition available. + Details Name: us-gaap_RelatedPartyTransactionsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(e)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/850/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1 + Details Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 24 R18.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies (Policies) 9 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] Â Basis of Presentation Basis of PresentationThe condensed consolidated financial statements include the accounts of Larimar and its wholly owned subsidiary. All intercompany balances and transactions have been eliminated. The accompanying condensed consolidated financial statements have been prepared in conformity with Generally Accepted Accounting Principles ("GAAP").The condensed consolidated balance sheet as of December 31, 2023 was derived from the Companyâ€™s audited financial statements but does not include all disclosures required by GAAP. The accompanying unaudited condensed consolidated financial statements as of September 30, 2024 and for the three and nine months ended September 30, 2024 and 2023, have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (â€œSECâ€) for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. However, the Company believes that the disclosures are adequate to make the information presented not misleading. These condensed consolidated financial statements should be read in conjunction with the Companyâ€™s audited consolidated financial statements and the notes thereto for the year ended December 31, 2023 included in the Companyâ€™s Annual Report on Form 10-K filed with the SEC on March 14, 2024 and the Company's Quarterly Reports on Form 10-Q filed with the SEC on May 9, 2024 and August 8, 2024.In the opinion of management, all adjustments, consisting only of normal recurring adjustments necessary for a fair statement of the Companyâ€™s condensed consolidated financial position as of September 30, 2024, condensed consolidated results of operations for the three and nine months ended September 30, 2024 and condensed consolidated statement of cash flows for the nine months ended September 30, 2024 have been made. The results of operations for the three and nine months ended September 30, 2024 are not necessarily indicative of the results of operations that may be expected for the year ending December 31, 2024. Liquidity and Capital Resources Liquidity and Capital ResourcesThe Companyâ€™s condensed consolidated financial statements have been presented on the basis that it will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business.Since its inception, the Company has incurred significant recurring operating losses and negative cash flows from operations. The Company has incurred net losses of $51.8 million and $24.0 million for the nine months ended September 30, 2024 and 2023, respectively. In addition, as of September 30, 2024, the Company had an accumulated deficit of $240.3 million. The Company expects to continue to generate operating losses for the foreseeable future. As of September 30, 2024, the Company had approximately $203.7 million of cash, cash equivalents and marketable securities available for use to fund its operations and capital requirements.The Company has funded its operations to date primarily with proceeds from sales of common stock and proceeds from the sale of prefunded warrants for the purchase of common stock, the acquisition in 2020 of cash, cash equivalents and marketable securities upon the merger with Zafgen, Inc. ("Zafgen") and, prior to the 2020 merger with Zafgen, capital contributions from Chondrial Holdings, LLC. In February 2024, the Company completed an underwritten public offering in which the Company issued and sold 19,736,842 shares of its common stock at a public offering price of $8.74 per share. The Company received net proceeds of approximately $161.8 million after deducting underwriting discounts, commissions and other offering expenses.In accordance with Accounting Standards Update (â€œASUâ€) No. 2014-15, "Disclosure of Uncertainties about an Entityâ€™s Ability to Continue as a Going Concern", the Company has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the Companyâ€™s ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are issued. As of the issuance date of these condensed consolidated financial statements, the Company expects its cash, cash equivalents and marketable securities will be sufficient to fund its forecasted operating expenses and capital expenditure requirements into 2026. If the timing of the Company's clinical assumptions are delayed, or if there are other forecasted assumption changes that negatively impact its operating plan, the Company could reduce expenditures in order to further extend cash resources. The Company has not yet commercialized any products and does not expect to generate revenue from the commercial sale of any products for several years, if at all. The Company expects that its research and development and general and administrative expenses will continue to increase, that sales and marketing expenses will become significant and, as a result, that it will need additional capital to fund its future operating and capital requirements. Unless and until the Company can generate substantial revenue, management continuously evaluates different strategies to obtain the required funding for future operations. These strategies include seeking additional funding through a combination of public or private equity offerings, debt or royalty financings, collaborations and licensing arrangements, strategic partnerships with pharmaceutical and/or larger biotechnology companies, or other sources. The incurrence of indebtedness would result in increased fixed payment obligations and the Company may be required to agree to certain restrictive covenants, such as limitations on its ability to incur additional debt, limitations on its ability to acquire, sell or license intellectual property rights, minimum required cash balances and other operating restrictions that could adversely impact the Company's ability to conduct its business. Any additional fundraising efforts may divert the Company's management from their day-to-day activities, which may adversely affect its ability to develop and commercialize its product candidates. There can be no assurance that the Company will be able to raise sufficient additional capital on acceptable terms, if at all. If such additional financing is not available on satisfactory terms, or is not available in sufficient amounts, or if the Company does not have sufficient authorized shares, the Company may be required to delay, limit, or eliminate the development of business opportunities and its ability to achieve its business objectives, its competitiveness, and its business, financial condition, and results of operations will be materially adversely affected. The Company could also be required to seek funds through arrangements with collaborative partners or otherwise at an earlier stage than otherwise would be desirable and it may be required to relinquish rights to some of its technologies or product candidates or otherwise agree to terms unfavorable to it, any of which may have a material adverse effect on the Company's business, operating results and prospects. In addition, geopolitical tensions, volatility of capital markets, and other adverse macroeconomic events, including those due to inflationary pressures, rising interest rates, banking instability, monetary policy changes and the ability of the U.S. government to manage federal debt limits as well as the potential impact of other health crises on the global financial markets may reduce the Company's ability to access capital, which could negatively affect its liquidity and ability to continue as a going concern. If the Company is unable to obtain sufficient funding when needed and/or on acceptable terms, the Company may be required to significantly curtail, delay or discontinue one or more of its research and development programs, the manufacture of clinical and commercial supplies, product portfolio expansion, pre commercialization efforts and/or commercial operations, which could adversely affect its business prospects, or the Company may be unable to continue operations. Use of Estimates Use of EstimatesThe preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. This process involves reviewing open contracts and purchase orders, communicating with our personnel and outside vendors to identify services that have been performed on our behalf and estimating the level of service performed and the associated costs incurred for the services when we have not yet been invoiced or otherwise notified of the actual costs. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual of research and development expense, the recording as prepaid expense of payments made in advance of the actual provision of goods or services, valuation of stock-based awards and valuation of leases. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. Research and Development Costs Research and Development CostsCosts associated with internal research and development and external research and development services, including drug development, clinical studies and non-clinical studies, are expensed as incurred. Research and development expenses include costs for salaries, employee benefits, subcontractors, facility-related expenses, depreciation, non-cash stock-based compensation, third-party license fees, laboratory supplies, and external costs of outside vendors engaged to conduct discovery, non-clinical and clinical development activities and clinical trials as well as to manufacture clinical trial materials, and other costs. The Company recognizes external research and development costs based on an evaluation of the progress to completion of specific tasks using information provided to the Company by its key service providers.Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. Such prepaid expenses are recognized as an expense when the goods have been delivered or the related services have been performed, or when it is no longer expected that the goods will be delivered, or the services rendered.Upfront payments, milestone payments and annual maintenance fees under license agreements are currently expensed in the period in which they are incurred. Patent Costs Patent CostsAll patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses. Stock-Based Compensation Stock-Based CompensationThe Company measures all stock-based awards granted to employees and directors based on the fair value on the date of grant using the Black-Scholes option-pricing model. Compensation expense of those awards is recognized over the requisite service period, which is the vesting period of the respective award. Typically, the Company issues awards with only service-based vesting conditions and records the expense for these awards using the straight-line method. The Company accounts for forfeitures as they occur.The Company classifies stock-based compensation expense in its condensed consolidated statements of operations and comprehensive loss in the same manner in which the award recipientâ€™s payroll costs are classified or in which the award recipientâ€™s service payments are classified.Prior to May 28, 2020, the Company had been a private company and lacked company-specific historical and implied volatility information for its common stock. Prior to January 1, 2023, the Company estimated its expected common stock price volatility solely based on the historical volatility of publicly

traded peer companies. Beginning on January 1, 2023, based on the availability of sufficient historical trading data of the Company's own common stock on the Nasdaq Global Market to calculate accurately its volatility, the Company began blending its volatility starting from June 2020 (following its merger with Zafgen in 2020) to the date of each stock-based award, and weighing the volatility of its peer group for the amount of time from May 31, 2020 backwards so that the blended volatility equals the expected term of the related stock-based award. The expected term of the Companyâ€™s stock options has been determined utilizing the â€œsimplifiedâ€ method for awards that qualify as â€œplain-vanillaâ€ options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected dividend yield considers the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future. Net Loss Per Share Net Loss Per ShareBasic net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period. Prior to August 11, 2023, basic shares outstanding includes the weighted average effect of the Companyâ€™s prefunded warrants issued in June 2020, the exercise of which requires little or no consideration for the delivery of shares of common stock. These prefunded warrants were exercised on August 11, 2023 and the Company received cash proceeds of less than $0.1 million. Accordingly, the 628,403 shares were issued upon the exercise of these warrants and are included in issued and outstanding common stock. Diluted net loss per share attributable to common stockholders is computed by dividing the diluted net loss attributable to common stockholders by the weighted average number of common shares, including potentially dilutive common stock equivalents assuming the dilutive effect of outstanding stock options, outstanding restricted stock units, and unvested restricted common shares, as determined using the treasury stock method. For periods in which the Company has reported net losses (all periods since inception), diluted net loss per common share attributable to common stockholders is the same as basic net loss per common share attributable to common stockholders, since dilutive common stock equivalents are not assumed to have been issued if their effect is antidilutive.The Company excluded 6,990,827 and 5,100,997 common stock equivalents outstanding as of September 30, 2024 and 2023, respectively, from the computation of diluted net loss per share for the three and nine months ended September 30, 2024 and 2023 because they had an anti-dilutive impact due to the net loss incurred for the periods presented. Recently Issued and Adopted Accounting Pronouncements Recently Issued and Adopted Accounting Pronouncements From time to time, new accounting guidance is issued by the FASB or other standard setting bodies that is adopted by us as of the effective date or, in some cases where early adoption is permitted, in advance of the effective date. We have assessed the recently issued guidance that is not yet effective and believe the new guidance will not have a material impact on the condensed consolidated results of operations, cash flows or financial position.In November 2023, the FASB issued new guidance designed to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant expenses per segment. The new standard must be adopted on a retrospective basis. We intend to adopt the new guidance for the fiscal year ending December 31, 2024, and subsequent interim periods. Given that the accounting standard update affects disclosures exclusively, we do not anticipate that its adoption will have a material impact on our consolidated financial statements.In December 2023, the FASB issued new guidance designed to improve income tax disclosure requirements primarily through increased disaggregation disclosures within the effective tax rate reconciliation as well as enhanced disclosures on income taxes paid. The guidance is effective for all fiscal years beginning after December 15, 2024. The new standard can be adopted on a prospective basis with an option for it to be adopted retrospectively and early adoption is permitted. We are currently evaluating this guidance to determine its impact on our consolidated financial statements. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesNo definition available. + Details Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2 + Details Name: us-gaap_EarningsPerSharePolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-30/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 920 -SubTopic 350 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 920 -SubTopic 350 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 920 -SubTopic 350 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478609/920-350-50-4 + Details Name: us-gaap_IntangibleAssetsFiniteLivedPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for estimating its liability as of the balance sheet date for the ultimate cost of settling reported and unreported claims incurred and claims adjustment expenses (including effects of inflation and other societal and economic factors). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/944-40/tableOfContent + Details Name: us-gaap_LiabilityReserveEstimatePolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1 + Details Name: us-gaap_ResearchAndDevelopmentExpensePolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.C.Q3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.1.Q5) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.3.Q2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.2.Q6) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContentReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8 + Details Name: us-gaap_UseOfEstimates Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 25 R19.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value Measurements and Marketable Securities (Tables) 9 Months Ended Sep. 30, 2024 Fair Value Disclosures [Abstract] Â Summary of Cash Equivalents and Marketable Securities The following tables summarize the Companyâ€™s cash equivalents and marketable securities as of September 30, 2024 and December 31, 2023:Â Â Â Total Â Â QuotedPrices inActiveMarkets (Level 1) Â Â SignificantOtherObservableInputs (Level 2) Â Â SignificantUnobservableInputs (Level 3) Â Â Â (in thousands) Â September 30, 2024 Â Â Â Â Â Â Â Â Â Â Â Â Cash equivalents: Â Â Â Â Â Â Â Â Â Â Â Money market funds invested in government securities Â $ 31,338 Â Â $ 31,338 Â Â $ â€” Â Â $ â€” Â Total cash equivalents Â Â 31,338 Â Â Â 31,338 Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â Â Â Â Â Â Â Â Â Marketable securities: Â Â Â Â Â Â Â Â Â Â Â Â U.S. Treasury Bills Â Â 10,944 Â Â Â 10,944 Â Â Â Â â€” Â Â Â Â â€” Â U.S. Government securities Â Â 157,696 Â Â Â â€” Â Â Â 157,696 Â Â Â â€” Â Total marketable securities Â Â 168,640 Â Â Â 10,944 Â Â Â 157,696 Â Â Â â€” Â Total cash equivalents and marketable securities Â $ 199,978 Â Â $ 42,282 Â Â $ 157,696 Â Â $ â€” Â Â Â Â Â Â Â Â Â Â Â Â Â Â December 31, 2023 Â Â Â Â Â Â Â Â Â Â Â Â Cash equivalents: Â Â Â Â Â Â Â Â Â Â Â Money market funds invested in government securities Â $ 24,701 Â Â $ 24,701 Â Â $ â€” Â Â $ â€” Â Total cash equivalents Â Â 24,701 Â Â Â 24,701 Â Â Â Â â€” Â Â Â Â â€” Â Â Â Â Â Â Â Â Â Â Â Â Marketable securities: Â Â Â Â Â Â Â Â Â Â Â Â U.S. Treasury Bills Â Â 17,334 Â Â Â 17,334 Â Â Â Â â€” Â Â Â Â â€” Â U.S. Government securities Â Â 35,719 Â Â Â â€” Â Â Â 35,719 Â Â Â â€” Â Corporate bonds Â Â 6,988 Â Â Â Â â€” Â Â Â 6,988 Â Â Â Â â€” Â Total marketable securities Â Â 60,041 Â Â Â 17,334 Â Â Â 42,707 Â Â Â Â â€” Â Total cash equivalents and marketable securities Â $ 84,742 Â Â $ 42,035 Â Â $ 42,707 Â Â $ â€” Â Summary of Marketable Securities The following table summarizes the Company's marketable securities as of September 30, 2024 and December 31, 2023. Â Â Â AmortizedCost Â Â GrossUnrealizedGains Â Â GrossUnrealized Losses Â Â Fair Value Â Â Â (in thousands) Â September 30, 2024 Â Â Â Â Â Â Â Â Â Â Â Â Assets: Â Â Â Â Â Â Â Â Â Â Â Â U.S. Treasury Bills Â $ 10,937 Â Â $ 7 Â Â $ â€” Â Â $ 10,944 Â U.S. Government securities Â Â 157,345 Â Â Â 351 Â Â Â â€” Â Â Â 157,696 Â Total marketable securities Â $ 168,282 Â Â $ 358 Â Â $ â€” Â Â $ 168,640 Â Â Â Â Â Â Â Â Â Â Â Â December 31, 2023 Â Â Â Â Â Â Â Â Â Â Â Â Assets: Â Â Â Â Â Â Â Â Â Â Â Â U.S. Treasury Bills Â $ 17,330 Â Â $ 4 Â Â $ â€” Â Â $ 17,334 Â U.S. Government securities Â Â 35,653 Â Â Â 66 Â Â Â â€” Â Â Â 35,719 Â Corporate bonds Â Â 6,977 Â Â Â 11 Â Â Â â€” Â Â Â 6,988 Â Total marketable securities Â $ 59,960 Â Â $ 81 Â Â $ â€” Â Â $ 60,041 Â X - DefinitionTabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 26 R20.htm IDEA: XBRL DOCUMENT v3.24.3 Prepaid Expenses and Other Current Assets (Tables) 9 Months Ended Sep. 30, 2024 Prepaid Expense and Other Assets [Abstract] Â Schedule of Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consisted of the following: Â Â Â September 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Â Â (in thousands) Â Prepaid research and development expenses Â $ 8,192 Â Â $ 1,994 Â Interest receivable Â Â 943 Â Â Â 332 Â Prepaid insurance Â Â 43 Â Â Â 682 Â Other prepaid expenses and other assets Â Â 371 Â Â Â 377 Â Â $ 9,549 Â Â $ 3,385 Â X - DefinitionTabular disclosure of the carrying amounts of prepaid expenses and other current assets. + ReferencesNo definition available. + Details Name: lrmr_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock Namespace Prefix: lrmr_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 27 R21.htm IDEA: XBRL DOCUMENT v3.24.3 Fixed Assets (Tables) 9 Months Ended Sep. 30, 2024 Assets [Abstract] Â Schedule of Fixed Assets, Net Fixed assets, net consisted of the following:Â Â Â Â Â September 30, Â Â December 31, Â Â Â Useful Life Â 2024 Â Â 2023 Â Â Â Â Â (in thousands) Â Computer equipment Â 5 years Â $ 117 Â Â $ 117 Â Lab equipment Â 5 years Â Â 1,528 Â Â Â 1,192 Â Furniture and fixtures Â 7 years Â Â 555 Â Â Â 555 Â Leasehold improvements Â lease term Â Â 45 Â Â Â 45 Â Â Â Â Â 2,245 Â Â Â 1,909 Â Less: Accumulated depreciation Â Â Â Â (1,466) Â Â (1,225) Â Â Â $ 779 Â Â $ 684 Â X - ReferencesNo definition

available. + Details Name: us-gaap_AssetsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 28 R22.htm IDEA: XBRL DOCUMENT v3.24.3 Accrued Expenses (Tables) 9 Months Ended Sep. 30, 2024 Payables and Accruals [Abstract] Â Schedule of Accrued Expenses Â Â September 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Â Â (in thousands) Â Accrued research and development expenses Â $ 10,329 Â Â $ 4,594 Â Accrued payroll and related expenses Â Â 2,377 Â Â Â 2,365 Â Accrued other Â Â 867 Â Â Â 427 Â Â $ 13,573 Â Â $ 7,386 Â X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of accrued liabilities. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 29 R23.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Equity and Stock Options (Tables) 9 Months Ended Sep. 30, 2024 Stockholders' Equity Note [Abstract] Â Assumptions used to Determine Fair Value of Stock Options Granted The following table presents, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted to employees:Â Â Â September 30, Â Â 2024 Risk-free interest rate Â 4.12% Expected term (in years) Â 6.22 Expected volatility Â 96% Dividend yield Â 0.00% Summary of Stock Option Activity The following table summarizes the Companyâ€™s stock option activity for the nine months ended September 30, 2024 (amounts in millions, except for share, contractual term, and per share data):Â Â Â

http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCash received on stock transaction after deduction of issuance costs. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockConsiderationReceivedOnTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPer share or per unit amount of equity securities issued. + ReferencesNo definition available. + Details Name: us-gaap_SharesIssuedPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 32 R26.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($) $ in Millions 3 Months Ended 9 Months Ended Aug. 11, 2023 Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Summary Of Significant Accounting Policies [Line Items] Â Â Â Â Â Â Common stock, shares outstanding Â 63,806,628 Â 63,806,628 Â 43,909,069 Common stock, shares issued Â 63,806,628 Â 63,806,628 Â 43,909,069 From Exercise of Warrants [Member] Â Â Â Â Â Â Summary Of Significant Accounting Policies [Line Items] Â Â Â Â Â Â Common stock, shares outstanding 628,403 Â Â Â Â Â Common stock, shares issued 628,403 Â Â Â Â Â Common Stock Equivalents [Member] Â Â Â Â Â Â Summary Of Significant Accounting Policies [Line Items] Â Â Â Â Â Â Total potentially dilutive shares Â 6,990,827 5,100,997 6,990,827 5,100,997 Â Maximum [Member] Â Â Â Â Â Â Summary Of Significant Accounting Policies [Line Items] Â Â Â Â Â Â Cash proceeds from exercises of warrants $ 0.1 Â Â Â Â Â Â X - DefinitionSummary of significant accounting policies. + ReferencesNo definition available. + Details Name: lrmr_SummaryOfSignificantAccountingPoliciesLineItems Namespace Prefix: lrmr_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe cash inflow associated with the amount received from holders exercising their stock warrants. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromWarrantExercises Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_StatementEquityComponentsAxis=lrmr_FromExerciseOfWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=lrmr_CommonStockEquivalentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 33 R27.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value Measurements and Marketable Securities - Summary of Cash Equivalents and Marketable Securities (Detail) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Â Â Cash equivalents $ 31,338 $ 24,701 Marketable securities 168,640 60,041 Total cash equivalents and marketable securities 199,978 84,742 US Treasury Bills [Member] Â Â Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Â Â Marketable securities 10,944 17,334 U.S. Government Securities [Member] Â Â Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Â Â Marketable securities 157,696 35,719 Corporate Bonds [Member] Â Â Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Â Â Marketable securities Â 6,988 Money Market Funds [Member] Â Â Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Â Â Cash equivalents 31,338 24,701 Quoted Prices in Active Markets, (Level 1) [Member] Â Â Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Â Â Cash equivalents 31,338 24,701 Marketable securities 10,944 17,334 Total cash equivalents and marketable securities 42,282 42,035 Quoted Prices in Active Markets, (Level 1) [Member] | US Treasury Bills [Member] Â Â Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Â Â Marketable securities 10,944 17,334 Quoted Prices in Active Markets, (Level 1) [Member] | Money Market Funds [Member] Â Â Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Â Â Cash equivalents 31,338 24,701 Significant Other Observable Inputs (Level 2) [Member] Â Â Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Â Â Marketable securities 157,696 42,707 Total cash equivalents and marketable securities 157,696 42,707 Significant Other Observable Inputs (Level 2) [Member] | U.S. Government Securities [Member] Â Â Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Â Â Marketable securities $ 157,696 35,719 Significant Other Observable Inputs (Level 2) [Member] | Corporate Bonds [Member] Â Â Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Â Â Marketable securities Â $ 6,988 X - DefinitionFair value portion of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_AssetsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_CashAndCashEquivalentsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=lrmr_USGovernmentSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 34 R28.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value Measurements and Marketable Securities - Additional Information (Details) - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Fair Value Disclosures [Abstract] Â Â Â Â Â Accrued interest receivable $ 900,000 Â $ 900,000 Â $ 300,000 Allowance for credit loss 0 Â 0 Â $ 0 Impairment losses on investment $ 0 $ 0 $ 0 $ 0 Â X - DefinitionAmount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-

gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4 + Details Name: us-gaap_AssetImpairmentCharges Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aaa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479106/326-30-50-9Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479106/326-30-50-9 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCarrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 310 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InterestReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 35 R29.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value Measurements and Marketable Securities - Summary of Marketable Debt Securities (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Schedule Of Available For Sale Securities [Line Items] Â Â Amortized Cost $ 168,282 $ 59,960 Gross Unrealized Gains 358 81 Fair Value 168,640 60,041 U.S. Government Securities [Member] Â Â Schedule Of Available For Sale Securities [Line Items] Â Â Amortized Cost 157,345 35,653 Gross Unrealized Gains 351 66 Fair Value 157,696 35,719 US Treasury Bills [Member] Â Â Schedule Of Available For Sale Securities [Line Items] Â Â Amortized Cost 10,937 17,330 Gross Unrealized Gains 7 4 Fair Value $ 10,944 17,334 Corporate Bonds [Member] Â Â Schedule Of Available For Sale Securities [Line Items] Â Â Amortized Cost Â 6,977 Gross Unrealized Gains Â 11 Fair Value Â $ 6,988 X - DefinitionAmount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aaa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3 + Details Name: us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_FinancialInstrumentAxis=lrmr_USGovernmentSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 36 R30.htm IDEA: XBRL DOCUMENT v3.24.3 Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Detail) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Prepaid Expense and Other Assets [Abstract] Â Â Prepaid research and development expenses $ 8,192 $ 1,994 Interest receivable 943 332 Prepaid insurance 43 682 Other prepaid expenses and other assets 371 377 Total prepaid expenses and other current assets $ 9,549 $ 3,385 X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, not separately disclosed. + ReferencesNo definition available. + Details Name: lrmr_OtherPrepaidExpenseAndOtherCurrentAssets Namespace Prefix: lrmr_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs related to research and development. + ReferencesNo definition available. + Details Name: lrmr_PrepaidResearchAndDevelopmentExpenses Namespace Prefix: lrmr_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InterestReceivableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5 + Details Name: us-gaap_PrepaidInsurance Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 37 R31.htm IDEA: XBRL DOCUMENT v3.24.3 Fixed Assets - Schedule of Fixed Assets, Net (Detail) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Fixed assets, gross $ 2,245 $ 1,909 Less: Accumulated depreciation (1,466) (1,225) Fixed assets, net 779 684 Computer Equipment [Member] Â Â Fixed assets, gross $ 117 117 Fixed assets, useful life 5 years Â Lab Equipment [Member] Â Â Fixed assets, gross $ 1,528 1,192 Fixed assets, useful life 5 years Â Furniture and Fixtures [Member] Â Â Fixed assets, gross $ 555 555 Fixed assets, useful life 7 years Â Leasehold Improvements [Member] Â Â Fixed assets, gross $ 45 $ 45 Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration] us-gaap:UsefulLifeTermOfLeaseMember Â X - DefinitionAmount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionUseful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment. + ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentUsefulLife Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionIndicates description of term of useful life for property, plant, and equipment when not stated as numeric value. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482190/360-10-35-3 + Details Name: us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration Namespace Prefix: us-gaap_

Data Type: enum2:enumerationSetItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 38 R32.htm IDEA: XBRL DOCUMENT v3.24.3 Fixed Assets - Additional Information (Detail) - USD ($) $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Depreciation expense $ 0.1 $ 0.1 $ 0.2 $ 0.2 Depreciation expenses related to sublet assets Â Â Â $ 0.1 Maximum [Member] Â Â Â Â Depreciation expenses related to sublet assets $ 0.1 $ 0.1 $ 0.1 Â Â - DefinitionThe amount of depreciation expenses recognized in the period, excluding depreciation for leased assets as part of a sublease agreement. + ReferencesNo definition available. + Details Name: lrmr_DepreciationExpenseExcludingLeasedAssets Namespace Prefix: lrmr_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of depreciation expense recognized in the period related to leased assets as part of a sublease agreement. + ReferencesNo definition available. + Details Name: lrmr_DepreciationExpensesRelatedToSubletAssets Namespace Prefix: lrmr_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 39 R33.htm IDEA: XBRL DOCUMENT v3.24.3 Accrued Expenses - Schedule of Accrued Expenses (Detail) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Payables and Accruals [Abstract] Â Â Accrued research and development expenses $ 10,329 $ 4,594 Accrued payroll and related expenses 2,377 2,365 Accrued other 867 427 Total accrued expenses $ 13,573 $ 7,386 X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for expenses related to research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesNo definition available. + Details Name: lrmr_AccruedResearchAndDevelopmentExpenseCurrent Namespace Prefix: lrmr_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_EmployeeRelatedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 40 R34.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders Equity and Stock Options - Additional Information (Detail) - USD ($) 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended Jan. 01, 2024 Aug. 11, 2023 Jan. 01, 2023 May 28, 2020 May 31, 2024 Feb. 29, 2024 Aug. 31, 2023 Nov. 30, 2022 Mar. 31, 2024 Sep. 30, 2023 Sep. 30, 2024 Dec. 31, 2023 Undesignated preferred stock, shares authorized Â Â Â Â Â Â Â Â Â Â 5,000,000 5,000,000 Undesignated preferred stock, par value Â Â Â Â Â Â Â Â Â Â $ 0.001 $ 0.001 Undesignated preferred stock, shares issued Â Â Â Â Â Â Â Â Â Â 0 0 Undesignated preferred stock, shares outstanding Â Â Â Â Â Â Â Â Â Â 0 0 Common stock, shares authorized Â Â Â Â Â Â Â Â Â Â 115,000,000 115,000,000 Common stock, par value Â Â Â Â Â Â Â Â Â Â $ 0.001 $ 0.001 Common stock voting rights Â Â Â Â Â Â Â Â Â Â Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Companyâ€™s stockholders. Â Dividend paid Â Â Â Â Â Â Â Â Â Â $ 0 Â Common stock, shares issued Â Â Â Â Â Â Â Â Â Â 63,806,628 43,909,069 Common stock, shares outstanding Â Â Â Â Â Â Â Â Â Â 63,806,628 43,909,069 Options to purchase shares of common stock granted Â Â Â Â Â Â Â Â Â Â 2,082,377 Â Aggregate intrinsic value of outstanding options granted Â Â Â Â Â Â Â Â Â Â $ 7,400,000 Â Restricted Stock Units [Member] Â Â Â Â Â Â Â Â Â Â Number of shares, Restricted stock units granted Â Â Â Â Â Â Â Â Â Â 245,372 Â Weighted average grant date fair value Â Â Â Â Â Â Â Â Â Â $ 4.21 Â Unrecognized compensation expense Â Â Â Â Â Â Â Â Â Â $ 2,600,000 Â Unrecognized compensation expense recognized period Â Â Â Â Â Â Â Â Â Â 2 years 7 months 24 days Â 2020 Equity Incentive Plan [Member] Â Â Â Â Â Â Â Â Â Â Share-based compensation arrangement by share-based payment award, description Â Â Â Â Â Â Â Â Â Â The maximum number of shares that may be issued in respect of any awards under the 2020 Plan is the sum of: (i) 1,700,000 shares plus (ii) an annual increase on January 1, 2021 and each anniversary of such date thereafter through January 1, 2030, equal to the lesser of (A) 4% of the shares issued and outstanding on the last day of the immediately preceding fiscal year, or (B) such smaller number of shares as determined by the Board (collectively, the â€œPlan Limitâ€). Â Minimum level of maximum number of shares allowed to be issued Â Â Â Â Â Â Â Â Â Â 1,700,000 Â Percentage of outstanding shares Â Â Â Â Â Â Â Â Â Â 4.00% Â Term of plan Â Â Â Â Â Â Â Â Â Â 10 years Â Unrecognized compensation expense Â Â Â Â Â Â Â Â Â Â $ 11,800,000 Â Unrecognized compensation expense recognized period Â Â Â Â Â Â Â Â Â Â 2 years 6 months 21 days Â Weighted-average grant date fair value of options granted Â Â Â Â Â Â Â Â Â Â $ 4.15 Â 2020 Equity Incentive Plan [Member] | From Prior Plans [Member] Â Â Â Â Â Â Â Â Â Â Increase in shares reserved for future issuance Â Â Â Â Â Â Â Â Â Â 1,242 224,437 Number of stock options remained outstanding under the plan Â Â Â Â Â Â Â Â Â Â 344,683 Â Stock option outstanding exercise price lower range limit Â Â Â Â Â Â Â Â Â Â $ 11.88 Â Stock option outstanding exercise price upper range limit Â Â Â Â Â Â Â Â Â Â $ 445.8 Â 2020 Equity Incentive Plan [Member] | Restricted Stock Units [Member] | Employees [Member] Â Â Â Â Â Â Â Â Â Â Number of shares, Restricted stock units granted Â Â Â Â Â Â Â Â Â Â 245,372 Â Weighted average grant date fair value Â Â Â Â Â Â Â Â Â Â $ 4.21 Â Vesting period of stock option Â Â Â Â Â Â Â Â Â Â 4 years Â Maximum [Member] Â Â Â Â Â Â Â Â Â Â Cash proceeds from exercises of warrants Â $ 100,000 Â Â Â Â Â Â Â Â Â Â Maximum [Member] | 2020 Equity Incentive Plan [Member] Â Â Â Â Â Â Â Â Â Â Maximum number of shares that may be issued under stock option incentive plan Â Â Â Â Â Â Â Â Â Â 8,000,000 Â Common Stock [Member] Â Â Â Â Â Â Â Â Â Â Issuance of common stock Â Â Â Â Â 19,736,842 Â Â 19,736,842 Â Â Â Share price per share Â Â Â Â Â $ 8.74 Â Â Â Â Â Â Exercise of warrants, shares Â Â Â Â Â Â Â Â 628,403 Â Â Proceeds net of issuance costs Â Â Â Â Â $ 161,800,000 Â Â Â Â Â Â Common Stock [Member] | 2020 Equity Incentive Plan [Member] Â Â Â Â Â Â Â Â Â Â Shares available for grant Â Â Â Â Â Â Â Â Â Â 779,926 Â Increase in shares reserved for future issuance 1,756,363 Â 1,730,768 Â Â Â Â Â Â Â Â Â Â Common Stock [Member] | 2020 Equity Incentive Plan [Member] | Employees [Member] Â Â Â Â Â Â Â Â Â Â Options to purchase shares of common stock granted Â Â Â Â Â Â Â Â Â Â 1,987,377 Â Vesting period of stock option Â Â Â Â Â Â Â Â Â Â 4 years Â Common Stock [Member] | 2020 Equity Incentive Plan [Member] | Directors [Member] Â Â Â Â Â Â Â Â Â Â Options to purchase shares of common stock granted Â Â Â Â Â Â Â Â Â Â 95,000 Â Vesting period of stock option Â Â Â Â Â Â Â Â Â Â 1 year Â Common Stock [Member] | 2020 Equity Incentive Plan [Member] | Employees and Directors [Member] Â Â Â Â Â Â Â Â Â Â Options to purchase shares of common stock granted Â Â Â Â Â Â Â Â Â Â 2,082,377 Â Common Stock [Member] | 2020 Equity Incentive Plan [Member] | First Anniversary [Member] | Employees [Member] Â Â Â Â Â Â Â Â Â Â Stock option vesting percentage Â Â Â Â Â Â Â Â Â Â 25.00% Â Inducement Stock [Member] Â Â Â Â Â Â Â Â Â Â Options to purchase shares of common stock granted Â Â Â Â Â Â Â Â Â Â 0 Â Unrecognized compensation expense Â Â Â Â Â Â Â Â Â Â $ 800,000 Â Unrecognized compensation expense recognized period Â Â Â Â Â Â Â Â Â Â 2 years 6 months 10 days Â ATM Offering Program [Member] | Common Stock [Member] Â Â Â Â Â Â Â Â Â Â Common stock, shares issued Â Â Â Â 0 Â Â Â Â 0 Â ATM Offering Program [Member] | Maximum [Member] Â Â Â Â Â Â Â Â Â Â Aggregate sale of shares of our common stock Â Â Â Â $ 100,000,000 Â Â $ 50,000,000 Â Â Â Â Private Placement [Member] Â Â Â Â Â Â Â Â Â Â Warrants price per share Â Â Â Â $ 11.87 Â Â Â Â Â Â Â Â Â Â Warrants exercise price Â Â Â Â $ 0.01 Â Â Â Â Â Â Â Â Â Â Gross proceeds Â Â Â Â $ 80,000,000 Â Â Â Â Â Â Â Â Â Â Transaction cost Â Â Â 4,600,000 Â Â Â Â Â Â Â Â Â Â Proceeds from issuance common stock and warrants net offering costs Â Â Â $ 75,400,000 Â Â Â Â Â Â Â Â Â Â Private Placement [Member] | Common Stock [Member] Â Â Â Â Â Â Â Â Â Â Issuance of common stock Â Â Â 6,105,359 Â Â Â Â Â Â Â Â Â Â Issuance of warrants Â Â Â 628,403 Â Â Â Â Â Â Â Â Â Â Share price per share Â Â Â Â $ 11.88 Â Â Â Â Â Â Â Â Â Â Exercise of warrants, shares Â Â Â Â Â Â 628,403 Â Â Â Â Â Â Cash proceeds from exercises of warrants Â Â Â Â Â Â Â $ 6,284 Â Â Â Â Â Private Placement [Member] | Common Stock [Member] | MTS Health Partners [Member] Â Â Â Â Â Â Â Â Â Â Issuance of common stock Â Â Â 35,260 Â Â Â Â Â Â Â Â Â Â Underwritten Public Offering [Member] | Common Stock [Member] Â Â Â Â Â Â Â Â Â Â Issuance of common stock Â Â Â Â Â 19,736,842 Â Â Â Â Â Â Â Share price per share Â Â Â Â Â $ 8.74 Â Â Â Â Â Â Â Proceeds net of issuance costs Â Â Â Â Â $ 161,800,000 Â Â Â Â Â Â Â X - DefinitionThe potential aggregate gross sales proceeds available under a sales agreement to sell shares of the Company's common stock. + ReferencesNo definition available. + Details Name: lrmr_AggregateGrossSalesProceedsUnderSalesAgreement Namespace Prefix: lrmr_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionProceeds from issuance of common stock and prefunded warrants to purchase common stock, net of offering costs. + ReferencesNo definition available. + Details Name: lrmr_ProceedsFromIssuanceCommonStockAndWarrantsNetOfferingCosts Namespace Prefix: lrmr_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe maximum number of shares that may be added annually to the threshold number of shares issued under the Plan, as a percentage of the shares issued and outstanding on the last day of the immediately preceding fiscal year. + ReferencesNo definition available. + Details Name: lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesPercentageOfOutstandingStock Namespace Prefix: lrmr_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe term of the plan. + ReferencesNo definition available. + Details Name: lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardDuration Namespace Prefix: lrmr_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThe minimum threshold number of shares used to determine the maximum number of shares that may be issued under the Plan. + ReferencesNo definition available. + Details Name: lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdNumberOfSharesAllowedToIssue Namespace Prefix: lrmr_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionCosts incurred during the period related to the issuance of stock and warrants. + ReferencesNo definition available. + Details Name: lrmr_StockAndWarrantIssuanceTransactionCosts Namespace Prefix: lrmr_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of shares of issued as a result of the exercise of warrants. + ReferencesNo definition available. + Details Name: lrmr_StockIssuedDuringPeriodSharesExerciseOfWarrants Namespace Prefix: lrmr_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionPer unit amount of prefunded warrant issued. + ReferencesNo definition available. + Details Name: lrmr_WarrantsIssuedPricePerShare Namespace Prefix: lrmr_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionDescription of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_CommonStockVotingRights Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCarrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -

Paragraph 1 -Subparagraph (SX 210.9-03(15)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 405 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478790/946-405-45-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(15)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_DividendsPayableCurrentAndNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of cost not yet recognized for nonvested award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe cash inflow associated with the amount received from entity's raising of capital via private rather than public placement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfPrivatePlacement Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from holders exercising their stock warrants. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromWarrantExercises Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCash received on stock transaction after deduction of issuance costs. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockConsiderationReceivedOnTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPeriod over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionNumber of additional shares authorized for issuance under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares authorized for issuance under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionDescription of terms of award under share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionPercentage of vesting of award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPer share or per unit amount of equity securities issued. + ReferencesNo definition available. + Details Name: us-gaap_SharesIssuedPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=lrmr_TwoThousandTwentyEquityIncentivePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=lrmr_FromPriorPlansMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=lrmr_EmployeesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=srt_DirectorMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=lrmr_EmployeesAndDirectorsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VestingAxis=lrmr_FirstAnniversaryMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=lrmr_InducementStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-

gaap_SubsidiarySaleOfStockAxis=lrmr_AtTheMarketEquityOfferingProgramMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionAxis=lrmr_MTSHealthPartnersMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 41 R35.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders Equity and Stock Options - Assumptions used to Determine Fair Value of Stock Options Granted (Detail) 9 Months Ended Sep. 30, 2024 Stockholders' Equity Note [Abstract] Â Risk-free interest rate 4.12% Expected term (in years) 6 years 2 months 19 days Expected volatility 96.00% Dividend yield 0.00% X - DefinitionThe estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionExpected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityNoteAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 42 R36.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders Equity and Stock Options - Summary of Stock Option Activity (Detail) $ / shares in Units, $ in Millions 9 Months Ended 12 Months Ended Sep. 30, 2024 USD ($) $ / shares shares Dec. 31, 2023 $ / shares shares Stockholders' Equity Note [Abstract] Â Â Number of shares, Outstanding | shares 4,273,502 Â Number of shares, Options granted | shares 2,082,377 Â Number of shares, Exercised | shares (6,967) Â Number of shares, Options forfeited/expired | shares (57,088) Â Number of shares, Outstanding | shares 6,291,824 4,273,502 Number of shares, Exercisable as of September 30, 2024 | shares 2,921,508 Â Number of shares, Vested and expected to vest as of September 30, 2024 | shares 6,291,824 Â Weighted average exercise price, balance | $ / shares $ 9.06 Â Weighted average exercise price, Options granted | $ / shares 5.22 Â Weighted average exercise price, Exercised | $ / shares 5.92 Â Weighted average exercise price, Options forfeited/expired | $ / shares 10.08 Â Weighted average exercise price, balance | $ / shares 7.79 $ 9.06 Weighted average exercise price, Exercisable as of September 30, 2024 | $ / shares 10.63 Â Weighted average exercise price, Vested and expected to vest as of September 30, 2024 | $ / shares $ 7.79 Â Weighted average remaining contractual term, outstanding 7 years 9 months 18 days 7 years 9 months 18 days Weighted average remaining contractual term, Exercisable as of September 30, 2024 6 years 6 months Â Weighted average remaining contractual term, Vested and expected to vest as of September 30, 2024 7 years 9 months 18 days Â Aggregate intrinsic value, outstanding | $ $ 7.4 Â Aggregate intrinsic value, exercisable as of September 30, 2024 | $ 1.7 Â Aggregate intrinsic value, Vested and expected to vest as of September 30, 2024 | $ $ 7.4 Â X - DefinitionThe number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionFor presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price of options that were either forfeited or expired. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionAmount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which option holders acquired shares when converting their stock options into shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityNoteAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 43 R37.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders Equity and Stock Options - Summary of Restricted Stock Units (Details) - Restricted Stock Units (RSUs) - USD ($) $ / shares in Units, $ in Millions 9 Months Ended 12 Months Ended Sep. 30, 2024 Dec. 31, 2023 Number of shares, Outstanding 615,000 Â Number of shares, Restricted stock units granted 245,372 Â Number of shares, Restricted stock units vested (153,750) Â Number of shares, Restricted stock units forfeited (7,619) Â Number of shares, Outstanding 699,003 615,000 Number of shares, Unvested and expected to vest as of September 30, 2024 699,003 Â Weighted average grant date fair value, balance $ 4.94 Â Weighted average grant date fair value, Restricted stock units granted 4.21 Â

Weighted average grant date fair value, Restricted stock units vested 4.94 Â Weighted average grant date fair value, Restricted stock units forfeited 4.64 Â Weighted average grant date fair value, balance 4.69 $ 4.94 Weighted average grant date fair value, Unvested and expected to vest as of September 30, 2024 $ 4.69 Â Weighted average remaining contractual term, Outstanding as of September 30, 2024 1 year 6 months 1 year 7 months 6 days Weighted average remaining contractual term, Unvested and expected to vest as of September 30, 2024 1 year 6 months Â Aggregate intrinsic value, Outstanding as of September 30, 2024 $ 4.6 Â Aggregate intrinsic value, Unvested and expected to vest as of September 30, 2024 $ 4.6 Â X - DefinitionIntrinsic value of awards that are unvested and expected to vest under share-based payment arrangement. Excludes share and unit options. + ReferencesNo definition available. + Details Name: lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestAggregateIntrinsicValue Namespace Prefix: lrmr_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that are unvested and expected to vest as of the balance sheet date. + ReferencesNo definition available. + Details Name: lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestOutstandingNumber Namespace Prefix: lrmr_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionPer share or unit weighted-average fair value of awards that are unvested and expected to vest under share-based payment arrangement. Excludes share and unit options. + ReferencesNo definition available. + Details Name: lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageGrantDateFairValue Namespace Prefix: lrmr_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining contractual term for equity-based awards excluding options that are unvested and expected to vest, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageRemainingContractualTerms Namespace Prefix: lrmr_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionWeighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionPer share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionIntrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options. + ReferencesNo definition available. + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 44 R38.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders Equity and Stock Options - Summary of Stock-Based Compensation Expense (Detail) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Â Total stock-based compensation expense $ 1,957 $ 1,821 $ 6,386 $ 5,697 Research and Development [Member] Â Â Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Â Total stock-based compensation expense 918 697 2,816 2,304 General and Administrative [Member] Â Â Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Â Total stock-based compensation expense $ 1,039 $ 1,124 $ 3,570 $ 3,393 X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 45 R39.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies - Additional Information (Detail) $ in Thousands 1 Months Ended 3 Months Ended 9 Months Ended Oct. 16, 2023 Oct. 01, 2023 USD ($) ftÂ² Mar. 09, 2023 ftÂ² Aug. 09, 2021 Oct. 27, 2020 USD ($) Aug. 04, 2020 May 28, 2020 USD ($) ftÂ² Dec. 11, 2019 USD ($) Aug. 08, 2019 Nov. 05, 2018 Sep. 30, 2023 ftÂ² Oct. 31, 2022 USD ($) Sep. 30, 2024 USD ($) Sep. 30, 2023 USD ($) Sep. 30, 2024 USD ($) Sep. 30, 2023 USD ($) Oct. 30, 2024 USD ($) May 10, 2024 USD ($) Dec. 31, 2023 USD ($) Sep. 01, 2023 USD ($) Nov. 30, 2016 USD ($) Other Commitments [Line Items] Â Operating lease liabilities Â Â Â Â Â Â Â Â Â Â Â Â $ 4,336 Â $ 4,336 Â Â Â $ 4,709 Â Â Operating lease right-of-use assets Â Â Â Â Â Â Â Â Â Â Â Â $ 3,026 Â $ 3,026 Â Â Â $ 3,078 Â Â Weighted average remaining lease term in years Â Â Â Â Â Â Â Â Â Â Â Â 4 years 8 months 12 days Â 4 years 8 months 12 days Â Â Â 5 years 6 months Â Â Weighted average discount rate Â Â Â Â Â Â Â Â Â Â Â Â 11.00% Â 11.00% Â Â Â 11.00% Â Â Lease expenses Â Â Â Â Â Â Â Â Â Â Â Â $ 100 $ 100 $ 400 $ 200 Â Â Â Â Â Pennsylvania [Member] | Office [Member] Â

Other Commitments [Line Items] Â Operating lease term Â Â Â Â Â Â Â 3 years 6 months Â Â Â Â Â Â Â Â Â Â Lease extension period Â Â Â Â Â Â Â 3 years Â Â Â Â Â Â Â Â Â Â Â Â Lease term commencement date Â Â Sep. 01, 2023 Â Â Â Â Â Feb. 15, 2020 Â Â Â Â Â Â Â Â Â Â Operating lease liabilities Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â $ 500 Â Operating lease right-of-use assets Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â $ 500 Â Area of office space | ftÂ² Â Â 4,642 Â Â Â Â Â Â Â Â Â Â 4,642 Â Â Â Â Â Â Â Â Â Â Â Â Lease term expiration date Â Â Aug. 31, 2023 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Pennsylvania [Member] | Office and Lab [Member] Â Other Commitments [Line Items] Â Lease extension period Â Â Â Â Â Â Â 2 years Â Â Â Â Â Â Â Â Â Â Â Â Lease term commencement date Â Â Â Â Â Â Â Jan. 01, 2019 Â Â Â Â Â Â Â Â Â Â Lease term expiration date Â Â Â Dec. 31, 2022 Â Dec. 31, 2021 Â Â Â Dec. 31, 2020 Â Â Â Â Â Â Â Â Â Â Â Â Pennsylvania [Member] | Additional Office [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â

when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 47 R41.htm IDEA: XBRL DOCUMENT v3.24.3 Related Party - Additional Information (Details) - Friedreich's Ataxia Research Alliances [Member] - Track-FA program [Member] - USD ($) $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2024 Related Party Transaction [Line Items] Â Â Cost related to Track-FA program Â $ 0.8 Minimum [Member] Â Â Related Party Transaction [Line Items] Â Â Cost related to Track-FA program $ 0.1 Â X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingCostsAndExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_RelatedPartyTransactionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=lrmr_FriedreichsAtaxiaResearchAlliancesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionAxis=lrmr_TrackFAProgramMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: EXCEL 48 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx
M4$L#!!0 (&J(7ED'04UB@0 +$ 0
9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX^Y!I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y
#OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " !JB%Y9J$ARLNT K @ $0 &1O8U!R;W!S+V-O&ULS9+/ M2L0P$(=?17)O)VG%0^CVLN))07!!\1:2V=U@\X=DI-VWMXV[740?
P&-F?OGF M&YA.1ZE#PN<4(B:RF&\F-_@L==RP(U&4 %D?T:E\?$S#05F-." #CUE$+4 UB\3 MXVD:.K@"%AAA0Z!]0UO;BO!JY;O&B%Y*X5X7UQ_^%V%73!V;_^Q M\46P[^#77?1?4$L#!!0 (
&J(7EF97)PC$ 8)PG 3 >&PO=&AE M;64O=&AE64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0&-H&VVVRH!M1...%V$RB;;C$R%)PG+R%B@+?*#ANH4(QCSGKZjRV"KLOBjlR69d]fy0WyPUz-
A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@ MV2_;UKNW+][@5S(D4P&:>O\, *I4Q>M5II ,,X?+&A T%116F]?(+3E'S/X%/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1
MTDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP M' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?= MTXZ)QJW0>
V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP M=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%, M4'RO0;:*X,*2TER0UL\IM5 :")K(@?
5'@B'%W*_]]9>[R:0S>IU].LYKE']I MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ MY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?
C8CWJV^:/5>A M6$G:A/@01AKBG'/F<]%L^P>E1M'V5;SC MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[?_1VC?"J_B"P#E_
M+GW/I>^Y]#VATK\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE" M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT
ML@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3 M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.' M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH
>#KU$"\E)58#%;Q@,KD*)\ M3(Q%Z'#GEUQ?X]&2X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^ M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON>;G*YZ(G;ZEW?! M8/+]
<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83 M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!
()O\UMND]MW@#'S4JUJE9"L1/TL' M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5 MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$% @
M:HA>6:-%*WKZ!0 U1\ !@ !X;"]W;W)K. V6??G82 MDO;D_&%1>=.2D.?!/]NQ']N#'>/?D@VE KV$093&D@;&I+DDL4T MDM^L& ^)D)=\;20QI\3+1&%@8-/L&2'QH]9PD-V;\N&
I2+P(SKE*$G#D/#] M'0W8[K9EM0XW9OYZ(]0-8SB(R9K.J?@23[F\,DH7SP]IE/@L0IRN;ELCZ\:Q M;27(GOC=I[ODU6>D4):,?5,7$^^V9:H2T8"Z0ED0^6]+'1H$RDF6XY_"M%7^ MIA*^_GQP?
\C@)71%TD#,V.XC+8"ZRL]E09+]1;O\ MV8[\13=-! L+L;P._2C_3UZ*BCA%@ L!_DY@=6H$=B'(:L[(2Y9AW1-!A@/. M=HBKIZ6;^I#53::6-'ZDFG$NN/S6ESHQO&=N*EM%(!)Y:!P)7^S1),J[AZKF
M-DHVA--D8 CY:TICN(7S7>Z,:YROT1.+Q":1KA[UWNH-6.YF]@>V4L!W(O>HFBWU, M=:2PW#+;GW5(H*HA4K=$ZH)Eâ......>+V-Z",A:QP3K5R1(=%7A@+*&4+T2JG=:
M.TTI]YEZHSTDQP5MD\%.Y=M6^[J!^H:<5R7GU6F<#W[BD@!]I82C!WE3.U#! M7G5\H*HA7[_DZ_\OOJ(Y:PEAM\^VC@_4-.2[+OFNP1(M./'\:(WF^W#) AT1 MK'^_>$:/'T6SR-
)JAQ%,8GT[=HP^<"Z MIJ!5]K'@R'(8B%@8RI7+7##WVP6:9\L7]"D5B9!K'%D!6N)W"C-%/>1NW+.@55- MV[+*/Q8<60[OY$8N\,&N"MO4=]5SI!^KBC\6G%]>#;'H.0V7VG'Q[HB]G"S; M=J]KZ2?
+6-R4 MMPI!^*00-/(\Z9Y<'#Z@1_D<^A1I \(1R\6&4XKN2$#0-"#_$C0FB="BGR,7 MX2H783C(@.B+'=.BPY;SU!<4=%OA[-[T?:+6E8V)#0KG*3?5)NFD2"\OR(2^TO MD$/@UQXRP(XU^1Y6-
>6L\I(-AYMR@_-S2KAD#?;%6D9+"'O5K;MA65/$*A?9 M<(BISDPXB1(_"[\ (VQ6NY"!=4TA7QV"G92&)I'+N$3+(WZ>$AR61H+O:Z>9 M(\[W8RWNN^8AX]7!J=H>R9(__]0 M2P,$% @
:HA>60@Z!665!0 %Q8 !@ !X;"]W;W)K2ENIKMM:XN%@N5 M[EE!U;FH6&G>[(0LJ#93>;M0E60T:Y2*?($AC!8%Y>5LO6J>76BX>K&9H]/?C*;_?:/EBL5Q6]95NFOU?7TLP6G96,%ZQ47)1
MLMW5[!.ZV.#(*C02?W/VH 9C8%VY$>+.3G[/KF;0(F(Y2[4U06 M#(X?K=%9]TVK.!P_6?^U<=XXZG(5?,?/+2R< ;26FE1M,H&0<'+PR_]V09BH(""$07<*N"7*I!6@32.'I U M;GVAFJY74CP ::6-
-3MH8M-H&V]X:9=QJZ5YRXV>7F]$F9E%81DP(R5RGE%M M)I]I3LN4@:TUK, 9^+[] CZ\^PC> 5Z";WM1*UIF:K70!H.UM$C;[WT^? ^/ M?&_+JG- X!Q@B
./^F9:_0M+C3IJU,FQ^L)XWKF/._=Q8X^,N5]+R4H-J%+& MSPN?/P<#@=^ /647JJ(INYJ98Z28O&>S]?M?4 0O?=Z]D;$C7TGG*YFROMY0 MM0=FU4!J!^Q'S>]I;ISWKN+!5-28LJG@?
DU"&,6KQ?W0'5<*1W&P[*2.< 8= MSF 2YW8OI#[33!9FH\L[INE-SH!B:2VYYLP+]V Q' !!41(%\ 2O*Q9!&" _ MWK##&T[BO9:LHCP#[&=E3Y)J8BSTGDES@(?;RP<\=! MPT$ #[!=(4*2T(\Z
MZE!'DZB_"4WS%P",G&]C1' 8G4!TQ980Q2,8XPYC_$QD#5U)_=A$U&[8RA"(MGH.2:1_4V,$0QZ>A=&6B)/"C3#J4R23*OPQ&JGEY"W)F" 5(RQQG8G=6F\EX M8!-W42$^#:M/*$[\>)
<=WN4DWJ],:L[*$+CI7;ADNR16<[I#<^;7.EE-/2FE/96UHZ=[DD-3;/:IS05M2$Q4-%'2Q1>AXF7'DZ7 MQ2.%$S*R*CV;H6DZ,P!ES7IZ\ +T\!<)8W**T!6+R<"/8X0]?Z%I CM-8(/] M,W]B""]JEY>0F\
(\4@F)1S#W[(5>0U\#Q%Z@+CNA" \8M$7J(3%3](Q [4D, M3;/81'B]8%V*"@AQHNJ1BN%8BNNI#$USV2&LSR%T60E#3Q)VQ5" T5B:Z^D+ M3?/71A0%U[82.)1:J2AM=%F9&KS@PY8Q*?0#"0?
O> GC?O3%?#FO?]OZ+AE MZ2D2P\D\O]4BO=N+/&-2O?\EP2B^;*HC_>AO8"8)]]4=S!M9._:]YV \S<%V M\4WWKVP(YN =/(<0F=0O@>EE:@;,40-J3R6[! B%U?ZV5-@-[Y%_WG3DPIBK67&WDC]
[%=&N'*#@Y>!Z98(3&*!1GN3Q M]:"L,NYY_A !+BQ-0CB)(D#$>:!]S7!_C9^J!#VG:-HC!G9V_O MRNX9N*6\]$)WBP$2)J>P7:%DI-W%?;V I^N% TFHT2SD1>NI%99) $\[=(]<
M@F(\MA_Z>@&_I%X8$%MS %_I0^1>=_CJ>X^\E*9*F%G M].!Y;(((@#[>0AXD657.1=R.T%D4SW#-JL%L!\WXG#.VU$WLWV-T%K_\#4$L# M!!0 (&J(7EF5UTIA\ (/T) 8 >&PO=V]R:W-
H965T&ULK99=;]HP%(;_BI5-TR9V@$0@ >16JJINYB$$BK9=3+&9B:3OGRGKT[.@B"*-0L&XMO3+9]7K_ 8+&"8V7EPU/[OBAOT!;BZE4%XEML/!;1CNY3HIPZQN1%#:'R(_]]Z>1SUQBQMWV!S=DOCLV@IX$QEC*IYE/1>/WNJFDFXDL&\$+^
MB%'NE?!#I_ 9,[)Z4C-*BZ"=:@Q0\2G'B^#1_D>V@N+U^)P[=>=!M:Q=5&7S%$*J-%]^8-CHJ2WEV(LK7,+H,,_6HB/=[RHF2E[%GJ[U$KJ_^86\Q)JJ&+I&M\9KYSJN%_,IQQ8/I/X6\ M/96_(Q%EL>.HNO$KZ&3ZR3HE1!2[ZE&R9V24ZBMYG63[62]P#G@!#H+M7\BJN=S(-F)B;G==A,JC! M^\S0+K9$E<3RL7')_SQ)5M2_
ZR,)6&>V@V5KQ0G,YA).0G4:P$5OM=*P<$\J M@S3!F/HC_L#L85RU]%3P!P(8=AKNA_>S6(KVNNC?8WSL=4+J>_0X&N,7O;@A%8UW.HX)8+^F+#O;"_.$!L1!+G!RN-!<$L/#*G"='1OZ;4T7&!PX=BEZ:8E&=5P->L]K2"_:.Y!H%;'I ?W8DV,26:!J3Q79Q7:31D;_WK&2:K^1=P+?U+GTWY^O"(6.)K=D\JD/&PD&3_K6BG>:X=G/"YW]#\)ZUT>7JJ;SNHMIDE3]NUY>'34XH?S2
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`UC_1?=_Q^9M6O1C!K3(3@42)EL!T80L^!L0)O4:S36M13IR(2;`=-,J7Q8"_)NS*K:BT#\Q:@YM[J#9EH)8N7F[T\`+,F=(+)G&GD?3@-%@AK!UYXPC$%!WU9!B$O(E4]!AF\E@1P%QUP%PHSO^A!\+R^H!5W)_<4Y`!Y=L.M?^8Q!F/@&'(Z@6Q*R`\JG@PDDAWJY-PEY[]I6A^,!(@:@6C;S+9WD>>Y0(?>=J6O`A!\,AE0W@@7?K+0=)^EWP%XHHT(?UVA5N2@JN=&\=A[]W5-ORNJBOLUTE2X?ATH(HYH!J88)$^8J(+;JGRAL1G!VN*#VE>@)Z>MK?WU&7TV+U@:7$QDC5?)_%?&_N9;8?/!RM\U.PTC[-IZP7N+0A*XNX*-9D1^NBG2U;/,;7J&30E23RT2A8)C[,%7AR8EI%XKVXAK>(CX^^:5+2Z5?,6E88'P[H+P\0X6UU_G>SA]<^]1)98]U0VLRE89AXDY=^N<7YU=,W;*3(G7JX"?AOSE`/5M@]F+P6J^$3,/U$N9D"6N`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

\35@9TZHOZZH.SR>KMFV^/SH*Q_,C/KOR+'UW75K8V5UZ%;KW6?O/25.[N M^>1DDAY\M,M52P^.7OS8Z*6Y-NWGYLKCTU&_2VG7I@[6UH7/WIWISR]C=WH
M"\PJKP9QMJ9+N6X]OK58U[YX94+A;<,2<@OUL@MX(02EZU*]U,$&>GKE33!U MJ^FM'X]:'$N+CXIXQ$LYXO2>([Y3'US=KH)Z79>F'*_KD]S:>)YI>G7]WP MVC0S=78\5:?'I^=?
V>^LE\$9[W=VSWZ_^J6N[>_,WE1=NCJXRI9:M 9RR-DG M<;RQM:X+JRMUC8<&*MH&];\7\]!Z*-G_[9.0$'"^GP RO.]#HPOS?-+06?[6 M3%[\[2\G3XY_^
I[YSU[YU_;_=]SQ5_XF2FOOD4]5Y["R!0GU;&2\9TK2W" M5+VMB]E4M6YI6CR'-;0K92'?T,V#+2V 0QW@&_6WOSP[/3W^X=*M&UUO^-/)
M#\KY]$7%K@Y#"\A1<^M:4ZQJ5[GE1A6REUHX&)XI%6@L MS2UPJ['U4K7 O%;N&EBH&C#!'T*W6!A/;RR\6_,FE?FBO/9&E3880$90)(TE M\U${[[*@*P) "L!JH3$M?
-0:B*XW*R&DJW1+JSI*D_AY4!=Q5C7=E5[2J@&Q) M3\T4NZXK/7>++C3J(/\ KDE:;^O6^)KE#K7]Q=78H_'6M"3/7_3:\#W1FY]K
MVX)WUNR@+DK7T$=^A=B^_/3V$'IYHI)$<2]%U^K:N"Y4&Z5<&@)0-.,V44Z V MQ#$G 9J]6W5K7$". [M>.9B\^>]?)C@(M#Z%*D#;97-R =(0)7MO6%2M7E]YJTK'^8EAUWH#)TAM;K$@33I[^
)II=TV[M7TP>S=2;"V&$+FQ*NR^AI 'TL$@6>+M*]PBBU=T*>PV'T"UWM9Y7ANB1FS&L M$[:@-Q184&7'WVJUI!NWA=+SFEQ*9=O-C/1?1356*QVB!I'4VSMLN:*#3U1H MN](:MJ+L?B$;=
<5OG*K2X3_F2U,Y+P9&2S939@-W N'1GI E>72%':"'YDL; M'2R_K ZB]?SZ_G6R'&)Z2Z87].P_=-U!>P2%B0M($18&!2KY,O9Z*8L^N<=G.E4S0*]\MH=VBK%%>B?DWKRYZYF&$!4FM
M1PZUVH4U8@&XE2YW#;9),>BN=$2*P&6IT^.;PSY@;[U(=B.PT!14NR^F(+@1&YCW:%S>Z@7:4)=EF+W86N M(2F+%I MX@02^8X597SQ;<$#P^_-
P0[N['3:TU_9!>D8X=RBPQ7O%5HNI%XV MI*-K7#7+NM&>37VT/%>3L^E(KJN75<7S-2.CA Q@TF=/E;K)3ZOB&\68C2? M*>"M\RS/Z:XIM9[H&=O>7L,@1L#4K2U%:^+!T.?0(+
P";5(6F1$'6@5A@18 M;%U4':WMZCD8H7\%O3 M[Q(,PHW(T5$#F87+T3=*S[[\I-E=?RW:O)HRU+ M24#!S/0ZNU\V+.V,NES<;^0*S&]DA,RJ0G3/7I+T;(UH%! &J^ H -7M@V+I M"=NK!7+
5Z1T]4YP.SF1/RV'"FG<(F-R3*DWMY1_0#TRAO\>[F=S+VN#&15P M\][TJ!U#*OA:N%,&4]9>R.'Q,9&+[Z"ZN?XR:LW=(<$N82WYXGO=A.AVYB72 M>76&YWS?I;:0Q@ 2+"T6TQLS]^0-V!F,
[UV0'-S< ^1T<.B* DX7F)%D%FG M1O8!SA[P?WN-%M(O+*@;#'>&H&AXB8"2?+77%1B^HV"M=14^LE=>>=N"%"1#3GK2L1S:XTXQDNTQ8M1PG;5@RP6-A*@HTJAD/$2&D:PN2:E=U+ M%
G:*9R(+@"?0)XRM[KJA# ; KG8@W!C)7.90ZY:HLWP*#J@[4L\.<>C38CJ MC6WF&^QI<)>.(W!\F=[NX,0K?G#ZC(XG]L5BZ#!11E%../6K7,JCEP_JYR=G MC[(U].#QH[04\D90Y?&U6]O?
R2B_/R&Q()@TI#YYQ(F-?Y\?CLRHE0@*DON M.D[^*.0!?[/@,8C+A \KE@5NO";;>PH2'M-7S5@U!BD34 MPZZD2!8O]%3N]4H4D2*>7MH8DR(M,T;4 188\'@S6$!K$H6]J<_49><]:W%B
M;OL592RK1K9-F5YZ@#^0<006=, A%C?QKCQIN8DQ=%S%DDB#C"X'5LA${\Q'C!,V<:6"<"ETD%. M@Q9S"NDD^GB410X5]. 0^K(>*Z >)R+;* .32(JQ'8:,W:5H!=WS-.<)D0(B M"AB,JTWN_?
K5Y GPU09A!VTC<#\=+EC#ED*0XD=!>E>0'I2=3V1DMS47HCB M(6?6QU\:DFN+E9%L$(1"0]9 5V\)AOF59H /V)!7T@&?YG(^[5K<:11'\!D M!]&K:TEFD>%?_OKA.@;"5+R=J5>L\
'+8O0C$9DX(K:&';2#^18"B15796I* MGX9K6'2>=:: GL":P< O.HM?!A6\>I4R.H$8.FV< @_'0(<@Y!"+"I1.0'XY M(.5>*65175-6\!% 5_&7*TW)QJF%H0-
5YL!+.!0W'G28$$E0>Y;,,O(85NP.@73G#Q[MDQ">?DV;&$ M+_'6$LYFB')1)\'@3@8+$8^(VPS)T6_!CJX"0VU*YV:4]FK/IX_]$E5M*.*+ M;H?9SA,D\+K4ODR\=L*>@$\>T9%48X$0>HQ+):
(1!39@J15-H=UT<5.[.X#_ MTL1\:+@D(W6G8D/2@CF'Z"*#_A@K$X92+MR0"O",P/-!?JLN;9],8VE0%'5 MP?>8M!7R@JZF+ V; =^NS1*E9=TW[P/P(L 49A'4.NK#7OB6%5C6IK5!H*C MBL78)*1.*
(;0>1*8IEX.0MH8CK-6P$/$&NLO$FFJ;U#02+9'J5-255M+0XLA ME5,0\2OC=+'7"+Q#T"VWFCEIJKP,A9YH/EQVR0Y@08TK+E(\'V7_1PI$N5EN" M$#T%Q-QP$>U+DTJV7ZTZ84,'BN$J0T%:?
W!R>GCRE*$>&U:EQ.$-$A0--UZH M WQ]DG^]7>(84Y7A5*HQ4DWEG?)=?6A3U$?I2$]"H%")Z ;#@I%@C5T/49)M M"%[K8 6E5R8D+[/E)*)"[QA^3'<&UT5G9=$##G+D+>3*(WQD@DI%
.)6F#G, M8Q*I89(P'^>KAJ@-1\BW@VR;/%M(SO+^1"=&V?]&J\A8*P?*&@706$0'BQ[NJD*R,?&UJ] M6$1DA,5%@F-I#DQ1@8EHGO?JQZD3<;!;T]ZI8;%%"MQ^H&(.-3=Y@Y^-
KMH5 MY7U0 B*2R]Q4H2 Z!G9S2%],IZ;X-(VM0,DC+NJMB[)_N%")?#DS&+> MM=3]4)5=,,UVMFXYT2WI&Z8@44,\E"T5L"B%+P0=WVY\5';M(&C'8M"^B%1S[MW9@-)7_!(8"OIM)(+!
(PY@W1@?JII$A6TQ:L;DMX;5\3DA,U#(>M@ @DS\A ME3<% UT>?/GTWF,YR2A2.%;FPK0=ZB MJZ41 UP68*>:W.Z^'(^-9,^.B6S04B5)&H2W9ASJC&(I;-,F?=['LE0+6K=[
MHZR'E(\M%ESY2Z?FD*'70.16.EX[G"(N*[&&X"F[6<1>'NFN!ZLL(/;VB8_A M0@^')B.V$\%"C6< =P/PW:[F\XWE@DI4D^T/%6P M34+_QO('[8$"C6Q2\+!#*)ML@LVTI_ZVCWA*T\P7 BO M=-
Z5AQ!L0S6;@\E/%X2WLZ_),3*H9$I.L[CZY/KLA..(L]AB/1OD>>79V.^1;)"E^#%TP!DE0!8J&N M77DC!E53 V; MY'CC]1=*89>\V=I*Z2UU\Z]?7 ;=? 9?TEV[WBN$&>(\L=D\?1,!N!;78D9W
M(4,SN!&1R MR6ADGYEE!C+W*/SJ$_%01B9N&?-=_ MW+OK1GV7;7G1+1%CJ6=I&.=M+(8U\- 2WJR1CBU-K Q3<:O\#2M87E,6J0VQ M#%S%EBFI-
@6^G>"QU6:E&YN^&D/[3_8.IKV%TL,/Q;&?"L^_TU M64:HDK.F(<_;?Z3,;^@-]YBX%&/*'=,A?=BVG7,U0VH#WU3:6&"YC,$H0H0/OTK6G&?X]X%&NWI;BEE5:D.X1FBLCI-V] K9DV#E@(4
M,28;JB4AF @H 0_#0O?Y D+(%# FL(@V@SC#2X5W'H=@9^K:$MQ;B;],(V7' M[1(ROJ+J>+D5$28+C+?$720J:HE"F*7<:JZ-%'WD8?^G^PZJ$<_$S4#N7]7C MD]DSH'M5);?W5P4X.>X??
9.>#\Z?QE^DR$ 5JU$WZWY3'TNGC&7?;DW.CII/ M7.ENA>[3\^/964 ?B/P;QGOH*; ME@3D_@OE,QPBV/142U1

!*_RKBP!9NRO.*A.1N&[Z*X5A Y@BVIJ),5D;9H ME^DV5KLBQ%36&\)8H&? 4G^I5=.RA#WO-%S5(5=U[K3Y"RA.2&0NQ;0W'%9/'U+8%'4/WOH/BF?,':6Z/]LJ<5O2,[IMRYD)N^32&?.":0F;'(8:R)'=
BE+/UZQ< MRK!W2PFJZRIX0%X^[_SFW5Y^N''^O_'5H.-_N>-HI\V^AVR=&!UV/I:5XIV_ MFGI36_E7]NZ%O.RX_O^6#[(^'SGCHK:9R\ZG>C(QDI[BW3@8SD;!I#]$,BUZ
M_:F8]>:=3T?!,PSZ\V$PFLW$A+SM'U=761=B&BRF,W&) 8MJ0-E#7-NN@P9. M9A VQ\@!@F'>HF.+KZ;!<#$(YOCT#/K-%J0D?QQWWM6O]L[-'Z*@#+#).1\" M]%#OIKT)?>[-.K\BTOU-6AGCJ:#
[V3^B$/GHZ#I->R>['.5F*PZ+F(][I(WP M2*_<$3:@%Z5*660XO:0L<=$SW^#:7 MDUH$]I!C. %PTH :*U[IC**TR=$K]:J3",(;LHF?#U_;S;+#8KH.1!;&,9].
MU+B]-5M6XM5B8AFIVZ#E8K:=6)>O"]1<_)TYZJWL#A$IS&/M6=J1.6E%7T2O M?!&M!AQ%^'&=:V/3T1.C= _TP7T8"(>OXRDRVJLB VFZX3/(QHWI.X<'_:S MJ0[;%/SB1]G.?XOV5IM![9XA<,>?
VC0@:TDKE9IP&+70$50NG?(MT; WF=H8 MH[/AJ'#7Q0WJPWE.+LF4]398DZ[&NK4J^\@Y%N,_)<9MJ;=L76M)?M_A2%' MWI!WU8F-->0O"1U7OJ^Z)'O^?G?_BVFB09OOH8Q_>ZAYS/!=
[2"$S)YF[I:2 M,I7'@_;2:98]ZOZB#M5X=XOK,PC+0!EW+ =+V-,CAS#56#TE[R$F/)5CR/-G(">8PC/^2%9+XYBF:5"EDO?] M7W$^FV9OR9Z/LKX?"/OLK_\^]9O:EQD8ZA9CD*%IYZ[MO+'& \
<35+$AQ@\' MY\:Z-+Q ,S4*9I,^F!Z)/S>\.F:^$+-@.ECP^.GX&XGA8H$MC.SK0@ML86(_ M=G[Q,Z:]J6MS7SLJ;U63 MM MCM.SV[1-7VP -$3VV9\!I3.^\<$B[%\J,)27*OF-41YSGG<\;:J_K;QP? M&?
(C1<_YYQW;S%#NEI\HK[!3/JH%!U8/*DYW7/W0SPVH*9DN9F3E8#Z8\M]1 M?]SY4270,.8Y,MH"F.RK<0]T:M0?(?*# 19 8SCKX]_18M1Y1BQV0J*H\1F0 MX& T)Y&3@)9H>W'XNO;&-
U_8T7OM])H&P-^^_%W^6KXZ?V/?&*^&V_?N/\AL M#=04L5IA:K\WFW3M]8G_DJ<[?G]\F>9YNN6/&R61+C0 SU=IFOLOM$#Y/Q2\ M^A]02P,$% @ :HA>6;\VNEW"#0 #RD !D
!X;"]W;W)K&ULS5I_4"J(NZ4I M_O>(H35LZ,CGRW44OJ!7:D";V;6+67 5S<_\BNG9,Z;EN9H='Q\>K24NNB] M>L'/KMRK%[8,1A?JR@E?+I?2;5XK8]\->]>!G/5\$>G#TZL5*SM6U"C>K
M*X=O1S657"]5X;4MA%.SE[V+X;/7$UK/"_ZNU=JW/@N29&KM_3E??ZR=TP, M*:.R0!0D_MVJ2V4,$0(;OR>:O?I(VMC^7%%_R[)#EJGTZM*:7W4>%B][YSV1 MJYDL3?C9KM^I),\)T9?TT-IP?OS
MAE':,&*^XT',Y1L9Y*L7SJZ%H]6@1A]85-X-YG1!1KD.#F\U]H57EW:YU %: M#E[((A>7M@BZF*LBT\J_. HX@A8>98GNY1TSO?&?D5>\T3XSUI=.B7]=3'UP M<)I_[])"/&2R^Q *I&=^)3/ULH=
(\$22W"9!_U+S?9 M?G+G [%?*>^+@*!!%)72B"L'/'!A(S[H#*&)U[\L%!%8R6(CM!D1=M5I&*X$!WQ]B$%VJX-_CV MT&0ZF[1-A[/VV$\J#<]A 3JJA&EY#9XUXO>W=&D,#@!3$D:%/-'=B1Q\20IG
M-W#3#;V1 DE2>!C(0$MZKH- M.'(@ 3)2D>:]A*"TY=&)\[F90:UYPK)FNT+ M[M<+Q4J@/XI"4XI;:72E0L@*#Z2UGIRMHC$0%UB9YYHT\)!&]DB+<^S4Z#E; M
B9]4/#*0Y<:X@1;*%H:O0=+RQ5M?BQ&@U-:8>AP+*:3Y'Q.?@Q/*5-J0C1DYEV<$[H3--#\B5Q MM4 =((8B Y;J#*2#@_,,.E 8"9$.=M'0D/+ZXDW<2,9ZH[*('<,A8\=35M-*
MPEP=K;'/AP7PZK$X'@PKW73/9H^3QN_1OB^GT7W(68*#@6/GO,7BE@I%O#Y MPXXG$J:S?^86F]7A+O^LR:HMQ^EX9LM?"/*&9_]0R:$I4LC@W6;EOT(5I-U M BI$^NR@/[VJC?
80'X/M=,5:ZCBL4WHY+1UV=A1&GA\#Y] IPXN!4IP"&4'8 M>6Z)>U@G=$(BUWY5!N7Y(8>@3N%>;![&-P:>! V.O'UM2P-P4^0T*_*LO&S" M-YWQ&?*12^ ?0P\04R]+F+LH*+FWD.@!/R-
S\^KE'PFM*=O\7FK7G$I!WS8& MR]CQ!E2V4)@.7R#!:5N"';N_1HCW-RS!IRQ80@U4QZ,M'"Z X&SSW'*0E+.H4SPF15DYMPL-.:<:Q0$^;&JB?6(R'(@KMO-#_P:D-
K*+C*:^/H6Y<7_IK;XH"05R:^ED>)R4ZPWN?@T MF^% <4T-@OA4B(MRCCY/G$?<[UH1["AR05W$BIJ*;TFU.0*4+$FH9",];CB(MG]99?7&EBL)OS*TLM.RW=!01M,DZ)]7IL<+$,=KF44'0NMA
%;$W\/I.+&./ MQ](R4ZQ-<*CNH,#H(@U_D4*KI&!B _$F>G(39JH@5]1+*G:3H?%^&MW+J-"4 MJ0:<&"B]OX6S.:I2.#-U QJI/:< $"OK80+?-CCQQF53[&5DAV>R7*LTP+:W
M:NI*B104U01D&I#A/K+7/N5'XRV[W:FL)(9E(LJ:81YJ-R;*5 =8E)>:]#+I MGTX0FK_C*-*A6B1>#MO"NY&?$J4M-#G#"\11YARI:5 MQOW):<,-
S8>V6:D1RJ/'J6T24]"VU"GK[Y>UHW1T_B$Y9]1P;:;+%MJXG)4< M*W2J&TD.3\)SN:S7"KZU2K7_HFY1:8(XJ!8E%&5\I4R(E%"D M25]=S#>4.6B7RLW!,;_^IYS-%96E/G-
Z&F4FDP(_%)G/4GAOQ.@\!GPWNF66 M($L";XK#C+ ?F1M%\4Z EBL@S9U>0H<&&'+6/SL^V1M8[7'#E5-+#1,ULX%V M>%%P^[;G)7,\%=S'48ZJU%SCSKU^K5WHT!R7"V\"K@ HY&
(<+W6HNB;NNKQ& MGH>4!#6/Q;#MH+ T/:4:V8$V2J%(FORXT\RUBI=)G_>!F0S)VNN9)NT2:Q[5 M+CME)OVB*AE2693'M$T%DD55S0EZE]-RJ52%<%7KT"P7]'?H@VMF&GY0X45&
M)2,24OL%F8RL55NYJE&06REXP*M."<4I*"8"62DNW;7Z4.,%4I6NLA,F3=! MEZNJVMA.6#[U2C&\#NWLL!7MX/!>L+>PH;.:9)PJXEXNK0MEU/\CBR/T)&-).0-D
O'TMTZ'H%4UQX;^$7L6Q_7V2#;5JQ_FB&>FN: MFVS-Q9BCD"8%@3)K%9^56]6$HO9C&6ZBLI*"*KZ[N:.NQ2:IQB GJ@I=CY(T M:+,KS!_ ONJ0+06C_2QC)\B)C@*&G!MOM6,%QXG6Q?6E&*-
_Z;UOWOP"9X;U MGXD/MI@??D 5F9-2R?LN.T'[3IFTASQ4M1UES\I0\RUMN<.\;$'/5S2QT8)"^6Z2^J]Z'%M#!^)C MECPN(B[69"5A##?^7,RD2[P=N_M;G"#Y4&4- J3+) 7^5[:)6$DCJ93O)C7;
MJ0!&^\1-4QS_DZGOZ;]P8D%HV^0,,)SI*9;SWF40!=6C/9TQY/&" S0U$"A M%8]"[,9YM*IRVC2E]5U&; S/_W1;RH4?*-?=R]5"&YDKLUI01[J_/^V$P_"I MB%4"ESTI8&K4' \3;'YN5[JV.WK2IAV?
[,Q/55O7#'7_X)AN3T6G]/?R/Q1M M)F)O.=S#1).4OS$CHYA:FD)_5Y,;^&HKNN*^HYJTU'!9#U7BRYDM71HL_$"% M$7RGU62G.GS296 N;U/#014L 4K:R6YR*[,ZT]6MODYU/6AUZA&ZK-LAX6?X
M><>Y_YHF;5<./FNYC? M3I=Q"(8E!6%SFJ#%\-G13/>KRU=@H8%%OI:GT5?S--YFZ2UA_!8'T<9K_BF, MR@\1GHYF)#L[AUG5LB!!A9T#!3"VC4ICEG$R...W)_ &#I\OYTU4O-%\@=,[MW[%\!5-
#JAN_[Z;O!1>Y81M'-I4?ULP-$%"!J@J=KG;O#6YH[M^^;=YJC/8- M9ARGTYDU:,+\LT>?*L4\.N!PL:6'5/Y)FE4_^H7=HO$&XG);Y F\:GP^?O0/ M O?
H,=M+3I"U3R9[EYQBR>1L[Y(S+!F=GNU;X*L- M-7[5-\NG_?/AY-$'X-\S0M8R8@89!]GV@-@Y&8DGCZ[H3@(^0=V2VFV/QZB, MQJ?Q:3H9F"JN[]((;LCX*1^@L4YK+] YF-(&+SU),6U(AY-"<%_)(Q
M5*[3O(&6UO>G<:).5Q4J;Q& +R#(?.<:JQ\'A:A1T8'3]:I/MX@TBZ*K9^*(M:ZZM>=FT!,Q 2_U6&,4N'X\:$"64C4,5<,4#FAGYVKYR.6C]2XTD<_12/ MKG(0?/'W:O73^M=^%_%';LWR^%-!U 1SB
JKS+#U>'!VTHM9I/H2[(I_\C:U M(=@E?UPH%)V.%N]3?JJ+W1 _1O(5_\%4$L#!!0 (&J(7EF9JU;:! 0 M ' (9 >&PO=V]R:W-H965T64..-XML=71Z-HOVR>!WQ5M_\$Q1R=K:^[CX
M5"RR223$FF6('@1^'OB^V72#BUKX?GM]NF;MIWM,8QEZX.M>S 8U,ITO^*QS\,!X&3R M'<"T!TP3[RY08GDA@EC.G=V2B];P%A^2U(0&.67BH=P&A[<*N+"\82T"%W0M M7-C-
\P"7\44N>_A9!Y]^!_Z!KJP)E:>?3<'%4WP.*@.?Z9[/V?1%A[?L&S>^!L^?K5T;O)QQ=(SP;2LY>__>AO S_,*:GLC\9NA*[E-(1A8KI MW-:-,#MB$]C!3)E@2:!'2L>,E@NHPE
ETTNGN'"L9/7ZUF$F@UR6U04N@1K94-+"MCM2UW(_2P*+A6$EP+DM =K:B! M2,/.C^D.$>4WWUNE=5P7K0PDR(C0.MA7"FWE=N1#6^S0PEZ5!DD ;?9!K+7R M%14*XCR_\0U+M4%$<\@?
M##"[A$SHF(1W>\1U#B++/HTM?HDK!VF8^+L&V5$ MY.2*M(;Q@RH8Y#!:E"=,68)VK?Z)88"%PX-@\#*H#DX)#;=/ MQM-S3HFH6#>T:1$UONK$ISRB@YU:MX&3F.%=EY@1N?
TYIPFJ@F(_2D !*3NP M[O+^-)9X@"@ID8?H5&"K=XHAU:F$,LA1P2- V:)Z&T <1OS6ANQ"&W>$Z776WR#?S[BZ^$@YU[I&D#:"3\?NW&;GN?NL6P3;I M3EG;@!LJ/5;X2\
N&N#]QJ)O^T4,,/S)6/X+4$L#!!0 (&J(7ED+_-5W MDA@ '%+ 9 >&PO=V]R:W-H965T)RWW23GS:QOJ^[J/D D)#&F" 8@1U9^_3W=#8"@ M1,F>Y/:+/2,10*/1_?33C>:\W!K[P:VU[K*/F[IQK\
[67==^=7'ABK7>*#KPJUU=N-9J5?*@37UQ-9_O=BHJCE[_9(_>V=?OS1]5U>-?FZ-IL7YU=GH4/?JE6ZXX^N'C]LE4K?:>[]^T[B]\NXBQEM=&-JTR3 M6;U\=79S^=6;2Q[
3_Q7I;GD9EE=E>MFFI9 M%:KILINB,'W35V?JJJBTR[X,/SUZ>=%A:9K@HO#+O)%EKHXL\R+[R33= MVF7?-*4NQ^,O('*4^RK(_>;JY(1WNIUEC^=Y=C6_NCXQW^.HA\<\W^,C\TUM
M^']N%JZSL)O_G=JPS'<]/1\YTU>N585^=09O<=K>Z[/7?_W+Y=/YUR>DO8[2 M7I^:_?4;Y2I'9_:.YFXZ118^)>0?F";[YUIGA<$Y-4Z7]).#0DK5X9=EU:BF
MJ%2=.3RLX9V=RZJFJ/M29QW&*5$C3_JCLA5L*U--F57X:+LV=0U+VS:8R?4+ M5Y453&^6W=0U)NFT+YUMM"ZR71=P1U(MJAE+3"OS:#K"AX@_3(F#:I7%ZT5:1_+
4W=)LJ7;-6/LRV^*+4%:D%T M:S:LX5O9Y5__\OSJ\MG74%%?5D?WMNB[K#20JC%=/"?L(BLK5]3&]3AW8.MO M?47;7NPRDGU"GWT3EGF(9F5?=Z0MV9AW5SY6:)?WTZVMUOQ) ^O,-@(3FF#B
MV%!23CYU;MA HJ*L[:WK"5FQHKG94MV:+$6'&*B7Z&,X.P!C9-)Y8JQ_7% M>EH[L^Q[L]7WVN8CS2[@??C4X4/5\3?I)B!6IDI8%82EZ3?J@Z!#JH)6(>2 MD&U"Q34X!6R-K<\]#('=&F
MM=785S#AG0;*B<4>.G%ZD%-"W#1-C\5^T:VQ709QB6QDE_/SOT.4&N.B^# [M^OXG97%:E]>)0R3S_H?+_M$K"X.$$QZ/ @*W'BC\! M6D?6&>VQ4&Z=+4&4AY4^:_[!U3?
P.\'O_]\-6+;]>$P5(U0)KDB<.AS/])(, M$1M%H)'ICRW8N"X/7(?L8=]WKK/9":KT)%*E)RZO:JF-W MDT6KK*5\>RG MT+;)P;@J0 4]HC>TQSB'#]U2R!9]55=J4=42%3U^
M>3<&];&.3W[1.VC((53<512!*J&$,"),,@X;:\5?P?_)\I-T8P %;SCX"='$ M^8#4Z)486NH@1(@&,YNE>A\OU(!B^/'SW(
M]08^@L,BXX:8]8[Q4I5E)3HXCCYC[928CH)YOZ'XBP617B(5Z43NJ^OY['&4 M,6OM]*%:PR;Q/XQ,JT6-G_L.\1M_//%;5MK/H+E=]@T MB3A_/'L61?2(ELNQ$\3:6O4\A$EAA M3/7.YQFL)US[AD"C]
<%X3$M."">C)(4-C4,B]E-H77K[/T=ZH6?I47BM7W&K+'*7;E V.!=8I;A-.F/NQP),L&QV^2)_]OAI_OSZ"HQ063DY.O;QZ2'A M.I@?&BBTN-GSV;/K#'8B0\S7$- P;%% 1\6=U1[O1VY3@(V! M,M1$6OI-
ZPT$\Y6Z5CL-+*-\?)D8E/A0(N0P,I,4WS.J0#*(VF*YHDLC!D%$ MK9I]^**LTY);ZW1SS)7@G-J*HBR+H#\"V$I1O-UL\3!:$ 5T("[2E4ZU^ M9Y#;$>-0@HA28UE'SG84[2VY"ZPXQJ9ALABF1A-
2@'*4YN,!,FZ8#Y1(2%G7 M1XB&D%"J'CG-&2D+A3EJTW(^0[^+1#7_K$H<:44%5:9RT4+&-!;; '$#0W7! MH24&#^8Y,B]OF]B?'A%*#FOLQ)*4Y&/6W&A2J>=G%-
*\A8[LFME08@#'&4)YETT(/I'H5I2+4_3QL0\K@& 5DO$8&(D2#5"5#C9-A>\N%"\;MM4DA+'\ MZ2'2!O)/#&+J:6&*3L,[2'=\"II+FS7=H%&-"G !0\((2U==D(@<>M-OAMTP MN(VJ]Y["1">*>XNE
4%150)]7 *^8]P?QV@"+=["D'O>0+=[EDM,@,%BN>0J M&*F^A$[M_N2)_P7$K$#7U.Z\,^?X3ZX..1B&G)KF&D16L'8O42*H!T-?_4G0 MG!_TV$OP4'(<%_LC"@3
6%"BS:'*,@^(==9@1R$H<[#&8H'VQ!]@6Y\"4J) MN0S2=C/&><1>L;%$C\%904DXV@SY&1'J4"XPH/=^/HJ_^X_"IE/)-I[NQE = M=Q6#&A=!TC%]MS:6(Z%0^_Q37L6$P-L]+Q4OC(2S)9$J*6+
4JEDVC?#3<"! MJZRI]#TR/WC\KY+ZDT(EX6@1J>@3^CZ/$X41>4+:(M7-??5]JHH6SILR#$JT MZD/["S=A8WJB:F?V=4-0SR[B!FA/P%9 -<%F;#> ;D3-+=F;XKP \;^N--=K M5VRJ3?+(-
I3F2^TJR^8@RI@Z-(M#:B@+7GN,86DIN/M,+B(YG0Z'G7TOVA,P M8"M;)Z+S4MT;&YR&+(,TA/+^?G8W0RH%89N-SQT$<+.E+ID=,D-@1^4[PRW% M("6ERA:Q6]B2#POD%;S]M0:;@)5"EX,_+
(V.*,U0QZ'K56Z0G= GR!0Z&5+EAWBH5#R(XDWC^ M"5A,2#+V JJ]>IA1 A7Z&L.Z5D4P[P.;X$"<#=L3P MZ*
<<+2;4.)S2H*&!6)^XJG@:KRJ>GKQ9>"^5P6]XL:4:=PT:OCXNP429[.),:K7E(6.FZRYTUL&DDN(]++!S:W M48U*SF#%Y.#(F&ZHSG@L.GFY.R5.3#3+W@J8AN>X)((83CJ5D[*@8YT!@B_
MY[Z*^TIO_:5&(V53%=+WH11,=0)?^^L;OE$C;R=5(RVA)9QI&BV^8_J.RE\9 M0+XTEJ,C?H4BEKN,>HRJ(E0SDELD;>D Y1:)IESHM:J74E:3LPH[J\FA:=M^ MKF1L!'?G#!0HU^:N2ZY90I$[RL&
(M=4B2BAKL$BD(CQ2CF,U'@$RT:=+7P_G MK(.7F8VZTXZ;F-7+6FX8)2U^8#7.Y\(Y-\Z$2T^.3(R>H4Y?6!(,8AZ%0V\W MN3<8*M5R2NO[-JHR/,%9M.2-CF]ON9^CO%<^ 4T4 0.
[KYSWXI4Q)7.=H&XP M!ZX6^.^YUGV^X.Q4;;D83#*.GJDI>85JWP9NL)8:0Q_+O[M@S:Q/N#?G4T'[M>9 LT)WH0=2T(J4'<1$7,#0P56K5";PAGE2<>);])]W,P6 E=/*]YUY%,]9& M",2/&L0I6'X68?
G925#])3WDM\DAWY)E3H'TGYG/_YOX&6,!,[-&='V\WD8U MQM-/#>8R,,32]JOTH7P(V*[#(^$6UC3G^U_D["7>EDGS$0]FV2^?<(ZA]"1(MPD5(52O+\]*-M=EI K%&+RLI@"P"B!J"3#
,9ESG2!M84V%BXC/P,](?$PB6 MG$H3J5=PCM8X%:ZI*UN>4Y:SB\6/I::I?!)$*>[-5T;*%O&)F>[!LVY6B(YE M6K5@?@4:LLO'^F1F%'X9'6NL/8R?Z2@Y&?-E,^)=XR=C/C/*(3RV[EUQ&2#M
M[UCOT]8D.Q=]\F5Z\$N/,$SAB1E28&0M\(5?P"C0+8+TK%/N UBP3T'2'C$@ M7BD*'+6?[=CK/^C=$*GD48O=_&P:N8*59-C:019,K,#]*05F"G[^SU?5/4@ M%JZBI39WQ/V2<[(!\\4E]B"?@AF56?
8_CN-8_3R2%.KC!$=3SG%8]B&^@[I3 M44NBJ80;\8:XMPDNP!R7IT0BSO6:K ;:\C6%;]&))2=9,!0@XG*1)L=U+'5) ML.N_;Y?64%;@E4ZEPAH@31E%/ B&:NE^H]<'.JIS%N)UG\3O=ZH[B?
Z?/YH[GUO^(&+8'JL2 M!M[HI)5Q"=#SUQ&4L^BB%S(J$RN"J")4GX^ HE@KZO<0O KQ*^0N4"A%K0$L&5^HS9$04X=/0K;",WE(I,_? MU J+W15KPQTIS&
[.J6N!'M@8>.5L+';"+Z4"Y$6L7(HQ=,;#]9&K.IUR?_A2 MR* KJ&M-'5C*GJ>:SYPD&D4$[]$\,WH#0EJ(J)'X2MJ&YX<-8QR% M5+PM#"]\<.H._>:Q$?GD1P@MX;C1))4;8B"E6F=-
*4,W(^_U_*32/S7;,.*P%RVTQST*,2R@IE;%^A"7A?%NZ06] [C8^'[.#J*E35] M&RL94@=BM54;WTU!YNW[D^/US8<30V:HF3"0\4G2UZ$,,>[3XV,) M*TXJ>>H0RHHR#5B4E\JWI#D?
T;FXN7=;RXT]U%^3,>/G7#1,PY<7!_VE$^T] M+=TY4_PJ\OY\'[H_"0O^AFN_R/%GW>0_H[N7B??_CPYR?3; MD(EXYX]\&0X^.JD[[4H4P_*!6\B<_(OR+&8,"U
M7FIZ6F&2GEN=D\9>@YZ8F+6S9:=MM5R6Q5?*'^1S6>7H:%VQMVN7%(-M#/,I.,?U_'$0EX7PVHG]T*E2A#1&H3E-D3PQOJV5M!>G1SA6P]NJ9J.H^H8R 7D9*SRT)[T:!9*!_'CF/6O>]"TG1
M)8IQ<'T6C"R^_#7+3L7QY.\\7'[BUJ&0FMD/ ZS=E.;P37;3&"H)<9HW&>K_ M#>MDW_*Q$5,C!>'_'"K:A@R=!JSZ2MYVJ&+8\UCW[H*Y>0ZDP*;LMQZ)6!&$[:$
M/O1*=3YQ=3>>=9;]RU^'TI6UUI.PR3 M%N?019>T,H4>FL9[R.>_^9JGK]Y1M>3@%5ON;OK9W(N7#,DUGX[?V$A*Z@=; M-0(U$,QBJ(=>_P+"BNOJR:U_VG2=)R]NA1XVW:QIYG+\,CJ7--
/>\%AO9PB0 M902[2+YH/QOB+'1EZ0V&[C<@0N?;1.@4^%Z2#Y7+U]+-2X\?GDE\WPZB^2;[MH^^]2O2C5G%LF'00_L" QX99]ATU%@YI1N(F4?Q>7OV1"U,XT)RQ@Z
MM3$FO#%$VTK5XE_P&;LMK>/?J: &+B30*KQ0'N[=)LV.W^$+DI*M(>\3(TN! M;%B'L^VZ3NV#$OA0#I*7C:+NZ)TM>2__P&Q]]_#(:MM]FY5B"MVPMTG5S%^"
MA:$C6Z^E2'<"_M@/]JYG_&4@DS(\.P";&6B;O##\0$N:"HD7R5]!XIH1_:TG MXM=P#?F#2/'3^/>D;N2O* V/RQ^C^DE9:!ZYDEYBZ'SV[,F9-*2&7SK3\M]4 M6IBN,QO^<:T5*!
<]@._ICWN$7VB!^%>V7O\?4$L#!!0 (&J(7EG27.34 M!00 &L, 9 >&PO=V]R:W-H965T T9YEVZ@5R^65*682&7;&7Q M#0.<:*$LM5S;#JT,D]P8#_7>
QL/:2%2DL,#0[S(,LR>IY#2WX5IU"J5X/%\C_Y1VRYM66 .,YK^ M31*Q'AD] R6PQ$4JOM#=9ZCLT01CFG+]1+OR;- W4%QP0;-*6#+(2%Z.^$?E MAR.!GOV*@%L)N)IWJ4BSO,,"CX>,
[A!3IR6:FFA3M;0D1W(5E+E@\BV1ZIJ4N]Q5=?71/<['FZ$.>0'(J;TG>-7EW3W[JM@+.8=-%GFTBUW;]%CRO M=H:G\;S+SK@C/$ZI\@='_TP67#"9/_\VV5Q"^LV0JJ8&?(-C&!FR:#BP+1CC
MMV^S7A/TV]/&\+"5$EVB&^1I]^%Z0+4[;(]AD1*N:9B,>UX"6-)55 M3?(5TDIX5=OD/T!"OI[1;(/SY[=O>JX3W7(4*XYPQC$[<.2'+,-<&24#+"!; M *NCK$7N(*YV';WK#3J/5. 4_550
0F:DU5.EB3&N3B>=]Z17/*B!9<@_'WG M)7IG=L9PT)$I"\\52;0LI" B^1:XTB/A5G0++%;"]TW^2N0>=K=]Y%CTR7\#.:DC3ER+'-ON_OAW,@+?&ID;X3
M1&;8#VN1LW5%O#EP3M@S0]^NE3>*_D0BW""GWS?[D7*A[YINSU5;%>K!ER]2 MXO>%TO7-R'.)U>'LI*HAE\)9223P=\//Q%*+S CIU]+G"X[,\HVE&$!:$&5 M.T*SWSNDW,FJ->BA;=J^LZ?4\?
-ZNZ(03SD&\ MDHTWNKH]%8[HI!S*HK_46CP_D(GHG+>7U@R[T8VEK'XO..VG5%9>;KJ6?P/ U 'Y?DGE-[A:* 7U_\7X?U!+ P04 " !JB%Y9 M#@&Y[K8" >!@ &0 'AL+W=OQ=]W=-:3_OK-KXU*)
MH!S ^S%OWIL9SWBZE^I9YX@&7LI"Z)F7&U--?%^G.99,7\D*!=ULI"J9H:W: M^KI2R#('*@L_#()KOV1<>,G4G2U5,I6U*;C I0)=ER53?Q98R/W,&WB'@R>^ MS8T]\)-
IQ;:X0O.M6BK:^9V7C)W6!36$&;RF3?R(,,-JPOS)/>?L8UG:/VELM#N'_: [3#V(*VUD64+)@4E%\V3O;1Y M. *,@E< 80L(G>Z&R*F\8X8E4R7WH*PU>;,+%ZI#DS@N;%%61M$M)YQ)E@HK
MQC.X?Z$R:]3 1 9?3(X*;FNE4!B8:XU&PX>O;%V@OISZAG@MVD];CD7#$;[" M,89'*4RNX5YDF/V/]TEO)SH\B%Z$9QVNL+J"*.A#&(3Q&7]1EX3(^8O>EH2C M'+2Q_YROM5'T!OTZ%7WC/#
[MW';51%_)BKHTJPL$N8$WU_)4$&=I3@=QX,-C/NGXTI:/-?E+)76Q-IA9F60 &UG0 M..!B.^E1,0V6:P+9BMYAVFX&_9XMKZUQU/O !>%DK8E"7_8.S%8*4VGNF#/< MT8RI2LO;2;J
47\P#NDYZ(_'<>]!&"24(6B*?&=?:1C'$411V'GE0M>*B12! M+JY'8:_)8?5ZN&V8T]"QCWA_&82*-^-!K"J3K[1SU;HMJZR60S50O3 MM&]WV@V_>=/S_\R;R?G(U)8T0X$;@@97-T,/5#.-FHV1E9L
:VEHGKAE3@,< ME36@^XV4YK"Q!-TG(?D+4$L#!!0 (&J(7ED/)1@!T@(_/<% 9 M>&PO=V]R:W-H965T?Q<[[A.91B,K/*@641K'XZAF7(;+ MN=^[U\NY:JW@$$$N\UF+:NF7Z^0J&VBS
)7S:^\DUEW4:TG#=L@P]HOS?WFKQH MSU+P&J7A2H+&,,N6 M@XA6N/F6E8CHN0OG^#^@G#Y;LWR3A^ M?T+@:"]P=(I]^4#M5K0"095P6)0!?$%[3.Q)NN-B.U[6\TIJ^5Q1>QE+NW2L
MK1!*):A/N=S, BJ!Q7J-VM?A!O/>20;!=X-E*^".E^@+Y)9A<,8E<:C6,%F8 M\^!:U4UK"8%_6MY0(UO(X!F9-O 6DF32K<$=6Q^)2 99>DEK,DV#VU9+;EN-
M0,10\IVS#4SZT"S+W#^X0^K.2HD">-UH]82.T(!PVT Z:AAE] O204I&,IC& M4\(8,X-5GK=U*YB[AP+IOG+._,PXH[#1> SGWDK3#,Z#MS"93$G[^'($Q^H> M'31CC7KC1XZAFVZE[?
IRO[N?:JNNF?^%=R/Q,],;+ET*)4'CBTD6@N[&3.=8 MU?C67BM+@*;%4UFU"Z WI=*V1?'';"?]&PO=V]R:W-H965TW#@)J :F]FF:?_]KDW"LBG-"_:U M[SD^]YKCZ4ZJ)UTB&GBIN=
SKS2FN0D"G9=8,WTE&Q2TLY&J9H9"M0UTHY 5 M#E3S(K#<5"S2GC9U*TM53:5K>&5P*4"W=8U4Z\+Y'(W\X;>8>&QVI;&+@39 MM&%;7*'YUBP514'/4E0U"EU) 0HW,V\^O%DD-M\E?
*]PIX_F8"M92_ED@R_% MS NM(.28&\O :'C&6^3<$I&,WWM.KS_2 H_G!_9/KG:J9A&]K+OPQ%@$KX! MB/: R.GN#G(J[YAAV53)'2B;36QVXDIU:!)7"7LI*Z-HMR*9YKEHLX/Z%
MKEFCAHNO;,U17TX#0_0V*I#"EAGM18/$O/B!9O;;HH&T1 MG25<87,%<>A#%$;)&;ZXKS5V?/$;?$OVZFH#)@IPA3.NX>=\K8VBO^/7J9([MQN0THW7,C6Y8CC./+*%1/:.7?7@W'(KW).?
9L10XL6HX@_#_/9W2 M>I;MM%9JL<%ZC&UGI4Y,=I:K_C40^0 MIB19DW$*290.B#?V1VE,O*D?3\9PJMG!D2EJ5%MG?0VY;(7I_&O]J_+O#/5 MW_3N:7I@:EL)#1PW! VOTI$'JK-[%QC9.
(NMI2'#NFE)+R0JFT#[&RG-(; ' M]&]N]@=02P,$% @ :HA>6:H#*E$0!@ L@\ !D !X;"]W;W)K&ULQ5?-4]LX%+_[KWB3MEN8,8GM)'9"@1DHM-M#6X9 M>]C9@[!?$@VVY4I*
OO7[WNR8P(3,FWWL)=$EM[WQT]Z1RNE[\P% 1QKQ"R[)PD?P3>+*;*R!/;E5ZHX_/F7'G8 PAQ3RQ($_2WQ M/>8Y"R(S?C0R.ZU*9MQ9G1]W1AW(<"H6N;U2JS^Q M\6?
(\E*5&_<+JYHVCCN0+HQ51<-,%A2RK/_%?1.'#891\ )#U#!$SNY:D;/R M7%AQ.%<=-QDG2T[*Q&HZE<1G3R96I7=SE6>HS5NX^+&0]@%$ MF8$[@*\5Q\[
WK6XS='L'_4L*6767MHH.*L51"\H&, G5=JY@8LRP^PI?X^, M;2V.UA:?13L%3K#J0C_P(0JBP0YY_38"?2>O_RL1^*(LPE^GM\9JJIN_M[E=
M2QULE\J]=&@JD>)QAYK%H%YBY^2/5V$;!+^LFIH29J4K,PF(%5 M<(X6-54(P@A]JAW2JOYPA3E5,3RW(&ELL!G&>E M-3YP?
\'*M0!9(Y:HJ:.Y720=6F(5SRV6I=L_RT5Z=S!)*0%H0#F*@TK+E+44 M*L.-!8T"Q]TPPC>>!?W%4$("R(;8(\,?T"AS3[$W2AZ M/%VJ7%B9<_6,8V([ETN9(772@\0\@Z
;!/!F1^Z';>Z'.Q,QJ>'S>6KAE/&- MM&]+[6Z)VU);@[3\AY+"(7^OBDJ4#W^\&D5A\LX\B72-K.PWW1&.NN1,%77; M([<]/(FZZUS8$X5:4/%P)10RSSEG/N!]2J1.DID+C3ZD)(>;<"%REP'?P5.%
M#0%0'8C]0^_[NOC:Q6E3A:>SF<89)=1;[UPA7U?L[">2+>F&2;TO"V<>1?7B M'G4J#3O]J+ENISVQ[TU8JX%+JE&$ZV#&)+NR/OZK(0C/QA%?C]8,@UMS[&QM(,]B#VQW$" M^T0P?
B2@,$Y1DH0>WE=2.\)A0L)&1!E228ZVV+@E5[$?C4_1*O79%\R9B/= MY00II(!5YNJ!^9<5UA6=R.J7>+RFIMVA7B#4^K4,,E2FE-9L0Y"=(K??=FM HA>-G=,#SG!R.;4; M@/+6P-7DQD"VT Y[?
A8\5I0U81K4,D_:KL60_PL_W!4+YUQY.Q%DXYK^[S 2 MAT,_H!OF-=U:XP$U5NQM)+>NO04G]Q%3!D "E(CHH_ EVF7=FWL0#OM^,@P(M-5C\2^0MW!!'XL?AV-''@Y\$F?&87.@[%^(QN3"LE]Y-
N?PMC'A!'NSHH:3M MH>27+N&#,\$PS%5- XMPUR*_#$J#V[III_#MW52KN75JTDTU6*MQ+9'F],Z2 M4_GXOJ+JS_B8F4JC@] /^I1O.&75U$JH@?"S#)" ;MJD5D.EW31->S#)0:PZ=F8[I?WO
M=W9"1C7*PUX2G^^[[[[S.9?Q3NE'DR):>,Z$),@M38?A:&)4\R8N50Y2O)L ME,Z8)5-O0Y K9(D/RD08M5K],&-\ WCCMS ML 97R5JI1V=\229!RPE"@;%U#(Q>3[A (1P1R?A=<09U2A=XN-ZS?
*U4RUK M9G"AQ'>>V'02#(<,,*8>_4[C-6]?0<7ZR$\4_8E=@!98P+8U56!9.=<5F^ MV7-U#@\\Y(W>H/W"FZ) M*37P42:8O(X/26,M--H+G487T*GU82H%75/\'7JPCN>K_?A5]S$PME
M"HWP<[8V5M/M^77L%,HDW>)W!XI]NJ(O "D$@MK +;.%YM9I)^L&Z:+"#6=K+LK-ZP+A@5JA*]]LJQ%]]<>J M.IGW>%6O!0B?1!P(2$A X078%)W/(U@M Y@/I#9;S-8$V_<:!G!LE:(*8 M4>-
KCIJY7C7.N20V51AJH+DH*S.-^Y0X(2NO'\J$D'"-<<7:KEC/H#/L-'X@ MTPZ#R3^0'K2;O>Y)2)\@W<%)R(@47]P"C(D2'MX1;J1QNK&DN>J1Z:R3%3' ME+.7\I#ZS6&[V[A!8T; L[RPQ,9*BW?
FH:B%4A;3E:ZMUZ,,_*>?077D[U6Z:W7!H2L*'0UN6@ M%X N)V5I6)7[Z;16EF:=7Z;T6:GC%]>E! 61T !D !X;"]W;W)K&UL MK9E;;Z,X&(;_BL6.5C/2M)P)=) (;8XDZJJ:3'Q^O P<,])F]TAQ
#WY,XI2-EQUAVIZHTV*$$TEN%C4/9'Q$.R*^ M"/@K0GMZ5-9B)"\8OXD#/QPIFN@0BE' ! 'ROWC)V/Y052-,'QWU'(=B/%54"(MC"/V1>\7Z)J/+;@!3BFQ2_85[&: H*< M,IQ48MZ#)$K+?_B]N@Y'
LYI%QB5P.@K,"N!>2JP+@BL2F#U%=B5P.XK<"J! MTUC:8>:TWI)ZLLND*[.D2+$I9' \)'@/B(CG M/%$H\K30\\R*4N&H#2/\;,1U;#Q%-"!15J0WWH*'G/(2@%,0_ :41%[1-! M%*4,%E$WX#X,
(U&$,?#3TM3BQ,V/MG0N M84X!$W?\][%N6YXW5-^/L_8\RM =8]",FK6P+,>VFE'S\RA/9!C&R=!_GF0K0]4*(A86W)T0JY-CA)F'UV5&\/23/-DMJ8R&YW)A,UEPA8R84N9,+_G1*UD M-
KJVSCQSH[NN?63X1J+;=:+;G8D^@717//($HH"^Y=$[C/D33^M:V(FZ-MWM M\T5 ,P?:R5HQE=GF3"9L+A.VD E;RH3Y_>9I);/ M218PQ%.[0BGVQ$X2?@S M_8;AX W\\XB2%T3^;7-#)^9:-
\B$367"9C)A;Q M.LVS$5]8048B[I<,D?*+:YMG2HQ[_(7C=G#ROC;I;.M:Q\B$S63"YC)A"YFP MI4R8+Q.VD@E;2X*5CE&/=D 21%Z+33K*[QYYRLHOH'5MO0]X7VQ_G=1/]+NE

MAN24$8G%))93=OSLS(GA*W(!]%UH_6^PZ;,L.FBJ;3@BQAJG5]DIJ":.MBFH;]NFH9]":B6K6F1_+Q\=B/BXV)PRER8GU<6*N=62AU0=GGNJVA&+; M0G&JM4=%MT=#-1W5#%0S4:CFHUJ M:B&J1:@6HUJ":BFJ99163ZNJ]6!32-CB=."9V@:QUC]L2$U!-175-%334OA5'4K-MR/^1<@6QVCJDT'H%5%-134,U'=4,5#-1S4(U&]4<5'-1S4,U'}4"5 M1+4*U M& 425$OEMVT0#2'UGRAPD*L&!UE\^^_G99%+B[ORG^TRlNU4TK]$C9T/H%5_-1S4 U$]4L5+-1S4$U%]4\5/-1+4"U$ 4B5(M1+4&U%-4R M2]OG5M4"(8MK(,[<"+SY."4G_R;\ (5@\0^LP0YLB4$U%-0W5=%0S4,U$-0O5 M;%1S4,U%-0_52%0+4"U$M0C58E1+4"U%M8S2LE6-5S(N[N0P;N$T6H+5%-0 M344U#=5T5#-0S40U"]5L5'-0S44U#]5\5 M0+42U"-5B5$M0+46UC-+]G\5; MU5UTA7PSOP;=D_=Ô.>AVN*CF MH9]/:@&]A:@6H5[,:@FJ:B645H]K*I*BZZX&Z#M'5=BKG5DH=46]*:BFH9] M.JH9]&:BFH5]IlE?!BN?5_?D-7XNNH-NCXMJ'JKY]!:@6HAJ$:K%]):@6HIJ M&:.75HZM:1=+IZD=6JA!1>HIJ*:AFHZJAFH9]*:A6HVJCFHYJ*:. MAVH^J@6H%J):A&HQJB6HEJ):1FGU<*N:.+\HOV:4:>Y *,E)34$U% 0W5=%0S M4,U$-0O5;%1S4,U% 0_5?%0+4"U$M0C58E1+4"U%M8S2ZD%6M61TQ2T9K2]_ MH?48]*:<>:K^>'VN-R$06=4D4U#=5T5# 0 MS40U"]5L5'-0S44U#]5\5 M0+42U"-5B5$M0+46UC-+]X535:W3%K1-_LGU0 MK+8.]=$E(45.J:*:AFHZJAFH9]*:A6HVJCFHYJ*:AVH^]@6H%]):A&HQJB6H MEJ):1FGUD*JZ-+KB+HT_T3XH%EL'U$X[{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}2"KZB]ZXOJ+/W%GL5ALG62D MJ"':BFH:JNFH9NRUPSNWY=&H,ZB? Y#+122U4LU'-0347U3O4\U$M0+40U2)4 MBU$M0:44U3)*JT=457f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{X#U]UA&M T$U!=545_-034U _5"5(M0+4:U!-525,LHK19DPZH.9"B\2_NB3X1VVC"]445%-1 M34,U'=4.5.#-1S4(U&]4<5'-1S4.U'}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f!&"R)OlSQ7M>\T1'>.927I!-\)%$0=-C"IH\ M1$T> (I?:.:+KB#7Y>;701N&K\JL-K9,HMDO8[V>H2[J$L84>GJ?8S))@8\GUP1$A@^)3&$)QO+SW0GKA+1!U{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d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end XML 49 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p ;if(e.style.display=='none'){d='block';p='-''}else{d='none';p='+'}e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} /* XML 50 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a{ display: block; font-weight: bold; } .report table.authRefData p{ margin-top: 0px; } .report table.authRefData .hide{ background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover{ background-color: #2F4497; } .report table.authRefData .body{ height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 52 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html 179 247 1 false 49 0 false 5 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.larimartx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 100030 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 100050 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss Sheet http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss Condensed Consolidated Statements of Operations and Comprehensive Loss Statements 4 false false R5.htm 100060 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity Sheet http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity Condensed Consolidated Statements of Changes in Stockholders' Equity Statements 5 false false R6.htm 100070 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements of Cash Flows Statements 6 false false R7.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 7 false false R8.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 8 false false R9.htm 995455 - Disclosure - Description of Business and Basis of Presentation Sheet http://www.larimartx.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentation Description of Business and Basis of Presentation Notes 9 false false R10.htm 995465 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.larimartx.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 10 false false R11.htm 995475 - Disclosure - Fair Value Measurements and Marketable Securities Sheet http://www.larimartx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecurities Fair Value Measurements and Marketable Securities Notes 11 false false R12.htm 995485 - Disclosure - Prepaid Expenses and Other Current Assets Sheet http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets Prepaid Expenses and Other Current Assets Tables 12 false false R13.htm 995495 - Disclosure - Fixed Assets Sheet http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureFixedAssets Fixed Assets Notes 13 false false R14.htm 995505 - Disclosure - Accrued Expenses Sheet http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureAccruedExpenses Accrued Expenses Notes 14 false false R15.htm 995515 - Disclosure - Stockholders' Equity and Stock Options Sheet http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptions Stockholders' Equity and Stock Options Notes 15 false false R16.htm 995525 - Disclosure - Commitments and Contingencies Sheet http://www.larimartx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 16 false false R17.htm 995535 - Disclosure - Related Party Sheet http://www.larimartx.com/20240930/taxonomy/role/DisclosureRelatedParty Related Party Notes 17 false false R18.htm 995545 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies 18 false false R19.htm 995555 - Disclosure - Fair Value Measurements and Marketable Securities (Tables) Sheet http://www.larimartx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesTables Fair Value Measurements and Marketable Securities (Tables) Tables http://www.larimartx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecurities 19 false false R20.htm 995565 - Disclosure - Prepaid Expenses and Other Current Assets (Tables) Sheet http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables Prepaid Expenses and Other Current Assets (Tables) Tables http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets 20 false false R21.htm 995575 - Disclosure - Fixed Assets (Tables) Sheet http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureFixedAssetsTables Fixed Assets (Tables) Tables http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureFixedAssets 21 false false R22.htm 995585 - Disclosure - Accrued Expenses (Tables) Sheet http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureAccruedExpensesTables Accrued Expenses (Tables) Tables http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureAccruedExpenses 22 false false R23.htm 995595 - Disclosure - Stockholders' Equity and Stock Options (Tables) Sheet

http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsTables Stockholders' Equity and Stock Options (Tables) Tables http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptions 23 false false R24.htm 995605 - Disclosure - Commitments and Contingencies (Tables) Sheet http://www.larimartx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://www.larimartx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingencies 24 false false R25.htm 995615 - Disclosure - Description of Business and Basis of Presentation - Additional Information (Detail) Sheet http://www.larimartx.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail Description of Business and Basis of Presentation - Additional Information (Detail) Details 25 false false R26.htm 995625 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) Sheet http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail Summary of Significant Accounting Policies - Additional Information (Detail) Details 26 false false R27.htm 995635 - Disclosure - Fair Value Measurements and Marketable Securities - Summary of Cash Equivalents and Marketable Securities (Detail) Sheet http://www.larimartx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail Fair Value Measurements and Marketable Securities - Summary of Cash Equivalents and Marketable Securities (Detail) Details 27 false false R28.htm 995645 - Disclosure - Fair Value Measurements and Marketable Securities - Additional Information (Details) Sheet http://www.larimartx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAdditionalInformationDetails Fair Value Measurements and Marketable Securities - Additional Information (Details) Details 28 false false R29.htm 995655 - Disclosure - Fair Value Measurements and Marketable Securities - Summary of Marketable Debt Securities (Details) Sheet http://www.larimartx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfMarketableDebtSecuritiesDetails Fair Value Measurements and Marketable Securities - Summary of Marketable Debt Securities (Details) Details 29 false false R30.htm 995665 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Detail) Sheet http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Detail) Details 30 false false R31.htm 995675 - Disclosure - Fixed Assets - Schedule of Fixed Assets, Net (Detail) Sheet http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureFixedAssetsScheduleOfFixedAssetsNetDetail Fixed Assets - Schedule of Fixed Assets, Net (Detail) Details 31 false false R32.htm 995685 - Disclosure - Fixed Assets - Additional Information (Detail) Sheet http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureFixedAssetsAdditionalInformationDetail Fixed Assets - Additional Information (Detail) Details 32 false false R33.htm 995695 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail) Sheet http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail Accrued Expenses - Schedule of Accrued Expenses (Detail) Details 33 false false R34.htm 995705 - Disclosure - Stockholders Equity and Stock Options - Additional Information (Detail) Sheet http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail Stockholders Equity and Stock Options - Additional Information (Detail) Details 34 false false R35.htm 995715 - Disclosure - Stockholders Equity and Stock Options - Assumptions used to Determine Fair Value of Stock Options Granted (Detail) Sheet http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAssumptionsUsedToDetermineFairValueOfStockOptionsGrantedDetail Stockholders Equity and Stock Options - Assumptions used to Determine Fair Value of Stock Options Granted (Detail) Details 35 false false R36.htm 995725 - Disclosure - Stockholders Equity and Stock Options - Summary of Stock Option Activity (Detail) Sheet http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsSummaryOfStockOptionActivityDetail Stockholders Equity and Stock Options - Summary of Stock Option Activity (Detail) Details 36 false false R37.htm 995735 - Disclosure - Stockholders Equity and Stock Options - Summary of Restricted Stock Units (Details) Sheet http://www.larimartx.com/20240930/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfRestrictedStockUnitsDetails Stockholders Equity and Stock Options - Summary of Restricted Stock Units (Details) Details 37 false false R38.htm 995745 - Disclosure - Stockholders Equity and Stock Options - Summary of Stock-Based Compensation Expense (Detail) Sheet http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsSummaryOfStockBasedCompensationExpenseDetail Stockholders Equity and Stock Options - Summary of Stock-Based Compensation Expense (Detail) Details 38 false false R39.htm 995755 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://www.larimartx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail Commitments and Contingencies - Additional Information (Detail) Details 39 false false R40.htm 995765 - Disclosure - Commitments and Contingencies - Schedule of Maturities of Lease Liabilities Due Under Lease Agreements (Detail) Sheet http://www.larimartx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnderLeaseAgreementsDetail Commitments and Contingencies - Schedule of Maturities of Lease Liabilities Due Under Lease Agreements (Detail) Details 40 false false R41.htm 995775 - Disclosure - Related Party - Additional Information (Details) Sheet http://www.larimartx.com/20240930/taxonomy/role/DisclosureRelatedPartyAdditionalInformationDetails Related Party - Additional Information (Details) Details 41 false false All Reports Book All Reports lrmr-20240930.htm lrmr-20240930.xsd http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 false false JSON 55 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "lrmr-20240930.htm": { "nsprefix": "lrmr", "nsuri": "http://www.larimartx.com/20240930", "dts": { "inline": { "local": ["lrmr-20240930.htm"] }, "schema": { "local": ["lrmr-20240930.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] } }, "keyStandard": 215, "keyCustom": 32, "axisStandard": 21, "axisCustom": 0, "memberStandard": 25, "memberCustom": 24, "hidden": { "total": 11, "http://fasb.org/us-gaap/2024": 7, "http://xbrl.sec.gov/dei/2024": 4 }, "contextCount": 179, "entityCount": 1, "segmentCount": 49, "elementCount": 511, "unitCount": 5, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 520, "http://xbrl.sec.gov/dei/2024": 30, "http://xbrl.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role": "http://www.larimartx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_677b6b19-dd5f-465b-a327-238e843e9257", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_677b6b19-dd5f-465b-a327-238e843e9257", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets", "longName": "100010 - Statement - Condensed Consolidated Balance Sheets", "shortName": "Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "C_f62fe1f2-b457-4cd8-8557-e0bbd061dc34", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f62fe1f2-b457-4cd8-8557-e0bbd061dc34", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical", "longName": "100030 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "C_f62fe1f2-b457-4cd8-8557-e0bbd061dc34", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "first": true }, "uniqueAnchor": null }, "R4": { "role": "http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "longName": "100050 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "C_8da0bc4b-821d-489b-8499-600c16d7a362", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_8da0bc4b-821d-489b-8499-600c16d7a362", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity", "longName": "100060 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity", "shortName": "Condensed Consolidated Statements of Changes in Stockholders' Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "C_a5baff11-79e8-45f4-8cf1-d30ecbad9c64", "name": "us-gaap:StockholdersEquity", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_af3178f9-70dd-49be-996b-c2c9d51c13e9", "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "unique": true } }, "R6": { "role": "http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows", "longName": "100070 - Statement - Condensed Consolidated Statements of Cash Flows", "shortName": "Condensed Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "C_677b6b19-dd5f-465b-a327-238e843e9257", "name": "us-gaap:ProfitLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_677b6b19-dd5f-465b-a327-238e843e9257", "name": "us-gaap:ProfitLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "first": true, "unique": true } }, "R7": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "C_8da0bc4b-821d-489b-8499-600c16d7a362", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "first": true }, "uniqueAnchor": null }, "R8": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "C_8da0bc4b-821d-489b-8499-600c16d7a362", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_8da0bc4b-821d-489b-8499-600c16d7a362", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.larimartx.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentation", "longName": "995455 - Disclosure - Description of Business and Basis of Presentation", "shortName": "Description of Business and Basis of Presentation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "C_677b6b19-dd5f-465b-a327-238e843e9257", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_677b6b19-dd5f-465b-a327-238e843e9257", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies", "longName": "995465 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "C_677b6b19-dd5f-465b-a327-238e843e9257", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_677b6b19-dd5f-465b-a327-238e843e9257", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.larimartx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecurities", "longName": "995475 - Disclosure - Fair Value Measurements and Marketable Securities", "shortName": "Fair Value Measurements and Marketable Securities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "C_677b6b19-dd5f-465b-a327-238e843e9257", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_677b6b19-dd5f-465b-a327-238e843e9257", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets", "longName": "995485 - Disclosure - Prepaid Expenses and Other Current Assets", "shortName": "Prepaid Expenses and Other Current Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "C_677b6b19-dd5f-465b-a327-238e843e9257", "name": "lrmr:PrepaidExpensesAndOtherCurrentAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_677b6b19-dd5f-465b-a327-238e843e9257", "name": "lrmr:PrepaidExpensesAndOtherCurrentAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureFixedAssets", "longName": "995495 - Disclosure - Fixed Assets", "shortName": "Fixed Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "C_677b6b19-

dd5f-465b-a327-238e843e9257", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_677b6b19-dd5f-465b-a327-238e843e9257", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureAccruedExpenses", "longName": "995505 - Disclosure - Accrued Expenses", "shortName": "Accrued Expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "C_677b6b19-dd5f-465b-a327-238e843e9257", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_677b6b19-dd5f-465b-a327-238e843e9257", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptions", "longName": "995515 - Disclosure - Stockholders' Equity and Stock Options", "shortName": "Stockholders' Equity and Stock Options", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "C_677b6b19-dd5f-465b-a327-238e843e9257", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_677b6b19-dd5f-465b-a327-238e843e9257", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.larimartx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingencies", "longName": "995525 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "C_677b6b19-dd5f-465b-a327-238e843e9257", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_677b6b19-dd5f-465b-a327-238e843e9257", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.larimartx.com/20240930/taxonomy/role/DisclosureRelatedParty", "longName": "995535 - Disclosure - Related Party", "shortName": "Related Party", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "C_677b6b19-dd5f-465b-a327-238e843e9257", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_677b6b19-dd5f-465b-a327-238e843e9257", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "longName": "995545 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "18", "firstAnchor": { "contextRef": "C_677b6b19-dd5f-465b-a327-238e843e9257", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_677b6b19-dd5f-465b-a327-238e843e9257", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.larimartx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesTables", "longName": "995555 - Disclosure - Fair Value Measurements and Marketable Securities (Tables)", "shortName": "Fair Value Measurements and Marketable Securities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "19", "firstAnchor": { "contextRef": "C_677b6b19-dd5f-465b-a327-238e843e9257", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_677b6b19-dd5f-465b-a327-238e843e9257", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables", "longName": "995565 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)", "shortName": "Prepaid Expenses and Other Current Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "20", "firstAnchor": { "contextRef": "C_677b6b19-dd5f-465b-a327-238e843e9257", "name": "lrmr:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "lrmr:PrepaidExpensesAndOtherCurrentAssetsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_677b6b19-dd5f-465b-a327-238e843e9257", "name": "lrmr:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "lrmr:PrepaidExpensesAndOtherCurrentAssetsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureFixedAssetsTables", "longName": "995575 - Disclosure - Fixed Assets (Tables)", "shortName": "Fixed Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "21", "firstAnchor": { "contextRef": "C_677b6b19-dd5f-465b-a327-238e843e9257", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_677b6b19-dd5f-465b-a327-238e843e9257", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureAccruedExpensesTables", "longName": "995585 - Disclosure - Accrued Expenses (Tables)", "shortName": "Accrued Expenses (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "C_677b6b19-dd5f-465b-a327-238e843e9257", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_677b6b19-dd5f-465b-a327-238e843e9257", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsTables", "longName": "995595 - Disclosure - Stockholders' Equity and Stock Options (Tables)", "shortName": "Stockholders' Equity and Stock Options (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "C_677b6b19-dd5f-465b-a327-238e843e9257", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_677b6b19-dd5f-465b-a327-238e843e9257", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.larimartx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesTables", "longName": "995605 - Disclosure - Commitments and Contingencies (Tables)", "shortName": "Commitments and Contingencies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "C_677b6b19-dd5f-465b-a327-238e843e9257", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_677b6b19-dd5f-465b-a327-238e843e9257", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.larimartx.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail", "longName": "995615 - Disclosure - Description of Business and Basis of Presentation - Additional Information (Detail)", "shortName": "Description of Business and Basis of Presentation - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "25", "firstAnchor": { "contextRef": "C_8da0bc4b-821d-489b-8499-600c16d7a362", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "first": true }, "uniqueAnchor": null }, "R26": { "role": "http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "longName": "995625 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)", "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "C_f62fe1f2-b457-4cd8-8557-e0bbd061dc34", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["us-gaap:CommonStockSharesIssued", "span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_d8863968-d5a2-438b-9a09-12fd76e9b66c", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "us-gaap:EarningsPerSharePolicyTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "unique": true } }, "R27": { "role": "http://www.larimartx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail", "longName": "995635 - Disclosure - Fair Value Measurements and Marketable Securities - Summary of Cash Equivalents and Marketable Securities (Detail)", "shortName": "Fair Value Measurements and Marketable Securities - Summary of Cash Equivalents and Marketable Securities (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "C_f62fe1f2-b457-4cd8-8557-e0bbd061dc34", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f62fe1f2-b457-4cd8-8557-e0bbd061dc34", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.larimartx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAdditionalInformationDetails", "longName": "995645 - Disclosure - Fair Value Measurements and Marketable Securities - Additional Information (Details)", "shortName": "Fair Value Measurements and Marketable Securities - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "C_f62fe1f2-b457-4cd8-8557-e0bbd061dc34", "name": "us-gaap:InterestReceivable", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_04c41b4b-ff9f-4c7a-9856-1e322269d1a5", "name": "us-gaap:InterestReceivable", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "unique": true } }, "R29": { "role": "http://www.larimartx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfMarketableDebtSecuritiesDetails", "longName": "995655 - Disclosure - Fair Value Measurements and Marketable Securities - Summary of Marketable Debt Securities (Details)", "shortName": "Fair Value Measurements and Marketable Securities - Summary of Marketable Debt Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "C_f62fe1f2-b457-4cd8-8557-e0bbd061dc34", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f62fe1f2-b457-4cd8-8557-e0bbd061dc34", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail", "longName": "995665 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Detail)", "shortName": "Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "C_f62fe1f2-b457-4cd8-8557-e0bbd061dc34", "name": "lrmr:PrepaidResearchAndDevelopmentExpenses", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "lrmr:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock", "div", "lrmr:PrepaidExpensesAndOtherCurrentAssetsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f62fe1f2-b457-4cd8-8557-e0bbd061dc34", "name": "lrmr:PrepaidResearchAndDevelopmentExpenses", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "lrmr:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock", "div", "lrmr:PrepaidExpensesAndOtherCurrentAssetsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureFixedAssetsScheduleOfFixedAssetsNetDetail", "longName": "995675 - Disclosure - Fixed Assets - Schedule of Fixed Assets, Net (Detail)", "shortName": "Fixed Assets - Schedule of Fixed Assets, Net (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "C_f62fe1f2-b457-4cd8-8557-e0bbd061dc34", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f62fe1f2-b457-4cd8-8557-e0bbd061dc34", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "U_USD", "xsiNil":

"false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureFixedAssetsAdditionalInformationDetail", "longName": "995685 - Disclosure - Fixed Assets - Additional Information (Detail)", "shortName": "Fixed Assets - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "C_8da0bc4b-821d-489b-8499-600c16d7a362", "name": "lrmr:DepreciationExpenseExcludingLeasedAssets", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_8da0bc4b-821d-489b-8499-600c16d7a362", "name": "lrmr:DepreciationExpenseExcludingLeasedAssets", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail", "longName": "995695 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail)", "shortName": "Accrued Expenses - Schedule of Accrued Expenses (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "C_f62fe1f2-b457-4cd8-8557-e0bbd061dc34", "name": "lrmr:AccruedResearchAndDevelopmentExpenseCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f62fe1f2-b457-4cd8-8557-e0bbd061dc34", "name": "lrmr:AccruedResearchAndDevelopmentExpenseCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail", "longName": "995705 - Disclosure - Stockholders Equity and Stock Options - Additional Information (Detail)", "shortName": "Stockholders Equity and Stock Options - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "C_f62fe1f2-b457-4cd8-8557-e0bbd061dc34", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_677b6b19-dd5f-465b-a327-238e843e9257", "name": "us-gaap:CommonStockVotingRights", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "unique": true } }, "R35": { "role": "http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAssumptionsUsedToDetermineFairValueOfStockOptionsGrantedDetail", "longName": "995715 - Disclosure - Stockholders Equity and Stock Options - Assumptions used to Determine Fair Value of Stock Options Granted (Detail)", "shortName": "Stockholders Equity and Stock Options - Assumptions used to Determine Fair Value of Stock Options Granted (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "C_677b6b19-dd5f-465b-a327-238e843e9257", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_677b6b19-dd5f-465b-a327-238e843e9257", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsSummaryOfStockOptionActivityDetail", "longName": "995725 - Disclosure - Stockholders Equity and Stock Options - Summary of Stock Option Activity (Detail)", "shortName": "Stockholders Equity and Stock Options - Summary of Stock Option Activity (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "C_04c41b4b-ff9f-4c7a-9856-1e322269d1a5", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_677b6b19-dd5f-465b-a327-238e843e9257", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "unique": true } }, "R37": { "role": "http://www.larimartx.com/20240930/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfRestrictedStockUnitsDetails", "longName": "995735 - Disclosure - Stockholders Equity and Stock Options - Summary of Restricted Stock Units (Details)", "shortName": "Stockholders Equity and Stock Options - Summary of Restricted Stock Units (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "C_cce5e9da-bb52-4653-bbd2-1d1e0100a3fe", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_45066cc0-d2d4-4e56-b7f3-1fabc7d40c78", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "unique": true } }, "R38": { "role": "http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsSummaryOfStockBasedCompensationExpenseDetail", "longName": "995745 - Disclosure - Stockholders Equity and Stock Options - Summary of Stock-Based Compensation Expense (Detail)", "shortName": "Stockholders Equity and Stock Options - Summary of Stock-Based Compensation Expense (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "C_8da0bc4b-821d-489b-8499-600c16d7a362", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_8da0bc4b-821d-489b-8499-600c16d7a362", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.larimartx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "longName": "995755 - Disclosure - Commitments and Contingencies - Additional Information (Detail)", "shortName": "Commitments and Contingencies - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "C_f62fe1f2-b457-4cd8-8557-e0bbd061dc34", "name": "us-gaap:OperatingLeaseLiabilityNoncurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_04c41b4b-ff9f-4c7a-9856-1e322269d1a5", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "unique": true } }, "R40": { "role": "http://www.larimartx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnderLeaseAgreementsDetail", "longName": "995765 - Disclosure - Commitments and Contingencies - Schedule of Maturities of Lease Liabilities Due Under Lease Agreements (Detail)", "shortName": "Commitments and Contingencies - Schedule of Maturities of Lease Liabilities Due Under Lease Agreements (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "C_f62fe1f2-b457-4cd8-8557-e0bbd061dc34", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f62fe1f2-b457-4cd8-8557-e0bbd061dc34", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.larimartx.com/20240930/taxonomy/role/DisclosureRelatedPartyAdditionalInformationDetails", "longName": "995775 - Disclosure - Related Party - Additional Information (Details)", "shortName": "Related Party - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "C_daf02a45-4980-459a-a859-16a9a5628843", "name": "us-gaap:OperatingCostsAndExpenses", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_daf02a45-4980-459a-a859-16a9a5628843", "name": "us-gaap:OperatingCostsAndExpenses", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "lrmr-20240930.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Legal Entity of Counterparty, Type [Axis]", "terseLabel": "Legal Entity of Counterparty, Type", "documentation": "Information by legal entity of counterparty. A counterparty is the other party that participates in a financial transaction." } } }, "auth_ref": ["r51", "r57"] }, "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureAccruedExpenses"], "lang": { "en-us": { "role": { "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]", "terseLabel": "Accrued Expenses", "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period." } } }, "auth_ref": ["r305"] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Accounts Payable, Current, Total", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r41", "r629"] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail", "http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses", "totalLabel": "Total accrued expenses", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r43"] }, "lrmr_AccruedResearchAndDevelopmentExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.larimartx.com/20240930", "localname": "AccruedResearchAndDevelopmentExpenseCurrent", "crdr": "credit", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail"], "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for expenses related to research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Research And Development Expense Current", "terseLabel": "Accrued research and development expenses" } } }, "auth_ref": [] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureFixedAssetsScheduleOfFixedAssetsNetDetail"], "lang": { "en-us": { "role": { "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance", "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance", "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less: Accumulated depreciation", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": ["r27", "r107", "r464"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive gain", "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": ["r12", "r13", "r58", "r110", "r460", "r481", "r482"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"], "lang": { "en-us": { "role": { "label": "AOCI

Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Gain (Loss) [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r1", "r7", "r13", "r325", "r328", "r373", "r477", "r478", "r754", "r755", "r756", "r761", "r762", "r763", "r765"] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": ["r689"] }, "lrmr_AdditionalOfficeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.larimartx.com/20240930", "localname": "AdditionalOfficeMember", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Additional Office [Member]", "label": "Additional Office [Member]", "documentation": "Additional office." } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "periodEndLabel": "Additional Paid in Capital, Common Stock, Ending Balance", "periodStartLabel": "Additional Paid in Capital, Common Stock, Beginning Balance", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": ["r52"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r491", "r761", "r762", "r763", "r765", "r821", "r883"] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": ["r702"] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": ["r702"] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": ["r702"] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": ["r702"] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"], "lang": { "en-us": { "role": { "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation expense", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": ["r34", "r35", "r266"] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "lrmr_AggregateGrossSalesProceedsUnderSalesAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.larimartx.com/20240930", "localname": "AggregateGrossSalesProceedsUnderSalesAgreement", "crdr": "credit", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "The potential aggregate gross sales proceeds available under a sales agreement to sell shares of the Company's common stock.", "label": "Aggregate Gross Sales Proceeds Under Sales Agreement", "terseLabel": "Aggregate sale of shares of our common stock", "verboseLabel": "Aggregate sale of shares of our common stock" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": ["r735"] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r661", "r671", "r681", "r713"] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": ["r664", "r674", "r684", "r716"] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": ["r736"] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": ["r702"] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": ["r709"] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": ["r665", "r675", "r685", "r709", "r717", "r721", "r729"] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": ["r727"] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsSummaryOfStockBasedCompensationExpenseDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Total stock-based compensation expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": ["r297", "r303"] }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivable", "crdr": "credit", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "periodStartLabel": "Accounts Receivable, Allowance for Credit Loss, Beginning Balance", "periodEndLabel": "Accounts Receivable, Allowance for Credit Loss, Ending Balance", "label": "Accounts Receivable, Allowance for Credit Loss", "terseLabel": "Allowance for credit loss", "documentation": "Amount of allowance for credit loss on accounts receivable." } } }, "auth_ref": ["r111", "r164", "r200", "r203", "r204", "r850"] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Amendment Flag", "verboseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfDebtDiscountPremium": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfDebtDiscountPremium", "crdr": "debit", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Amortization of Debt Discount (Premium)", "terseLabel": "Amortization of premium on marketable securities", "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense." } } }, "auth_ref": ["r5", "r62", "r236", "r831"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Total potentially dilutive shares", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": ["r153"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": ["r20"] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": ["r20"] }, "lrmr_AreaOfOfficeSpace": { "xbrltype": "areaItemType", "nsuri": "http://www.larimartx.com/20240930", "localname": "AreaOfOfficeSpace", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Area of office space.", "label": "Area Of Office Space", "terseLabel": "Area of office space" } } }, "auth_ref": [] }, "us-gaap_AssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetImpairmentCharges", "crdr": "debit", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "totalLabel": "Asset Impairment Charges, Total", "label": "Asset Impairment Charges", "terseLabel": "Impairment losses on investment", "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill." } } }, "auth_ref": ["r5", "r25"] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets", "totalLabel": "Total assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r83", "r90", "r109", "r130", "r156", "r158", "r159", "r160", "r197", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r318", "r322", "r355", "r455", "r523", "r601", "r602", "r629", "r652", "r790", "r791", "r837"] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets, Current", "totalLabel": "Total current assets", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": ["r102", "r112", "r130", "r197", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r318", "r322", "r355", "r629", "r790", "r791", "r837"] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail"], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure", "totalLabel": "Total cash equivalents and marketable securities", "documentation": "Fair value portion of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r336", "r337", "r618"] }, "lrmr_AtTheMarketEquityDistributionAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.larimartx.com/20240930", "localname": "AtTheMarketEquityDistributionAgreementMember", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Prior ATM Agreement", "label": "At The Market Equity Distribution Agreement [Member]", "documentation": "At the market equity distribution agreement." } } }, "auth_ref": [] }, "lrmr_AtTheMarketEquityOfferingProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.larimartx.com/20240930", "localname": "AtTheMarketEquityOfferingProgramMember", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "At-the-market equity offering program.", "label": "At The Market Equity Offering Program [Member]", "terseLabel": "ATM Offering Program [Member]" } } }, "auth_ref": [] }, "lrmr_AtTheMarketOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.larimartx.com/20240930", "localname": "AtTheMarketOfferingMember", "presentation": [

```
"http://www.larimartx.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "At the market offering member.", "label": "At The Market Offering [Member]", "terseLabel": "ATM Offering [Member]" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfMarketableDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Gross Unrealized Gains", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r171" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfMarketableDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "terseLabel": "Gross Unrealized Losses", "negatedLabel": "Gross Unrealized Losses", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r172" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfMarketableDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Amortized Cost", "terseLabel": "Amortized Cost", "totalLabel": "Amortized Cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r168", "r208", "r454" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail",
"http://www.larimartx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfMarketableDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Fair Value", "terseLabel": "Marketable securities", "label": "Debt Securities, Available-for-Sale", "totalLabel": "Debt Securities, Available-for-Sale, Total", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r169", "r208", "r336", "r449", "r618", "r621", "r772", "r825", "r826", "r827" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "crdr": "debit", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term marketable securities", "label": "Debt Securities, Available-for-Sale, Current", "verboseLabel": "Fair Value", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current." } } }, "auth_ref": [ "r166", "r208" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent", "crdr": "debit", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term marketable securities", "label": "Debt Securities, Available-for-Sale, Noncurrent", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent." } } }, "auth_ref": [ "r105", "r166", "r208" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": [ "r724" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": [ "r725" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": [ "r720" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": [ "r720" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": [ "r720" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": [ "r720" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": [ "r720" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": [ "r720" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfRestrictedStockUnitsDetails",
"http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r268", "r269", "r270", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r292", "r293", "r294", "r295", "r296" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": [ "r723" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r722" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": [ "r721" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": [ "r721" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "presentation": [ "http://www.larimartx.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentation" ], "lang": { "en-us": { "role": { "label": "Business Description and Basis of Presentation [Text Block]", "terseLabel": "Description of Business and Basis of Presentation", "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [ "r40", "r67", "r68" ] }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalExpendituresIncurredButNotYetPaid", "crdr": "credit", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Purchases of property and equipment included in accounts payable and accrued expenses", "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred." } } }, "auth_ref": [ "r17", "r18", "r19" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance", "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance", "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r16", "r104", "r594" ] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Cash equivalents", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r823", "r824" ] }, "lrmr_CashAndNonCashOperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.larimartx.com/20240930", "localname": "CashAndNonCashOperatingLeaseExpense", "crdr": "debit", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Lease expense", "label": "Cash and Non Cash Operating Lease Expense", "documentation": "The amount of lease expense, both cash and non-cash, related to operating leases." } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsAndShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsAndShortTermInvestments", "crdr": "debit", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash, Cash Equivalents, and Short-Term Investments", "totalLabel": "Cash, Cash Equivalents, and Short-Term Investments, Total", "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable." } } }, "auth_ref": [ "r753" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r16", "r64", "r127" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase in cash, cash equivalents and restricted cash", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not
```

limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r0", "r64"] }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "Supplemental disclosure of non-cash investing and financing activities:" } } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": ["r700"] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": ["r697"] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth_ref": ["r695"] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Warrants exercise price", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": ["r252"] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Issuance of warrants", "verboseLabel": "Warrants issued", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": ["r252"] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": ["r701"] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": ["r701"] }, "us-gaap_CommercialPaperMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommercialPaperMember", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail"], "lang": { "en-us": { "role": { "label": "Commercial Paper [Member]", "terseLabel": "Commercial Paper [Member]", "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds." } } }, "auth_ref": ["r73", "r225", "r645", "r646", "r647", "r648"] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies (See Note 8)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": ["r47", "r85", "r457", "r510"] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingencies"], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": ["r72", "r219", "r220", "r580", "r784", "r789"] }, "lrmr_CommonStockEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.larimartx.com/20240930", "localname": "CommonStockEquivalentsMember", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Common Stock Equivalents.", "label": "Common Stock Equivalents [Member]", "terseLabel": "Common Stock Equivalents [Member]" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail", "http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail", "http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r641", "r642", "r643", "r645", "r646", "r647", "r648", "r761", "r762", "r765", "r821", "r881", "r883"] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail", "http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value per share", "verboseLabel": "Common stock, par value", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r50"] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail", "http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r50", "r511"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail", "http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "totalLabel": "Common Stock, Shares, Issued, Total", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued", "verboseLabel": "Common stock, shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r50"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail", "http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance", "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding", "verboseLabel": "Common stock outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r8", "r50", "r511", "r529", "r883", "r884"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, $0.001 par value per share; 115,000,000 shares authorized as of September 30, 2024 and December 31, 2023; 63,806,628 and 43,909,069 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively", "periodEndLabel": "Common Stock, Value, Issued, Ending Balance", "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance", "totalLabel": "Common Stock, Value, Issued, Total", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r50", "r459", "r629"] }, "us-gaap_CommonStockVotingRights": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockVotingRights", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Common Stock, Voting Rights", "terseLabel": "Common stock voting rights", "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights." } } }, "auth_ref": ["r29"] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": ["r706"] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": ["r705"] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": ["r707"] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": ["r704"] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Total comprehensive loss", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r14", "r115", "r117", "r121", "r450", "r470", "r471"] }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTaxAbstract", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Comprehensive loss:" } } }, "auth_ref": [] }, "us-gaap_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComputerEquipmentMember", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureFixedAssetsScheduleOfFixedAssetsNetDetail"], "lang": { "en-us": { "role": { "label": "Computer Equipment [Member]", "terseLabel": "Computer Equipment [Member]", "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems." } } }, "auth_ref": [] }, "us-gaap_CorporateBondSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateBondSecuritiesMember", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail", "http://www.larimartx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfMarketableDebtSecuritiesDetails"], "lang": { "en-us": { "role": { "label": "Corporate Bond Securities [Member]", "terseLabel": "Corporate Bonds [Member]", "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount)." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss", "crdr": "credit", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Allowance for credit loss", "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss", "periodEndLabel": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Ending Balance", "periodStartLabel": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Beginning Balance", "totalLabel": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Total", "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income

```
(available-for-sale)." } } }, "auth_ref": [ "r170", "r208", "r213", "r214" ] }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger", "crdr": "debit", "presentation": [ "http://www.larimartx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investments in continuous loss position for 12 months or longer", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r91", "r210", "r604" ] }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleTable", "presentation": [ "http://www.larimartx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfMarketableDebtSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale [Table]", "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178" ] }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleUnrealizedGainLoss", "crdr": "credit", "presentation": [ "http://www.larimartx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Debt Securities, Available-for-Sale, Unrealized Gain (Loss), Total", "label": "Debt Securities, Available-for-Sale, Unrealized Gain (Loss)", "terseLabel": "Unrealized gains or losses related to available-for-sale investments", "documentation": "Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r774", "r775" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "presentation": [ "http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Depreciation, Total", "label": "Depreciation", "terseLabel": "Depreciation expense", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r5", "r26" ] }, "lrmr_DepreciationExpenseExcludingLeasedAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.larimartx.com/20240930", "localname": "DepreciationExpenseExcludingLeasedAssets", "crdr": "debit", "presentation": [ "http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureFixedAssetsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "The amount of depreciation expenses recognized in the period, excluding depreciation for leased assets as part of a sublease agreement.", "label": "Depreciation Expense Excluding Leased Assets", "terseLabel": "Depreciation expense" } } }, "auth_ref": [] }, "lrmr_DepreciationExpensesRelatedToSubletAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.larimartx.com/20240930", "localname": "DepreciationExpensesRelatedToSubletAssets", "crdr": "debit", "presentation": [ "http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureFixedAssetsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "The amount of depreciation expense recognized in the period related to leased assets as part of a sublease agreement.", "label": "Depreciation Expenses Related to Sublet Assets", "terseLabel": "Depreciation expenses related to sublet assets" } } }, "auth_ref": [] }, "srt_DirectorMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "DirectorMember", "presentation": [ "http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Directors [Member]", "label": "Director [Member]" } } }, "auth_ref": [ "r771", "r882" ] }, "us-gaap_DividendsPayableCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsPayableCurrentAndNoncurrent", "crdr": "credit", "presentation": [ "http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Dividends Payable", "terseLabel": "Dividend paid", "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding." } } }, "auth_ref": [ "r43", "r46", "r84", "r649", "r848" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.larimartx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3, 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.larimartx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.larimartx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K, the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.larimartx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r656" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://www.larimartx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "terseLabel": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r688" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://www.larimartx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRfldtdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRfldtdInTtlCompForCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": [ "r699" ] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Earnings Per Share, Basic, Total", "label": "Earnings Per Share, Basic", "terseLabel": "Net loss per share, basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r122", "r136", "r137", "r138", "r139", "r140", "r141", "r146", "r148", "r150", "r151", "r152", "r155", "r313", "r316", "r333", "r334", "r451", "r472", "r598" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss per share, diluted", "totalLabel": "Earnings Per Share, Diluted, Total", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r122", "r136", "r137", "r138", "r139", "r140", "r141", "r148", "r150", "r151", "r152", "r155", "r313", "r316", "r333", "r334", "r451", "r472", "r598" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Net Loss Per Share", "label": "Earnings Per Share, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r20", "r21", "r154" ] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "presentation": [ "http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail" ], "lang": { "en-us": { "role": { "totalLabel": "Employee-related Liabilities, Current, Total", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued payroll and related expenses", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r43" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "totalLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized compensation expense", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r298" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Unrecognized compensation expense recognized period", "documentation": 'Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in \'PnYnMnDTnHnMnS\' format, for example, \'P1Y5M13D\' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r298" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "lrmr_EmployeesAndDirectorsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.larimartx.com/20240930", "localname": "EmployeesAndDirectorsMember", "presentation": [ "http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Employees and directors.", "label": "Employees and Directors [Member]", "terseLabel": "Employees and Directors [Member]" } } }, "auth_ref": [] }, "lrmr_EmployeesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.larimartx.com/20240930", "localname": "EmployeesMember", "presentation": [ "http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Employees.", "label": "Employees [Member]", "terseLabel": "Employees [Member]" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.larimartx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.larimartx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.larimartx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.larimartx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.larimartx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.larimartx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r654" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.larimartx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "verboseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.larimartx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label":
```

"Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r654"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "terseLabel": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r654"] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": ["r738"] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r654"] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "terseLabel": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r654"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Small Business", "terseLabel": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r654"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r654"] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": ["r693"] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": ["r734"] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": ["r734"] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": ["r734"] }, "us-gaap_EquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquipmentMember", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureFixedAssetsScheduleOfFixedAssetsNetDetail"], "lang": { "en-us": { "role": { "label": "Equipment [Member]", "terseLabel": "Lab Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services." } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail", "http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail", "http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "terseLabel": "Equity Component", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": ["r8", "r100", "r118", "r119", "r120", "r131", "r132", "r133", "r135", "r140", "r142", "r144", "r157", "r198", "r199", "r215", "r253", "r308", "r309", "r310", "r311", "r312", "r314", "r315", "r316", "r324", "r325", "r326", "r327", "r328", "r329", "r332", "r356", "r357", "r358", "r359", "r360", "r361", "r363", "r364", "r373", "r468", "r477", "r478", "r479", "r491", "r553"] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": ["r703"] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": ["r661", "r671", "r681", "r713"] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": ["r658", "r668", "r678", "r710"] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": ["r709"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail"], "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r336", "r337", "r347", "r618"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail"], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": ["r336", "r337", "r347", "r618"] }, "us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesTables"], "lang": { "en-us": { "role": { "label": "Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]", "terseLabel": "Summary of Cash Equivalents and Marketable Securities", "documentation": "Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2." } } }, "auth_ref": ["r336", "r337"] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail"], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": ["r235", "r255", "r256", "r257", "r258", "r259", "r260", "r335", "r337", "r338", "r339", "r340", "r346", "r347", "r349", "r384", "r385", "r386", "r606", "r607", "r610", "r611", "r612", "r618", "r621"] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecurities"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements and Marketable Securities", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": ["r342", "r344", "r345", "r346", "r349", "r350", "r351", "r352", "r353", "r448", "r618", "r622"] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail"], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Quoted Prices in Active Markets, (Level 1) [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": ["r235", "r255", "r260", "r337", "r347", "r384", "r610", "r611", "r612", "r618"] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail"], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Significant Other Observable Inputs (Level 2) [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": ["r235", "r255", "r260", "r337", "r338", "r347", "r385", "r606", "r607", "r610", "r611", "r612", "r618"] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail"], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Significant Unobservable Inputs (Level 3) [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r235", "r255", "r256", "r257", "r258", "r259", "r260", "r337", "r338", "r339", "r340", "r347", "r386", "r606", "r607", "r610", "r611", "r612", "r618", "r621"] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail"], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": ["r235", "r255", "r256", "r257", "r258", "r259", "r260", "r335", "r337", "r338", "r339", "r340", "r346", "r347", "r349", "r384", "r385", "r386", "r606", "r607", "r610", "r611", "r612", "r618", "r621"] }, "lrmr_FinalSubleaseYearMember": { "xbrltype": "domainItemType", "nsuri": "http://www.larimartx.com/20240930", "localname": "FinalSubleaseYearMember", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Final sublease year", "label": "Final Sublease Year [Member]", "terseLabel": "Final Sublease Year [Member]" } } }, "auth_ref": [] }, "us-

gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail",
"http://www.larimartx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfMarketableDebtSecuritiesDetails"], "lang": { "en-us": { "role": {
"label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": ["r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175",
"r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r201", "r202", "r205", "r206",
"r207", "r209", "r211", "r212", "r237", "r250", "r330", "r354", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r397", "r398",
"r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r469", "r604", "r618", "r619", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r630",
"r742", "r743", "r744", "r745", "r746", "r747", "r748", "r776", "r777", "r778", "r779", "r822", "r825", "r826", "r827", "r828", "r829"] }, "lrmr_FirstAnniversaryMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.larimartx.com/20240930", "localname": "FirstAnniversaryMember", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "First
Anniversary [Member]", "label": "First Anniversary [Member]", "documentation": "First anniversary." } } }, "auth_ref": [] }, "lrmr_FirstSubleaseYearMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.larimartx.com/20240930", "localname": "FirstSubleaseYearMember", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "First sublease year
member.", "label": "First Sublease Year [Member]", "terseLabel": "First Sublease Year [Member]" } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
"xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery
due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": ["r665", "r675", "r685", "r717"] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype":
"monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to
Expense of Enforcement, Amount" } } }, "auth_ref": ["r665", "r675", "r685", "r717"] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": {
"en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } },
"auth_ref": ["r665", "r675", "r685", "r717"] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone
Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": ["r665", "r675", "r685", "r717"] },
"ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r665", "r675", "r685",
"r717"] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Prior
Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of
Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": ["r698"] },
"lrmr_FriedreichsAtaxiaResearchAlliancesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.larimartx.com/20240930", "localname": "FriedreichsAtaxiaResearchAlliancesMember",
"presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureRelatedPartyAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Friedreich's Ataxia
Research Alliances.", "label": "Friedreich's Ataxia Research Alliances [Member]", "terseLabel": "Friedreich's Ataxia Research Alliances [Member]" } } }, "auth_ref": [] },
"lrmr_FromExerciseOfWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.larimartx.com/20240930", "localname": "FromExerciseOfWarrantsMember", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "From
Exercise of Warrants [Member]", "label": "From Exercise of Warrants [Member]", "documentation": "From exercise of warrants." } } }, "auth_ref": [] }, "lrmr_FromPriorPlansMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.larimartx.com/20240930", "localname": "FromPriorPlansMember", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "From Prior
Plans [Member]", "label": "From Prior Plans [Member]", "documentation": "From Prior Plans [Member]" } } }, "auth_ref": [] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FurnitureAndFixturesMember", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureFixedAssetsScheduleOfFixedAssetsNetDetail"], "lang": { "en-us": { "role": { "label": "Furniture and Fixtures [Member]",
"terseLabel": "Furniture and Fixtures [Member]", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities.
Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "totalLabel":
"General and Administrative Expense, Total", "label": "General and Administrative Expense", "terseLabel": "General and administrative", "documentation": "The aggregate total of expenses of
managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product
or product line." } } }, "auth_ref": ["r60", "r533"] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "GeneralAndAdministrativeExpenseMember", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsSummaryOfStockBasedCompensationExpenseDetail"], "lang": { "en-us": { "role": {
"label": "General and Administrative Expense [Member]", "terseLabel": "General and Administrative [Member]", "documentation": "Primary financial statement caption encompassing general
and administrative expense." } } }, "auth_ref": ["r60"] }, "lrmr_GoingConcernPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.larimartx.com/20240930", "localname":
"GoingConcernPolicyTextBlock", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": {
"role": { "documentation": "Disclosure of accounting policy for the assessment of the ability to continue as a going concern.", "label": "Going Concern Policy [Text Block]", "terseLabel": "Going
Concern Assessment" } } }, "auth_ref": [] }, "us-gaap_IPOMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IPOMember", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Public Offering
[Member]", "documentation": "First sale of stock by a private company to the public." } } }, "auth_ref": [] }, "lrmr_IncentiveStockOptionsMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.larimartx.com/20240930", "localname": "IncentiveStockOptionsMember", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Incentive
stock options member.", "label": "Incentive Stock Options [Member]", "terseLabel": "Incentive Stock Options [Member]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] },
"us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsSummaryOfStockBasedCompensationExpenseDetail"], "lang": { "en-us": { "role": {
"label": "Statement of Income Location, Balance [Axis]", "terseLabel": "Income Statement Location", "documentation": "Information by location in statement of income where disaggregated
amount has been reported." } } }, "auth_ref": ["r216", "r217", "r218", "r341", "r343", "r348", "r474", "r476", "r538", "r592", "r620", "r852"] }, "us-gaap_IncomeStatementLocationDomain": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsSummaryOfStockBasedCompensationExpenseDetail"], "lang": { "en-us": { "role": {
"label": "Statement of Income Location, Balance [Domain]", "terseLabel": "Income Statement Location", "documentation": "Location in statement of income where disaggregated amount has
been reported." } } }, "auth_ref": ["r217", "r218", "r341", "r343", "r348", "r474", "r476", "r538", "r592", "r620", "r852"] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "totalLabel": "Increase (Decrease) in
Accounts Payable, Total", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable", "documentation": "The increase (decrease) during the reporting period in the
aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } },
"auth_ref": ["r4"] }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"],
"lang": { "en-us": { "role": { "totalLabel": "Increase (Decrease) in Accrued Liabilities, Total", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued expenses",
"documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": ["r4"] }, "us-
gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
"presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase
(Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "crdr": "credit", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Other
Noncurrent Assets", "negatedLabel": "Other assets", "documentation": "Amount of increase (decrease) in noncurrent assets classified as other." } } }, "auth_ref": ["r758"] }, "us-
gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "totalLabel": "Increase (Decrease) in
Prepaid Expense and Other Assets, Total", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets", "documentation":
"Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": ["r4"] }, "lrmr_IndianaUniversityResearchAndTechnologyCorporationMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.larimartx.com/20240930", "localname": "IndianaUniversityResearchAndTechnologyCorporationMember", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Indiana University
Research and Technology Corporation.", "label": "Indiana University Research And Technology Corporation [Member]", "terseLabel": "IU [Member]" } } }, "auth_ref": [] }, "ecd_IndividualAxis":
{ "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label":
"Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": ["r665", "r675", "r685", "r709", "r717", "r721", "r729"] }, "lrmr_InducementStockMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.larimartx.com/20240930", "localname": "InducementStockMember", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation":
"Inducement Stock.", "label": "Inducement Stock [Member]", "terseLabel": "Inducement Stock [Member]" } } }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype":
"stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]",
"terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": ["r727"] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and
Procedures:" } } }, "auth_ref": ["r657", "r733"] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"InsiderTrdPoliciesProcAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures
Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": ["r657", "r733"] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider
Trading Policies and Procedures Not Adopted" } } }, "auth_ref": ["r657", "r733"] }, "us-gaap_IntangibleAssetsFiniteLivedPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "IntangibleAssetsFiniteLivedPolicy", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Intangible Assets, Finite-Lived,
Policy [Policy Text Block]", "terseLabel": "Patent Costs", "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the
amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets." } } }, "auth_ref": ["r413", "r414", "r415", "r417", "r596",
"r782"] }, "us-gaap_InterestReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestReceivable", "crdr": "debit", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Interest
Receivable", "terseLabel": "Accrued interest receivable", "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or
accrued interest receivable." } } }, "auth_ref": ["r752", "r885"] }, "us-gaap_InterestReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"InterestReceivableCurrent", "crdr": "debit", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail"], "lang": { "en-us": {
"role": { "terseLabel": "Interest receivable", "label": "Interest Receivable, Current", "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received.

Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r752"] }, "us-gaap_InvestmentTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentTypeAxis", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail"], "lang": { "en-us": { "role": { "label": "Investment Type [Axis]", "terseLabel": "Investment Type", "documentation": "Information by type of investments." } } }, "auth_ref": ["r493", "r495", "r496", "r498", "r500", "r561", "r563", "r565", "r568", "r569", "r570", "r572", "r573", "r574", "r575", "r576", "r643"] }, "us-gaap_InvestmentTypeCategorizationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentTypeCategorizationMember", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail"], "lang": { "en-us": { "role": { "label": "Investments [Domain]", "terseLabel": "Investments", "documentation": "Asset obtained to generate income or appreciate in value." } } }, "auth_ref": ["r493", "r495", "r496", "r498", "r500", "r561", "r563", "r565", "r568", "r569", "r570", "r572", "r573", "r574", "r575", "r576", "r643"] }, "lrmr_LabSpaceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.larimartx.com/20240930", "localname": "LabSpaceMember", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Lab Space [Member]", "label": "Lab Space [Member]", "documentation": "Lab space." } } }, "auth_ref": [] }, "us-gaap_LeaseContractualTermAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseContractualTermAxis", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Lease Contractual Term [Axis]", "terseLabel": "Lease Contractual Term", "documentation": "Information by contractual term of lease arrangement." } } }, "auth_ref": ["r372", "r741"] }, "us-gaap_LeaseContractualTermDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseContractualTermDomain", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Lease Contractual Term [Domain]", "terseLabel": "Lease Contractual Term", "documentation": "Contractual term of lease arrangement." } } }, "auth_ref": ["r372", "r741"] }, "us-gaap_LeaseExpirationDate1": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseExpirationDate1", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Lease Expiration Date", "terseLabel": "Lease term expiration date", "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "lrmr_LeaseTermCommencementDate": { "xbrltype": "dateItemType", "nsuri": "http://www.larimartx.com/20240930", "localname": "LeaseTermCommencementDate", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Lease term commencement date.", "label": "Lease Term Commencement Date", "terseLabel": "Lease term commencement date" } } }, "auth_ref": [] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseholdImprovementsMember", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureFixedAssetsScheduleOfFixedAssetsNetDetail"], "lang": { "en-us": { "role": { "terseLabel": "Leasehold Improvements [Member]", "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": ["r71", "r371"] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LegalEntityTypeOfCounterpartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LegalEntityTypeOfCounterpartyDomain", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Legal Entity Type of Counterparty [Domain]", "terseLabel": "Legal Entity Type of Counterparty", "documentation": "Nature of the other party participating in a financial transaction." } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesTables"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "terseLabel": "Schedule of Maturities of Lease Liabilities Due Under Lease Agreements", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": ["r834"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnderLeaseAgreementsDetail"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total lease payments", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": ["r370"] }, "lrmr_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.larimartx.com/20240930", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour", "crdr": "credit", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnderLeaseAgreementsDetail"], "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due After Year Four", "terseLabel": "Thereafter" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnderLeaseAgreementsDetail"], "lang": { "en-us": { "role": { "terseLabel": "Year ended December 31, 2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r370"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnderLeaseAgreementsDetail"], "lang": { "en-us": { "role": { "terseLabel": "Year ended December 31, 2028", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r370"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnderLeaseAgreementsDetail"], "lang": { "en-us": { "role": { "terseLabel": "Year ended December 31, 2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r370"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnderLeaseAgreementsDetail"], "lang": { "en-us": { "role": { "terseLabel": "Year ended December 31, 2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r370"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnderLeaseAgreementsDetail"], "lang": { "en-us": { "role": { "terseLabel": "Three months ending December 31, 2024", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": ["r834"] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnderLeaseAgreementsDetail"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: imputed interest", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": ["r370"] }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseRenewalTerm", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Lease extension period", "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r833"] }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Operating lease term", "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r833"] }, "us-gaap_LetterOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LetterOfCreditMember", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Letter of Credit [Member]", "terseLabel": "Letter of Credit", "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit)." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities", "totalLabel": "Total liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": ["r11", "r42", "r43", "r44", "r45", "r46", "r47", "r48", "r130", "r197", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r319", "r322", "r323", "r355", "r509", "r599", "r652", "r790", "r837", "r838"] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": ["r56", "r86", "r462", "r629", "r760", "r780", "r830"] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Stockholders\u2019 Equity" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities, Current", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": ["r44", "r103", "r130", "r197", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r319", "r322", "r323", "r355", "r629", "r790", "r837", "r838"] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "auth_ref": [] }, "us-gaap_LiabilityReserveEstimatePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilityReserveEstimatePolicy", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Liability Reserve Estimate, Policy [Policy Text Block]", "terseLabel": "Liquidity and Capital Resources", "documentation": "Disclosure of accounting policy for estimating its liability as of the balance sheet date for the ultimate cost of settling reported and unreported claims incurred and claims adjustment expenses (including effects of inflation and other societal and economic factors)." } } }, "auth_ref": ["r853"] }, "lrmr_LicenseAgreementConsiderationDeductionPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.larimartx.com/20240930", "localname": "LicenseAgreementConsiderationDeductionPercentage", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "The amount that may be deducted from consideration due to Licensor 2 as a percentage of consideration paid to Licensor 1, whereby Licensor 1 is the identified party.", "label": "License Agreement Consideration Deduction Percentage", "terseLabel": "License agreement consideration deduction percentage" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "country_MA": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "MA", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "MOROCCO", "terseLabel": "Massachusetts [Member]" } } }, "auth_ref": [] }, "lrmr_MTSHealthPartnersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.larimartx.com/20240930", "localname": "MTSHealthPartnersMember", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "MTS Health Partners.", "label": "M T S Health Partners [Member]", "terseLabel": "MTS Health Partners [Member]" } } }, "auth_ref": [] }, "us-gaap_MarketableSecurities": { "xbrltype":

"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecurities", "crdr": "debit", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Marketable securities", "totalLabel": "Marketable Securities, Total", "label": "Marketable Securities", "documentation": "Amount of investment in marketable security." } } }, "auth_ref": ["r87", "r751"] }, "lrmr_MarketableSecuritiesWithRemainingMaturitiesGreaterThanTwoYears": { "xbrltype": "monetaryItemType", "nsuri": "http://www.larimartx.com/20240930", "localname": "MarketableSecuritiesWithRemainingMaturitiesGreaterThanTwoYears", "crdr": "debit", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "The value of marketable securities with remaining maturities greater than two years, as of the balance sheet date.", "label": "Marketable Securities With Remaining Maturities Greater Than Two Years", "terseLabel": "Marketable securities with remaining maturities greater than two years" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://www.larimartx.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail",
"http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureFixedAssetsAdditionalInformationDetail",
"http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail",
"http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum [Member]" } } }, "auth_ref": ["r221", "r222", "r223", "r224", "r262", "r304", "r340", "r412", "r473", "r475", "r483", "r501", "r502", "r562", "r564", "r566", "r567", "r571", "r590", "r591", "r603", "r608", "r613", "r621", "r622", "r626", "r627", "r639", "r792", "r839", "r840", "r841", "r842", "r843", "r844"] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": ["r701"] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": ["r701"] }, "lrmr_MilestoneExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.larimartx.com/20240930", "localname": "MilestoneExpenses", "crdr": "debit", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized during the period related to milestones. Such amount may include, but is not limited to, amounts due for attainment of milestones as well as deductions granted as part of a license agreement.", "label": "Milestone Expenses", "terseLabel": "Milestone expenses" } } }, "auth_ref": [] }, "lrmr_MilestoneLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.larimartx.com/20240930", "localname": "MilestoneLiability", "crdr": "credit", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Amount of payment due for milestones that have been achieved", "label": "Milestone Liability", "terseLabel": "Milestone payments due" } } }, "auth_ref": [] }, "lrmr_MilestonePaymentAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.larimartx.com/20240930", "localname": "MilestonePaymentAmount", "crdr": "credit", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Amount of payment due upon reaching milestone.", "label": "Milestone Payment Amount", "terseLabel": "Milestone payments" } } }, "auth_ref": [] }, "lrmr_MinimumAnnualRoyaltyObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.larimartx.com/20240930", "localname": "MinimumAnnualRoyaltyObligation", "crdr": "credit", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "The minimum annual royalty payment that is required under a contractual arrangement.", "label": "Minimum Annual Royalty Obligation", "terseLabel": "Annual royalty pay obligation" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://www.larimartx.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail",
"http://www.larimartx.com/20240930/taxonomy/role/DisclosureRelatedPartyAdditionalInformationDetails",
"http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureFixedAssetsAdditionalInformationDetail",
"http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail",
"http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum [Member]" } } }, "auth_ref": ["r221", "r222", "r223", "r224", "r262", "r304", "r340", "r412", "r473", "r475", "r483", "r501", "r502", "r562", "r564", "r566", "r567", "r571", "r590", "r591", "r603", "r608", "r613", "r621", "r622", "r626", "r639", "r792", "r839", "r840", "r841", "r842", "r843", "r844"] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": ["r720"] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MoneyMarketFundsMember", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail"], "lang": { "en-us": { "role": { "label": "Money Market Funds [Member]", "terseLabel": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": ["r794"] }, "srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Real Estate, Type of Property [Axis]", "terseLabel": "Real Estate, Type of Property" } } }, "auth_ref": ["r579", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589"] },
"srt_MortgageLoansOnRealEstateNamePropertyTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MortgageLoansOnRealEstateNamePropertyTypeDomain", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Real Estate [Domain]" } } }, "auth_ref": ["r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589"] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": ["r728"] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": ["r702"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": ["r126"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by (used in) investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r126"] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities:", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r64", "r65", "r66"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail",
"http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity",
"http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "negatedLabel": "Net loss", "verboseLabel": "Net loss", "totalLabel": "Net loss", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r59", "r66", "r88", "r101", "r113", "r116", "r120", "r130", "r134", "r136", "r137", "r138", "r139", "r140", "r143", "r144", "r149", "r197", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r313", "r316", "r334", "r355", "r467", "r531", "r551", "r552", "r650", "r790"] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Issued and Adopted Accounting Pronouncements", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": ["r701"] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": ["r665", "r675", "r685", "r709", "r717"] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": ["r692"] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": ["r691"] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": ["r709"] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r728"] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r728"] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "terseLabel": "Other income net", "totalLabel": "Nonoperating Income (Expense), Total", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": ["r61"] },
"lrmr_OfferingCostsIncludedInAccountsPayableAndAccruedExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.larimartx.com/20240930", "localname": "OfferingCostsIncludedInAccountsPayableAndAccruedExpense", "crdr": "credit", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Offering costs included in accounts payable and accrued expense", "label": "Offering Costs Included In Accounts Payable And Accrued Expense", "documentation": "The amount of offering costs that were incurred, but not yet paid, during the period." } } }, "auth_ref": [] }, "lrmr_OfficeAndLabMember": { "xbrltype": "domainItemType", "nsuri": "http://www.larimartx.com/20240930", "localname": "OfficeAndLabMember", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Office and Lab [Member]", "label": "Office And Lab [Member]", "documentation": "Office and Lab." } } }, "auth_ref": [] }, "lrmr_OfficeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.larimartx.com/20240930", "localname": "OfficeMember", "presentation": [

"http://www.larimartx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Office [Member]", "label": "Office [Member]", "documentation": "Office." } } }, "auth_ref": [] }, "lrmr_OfficeSubleaseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.larimartx.com/20240930", "localname": "OfficeSubleaseMember", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Office Sublease [Member]", "label": "Office Sublease [Member]", "documentation": "Office Sublease" } } }, "auth_ref": [] } }, "us-gaap_OperatingCostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingCostsAndExpenses", "crdr": "debit", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureRelatedPartyAdditionalInformationDetails"], "lang": { "en-us": { "role": { "totalLabel": "Operating Costs and Expenses, Total", "label": "Operating Costs and Expenses", "terseLabel": "Cost related to Track FA program", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Operating Expenses", "totalLabel": "Total operating expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Operating Income (Loss)", "totalLabel": "Loss from operations", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": ["r89", "r600", "r766", "r767", "r768", "r769", "r770"] }, "us-gaap_OperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseExpense", "crdr": "debit", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Operating Lease, Expense", "terseLabel": "Lease expenses", "documentation": "Amount of operating lease expense. Excludes sublease income." } } }, "auth_ref": ["r832"] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnderLeaseAgreementsDetail"], "lang": { "en-us": { "role": { "totalLabel": "Operating Lease, Liability, Total", "label": "Operating Lease, Liability", "terseLabel": "Operating lease liability", "verboseLabel": "Present value of lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": ["r366"] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liabilities, current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": ["r366"] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": ["r366"] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": ["r365"] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted average discount rate", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": ["r369", "r628"] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease term in years", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r368", "r628"] }, "us-gaap_OptionIndexedToIssuersEquityEquityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OptionIndexedToIssuersEquityEquityAxis", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Option Indexed to Issuer's Equity [Axis]", "documentation": "Information by type of options indexed to an issuer's equity." } } }, "auth_ref": ["r28", "r36", "r37", "r82"] }, "us-gaap_OptionIndexedToIssuersEquityTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OptionIndexedToIssuersEquityTypeDomain", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Option Indexed to Issuer's Equity, Type [Domain]", "terseLabel": "Option Indexed to Issuer's Equity, Type", "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding." } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail"], "lang": { "en-us": { "role": { "label": "Other Accrued Liabilities, Current", "terseLabel": "Accrued other", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r43"] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Other Assets, Noncurrent, Total", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": ["r108"] }, "us-gaap_OtherCommitmentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCommitmentsLineItems", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Other Commitments [Line Items]", "terseLabel": "Other Commitments [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_OtherCommitmentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCommitmentsTable", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Other Commitments [Table]", "terseLabel": "Other Commitments [Table]", "documentation": "Disclosure of information about obligations resulting from other commitments." } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "credit", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity", "http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gain (loss) on marketable securities", "verboseLabel": "Unrealized gain (loss) on marketable securities", "totalLabel": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent, Total", "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent", "negatedLabel": "Unrealized gain (loss) on marketable debt securities", "documentation": "Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent." } } }, "auth_ref": ["r3", "r7", "r81"] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "crdr": "credit", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "totalLabel": "Total other comprehensive gain (loss)", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": ["r3", "r7", "r81", "r114", "r117", "r140"] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive gain (loss):", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": ["r701"] }, "lrmr_OtherPrepaidExpenseAndOtherCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.larimartx.com/20240930", "localname": "OtherPrepaidExpenseAndOtherCurrentAssets", "crdr": "debit", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail"], "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, not separately disclosed.", "label": "Other Prepaid Expense And Other Current Assets", "terseLabel": "Other prepaid expenses and other assets" } } }, "auth_ref": [] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r663", "r673", "r683", "r715"] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": ["r666", "r676", "r686", "r718"] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r666", "r676", "r686", "r718"] }, "us-gaap_OverAllotmentOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OverAllotmentOptionMember", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Underwritten Public Offering [Member]", "label": "Over-Allotment Option [Member]", "documentation": "Right given to the underwriter to sell additional shares over the initial allotment." } } }, "auth_ref": [] }, "stpr_PA": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/stpr/2024", "localname": "PA", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "PENNSYLVANIA", "terseLabel": "Pennsylvania [Member]" } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": ["r690"] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "auth_ref": [] }, "lrmr_PaymentForLicenseAgreements": { "xbrltype": "monetaryItemType", "nsuri": "http://www.larimartx.com/20240930", "localname": "PaymentForLicenseAgreements", "crdr": "credit", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Payment for license agreements.", "label": "Payment for license agreements" } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "crdr": "credit", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Payments to Acquire Debt Securities, Available-for-Sale", "negatedLabel": "Purchases of marketable securities", "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r15", "r123", "r165"] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total", "label": "Payments to Acquire Property, Plant, and Equipment", "terseLabel": "Purchase of property and equipment", "negatedLabel": "Purchase of property and equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": ["r63"] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype":

"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": ["r700"] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": ["r700"] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": ["r692"] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": ["r709"] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": ["r702"] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": ["r691"] }, "lrmr_PercentageOfCompensationForServicesEqualToGrossProceeds": { "xbrltype": "percentItemType", "nsuri": "http://www.larimartx.com/20240930", "localname": "PercentageOfCompensationForServicesEqualToGrossProceeds", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "The fee for services as a percentage of gross proceeds resulting from the sale of shares of common stock under a sales agreement.", "label": "Percentage Of Compensation For Services Equal To Gross Proceeds", "verboseLabel": "Percentage of compensation for services equal to gross proceeds" } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "terseLabel": "Plan Name", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": ["r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820"] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": ["r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820"] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": ["r693"] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": ["r737"] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": ["r692"] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail", "http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "netLabel": "Undesignated preferred stock, par value", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value per share", "verboseLabel": "Preferred stock, par value", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": ["r49", "r239"] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail", "http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "verboseLabel": "Undesignated preferred stock, shares authorized", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r49", "r511"] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail", "http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "verboseLabel": "Undesignated preferred stock, shares issued", "totalLabel": "Preferred Stock, Shares Issued, Total", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": ["r49", "r239"] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail", "http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "verboseLabel": "Undesignated preferred stock, shares outstanding", "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance", "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": ["r49", "r511", "r529", "r883", "r884"] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock; $0.001 par value per share; 5,000,000 shares authorized as of September 30, 2024 and December 31, 2023; no shares issued and outstanding as of September 30, 2024 and December 31, 2023", "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance", "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance", "totalLabel": "Preferred Stock, Value, Issued, Total", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r49", "r458", "r629"] }, "us-gaap_PrepaidExpenseAndOtherAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsAbstract", "lang": { "en-us": { "role": { "label": "Prepaid Expense and Other Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail", "http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets", "totalLabel": "Total prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r753"] }, "lrmr_PrepaidExpensesAndOtherCurrentAssetsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.larimartx.com/20240930", "localname": "PrepaidExpensesAndOtherCurrentAssetsTextBlock", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets"], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for prepaid expenses and other current assets.", "label": "Prepaid Expenses And Other Current Assets [Text Block]", "terseLabel": "Prepaid Expenses and Other Current Assets" } } }, "auth_ref": [] }, "us-gaap_PrepaidInsurance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidInsurance", "crdr": "debit", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail"], "lang": { "en-us": { "role": { "label": "Prepaid Insurance", "terseLabel": "Prepaid insurance", "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r595", "r605", "r781"] }, "lrmr_PrepaidResearchAndDevelopmentExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.larimartx.com/20240930", "localname": "PrepaidResearchAndDevelopmentExpenses", "crdr": "debit", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail"], "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs related to research and development.", "label": "Prepaid Research And Development Expenses", "terseLabel": "Prepaid research and development expenses" } } }, "auth_ref": [] }, "us-gaap_PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrivatePlacementMember", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Private Placement [Member]", "terseLabel": "Private Placement [Member]", "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts." } } }, "auth_ref": [] }, "lrmr_ProceedsFromIssuanceCommonStockAndWarrantsNetOfferingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.larimartx.com/20240930", "localname": "ProceedsFromIssuanceCommonStockAndWarrantsNetOfferingCosts", "crdr": "debit", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of common stock and prefunded warrants to purchase common stock, net of offering costs.", "label": "Proceeds From Issuance Common Stock And Warrants Net Offering Costs", "verboseLabel": "Proceeds from issuance common stock and warrants net offering costs" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfPrivatePlacement", "crdr": "debit", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Private Placement", "terseLabel": "Gross proceeds", "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement." } } }, "auth_ref": ["r2"] }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOrSaleOfEquity", "crdr": "debit", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of equity securities, net of issuance costs", "label": "Proceeds from Issuance or Sale of Equity", "totalLabel": "Proceeds from Issuance or Sale of Equity, Total", "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity." } } }, "auth_ref": ["r2", "r485"] }, "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities", "crdr": "debit", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Maturities and sales of marketable securities", "totalLabel": "Proceeds from Sale and Maturity of Debt Securities, Available-for-sale, Total", "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale", "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r123", "r124", "r773"] }, "lrmr_ProceedsFromStockOptionsAndWarrantExercises": { "xbrltype": "monetaryItemType", "nsuri": "http://www.larimartx.com/20240930", "localname": "ProceedsFromStockOptionsAndWarrantExercises", "crdr": "debit", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds From Stock Options And Warrant Exercises", "terseLabel": "Proceeds from exercise of stock options and warrants", "documentation": "The cash inflow from the exercise of options under share-based payment arrangements and from holders exercising their stock warrants." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromWarrantExercises": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromWarrantExercises", "crdr": "debit", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail", "http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Cash proceeds from exercises of warrants", "label": "Proceeds from Warrant Exercises", "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants." } } }, "auth_ref": ["r757"] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total", "terseLabel": "Net loss", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": ["r101", "r113", "r116", "r125", "r130", "r134", "r140", "r143", "r144", "r197", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r313", "r316", "r317", "r320", "r321", "r334", "r355", "r452", "r466", "r490", "r531", "r551", "r552", "r616", "r617", "r651", "r756", "r790"] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureFixedAssetsScheduleOfFixedAssetsNetDetail"], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Long-Lived Tangible Asset", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": ["r6", "r371"] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureFixedAssets"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Fixed Assets", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": ["r70", "r95", "r98", "r99"] }, "us-

gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureFixedAssetsScheduleOfFixedAssetsNetDetail"], "lang": { "en-us": { "role": { "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance", "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance", "totalLabel": "Property, Plant and Equipment, Gross, Total", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Fixed assets, gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r71", "r106", "r465"] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureFixedAssetsScheduleOfFixedAssetsNetDetail", "http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance", "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Fixed assets, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r6", "r371", "r453", "r465", "r629"] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureFixedAssetsTables"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of Fixed Assets, Net", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": ["r6"] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureFixedAssetsScheduleOfFixedAssetsNetDetail"], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Long-Lived Tangible Asset", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": ["r71", "r371"] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureFixedAssetsScheduleOfFixedAssetsNetDetail"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Property Plant And Equipment Useful Life", "verboseLabel": "Fixed assets, useful life", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureFixedAssetsScheduleOfFixedAssetsNetDetail"], "lang": { "en-us": { "role": { "label": "Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]", "documentation": "Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value." } } }, "auth_ref": ["r783"] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [
"r690"] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } },
"auth_ref": ["r690"] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://www.larimartx.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail",
"http://www.larimartx.com/20240930/taxonomy/role/DisclosureRelatedPartyAdditionalInformationDetails",
"http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureFixedAssetsAdditionalInformationDetail",
"http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail",
"http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement" } } }, "auth_ref": ["r221", "r222", "r223", "r224", "r254", "r262", "r293", "r294", "r295", "r304", "r340", "r387", "r396", "r412", "r473", "r475", "r483", "r501", "r502", "r562", "r564", "r566", "r567", "r571", "r590", "r591", "r603", "r608", "r613", "r621", "r622", "r626", "r627", "r639", "r643", "r788", "r792", "r826", "r840", "r841", "r842", "r843", "r844"] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://www.larimartx.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail",
"http://www.larimartx.com/20240930/taxonomy/role/DisclosureRelatedPartyAdditionalInformationDetails",
"http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureFixedAssetsAdditionalInformationDetail",
"http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail",
"http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement" } } }, "auth_ref": ["r221", "r222", "r223", "r224", "r254", "r262", "r293", "r294", "r295", "r304", "r340", "r387", "r396", "r412", "r473", "r475", "r483", "r501", "r502", "r562", "r564", "r566", "r567", "r571", "r590", "r591", "r603", "r608", "r613", "r621", "r622", "r626", "r627", "r639", "r643", "r788", "r792", "r826", "r840", "r841", "r842", "r843", "r844"] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": ["r658", "r668", "r678", "r710"] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureRelatedPartyAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Domain]", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": ["r163", "r261", "r377", "r378", "r456", "r463", "r504", "r505", "r506", "r507", "r508", "r528", "r530", "r560"] }, "us-gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionAxis", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureRelatedPartyAdditionalInformationDetails",
"http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } } }, "auth_ref": ["r377", "r378", "r836"] }, "us-gaap_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionDomain", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/DisclosureRelatedPartyAdditionalInformationDetails",
"http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Domain]", "documentation": "Transaction between related party." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionLineItems", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/DisclosureRelatedPartyAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r163", "r534", "r535", "r538"] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureRelatedPartyAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": ["r163", "r261", "r377", "r378", "r456", "r463", "r504", "r505", "r506", "r507", "r508", "r528", "r530", "r560", "r836"] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureRelatedParty"], "lang": { "en-us": { "role": { "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Party", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": ["r374", "r375", "r376", "r378", "r379", "r487", "r488", "r489", "r536", "r537", "r538", "r557", "r559"] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "totalLabel": "Research and Development Expense, Total", "label": "Research and Development Expense", "terseLabel": "Research and development", "verboseLabel": "Research and development expense", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": ["r307", "r592", "r601", "r845"] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsSummaryOfStockBasedCompensationExpenseDetail"], "lang": { "en-us": { "role": { "label": "Research and Development Expense [Member]", "terseLabel": "Research and Development [Member]", "verboseLabel": "Research and Development Expenses [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development Costs", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": ["r306"] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": ["r659", "r669", "r679", "r711"] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": ["r660", "r670", "r680", "r712"] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": ["r667", "r677", "r687", "r719"] }, "us-gaap_RestrictedCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCash", "crdr": "debit", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "totalLabel": "Restricted Cash, Total", "label": "Restricted Cash", "terseLabel": "Letter of credit", "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [
"r749", "r759", "r846", "r849"] }, "us-gaap_RestrictedCashNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashNoncurrent", "crdr": "debit", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Restricted Cash, Noncurrent", "terseLabel": "Restricted cash", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": ["r92", "r750", "r759"] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockMember", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Restricted Stock [Member]", "terseLabel": "Restricted Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": ["r20"] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfRestrictedStockUnitsDetails",
"http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Stock Units (RSUs)", "verboseLabel": "Restricted Stock Units [Member]", "documentation": "Share instrument which is convertible to stock or

an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail", "http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance", "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance", "totalLabel": "Retained Earnings (Accumulated Deficit), Total", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r53", "r75", "r461", "r480", "r482", "r486", "r512", "r629"] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r100", "r131", "r132", "r133", "r135", "r140", "r142", "r144", "r198", "r199", "r215", "r308", "r309", "r310", "r311", "r312", "r314", "r315", "r316", "r324", "r326", "r327", "r329", "r332", "r363", "r364", "r477", "r479", "r491", "r883"] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Leased assets obtained in exchange for new operating lease liabilities", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": ["r367", "r628"] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r728"] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r728"] }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockConsiderationReceivedOnTransaction", "crdr": "debit", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail", "http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "verboseLabel": "Proceeds net of issuance costs", "label": "Sale of Stock, Consideration Received on Transaction", "documentation": "Cash received on stock transaction after deduction of issuance costs." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail", "http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "lrmr_SalesAgreementDescription": { "xbrltype": "stringItemType", "nsuri": "http://www.larimartx.com/20240930", "localname": "SalesAgreementDescription", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Description of sales agreement..", "label": "Sales Agreement Description", "verboseLabel": "Sales agreement, description" } } }, "auth_ref": [] }, "srt_ScenarioForecastMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioForecastMember", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Forecast [Member]", "label": "Forecast [Member]" } } }, "auth_ref": ["r263", "r764"] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioUnspecifiedDomain", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Scenario [Domain]" } } }, "auth_ref": ["r145", "r263", "r739", "r764"] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureAccruedExpensesTables"], "lang": { "en-us": { "role": { "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of Accrued Expenses", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfMarketableDebtSecuritiesDetails"], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale [Line Items]", "terseLabel": "Schedule Of Available For Sale Securities [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178"] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesTables"], "lang": { "en-us": { "role": { "terseLabel": "Summary of Marketable Securities", "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsTables"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Summary of Stock-Based Compensation Expense", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": ["r33"] }, "lrmr_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.larimartx.com/20240930", "localname": "ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables"], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amounts of prepaid expenses and other current assets.", "label": "Schedule Of Prepaid Expenses And Other Current Assets Table [Text Block]", "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureRelatedPartyAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Table]", "documentation": "Disclosure of information about related party transaction." } } }, "auth_ref": ["r38", "r39", "r534", "r535", "r538"] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsSummaryOfStockBasedCompensationExpenseDetail"], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": ["r265", "r267", "r268", "r269", "r270", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r292", "r293", "r294", "r295", "r296"] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsTables"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Summary of Stock Option Activity", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": ["r9", "r10", "r76"] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsTables"], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Assumptions used to Determine Fair Value of Stock Options Granted", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": ["r80"] }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsTables"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Summary of Restricted Stock Units", "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r653"] }, "us-gaap_SecurityDepositLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecurityDepositLiability", "crdr": "credit", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Security Deposit Liability", "terseLabel": "Lease security deposits letters of credit", "documentation": "This element represents money paid in advance to protect the provider of a product or service, such as a lessor, against damage or nonpayment by the buyer or tenant (lessee) during the term of the agreement. Such damages may include physical damage to the property, theft of property, and other contractual breaches. Security deposits held may be interest or noninterest bearing." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r655"] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical" } } }, "auth_ref": ["r161", "r162", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r494", "r497", "r499", "r563", "r565", "r569", "r572", "r579", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r593", "r609", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r640", "r643", "r793", "r851", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880"] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r4"] }, "lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesPercentageOfOutstandingStock": { "xbrltype": "percentItemType", "nsuri": "http://www.larimartx.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesPercentageOfOutstandingStock", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "The maximum number of shares that may be added annually to the threshold number of shares issued under the Plan, as a percentage of the shares issued and outstanding on the last day of the immediately preceding fiscal year.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Additional Shares Percentage Of Outstanding Stock", "verboseLabel": "Percentage of outstanding shares" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "terseLabel": "Vesting period of stock option", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": ["r614"] }, "lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardDuration": { "xbrltype": "durationItemType", "nsuri": "http://www.larimartx.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDuration", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Term of plan", "documentation": "The term of the plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Duration" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [

"http://www.larimartx.com/20240930/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Number of shares, Restricted stock units forfeited", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": ["r285"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant date fair value, Restricted stock units forfeited", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": ["r285"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfRestrictedStockUnitsDetails", "http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Number of shares, Restricted stock units granted", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r283"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfRestrictedStockUnitsDetails", "http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "verboseLabel": "Weighted average grant date fair value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant date fair value, Restricted stock units granted", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r283"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodStartLabel": "Number of shares, Outstanding", "periodEndLabel": "Number of shares, Outstanding", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": ["r280", "r281"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodStartLabel": "Weighted average grant date fair value, balance", "periodEndLabel": "Weighted average grant date fair value, balance", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": ["r280", "r281"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Weighted average remaining contractual term, Outstanding as of September 30, 2024", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms", "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r79"] }, "lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.larimartx.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestAggregateIntrinsicValue", "crdr": "debit", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate intrinsic value, Unvested and expected to vest as of September 30, 2024", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options Unvested And Expected To Vest, Aggregate Intrinsic Value", "documentation": "Intrinsic value of awards that are unvested and expected to vest under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [] }, "lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://www.larimartx.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestOutstandingNumber", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of shares, Unvested and expected to vest as of September 30, 2024", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Unvested And Expected To Vest Outstanding Number", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that are unvested and expected to vest as of the balance sheet date." } } }, "auth_ref": [] }, "lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://www.larimartx.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageGrantDateFairValue", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Weighted average grant date fair value, Unvested and expected to vest as of September 30, 2024", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options Unvested And Expected To Vest, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of awards that are unvested and expected to vest under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [] }, "lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageRemainingContractualTerms": { "xbrltype": "durationItemType", "nsuri": "http://www.larimartx.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageRemainingContractualTerms", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Weighted average remaining contractual term, Unvested and expected to vest as of September 30, 2024", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options Unvested And Expected To Vest, Weighted Average Remaining Contractual Terms", "documentation": "Weighted average remaining contractual term for equity-based awards excluding options that are unvested and expected to vest, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Number of shares, Restricted stock units vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": ["r284"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Weighted average grant date fair value, Restricted stock units vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": ["r284"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAssumptionsUsedToDetermineFairValueOfStockOptionsGrantedDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Dividend yield", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": ["r294"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAssumptionsUsedToDetermineFairValueOfStockOptionsGrantedDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected volatility", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": ["r293"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAssumptionsUsedToDetermineFairValueOfStockOptionsGrantedDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": ["r295"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsSummaryOfStockBasedCompensationExpenseDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r265", "r267", "r268", "r269", "r270", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r292", "r293", "r294", "r295", "r296"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized", "verboseLabel": "Increase in shares reserved for future issuance", "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Share-Based

Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "terseLabel": "Maximum number of shares that may be issued under stock option incentive plan", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": ["r615"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "verboseLabel": "Shares available for grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": ["r30"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsSummaryOfStockOptionActivityDetail"], "lang": { "en-us": { "role": { "terseLabel": "Number of shares, Exercisable as of September 30, 2024", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": ["r274"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsSummaryOfStockOptionActivityDetail"], "lang": { "en-us": { "role": { "terseLabel": "Weighted average exercise price, Exercisable as of September 30, 2024", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": ["r274"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsSummaryOfStockOptionActivityDetail"], "lang": { "en-us": { "role": { "terseLabel": "Number of shares, Forfeited/Expired", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period", "totalLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Total", "negatedLabel": "Number of shares, Options forfeited/expired", "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired." } } }, "auth_ref": ["r801"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsSummaryOfStockOptionActivityDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "negatedLabel": "Weighted average exercise price, Forfeited/Expired", "terseLabel": "Weighted average exercise price, Options forfeited/expired", "documentation": "Weighted average price of options that were either forfeited or expired." } } }, "auth_ref": ["r801"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail", "http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsSummaryOfStockOptionActivityDetail"], "lang": { "en-us": { "role": { "terseLabel": "Options to purchase shares of common stock granted", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "verboseLabel": "Number of shares, Options granted", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": ["r276"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average grant date fair value of options granted", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": ["r286"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail", "http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsSummaryOfStockOptionActivityDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "periodEndLabel": "Aggregate intrinsic value, outstanding", "terseLabel": "Aggregate intrinsic value of outstanding options granted", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": ["r30"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsSummaryOfStockOptionActivityDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Number of shares, Outstanding", "periodStartLabel": "Number of shares, Outstanding", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": ["r272", "r273"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsSummaryOfStockOptionActivityDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted average exercise price, balance", "periodStartLabel": "Weighted average exercise price, balance", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": ["r272", "r273"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "crdr": "debit", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsSummaryOfStockOptionActivityDetail"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate intrinsic value, Vested and expected to vest as of September 30, 2024", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r288"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsSummaryOfStockOptionActivityDetail"], "lang": { "en-us": { "role": { "terseLabel": "Number of shares, Vested and expected to vest as of September 30, 2024", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r288"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsSummaryOfStockOptionActivityDetail"], "lang": { "en-us": { "role": { "terseLabel": "Weighted average exercise price, Vested and expected to vest as of September 30, 2024", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r288"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Terms of Award", "verboseLabel": "Share-based compensation arrangement by share-based payment award, description", "documentation": "Description of terms of award under share-based payment arrangement." } } }, "auth_ref": ["r31"] }, "lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdNumberOfSharesAllowedToIssue": { "xbrltype": "sharesItemType", "nsuri": "http://www.larimartx.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdNumberOfSharesAllowedToIssue", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Minimum level of maximum number of shares allowed to be issued", "documentation": "The minimum threshold number of shares used to determine the maximum number of shares that may be issued under the Plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Threshold Number Of Shares Allowed To Issue" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfRestrictedStockUnitsDetails", "http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r268", "r269", "r270", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r292", "r293", "r294", "r295", "r296"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsSummaryOfStockOptionActivityDetail"], "lang": { "en-us": { "role": { "terseLabel": "Weighted average exercise price, Exercised", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": ["r277"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsSummaryOfStockOptionActivityDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price, Options granted", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": ["r276"] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Policy Text Block]", "terseLabel": "Stock-Based Compensation", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": ["r264", "r271", "r290", "r291", "r292", "r293", "r296", "r299", "r300", "r301", "r302"] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Stock option outstanding exercise price lower range limit", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit", "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range." } } }, "auth_ref": ["r32"] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

"ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Number of stock options remained outstanding under the plan", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding", "periodEndLabel": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding, Ending Balance", "periodStartLabel": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding, Beginning Balance", "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices." } } }, "auth_ref": ["r77", "r78"] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Stock option outstanding exercise price upper range limit", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit", "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range." } } }, "auth_ref": ["r32"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage", "terseLabel": "Stock option vesting percentage", "verboseLabel": "Award vesting", "documentation": "Percentage of vesting of award under share-based payment arrangement." } } }, "auth_ref": ["r795"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding", "crdr": "debit", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate intrinsic value, Outstanding as of September 30, 2024", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding", "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAssumptionsUsedToDetermineFairValueOfStockOptionsGrantedDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term (in years)", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r292"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsSummaryOfStockOptionActivityDetail"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate intrinsic value, exercisable as of September 30, 2024", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": ["r30"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsSummaryOfStockOptionActivityDetail"], "lang": { "en-us": { "role": { "terseLabel": "Weighted average remaining contractual term, Exercisable as of September 30, 2024", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r30"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsSummaryOfStockOptionActivityDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted average remaining contractual term, outstanding", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r79"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsSummaryOfStockOptionActivityDetail"], "lang": { "en-us": { "role": { "terseLabel": "Weighted average remaining contractual term, Vested and expected to vest as of September 30, 2024", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r288"] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssuedPricePerShare", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail", "http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Shares Issued, Price Per Share", "terseLabel": "Share price per share", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Shares, Outstanding", "periodEndLabel": "Ending balance, shares", "periodStartLabel": "Beginning balance, shares", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_ShortTermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtTypeAxis", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Short-Term Debt, Type [Axis]", "terseLabel": "Short-term Debt, Type", "documentation": "Information by type of short-term debt arrangement." } } }, "auth_ref": ["r42", "r785", "r786", "r787"] }, "us-gaap_ShortTermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtTypeDomain", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Short-Term Debt, Type [Domain]", "terseLabel": "Short-term Debt, Type", "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing." } } }, "auth_ref": ["r41", "r785", "r786", "r787"] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies"], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": ["r67", "r128"] }, "lrmr_SixthSubleaseYearMember": { "xbrltype": "domainItemType", "nsuri": "http://www.larimartx.com/20240930", "localname": "SixthSubleaseYearMember", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Sixth sublease year member", "label": "Sixth Sublease Year [Member]", "terseLabel": "Sixth Sublease Year" } } }, "auth_ref": [] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail", "http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail", "http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "terseLabel": "Equity Components", "documentation": "Information by component of equity." } } }, "auth_ref": ["r8", "r50", "r54", "r55", "r100", "r118", "r119", "r120", "r131", "r132", "r133", "r135", "r140", "r142", "r144", "r157", "r198", "r199", "r215", "r253", "r308", "r309", "r310", "r311", "r312", "r314", "r315", "r316", "r324", "r325", "r326", "r327", "r328", "r329", "r332", "r356", "r357", "r358", "r359", "r360", "r361", "r363", "r364", "r373", "r468", "r477", "r478", "r479", "r491", "r553"] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical" } } }, "auth_ref": ["r161", "r162", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r494", "r497", "r499", "r563", "r565", "r569", "r572", "r579", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r593", "r609", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r640", "r643", "r793", "r851", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880"] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail", "http://www.larimartx.com/20240930/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfRestrictedStockUnitsDetails", "http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureFixedAssetsAdditionalInformationDetail", "http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureFixedAssetsScheduleOfFixedAssetsNetDetail", "http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail", "http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r131", "r132", "r133", "r157", "r364", "r416", "r484", "r492", "r503", "r504", "r505", "r506", "r507", "r508", "r511", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r524", "r525", "r526", "r527", "r528", "r530", "r532", "r533", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r553", "r644"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementScenarioAxis", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "auth_ref": ["r145", "r263", "r739", "r740", "r764"] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail", "http://www.larimartx.com/20240930/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfRestrictedStockUnitsDetails", "http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureFixedAssetsAdditionalInformationDetail", "http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureFixedAssetsScheduleOfFixedAssetsNetDetail", "http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail", "http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Statement [Table]", "terseLabel": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": ["r131", "r132", "r133", "r157", "r163", "r364", "r416", "r484", "r492", "r503", "r504", "r505", "r506", "r507", "r508", "r511", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r524", "r525", "r526", "r527", "r528", "r530", "r532", "r533", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r553", "r644"] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": ["r662", "r672", "r682", "r714"] }, "lrmr_StockAndWarrantIssuanceTransactionCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.larimartx.com/20240930", "localname": "StockAndWarrantIssuanceTransactionCosts", "crdr": "debit", "presentation": ["http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Costs incurred during the period related to the issuance of stock and warrants.", "label": "Stock And Warrant Issuance Transaction Costs", "terseLabel": "Transaction cost" } } }, "auth_ref": [] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": [

```
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] },
"lrmr_StockIssuedDuringPeriodSharesExerciseOfWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://www.larimartx.com/20240930", "localname":
"StockIssuedDuringPeriodSharesExerciseOfWarrants", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail",
"http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise of warrants, shares", "label": "Stock Issued During Period Shares Exercise of Warrants", "documentation": "Number of shares of issued as a result of the exercise of warrants." } } }, "auth_ref": [] },
"us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues",
"presentation": [ "http://www.larimartx.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail",
"http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail",
"http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "verboseLabel":
"Issuance of common stock, net, shares", "terseLabel": "Issuance of common stock", "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r8", "r49", "r50", "r75", "r485", "r553", "r577" ] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "xbrltype": "sharesItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting of restricted stock units, shares", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross", "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards." } } }, "auth_ref": [ "r8", "r75" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsSummaryOfStockOptionActivityDetail",
"http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise of stock options, shares", "negatedLabel": "Number of shares, Exercised", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
"documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r8", "r49", "r50", "r75", "r277" ] },
"lrmr_StockIssuedDuringPeriodValueExerciseOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.larimartx.com/20240930", "localname":
"StockIssuedDuringPeriodValueExerciseOfWarrants", "crdr": "credit", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise of warrants", "label": "Stock Issued During Period Value Exercise of Warrants", "documentation": "Value of stock issued as a result of the exercise of warrants." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr":
"credit", "presentation": [ "http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role":
{ "terseLabel": "Issuance of common stock, net", "label": "Stock Issued During Period, Value, New Issues", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r8", "r49", "r50", "r75", "r491", "r553", "r577", "r651" ] }, "us-
gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockIssuedDuringPeriodValueRestrictedStockAwardGross", "crdr": "credit", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting of restricted stock units", "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross", "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period." } } }, "auth_ref": [ "r8", "r49", "r50", "r75" ] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise of stock options", "label": "Stock Issued During Period, Value, Stock Options Exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [
"r8", "r50", "r54", "r55", "r75" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit",
"presentation": [ "http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets",
"http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total stockholders\u2019 equity", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r50", "r54", "r55", "r69", "r513", "r529", "r554", "r555", "r629", "r652", "r760", "r780", "r830", "r883" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockholdersEquityAbstract", "presentation": [ "http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": {
"label": "Equity, Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 equity:" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteAbstract": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteAbstract", "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock",
"presentation": [ "http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptions" ], "lang": { "en-us": { "role": { "label": "Equity [Text Block]",
"terseLabel": "Stockholders' Equity and Stock Options", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r74", "r129", "r238", "r240", "r241", "r242", "r243", "r244",
"r245", "r246", "r247", "r248", "r249", "r251", "r253", "r331", "r556", "r558", "r578" ] }, "lrmr_SubleaseAnnualBaseRent": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.larimartx.com/20240930", "localname": "SubleaseAnnualBaseRent", "crdr": "debit", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Annual base rent",
"label": "Sublease Annual Base Rent", "documentation": "Sublease annual base rent." } } }, "auth_ref": [] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://www.larimartx.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail",
"http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r362", "r380" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://www.larimartx.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail",
"http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r362",
"r380" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://www.larimartx.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail",
"http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r362", "r380" ] },
"us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail",
"http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "lrmr_SummaryOfSignificantAccountingPoliciesLineItems": {
"xbrltype": "stringItemType", "nsuri": "http://www.larimartx.com/20240930", "localname": "SummaryOfSignificantAccountingPoliciesLineItems", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation":
"Summary of significant accounting policies.", "label": "Summary Of Significant Accounting Policies [Line Items]", "terseLabel": "Summary Of Significant Accounting Policies [Line Items]" } } },
"auth_ref": [] }, "lrmr_SummaryOfSignificantAccountingPoliciesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.larimartx.com/20240930", "localname":
"SummaryOfSignificantAccountingPoliciesTable", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation":
"Summary of significant accounting policies.", "label": "Summary Of Significant Accounting Policies [Table]", "terseLabel": "Summary Of Significant Accounting Policies [Table]" } } },
"auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": [ "r708" ] },
"srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualAxis", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Title and Position [Axis]" } } }, "auth_ref": [ "r771", "r835" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname":
"TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Title and Position [Domain]" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt",
"presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } },
"auth_ref": [ "r700" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": [ "r707" ] }, "lrmr_TrackFAProgramMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.larimartx.com/20240930", "localname": "TrackFAProgramMember", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/DisclosureRelatedPartyAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Track FA program.", "label": "Track F A Program [Member]", "terseLabel": "Track FA program [Member]" } } }, "auth_ref": [] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel":
"Trading Arrangement;" } } }, "auth_ref": [ "r727" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable",
"presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading
Arrangements, by Individual" } } }, "auth_ref": [ "r729" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol",
"presentation": [ "http://www.larimartx.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel":
"Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-
gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail",
"http://www.larimartx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfMarketableDebtSecuritiesDetails" ], "lang": { "en-us": { "role": {
"label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186",
"r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r237", "r250", "r330", "r354", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391",
"r392", "r393", "r394", "r395", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r469", "r618", "r619", "r621", "r622", "r623",
"r624", "r625", "r626", "r627", "r630", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r776", "r777", "r778", "r779", "r822", "r825", "r826", "r827", "r828", "r829" ] },
"ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": [ "r730" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": [
"r731" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": [
"r731" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r729" ] },
"ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": [
```

```
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": [ "r729" ] },
"ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate
Available" } } }, "auth_ref": [ "r732" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate",
"presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" }
} }, "auth_ref": [ "r730" ] }, "lrmr_TwoThousandTwentyEquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.larimartx.com/20240930", "localname":
"TwoThousandTwentyEquityIncentivePlanMember", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "2020 Equity
Incentive Plan [Member]", "label": "Two Thousand Twenty Equity Incentive Plan [Member]", "documentation": "Two thousand twenty equity incentive plan." } } }, "auth_ref": [] },
"lrmr_TwoThousandTwentyTwoEquityDistributionAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.larimartx.com/20240930", "localname":
"TwoThousandTwentyTwoEquityDistributionAgreementMember", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "2022 Equity
Distribution Agreement [Member]", "label": "Two Thousand Twenty Two Equity Distribution Agreement [Member]", "documentation": "Two thousand twenty two equity distribution agreement
member." } } }, "auth_ref": [] }, "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"USGovernmentCorporationsAndAgenciesSecuritiesMember", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail",
"http://www.larimartx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfMarketableDebtSecuritiesDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "U.S. Government and Agency Securities [Member]", "label": "US Government Corporations and Agencies Securities [Member]", "verboseLabel": "U.S Government and Agency
Securities (due within 1 year) [Member]", "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US
Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae)
and the Federal Home Loan Mortgage Corporation (Freddie Mac)." } } }, "auth_ref": [ "r847" ] }, "lrmr_USGovernmentSecuritiesMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.larimartx.com/20240930", "localname": "USGovernmentSecuritiesMember", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail",
"http://www.larimartx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfMarketableDebtSecuritiesDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "U.S. Government Securities [Member]", "label": "U.S. Government Securities [Member]", "documentation": "U.S. Government securities." } } }, "auth_ref": [] }, "us-
gaap_USTreasurySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USTreasurySecuritiesMember", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail",
"http://www.larimartx.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAndMarketableSecuritiesSummaryOfMarketableDebtSecuritiesDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "US Treasury Bills [Member]", "label": "US Treasury Securities [Member]", "documentation": "This category includes information about debt securities issued by the United States
Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes
(intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)." } } }, "auth_ref": [ "r597", "r610", "r612", "r618", "r847" ] },
"ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market
Price Change" } } }, "auth_ref": [ "r726" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates",
"presentation": [ "http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Use of Estimates,
Policy [Policy Text Block]", "terseLabel": "Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity
with generally accepted accounting principles." } } }, "auth_ref": [ "r22", "r23", "r24", "r93", "r94", "r96", "r97" ] }, "lrmr_VestOneYearMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.larimartx.com/20240930", "localname": "VestOneYearMember", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Vest one
year.", "terseLabel": "Vest One Year [Member]", "label": "Vest One Year [Member]" } } }, "auth_ref": [] }, "lrmr_VestOverFourYearsMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.larimartx.com/20240930", "localname": "VestOverFourYearsMember", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Vest over
four years.", "label": "Vest Over Four Years [Member]", "terseLabel": "Vest Over 4 Years [Member]" } } }, "auth_ref": [] }, "us-gaap_VestingAxis": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "VestingAxis", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Vesting [Axis]",
"terseLabel": "Vesting", "documentation": "Information by vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r795", "r796", "r797", "r798", "r799", "r800",
"r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820" ] }, "us-gaap_VestingDomain": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingDomain", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Vesting [Domain]",
"terseLabel": "Vesting", "documentation": "Vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r795", "r796", "r797", "r798", "r799", "r800", "r801",
"r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820" ] },
"ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of
Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth_ref": [ "r696" ] },
"lrmr_WakeForestUniversityHealthSciencesAndIndianaUniversityResearchAndTechnologyCorporationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.larimartx.com/20240930",
"localname": "WakeForestUniversityHealthSciencesAndIndianaUniversityResearchAndTechnologyCorporationMember", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Wake forest
university health sciences and indiana university research and technology corporation.", "label": "Wake Forest University Health Sciences And Indiana University Research And Technology
Corporation [Member]", "terseLabel": "WFUHS and IU [Member]" } } }, "auth_ref": [] }, "lrmr_WakeForestUniversityHealthSciencesMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.larimartx.com/20240930", "localname": "WakeForestUniversityHealthSciencesMember", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Wake Forest
University Health Sciences (WFUHS) [Member]", "label": "Wake Forest University Health Sciences [Member]", "terseLabel": "WFUHS [Member]" } } }, "auth_ref": [] },
"lrmr_WarrantsIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.larimartx.com/20240930", "localname": "WarrantsIssuedPricePerShare", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Per unit
amount of prefunded warrant issued.", "label": "Warrants Issued Price Per Share", "terseLabel": "Warrants price per share" } } }, "auth_ref": [] }, "us-
gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel":
"Weighted average common shares outstanding, diluted", "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total", "label": "Weighted Average Number of Shares
Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based
on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r147", "r152" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [
"http://www.larimartx.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel":
"Weighted Average Number of Shares Outstanding, Basic, Total", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average common shares
outstanding, basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding,
determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r146", "r152" ] },
"ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-end Fair Value of
Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and
Unvested" } } }, "auth_ref": [ "r694" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph":
"1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-
10-45-10A" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic":
"10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20" }, "r4": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
"Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r6": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r8": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r10": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99",
"Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r12": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220",
"SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r14": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic":
"10", "Section": "45", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r16": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic":
"10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-
50-4" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
"Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r21": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic":
"10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
"Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-
50-8" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
"Topic": "360", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4" }, "r26": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic":
"10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r28": { "role": "http://fasb.org/us-
```

gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "55", "Paragraph": "63", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-63" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "40", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-4" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "40", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/360/tableOfContent" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-12A" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-3" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-7" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "210", "Topic": "954", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r107": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-11" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-2" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name":

"Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-5" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715",

"SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" },

"r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/850/tableOfContent" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "920", "SubTopic": "350", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "920", "SubTopic": "350", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "920", "SubTopic": "350", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-4" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924",

~~"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r491": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5D", "Subparagraph": "(SX 210.12-13D(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5D" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r593": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r594": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r597": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r599": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r600": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r601": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r602": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r603": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r604": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8" }, "r605": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5" }, "r606": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r607": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r608": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r609": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r610": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r613": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r614": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r615": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r616": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r617": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r618": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r619": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r620": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r621": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r622": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r623": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r624": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r625": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r626": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r627": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r628": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r629": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r630": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4" }, "r631": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r632": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r633": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r634": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r635": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479916/932-235-55-2" }, "r636": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r637": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479916/932-235-55-5" }, "r638": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r639": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r640": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r641": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r642": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r643": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r647": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r648": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r649": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "405", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478790/946-405-45-2" }, "r650": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r651": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r652": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r653": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r654": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r655": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r656": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r657": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "I", "Paragraph": "a" }, "r658": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r659": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r660": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r661": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r662": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r663": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r664": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r665": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r666": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r667": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r668": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r669": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r670": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r671": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r672": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r673": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r674": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r675": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r676": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r677": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r678": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r679": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r680": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r681": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r682": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r683": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r684": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r685": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r686": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r687": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r688": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r689": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r690": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r691": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r692": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r693": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r694": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r695": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r696": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r697": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r698": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r699": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r700": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r701": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r702": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r703": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r704": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r705": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r706": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r707": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r708": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r709": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r710": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r711": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r712": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r713": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r714": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r715": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r716": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r717": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r718": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r719": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r720": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r721": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r722": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r723": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r724": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r725": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r726": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r727": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r728": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r729": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r730": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r731": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r732": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r733": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r734": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r735": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r736": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r737": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r738": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r739": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10" }, "r740": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3" }, "r741": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r742": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)",

"Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r743": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r744": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(2)", "Publisher": "SEC" }, "r745": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(3)", "Publisher": "SEC" }, "r746": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "e", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r747": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "e", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r748": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "e", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r749": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r750": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r751": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r752": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r753": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r754": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r755": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r756": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r757": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r758": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r759": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r760": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r761": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r762": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r763": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r764": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r765": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r766": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r767": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r768": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r769": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r770": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r771": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r772": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1" }, "r773": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11" }, "r774": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r775": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r776": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r777": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r778": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r779": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r780": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r781": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1" }, "r782": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r783": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482190/360-10-35-3" }, "r784": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r785": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r786": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r787": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r788": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r789": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r790": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r791": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r792": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r793": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r794": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r795": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r796": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r797": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r798": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r799": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r800": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r801": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r802": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r803": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r804": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r805": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r806": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r807": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r808": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r809": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r810": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r811": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r812": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r813": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r814": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r815": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r816": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r817": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r818": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r819": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r820": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef",

"Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r821": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r822": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r823": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r824": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r825": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r826": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r827": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r828": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r829": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r830": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r831": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3" }, "r832": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4" }, "r833": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r834": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r835": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r836": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r837": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r838": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r839": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r840": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r841": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r842": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r843": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r844": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r845": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r846": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r847": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2" }, "r848": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r849": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r850": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r851": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r852": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r853": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/944-40/tableOfContent" }, "r854": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r855": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r856": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r857": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r858": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r859": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r860": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r861": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r862": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r863": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r864": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r865": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r866": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r867": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r868": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r869": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r870": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r871": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r872": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r873": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r874": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r875": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r876": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r877": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r878": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r879": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r880": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r881": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r882": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r883": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r884": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r885": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" } } } ZIP 56 0000950170-24-119100-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-119100-xbrl.zip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|X9>LQR&NS?CK*Z'],O7Q4=10!,#D;>V100 M<8"&-M22()+F*'.$T],2'+7V.U7]NC@Q*)6:,YD<'UCF;F8OK9E_7_M:!I_/U[\ M^3=X(MK5X[=H54^+]>*B-^.CZ:1IK^!74/7Z@YD'R-^ -=M&./TVU]4]5$% M0"[^7HW#7O33NIR K[A6W2)6]%LTUPRX!< EF!(9P0.R!KP-43 EM>42@'3? M& 4%?]>"5]Y1HM4#]EMY,#U<%=5W?*N@FG?5)#;M;@%_V.%\?YN]+\8L%I M;GX'AMP'G=,NS/OT_N^*]1'(^#&]JG25EiY_VS_BZ GP\^30NV]VDR?'20%U-M#O9\V0)H>,6;<2CMV)Y6F3C.$%"10AI8Z:6 ,^GJ=)I.A9=_[TC2>O#,+\OL00"^4R!2 RF=;QY;YO M^_?F* ZG! =#0I(K"-MB,0EP\ 1SW/#I&886^LID:[BZV\@BA.?7O1WJ3R-M?

ZZ5+/*T.W8KL@1AK73@5WM?@#X/ .,C^!-"*!$+#FM9](XL*P)R>U/0R/9* M-[L/T/54B MCS!@1G';AGZ5YO2[K9C*?%D;]U\J%%+,)>+$:+LR#T)$"C "W M1:J<$E-X0XI"*B%-4M[TSF,YB?-\ 2.--
YU7V'^ FCC^P]9_QLGKZ3ALCK(. MECHO'0&%#>Z -O"7-(;DE'J6A**G*^;'C_J.(%2+*X9!I$K#&>%6.0#_Q$3.A)2REZS_'5[#_*;M#_:-*'RFI&FY4MOHS -S5W2P1 5<6,VF0#.&H^$\L"BT2S:V#O
V;NX\5G# M=]WXOUQ=_-]PFRL)TD\]9HXP08EUS!)F0!/DN9/1]39BN$+(=NUWKB)*R3;% MJS2*Q>1Z;UIV D 2N ".[J3C0B!2.&Z
MVXJG+KV56LFUDDDI(D1>@'D0@9B4*Y*4,"P40M'4V^UAC.&]LX?+4=R/7ZN/ M!]6TL>/P\2L\[;BS'&_&'E_W)>(MJ](PU[1.F+!6C=<4I+I%@@%;%03P^G([@VO)\5?G.5UN',QN"F)7Z 5:_QA?
=@4]Q7=6]PF#:M;(S M>\8QO8>-=P06*>8(7M/4+U]Z*WZQ.M"@&6%:1/!!=2).!@&(,>6:L419Z)V& MZ3V_K-_-.+UGL>PYW I)6%/D.4M$2TQ[-GE.C-*6N"@T$S8)4?1V#VDWMO#@
M0YL'@N5M7<)__OQ\B^GC$$90QU+?]#L3.RWTBX2/T:C$FLY;QVWN"AIIARO M,FGFDDDOF]S:^C]?[P"3@I1<]=X5F+Q[V#\R+A@J;2")>0?X5S!B"PE_)>M] M9 I^S_O*M?
>2];0.OKY6,MBM%!W+"6.KYD0Z;> O#P@[_=YF MW-."I;ZR3"\R:?J_=(-1/L]Q[R,W1"JMB1&@?T00SDD3:)Y"WV@X()=>8-XH M#&?;4GYA MA5.<2TW ?E,B826)HUAZ2K5+CD9>J-
[JYTTH6KLN2EMAT1J0U'IT+P,#;U,F M[\'+H)Y8$7(=+2CLY/M*TCYL"YR.'8M5"9IR-B7 586)&E6A)-HG1H*@T3L; MC,_7GDIP?UH&\R=XB" /%+2,U;2;/&-22L6MM+&W[FZ/[8!8(7L6R=!4<.*I
M!DMM)"=.A0*,@6'&\V3YQEOJZRN-:[]Y/9'WN_425K65:2V@!>X-88%B);]5 M1*<$CE_0.?R0G#"]-3N]1Q+WX_A9YUBA 2)%%M%XYH91Q1*MB81\L+V=OT MMVN1]*]Q'&OP"
<=A)QR6X[*98.79EWAG1+V'()[UFA?<>4*5\8#XBQPT?2X(M*V(NBT)3E_B7T+HG^$7/, M>I*@P%7--2L\<> 3 !,D1ZQ)]RQZFP#!BBMYY";\K?5DF/J)FF8$ *Y161 M3DBB:1$)9U8I:@OC+>TK/?
H0[NF#)4Z"%3H94M 0P/EVD1B3.^+!G0J*>2;B MVE.)UFJ!3H4I;K-2CE*51,%),+B)F,M C,T-? Q,%[FCTO8NB:9W!3GKT4.. MVT2-,>#PYV -C)?$2# 3)G!O8V0%][U-AK^_"-+>U#7@D=CZ>]I??CI
MM[[_$NN=T:AJ[=;[H_5W1D&NX-=W3#GA*]DL=)@/X#5V!&T92!<(+!@XICZ: M*%0LBMYFE_0M2-R#. ,V756\4"1$H*14WA&=P&U@O& F:F]5ZEW,_R[S;7H0
MW[M6J]P>DJC7B1WK3T1EIJUP7O32NXW5]DQ;4_A ' TYL !51$>5B"I"8E)(MS>7:I70S0#JVYJ*,YD3[B'XO.+\:^W@5W/C"8PJO'/+]?U18WEJW=V3O(F^;
MY2L1%\YXX,P3#50B4C@#1HT)X@"M2"\4-_SQ@-R[-7JKM_;[ZB0/1_K;ZU9R^]%8F4-5* 7B]:^*N,! SD&;B.5!@>\URP31>U.\PJ M79D"S)/1T0N"^Z](E4 30OBO;!")I9H*AX-5:[]YJN+^?[XN-
=5*]'^KR"PSOP\AVA45K5B?WT\/?%]3K4'BBBHC'[&X5*/P!C!X]:6EZ,:T5O4%9X%&253"OFD"$X(Y]21(4V@5 M=>#];4]S)N-
B*8MS4I<>Q+\5O4_CVAN4(P[_TD8;Y0OK..MMJM>&A,I66&'F/;>28P$GXWBL*L6S8'-/?6F1U. JPKH@\DB@L(U(G!5:[8("C $45@0G)>FNUARCFVC&= MCRJ:8(ES"I/:E("_
B5EE>'1Z/J.+9'<;TLZ^@GU>K" M&D,WV5[X$4D51H&[;C!O3@9LN/(OPT]['.MIF"M;@ M;@XB7*&&#Y19+*PC@9OV(&U'K/"!>$IS4.Z IEGO]C?N\L3*WBC^0)WRF'H/
MO@[V8\XI<86GQ"=OVS,?XOH/?+[!?M]'*D<. >@(A3Q3!7 TH4BSF![BP2. MH9%6>[WI.P_W[1NNDJ]Y*D3*.#5FX2)H H;85A)4@HF
MY]+F.O86E#_01ACWXS8'FRA@((4U9Q23:"RQ6H&8YM98E7.M^WOV0P^;W M9?9]\);G4AK0*JUJD=C^3O. ^_5:,:Z#5*JWO-4SPRQ7MZL;O&0R18-)_]B,
MD6FB$Y8$."WP+.>"R=X&ROI6:KJ>???(10%N:4XL=SF15C',#U/$2_!V4AZ+ MG/;..#^XHXIOJW+/G-_[_=3"4Y?>1N5&$9S' [HL8^ H2ZV(!;>(%,EH9QT> M5-#;PS[['VQ=850*A-UGCN2>R"/Y
:/0V'@%7N0?OB+Z?[FLOU0#NCK*<#O MR;2.[9$3W_"OC=FZB)J[8!BX1= F-[T5H'[#F)5) MC]5%H?-$?,$22(\Q(#@T$:.Y%5H;(=9?H':#_:0?* %;E:,4'?6Y<9*H"L+
M,@1\>+1NGJ+24A;*V[7O)ZUUI5;6A3$Z/%W8.P(>"Y9.8-PJR0*COHX:6Q32 M]K<&?2A_F=%02Y?K'*RJQ,.0G";&V4 TD- Z!H!(K]V]N3_?#@"$X+F?=0H3 M1H
^S#&QVDE*H[;:]>X\H9[&1%8))B*/((@5!(O ? >[T@".\P?,JA,F% !RX MZ1OZ=UQ+?3_]+1(%5*Y M7B%-?$)_&H3"XQK>\V*0*.0FT['7AQ2?1^D98HG MP$.8F 0BJG)#G&>
P!@5N:76IK#IN[SW3]K[2:=*PN%)0)JP(L<-_#P2%PI# M@.*6Y2#20]'R*>5A@F M2KE/WFB/+8PMGBJ10#5%!W])H< '+ES_^O3TOCM:MQ^P,PYOK5NSR+"VI>"U MSH<\
<^FM1*;0R4;P]ZD)H/7R(A";./A"0?B0! -WJ+^N;"\QY_WT1DQ:L<"9 M(,GF6,$$<-/D@)!LLE0ZZD7!>Y>;>)^]7N\A?31A25F2J)8=MJ\$H3/64>(] M@$G<+_.T=R5-FX =UQ,B28 8E
5HSWF,>%HD)P8(1_)H8I*\ ()M>F1_\PI& M^ZM2.![8?CV5PD^?[7XKE>*+O&#@J02/R7,N&&P/H(E0$4\8PPVHWFG]N]QH MO_Y@+MNG;+GVT]Y?JR^Q'N/7F[='F<# Y-XZ<,FPE-
9:2JR'ITO*J*4J)4U[MJ\EZ<[SG>GPV6+,$$(#B1AM L8-T2(QXCD':!!C8NL_DGCPV6ZL]9ENM;ZZ MAM8_>^EMM#YE7#L;-$G24R(C'L%36(Y)!^_;1@:>V]HS6C@:N9 MPJH<-KVMV3FX=9.W4-
8B4HOF9..I(0VSA>6&*URPJ+@G.E>DT*M,K"6RG$FNNA59 M"@GP"@QICAM2,@)9C!2.Y#H:@U2Q_>VVLB&A3KY"(;(2R^(\8&-K\! R11RU M..8;L>_[GF4MO97%L,#J@_YDSCYD2E&@%G,,H
M+;3C+!6ZMYD2CZHG!75YH0V0)S);$$E%(MJS@@@1F*!>85%?WP@U"/9B9_C. M-Y&I-[VO8R Y-5B4J]J.4CG1*T23'B?]VX[H6NIDM5;J4JOA,ZU(B(A!@+_@3AN!(FYHC9*E:CB??.B5M8E!R8?
>.XE M*4P .Q$-GNFN<\#LP0$PI-[9WI8#_% 9.!=6B/7BHHVQY,&"(^\4\6#*@3T- M.%0*,)T*1<&5I3FGO:70L-'[/299Y6YB,H5CQA%:M:O*,@0^K-"=*&$YD*!BQADJ2T47B7J5;KT9>L/?/24(QV:4D2;
MD!..:"P2YRGZWJJ,WMFQ%8(=9KUR3.:$IR0 [*1(-(/_*)<'/!7 IZ*W]7,K M/8UA$U3 M0X\>)![]LS)**(";U'(&RJ'&!R[DGNN-?2X(%]/8-;*^S?QGS. MO0L>Z-[[_;1,83$D'X'R0N.IV2X5Q-
G"DMP7EL>4[!WLO:_9 MZ>A%.?]'(C.$@]:>P9JC2$X%#EQA8K@608:G37&Y[T#AW<0!+Z;[9/K,_$* M8]$_Y#3'?TY1=+[$BQKJG[E@S?X0HRNRZ9Q&#BX10 33.L'2$!M-09BR.B^L
M=9'V;ONG3O7PZ\G.X%QX2?%Q#M";C,$3;;DEUBI82,H*3GM7([!D/%#G-.^J M26Q:=='V7VQ=U_'^;O01X($;Q>;WX[=Q']1(.WR05[PKUD=MX^J%>+7Z QT- M.[;@08&#V\#5B^[9X.A$?
S"N1M7^\;RM((QFG71F^>E:KMO1V23GA2.*!B1 M&+C51D3B;2' W!A5]*\2>T,VZ]=5"[+$"&?*.V[%""I0184EW @\LP*0AVFS MPE41@J-%X&[M6Y$W%?AK'3"^)+$O<7.G:K?
B7MW5\>+WD*/+K=+@%CK"'"N(MM KC0J,Q&2B2H[JHG^;$_=62GL_#12X,R8/3)) ':C?9 *Q&-#@G&O 10'(MU]N@XR:YV\4GW(*)>!YWD8K<]-;,];/SS#W9ML13%-ARJL!F_\)9XJ*+\/0B
M%%1H:?MW4G-_I6M5\7F>'$@7N/$%I1%/O<%N=D:3$ 36OB8KPJ8>?':_C##2RC&PTIH!ENJ=&AFBX/>9D;VR&D(A.)5267@2).
M<,"'@28NA,BM[ZU^['^5T0K3J$0(2N9%0;P4"MPK+8FV'AL8<)%3P[#5?%\) MM=)TG3O=Z%S9818B4F.CI-C>+A#I-)Z/J#QA(BJ%W<6<["WY>I<%MTJOBLHY M3@7):3) E^B
+@#C=0CP=1X8ZU]I>^_W];7$N0T$RC"5L0$5N46MX*H N%4 M$OYR.B>Q,"[HF',I>FL$U[X7<'TMO_IMR/^T?\;750UVXF0G\F_ BI.#/5]& M/,077M&#O:' MJLO:FL^#:A3>'![58'GPNLTQ-\F -
R<\,8QB4[E<$F>3Q,YRB.Z82+ZW5.I; MP*@'>QXBN92KD.!QK= 91C1N@1C/<\M4S//^'AK9FZ:?/4@RE\QY3JT@PE!' M)--M5H@AG!9::D8U3;UKX="[79+UI,!+%A/GSI"@"TFDQ.;+F
:5(YG^7".@":Z9'2TFO6AFO^L?KF'(W,DGB=L M62 QB(0.1HY'1D@2,'1CHH7EZF]SZ!\!9W=3\K]"0"85S7/O*0D\@'J)>,AH MD03!CM$>B$9]T;M\P%Z&U>[)-JUW_Y8XJ=2QUS)IPCI@WR22<
IKN^[UW4/14,@YL':J$E@6_&F"9.1" G$#,7JO!Q_4=H/TARWD_[>.FXI@[! MHS!X.!I-Q"I1D-@>]JFB"+ZWTGFMZ.M?XQ@4ZPBPTTXX+,>-;F[PV9S5_310Z0R^H$^ M>KGDS<1RHC
M\:#P@3*.$2U#(KE6N0R:&LUZZQ'?RT;7IA38*25**PET>>* $D]T0PXT9'7PG;LT3E%7I *N>*6LL(=DU!R(R])YT$Z5.\D$SIR#<]P'UOD/D> MXHF@(U-N0T&,MSEVQ/#$,6\)2)[B0C
9UW\$]YW8M;MM);I*@=,\T.0%2)@! M_!NH)Y:A4Q.4D5'97/O>VK<^%[JM9Y-)64L],QHDF>.V?*&)MH$13Y7A*G%N M5>\2L'M=)3"_Y#U@F9W1J)K@-\?K;M3
/($)]RLA">\\10KPH/B>.)/$62E=)R:GBR&Y^J<>^EJO=33*>B=+G6\$1GP'QZC <;[TF._<9"SJEEO8TX M]5K<-_4DI1S#C!R65"# M->4%YFGGAIB\$(0GJGU"ZK'>.C##1M]=197R A-
=F2AXG/N7*8!%L0+G34 M4D0 2R*M5D1JK$?)@0YYSC3(DO0A]+9;PV9LNMQ# M.FIN@RVT+XAC,:(;(XFFN21,LSSF25J3]\Z-N7&I[[7996B/]@,<%)66#O P
M"Q@GS%DB6AA!'C'N32KTF[)4*H#R>U51@#QD!9L()XTB0 M-/J@BL3[6R/\R-VELT9)7]\HZ16E=Q24AR+7@,D\>>.TW@7F%SJ((E+2. 9,V4(%)Y2TQTB42>U;ET)2&*(D^Q\"8GSCOPT63"1A!1
MDIAH;ATS28O>!K)Z:@Y75<]4%(&SG"LBK$]X0&=!M*8.#W*F7GKX;^C=">WW MCW,W_%2D:_S_\9F MQ*BVR;B8[XRX(#B_5]G9JXHI%=9I)E-.5 %:2M* M%3;!$V63+'@.Z-
YL^N$K:\WG.DM"?GT2+N]DWXJ$(?%(M25YM F[5#KPY*TC M1<@3@SR3']FPSQ)"DY!3%PH-0,'U+EZ[&8!] M99 @I61U04FT14%DPM 73X+XP'.G:%31/)ZVNX\%$FR*H9Z.RXY//WT^FM8G
MZ82'K3Z,O\V> 7_.'S#_9?X9GW#!TYI_ILFYITTG]3;^*//PO/LFDO&UOWX M@T_$@F:L;8:%:MZGG4-8(V]?5J.1K9OV]+S%RUH>B,N/>-<6I+:3JCX[GK*I M)&<%F).7WQO.N?
OQRY=Q7!V"G;K@L=>=YJE'/#L]^BM68^_EN<6]YF3@0_EM M&T9636L?F^[C0;2A%0)X_6__(\M^@7^S9G(\ OUU!$!(#"95$?;]*DJQ__M1 .1!CO4;1_5D7RM[='S MI7=S>/=W7P?
O^EJ&R<%V*B>D%QYV/K_;F2]&# M<65+9'E4!-E[]>+3[IN/;U[M93OO7F:O_NO%WW;>_?55]N+]'W^\V=M[_[= M0*753?RFJN,_;7, BG%2C;>RET]?/,TX5=*L@3(W'>_-*)-?]:H-D:#757V8
M742*'W@VS 1LZ[@:MP"B]*WQ?OTY><5-2CEX?(4"]\)2<"^T)CE\BYW'1"SR M)]D,]NW&=.T$(L=Q^6?G6;<;X>3\6E%'R]P4[G5J6WS9;%XF;<_Q%
M..5V$S*Y#]GX/:W&)YW[S'F*5U<[]&).&HBN'Y'%F!^A%?#Z^!]]?QE M7\JF=.4(','M^=6SB^"JL$"8[;/E4R7_L@Q[9Q/J<.^S2^XRZFDWA>_=]LNS M27UV:'/PC4QY(6&^PBR)JZ/]
<[O]+\$O+AC]:9A/J4 X/_MNOLKMEU]B/<&= MP!D/P_6+Z^8\?N;VNAWB_-L[Q/X7Z]^8G)=41:(I'C$O@R3&"D&LY\& "N:*
M^U7IW[]/;0U&;72\&X^J>O(D2V!7[.37)R4,N(D>9*4:.8O%4D#H'U<%EWLE MII#Y\RL4;NNM3,*CX(7;Z+++5OGOGW9V/[[:??N/;/?5A_>['[,/GW;W/NV\ M^YA]?)\!!O\
(0#MC(GN_FS'U4_@Y>_\Z^_BW5]D2/%] \YT7'_%G9H1-CF(V3_G IMU8;@LCD,,5R'!J]YZ"1*, M1?0AMQXUD22R4*"))+;'\,XEP(3.Z;0J3?2AG%TVH#.QIQ"(N M6^>/NSOO]MZTB'@ RQMN_^9@>;
(0VCE:3G5UF'W^_#F;5/C/Y\T/(-]TC3## MHFPP1R%[78)!!HT"'"9[3?#52Q:289)HALTM'"!7:Q0%+1RM4D%JSFZMJE^U MJ1 XF6XN_5AG2AD1N<(SP>XJN+PJI'8?TG#[[0L7F&4I.,
(=)A9JS8D1P#L% M#T%:PX*+;C6LMAOWVPKN\03SBOJQC?%V9_?-'SN[:)EV=SZ\^O3QS8N]K>S- MNQ=/[XS_N'RL&ZTW%;R?7GVS?M+R5U:EK%[P56:;K#F*'I/N0E:.LW+29/Z@
M#0&M82=D]9KCK'_WE[-ONZ=TFBOUUG6S:;[KT=KII/H!?Y91^EV'=O;H#GBW MS[Z5BZOHCSNX5]^S0N_V/(E[[MZL2!M=;-=,$I%1J4DN\+P(&\"N47!^O2B2
MX3HEKU8$H;"5R:))1)O2^*)KZ_VB"O&\X]O6Q.&IA_B%5"97@A:.WCI>W''+1_OMS2PQO&MY MLS+T?7DHF BMBKRX"E-?Y!)?H)?T U-+NG<8Z5+@TVJ7#-SU"EL]9O\]K1K7.WYJ".,?O=CFSV
M863_9;-7MIFL.<)UV5A.IWQ<3 <5O-?<:*)H'@&.%PX/O5 DCT+$4'CA;5@7 M'?@:Z; WA;LSF-3@DETIB[HPS!?!$\^B!0=>)N(8.&?*<07^.^?1K\B!GQ'_M0P6N^>C_+X]:OWU]3, ,I5?FY@S:?
OTAQQJ>)Z;RF!>$:H7AN%2#B)='=I3%;]%/L7(=OL8.<\WCCAVMV/_\P7RINYC, MFO8L'_>^GH2F@2-6C'-B(G>$UD4GCA:""*DP$/O@BX#_'E-.6P%-8GJ/"?
<>4#72B1BE,Z)TYYQ93CCXM;H&H^-&'TX MJ,:]RF%3#/BN2)MW'9PED\4ZANQH6C=3S"J;5!E< MT6XC,?Z3^QDA)N9+[_C)]NJ%^::3&)+*-C"I3-X@J8S?X)ZKWW.73NUL=3L7
MJU!'DZRI1F7(YB)SU@?+P5V:W3/WH2ZX:W;%C,^_\]B%&Y>?=^,.RQ!&\2)/ M;FD0BV^_\Y(39R_OKW=]Z7X1=F!$-1>M/\C\R#;-57[S>F@ZD.S:)*MM"U7V MC@_!H/QT=:!C(-
C]$NS=+'V]%;'XS1_@ 6H98 QX"GQS D3Z%H)\J-IXS=#V M-$M>XC0;5C"F'/B/V*Y=)DQ T"$0;Y7Q7G"JV*WC)#.T>\RX:_7\ZEBZ:T.< MM7V(MS) 3-D7/(4T^U^X\
R+"K.VC>J*=K\W5"/U@<]$L%Y1[HG)!2?2%I*X MW OXF%,6/W8&![IN!9')E:)Z-3..;=G@N7H*-)TW+:6X/%\J9N]L$^P_L[^.*F='&3;4 MBU>E3-WG'LE].^!];?QUJYZ%V(+>8\J].\[\0?1_9H?
86/'K06SS[S$(M%1] M^!/[.3NP39;*40R9'8W@1VQ^@5&E?TY+C"E-JLS%V07PS$5826".>]#='!_(&O[O_AAG@]>VEKR'6)3E)%*@(7BACN02<9BS"*)<*5
MSZ,"E63HBC+&7DSK&F;7]39!&S>QDQMW?KH5A_XC-FO89KA=H\]9M\+L796= M:<=R]V.YTQK]#=%3*+\@NH?E9 +"'D<@PG4U1C0S.LXB()OC[T" ^O;S(F7 M=F*[IA=GU-
C),Y9#Y;M3N%)2A9IJ_^Y/1UT!QA[YF/V$EJ-XGG'!G\ZNF!R4 M;8GV$99HKUNI=0->Z*K8_+PF3125UPD -1%Y%(B.RRAE^R4$'/E_/^U;WRS ?&+-&TL$2&''LG MRT
2S8VA!K1]6M$N4$NCWZ=-.8Y-<_H,EM:W)Y-ZNL+LFA_!.H!PXI!R0VK M-:S60U^M6VC+5Q?'SWN^F/=O/@65+,^U(*GM!Z^T)8YQ1B1-(IE@>%A5ZZ4Y MA?
[:$NA%1Y\>'Q0S9'0]A(RN])U]0"SYO'#[LDP7Y5"TF1/@:(^K-O%AVG1[MB##+[I3!"\Y3J>KV7: C?/G7$EX-K\W&,.P*L?Z7LFD=][$=^]*.,%:.K:3Q MXF9BQ\'6HE$I:$:$##6SR:QL!?
@L>"4\>YRHN6E[AUO1]7KNUR!5ZYGF3IN/\=Y/*CPXE.NM#^XW)YJ&/V M%?]S.\:_!92829/2LR MWIH4:0A$)F6)C,D2DVM-_RGSVWQ3?,$M(LO#T&.?GWRYMWKTT(VGAZ24$W([)(GO^5B2]-
^=Z MSO+S>=XCSW<3F>O#^GPSA].52//ZHT5!TJ(2:2NK3M:J/RDSH?S25=VB0[(? MR;@<7XY\!O^/!O>OPA EOAMFXCG:12_D5#6'1+))#IX?AY*)NCD3W>QE_/ M>RBJ[8U[R<)'_]
[VDS*=#Q_77LC 4#S_*CJP,QV'3&G\TM<3K!8E+A\NP_/ MY@JR,+XJ7/S+,UC[V7^14 >+N-ILQ.5X!(:; $O5LT2=TS_ 0G9?MW3M(FPV M36*];4=?[7$SRTY9)O%IEQ0IMD3T,\0;:'2T1)U-
ZU]R\],)=S[A>9L[N__(MWKW_^"K;??77G=V7;][]-7O]?O<_X4_R]OW[_\#/>Q]W/K[ZX]6[CWN;T(:H M76_D==!#^=,\+_K2NV1UW'KI?.53)<2=S?>'S-S-CW[')JQ=7="A#1'=F[8
MX._3]HRVT7'6E=1@&?QK0"49H^3O76H_&.O6T6Y.'@'F'VZ>5#7&X="!]EWV M>Y8 H#3M';-D6D X7\%W)]J.J^G/F3,\>,L^G15^\'4W,#J,=XT4S=/&A+K^@ M.[=4D/46_MGORAH
6>$X%Y591FWA*72 T# $\!1G<._3[VP3W48,V^;".\[KJ;P)^+?]NB-X^SR94?G M& @.?)\MW_2ZZ&1V)/STD\]TO3@!-V]EL71V7\#0'I_]:D'OLS\@/YS[KHYX'U\3XY_GOCNX:-$F MF !Z[I5?
R]&Y9W[%VY>SXKL#CYH2U V@>%@\[/7:<3JTYFM'1/'1,&%COQQ!M2-^3JJ!QWDQO/ MW)Y1_((QI%D9YM/L8SODRZ5N:]9;!%=KJ7:S+IL_X;?-6N/AFE?_'9?6'(8\6]D+%\6)*(=Y !;=MPFX
+]%ZSB>E=ZD:C:JO MR'/E(9IQ.[/%5=UDK1;-;$ISUI[Q"M6<_+H00&!"D$$8 M+/!M*.%I=8;:M2[;XL7VO/+NSIF* 9"10 :?W8D;/OJ2R5D^W)''%;TD(P M;Q"0.[RX755@[B<7U7\
;G^RVGO^PSU+W2T6\?Q>4MG@F]LMAT85W0=SW'$ M"9&0V0 :WQ.+R*>%XJS0N31<%++@ZB+621_QG@$HQHMUF+F";=+\ITU0*P, M:O(DXKKD$B^*9OYRYJGW(Q:G-2\[D
MK1R!5B_!OARW C&#HG W?!'B(:C95E%FC4UQH MF=L2UQ/[V(!I:SIQ/$;Q08G]A*>_O:ZJT-[\LI[N9SL!IMG&TUJ ^]/,>KU^ MN3,S6S]O9:^F-
>!%6.8_T.2B0LYV]N,87OO3DU=_[#SY&1_W["*K67<5P3@$ M.P5)G2%JA*.';8N-MMWJ$>YQPST8/SPM34%H>HX2AO;==4[#G: H#&/11=93-O(>96L-W3L<=R(NHV9HY M@?
&>CN)=\!IUUHE#>#J\-*B?0?U9M66RRXY MCJUZPC,8X#OTQ>.X!E2 #-LU$#DSV'8/.V:A-=D-:,/V48,\#/*P,GEP<1SA M@@X<@AV:N18M3.UT]LRVM3M'>].C-@+56H2YA?Z(^!)-QA?
T:>#&732H+\LF M C>@VP4CCU-X<+.0H+V/.[L?YS*4'96C:H*69+^VAXN>.#/3@=R+(K-DW 8! M& 1@57@4N*4"1QQA2)MQA)RWP)[++-BJ[R5\=@D*6S8(BZ 0/ AFWL?
O)89;4,K>EA[L5LQVCL"Q M\Z>1ZN]O%TBUZ_C2!HK:62R71\VGMSR=HS@C91+VP0@ M6N?UQHE3V[JFJ%YFGZ^A-*YD]>]Q^=;"A9M%=%&>\:L6Q.((VFA4^X)N)V$V
MBD$\!O&XN7@<5%^S486)NK'=UYIO$+7]$:2V+HU3F<"IAAN7[Q[:SG>/MO" MV<)+HZU1'N"QRY:^#4?@P([*B1V=;MBX<-):+[+].(XQ=#&:^28'"GCWPO'^ M(&2#D-
W.63NU,WW"*CP<2N@/=&Q\AT3HA.'K0%G6/+T;M-X'[BZQ!3_XX$K M!ZY<20CA!'S,/8.N;24L!P83CD&3CZ<85@<^K%L<$\?[=C]BBC\ BA8QB9,WM#X7RL),,\,KEEX/X
?!7!MW^R=6AG1&9=G):EV:$K,U MX/9.5EJL%.%#Z[35K0V97W8F++&BP/@9-VL.)=OON\1%4 0'Y=%\5W \J=N, MGH6!_3,>9U_B..#&XFP9%DDGR[?,2FQ&W0Y!;#?<(R:PX-[TD,&93$HBY7%
M&V':HT[DCV?IYJW16A:CV>[8C1TB_#3"%$R4SW*,VT@@\FT>1X?UEIVZ%ME MP^*A;6P$4T*N(7I#"GR?$E:'%/A-H=%@P08+=B,+UI4H=^!I*;9W.DS0Q;'; M3,CJ="KQ2;[FTLU+X8?
%+L'IA(R3V]JBYQILUX#+!JZ^77B[F3M?LT3365+__MR9Y2!TB:"S:YEM',K?V>;ENK38[H@G'[=6PC&^< T8^Y7&?&>2/_JXGUEWG" MY6PY!L$;!._F@K5K$ MZYVMLQS;;46=VH?*NHJ,61 1G@-
,LC]KB-X^%X.,H;4W2U9IEI'1;,W#"'"',)L<=ID:+FD98YC+%'2O,)L90:MLB"]A_'Y[13+HH M:Y>R-6#!@6=OBP7/5S)B64C[<9$854]',Z-4+\ZN6C2:P!R?G]K4GM'HO(>S ME,_^\V*/8,Z]V?
1H<;3S5\S\.XIM_'W)5ISL*"S"UXL-W*K>M^/R7[/A_/3D MQ>[[YLG/&+(?XVZP;8N[NDC=R6-F0?RZK=E:VJ/8PM)3*_<%(U-=Q_F535M M N.LO=00%!\$;J5!
<5]/RWF.86LCKRE1Z\%VB/V@WJ99WHK9F=F5L M]UL&0R%NJO$XCN:(;?:T;A\9D]V[^DUXY,## P^ODH=/T$V+5S 'R'?),//J
MJUDFS_&\%K;L:I.ZWF[329NBAOLP7<>EMNSBN$%NF+E!;8%RZ_%_J4HP4,G+:HKQLTD];=H DFSX KH<@U.^KG#_OCHL_:R:_S2& MPA!6Z#+T0,HZ^&9;/S\V#8 ?N+PNFZ[T \01!*:-
R<'7SH[_[+Y'?WN6^7%8 MC;LZ0IR$QWZ.V'<1KEX,HAE57U'ZFJZ!IY]U)=C*#J(= :,1X"EX,*VOAZ] M] 8/3F[[C\:Q+T^%O:OII&66+F,#3.!T/(NPAZ[29%Y%/9/8,_F'78AQ*1_Q M'
9=1J!U'!W/VQZ.E'TMDV>;=OU7+3_=+;.\X%470=.A=CE @\%W[^,VX M%; V,S^4Z,2=]+\X(RF/J!G%5=U.VF HBFU Q7?B0BS2ZN;1W>7TTZV3U.LM
M?';T=DZDY5XG73>4<[N>LQ(%D":,Z2YIVT[#QK/>S&(HRWU>3G5=F76]VI]: M[&\9NXR\>2AZ*9X!FOQL*=4RWV> M8*S'U2R*UP8JJE';_V:1C]1MNYW@RW/=$297MJDY/NDS@K-
O;54;0/D>M9NS M'8!.=?UYFNV W%73_98>LT8\LW[=I[*/TZRK]WS;[/O\!;H5W%$TTEO+NVRS M)/VM3H[;T;2'=+>HX@S=EKH2^;+VT\.FW0?\L;&@$<6E<-4V/JF\1Q]F M@A&KMC_0:>(N-
URI9N3$L%"4M>+Y1QOF8K+KZ[O8I3S;&*XYW1ENZ?;CS"S= MNS/=!R',9FV"D?:CJRBYE !0C;'_QB+L%]K4T;DTPS?'7:]X]KR=_CH6^X.W=[P][JF;2VZB&.+ MN7D7"<1=H"R7O,JM,PVOYF[?
5X"169MJM32O=)T6? @4JT5GJM90^4Y]=AO6 M..[I>+EMTUSJVE;>H' 6X+*K7DE+[?KF2!&\5/BV:Y5_HOJZ]F>=#9TU]>F6 M:;F#UU*WKS/2?ZK[U'0\PMM/>@/!.B*;=WIYIG%:ZH,
<82%G=\E2ET%TIY\N M95H-J8J]3X,;4A7[3Z-'U:WW+>A#&.NIOA%; *'\K9K:W55/WLNIJ_-IL6MR#%3=3!36=V83OD657L^6A.JXIG>A''@FH2NXK"Y02L)KAD MW2$ASQ>!B:?
T+_,;@'8C>]3$[29B,[+)(I+3GW[__M_-G(-ZB^0(@U^+0V.ZCQA*]_PXW>S^6B%;N.:W9[H9;I_9_=C]B8CV>LW[W;>O7BS\S9[\^[U^]T__M=O"XF@57V'59AGY0?
%7:_Z%ILV&UAM4:5JL/JW5=7+&J]=L07-$[2W+?1X!= M&C"=Q,.,]8:=^[)?LB'2?T?+M4"IF%#WF7T^@:DG.]P_CE)_')2^7G1*7#J. M[J?IV$[;\M"?+X.E#YDV#X65KVO(5K:
%UJR6VA2L=Y063_8=X!APVH-JS6L M5G]7:W"(-L.2#$!H6*X-6JZ%"X0]:/&4A? 9*_AQ-QB39C\[.\)$U<_-08QW MXPR]F \D>[$TD.SW;B#97CN062[T7CP"=\G%.A-T*=?Z9?2S;UG[K1@G_380*
<)RR+K>(=4;[$["TVZUDT/SW UL#MN5OP5NQ!,CEHLJX& M\A(7;/"Z-EMZ-M[KDH/7]7BY=UBM8;6&U>K#:@U>UV98D@$(#_7/Z?Q@B,'G>I2RL_$^EQI\KL?+ MO<-J#:LUK%8?
5FOPN3;#D@Q :%BN#5JN'_&Y;'/P.?7'YX+A9*]'U=>3+:W! MJ7HDPK'Q3E4Q.%6/EWN'U1I6:UBM/JS6X%1MAB49@-"P7!NT7 NG:EQ-8O-Y M4GV^Q+N:]Z:X"Z?
J7=6>AE5EEWA7%_6K6/:15H1\L\?&#_]%=C;>Y]*#S_5X MN7=8K6&UAM7JPVH-/M=F6))>-P'D3WO#SP.,[. RG>X"R#^?'(;9?)Z=' AN MTV?X=G3+L70'"L[&@QM<)PX9>FSM"5[M-
;NSL^U.57L- MNUF;*Q(;[UEQ/KA6CY=]A]4:5FM8K3ZLUN!:;88EZ;5K)0;7:D/%_UY<*_'Y MGU,\D'O2GBR,'T;SO]'/&E7-]"YX@L*@='#5__Z1#WI"6^OS,B?<, " MO1[9>O*Y+#]7]>=RG*KZL
6=/XY:VQ%][8CAJE&X 8S]L+/[,7OS)B/9^X]_ M>[6;O7GW^OWN'SL?W[Q_-^>&VP[JZD(6.P"6QZ@FA]4:5FM8K3ZLU@!8-L.2 M]#IZRX;H[8:*_[U$;]GG4=RWHRYL&W%4=Q*W?
8LO[0*VW4N'B.WF,N[F1VR' MQ/]'S+[#:@VK-:Q6'U9K<(VPY+TVP':&3R@#97_^_& [.>Z;/[\G*R?5/6= M>#^8KY^][MXW.#Z;RZ^#X[,1YFJ 6\-J#:LUK%9_5VMP?#;#DO3:\1F:26VJ M^-
]3,ZGIN([[90/J!D](L:/8?*[2Y]B>]7@7;M"GI?=G>_A^; 8U.VMR+_II M74[*V.7V?VHB_CC;,1]\I@WF]L%KV@A; V"U8;6&U1I6J[^K-7A-FV%)>NTU M/>X^4;/1'8%QMF-4B,EB"]O/TZ-
J_+F)X[*JX9^YWW(7+M3+V1"R3S $ M\)EP"$NNT^_F/7SK-KA) SCK(?L.JS6LUK!:?5BMP4W:#$O25Z_-(4:W*3; MM(>"E8F?&YOBY'C12_>.VD/] 3]F>^VKE[OG#F[1P[=F@ULT@+$>LN^P6L-J
M#:O5A]4:W*+-L"1]!?:M6Z0>M5NTR>)_+\Z0^EQ-#N(M^XW]N!OT'E^:O3EY MZ>_;2[C#@[01IBM 78-JS6LUK!:_5VMP0':#$O2:PW& \L_Q MVT'IRLF=;/^\FKUK<'-EW6*UAM8;5ZL-J#>
[.599D'#'?YQ#HPU\:R/J,S[N6P@'\/O(P*__MGOJ"?ZT;Q?;/7K#%F7=_]W77Y2"<7"B_9'YDFP9Y9S^2<17B_!X8%_X\&]:_M2 G*X]LV$<_3*'XCH:RC;Y4*4&%Z.'X>RN9H9(^W\=?SS*3*;F1S8P ?
_WO: M3,IT/']=>R.)X_#\J&K*]LEU'('>^A*?N^H;SAZ>"/JD!AT&#_YV399C_*H% MNYP^)[Q]$PUX.WJ=WHP"2LS^BV0[6!C7V>#+,6IUTDQL/=FVTTGU_/0/L*S=
MURV5.RMK$\QMVXZ^VN/F^9-G"WZX4)<@_998X PI5TNQ.Q6G*[GC^@IY3IWU M3S$K Q((CPE+Y=B.?6E'U]N[O[;)7@$'=X>'D==OWNV\>_%FYXH#P^YR9&]_
MX""SNQQ7=D8]+SBIY0"4/M"3A+&G0O*_G+;LC#YENOC+V5$L\5Q^C>M2KON.4=7W9517 MK0EV=M_\L;:;X>F&.Q]>??KXYL7>%FB'%T\WG$ K0#VMO,,H0.LT,>!IZDTU M*@-
P/_NY:MW>Z]>9O#7WONW;U[N?.P1%6%C/.)@?5M+'CT&QE\9N/1Y.L.;!U M;-O['<5Z]@GXWOX\D.S^)_[3I[&=!GA9>*SDN%<_!R?71D?.N* M"FU]S)G# MAV-!_P^&CI>3D3VNIN#FE]]B>-
Z]BE'ZE/YE?@-0;F2/FKC=1/!MP,S,UZ"+ M/;7/?G(VNORE;$I7CLK)\?;_@LV(;O7Y?E38\1?EIW3V40[[_39)?>QISF__MP5TWN(4_U5K0D__=Y!F/?7[?V8- U.JL_W._KJ;C0&:J(K7_NUTJUIF :B>U
M%\GL!7I!KU5+KR',?/%DUSNY=4?0%WM,_$G_:;K*/9@] #SQT '.$73K9I3O MPY(,;#ZP^??8_&7T,RYG Y?/L80F27ZEYQI2@ M?I;]7)OA=IHF+M58K$ +;4P^V$U@_CTFMW1J< MT?

Y:NTLWNZ=U#7]EMC5RVX-^>#0"\\CTP\#%CY2L#VJZ-_?IKFG0EC-$+R^U MNL+L+6_EMP]9?BK]3FYI;ZRB;0[:O!V/?^")H5_L:#G=\C(6O,YJ/0QU<\$C MQU6_IGN: 2Z;Y_]:(4W[H6MNP?B_E-^
C./7M6V+? W,\)4.)3LP1 M*8N".&LDT46*A2L"\S(\R=JG?)OL8OWAB\\IYRFRQ(F3JB#2!TVT@K\B=2[0 MG 4OY) L;]AP-.&[%M[M(UBMS,.^,^K$YG;F;RP=7UDE"U58QXQ9/? MA-
JB>?'+L],3_FV3^7UUDCRHKD%U/0S5I0-EU E*9&$-D88&8A(7Q(E")Q># ML.&JO*R0WL5D2?(_;:7AC)@H0)E]2%+RJ 6![7X\-5B+)13-@_$"&.(S*DA&K0=$:X(5B<;
ME>*K@.YWIQ;%EM!J4(O]BG+S52!ZOHF(_F,UL:,!O#\F7WD(#IV*;%.E$TN4 MT" LD:X "\.D)SP/.B\D56(UP'L=MH0SL<55_LAC/X J>NRD?*"J2=H00V"* MF(1I'#XR8I7CQ"?O+.>F8#Q?
2=QZ'=X_W6+%&G'N1K#SVJ/2-X&L_<>D'^KJ M".9PW$:7,07Y"!N^;F7C.!GT_X,6F$'_GJJWI(5W+L\QVU@-/62.&X+P*S47N75R5.2B*QYZU-VBIQT[*!ZJEG'&>
M2P_8U'A/)'64F&@I"1Z@3RI/2< WVS$.W:M52NY2/74FN/NCY,Q/H>.-.. MRO%^-HJVB5DK>:1*9 H?AJ#J(Q">)!$<&,(M(H11P5D3!J/1=6 MMRD?*"*BEDJ)2!.PK0# MI6.<)$;(1(R-W
100C;&58#7.U)4A7[DBFJ(N-Y(.'9C,ZE+/XE=WX?!!#QH M(1E,P+()\#(:R0,%_1TYD8Q)0*#<$R987C@FA.!^%5CU1,:P5/I=-?:KK6'; M$F*(L0XZZG&3\H'JJ,2HT;J(!!12)-
)%2[3,&Q"]44V\W=HSVZ^T:< MUUF(!VJ:BMQR1X,AP2I'9,X$T3(DPGE!77)<%FDEJ;Z=55I9^9G9HG<'R\\P MQ&99I$$5#JIP4(77RQT+_,JM)30:023#S&)M03,F*6P242:=5E?UMJIR-[5E
MQ)VU==AH33@<5[6:PQG?EM:5H[:A8%LHMS>I_)\'<$>LF__];YJSXGF&.?*3 MX^%0H._-LQ]J= U6=YCNP,4/E:P/:KK#<<6W.L!Q=&((AU,<'X_4/#(E,7#Q M(R7K@YKN<';-G9C&'>]A#2=-
=F2/L2']$)'D'%35BE25L053 M(DE2% Q4E<@3L5I$$KRGRFD9HU[-$37K555NJH;,H[L"N/4TGAQ$,UB- M!RU5@[%8-A942TDQ<34R0+-2:#PK!NQ (;F2R=,0N%D1KD4A6]IH7+&]$%NJ
M>.P&8]!2CYV4#U1+I4$"^+N5$4X-'B&E1 M"%L4!5U):OWI%E]S8.-BH!^T?#Y&?9?NB MF+?*R@00.VDBN08<'2PGQNI"64-SJ]PJ$/?Z M/Y%E_G(;T/F:<']?1@2/E
MU9/VG@G)!"D<=T2"3B(V:0M0MI!,)L7D^<,);@)_UZ:>S):B0T1ZB$C?;T1Z ML!E#V&4(N_Q(HW$3@PE*$*4P$(UGCAOC"I(7A4[,_3_VWK2YK>18T/XKB)[K MB78$4JY]D=
[Y0$NRK9EN4B.R[XWYU%%+EHAK$* !4"WYU[]U#DB)(DB) @_V M[(BF0&([=;+RR:6J,EE@0JPP$=UY*3+5EY)RT>1($Q0)BLOW.!>%>U$B9.,< MJ%P08@D9? @5D.A0=E23<6U0M(PJ-
%)">DO\]WE"FKQV,E!DH);,%A55_?5L M0%OM01E1/?!H(VCN4:$6(=H%_-7$9'97Y1E9GXJFDX-._"/^/<5!3X5SS@JD M*"O_))/@@A7 18Z6)^61=[*-NWO^<=47?&TU&7>8?
X=8D?'K>P933##X".># M7%W[YW_[G64MFN5JT+Z9P9E'K,G6!ZTZU-^7XXN+P>P"F[H?34'(YID:\.(H-24B?SY%[!V/9]AS M?_X\">[]AXH.;>U:*!4=HM)9-(L/I_K=:TTL222<+%)DK,D3+-+G$%S
M^ BDE%E:Q[F1H8O$^N?AM9[VS YF9S.P@SS?X;A%;[%R>EYF.#7.:?ZL'E] M?=7TI!Q=X*3*_]5X. R3Z?6KO^2AWAS_[3N)J =VR:O 9.$)0G,42R'G]1'7
MX%+.@;$2@NUD&^KFQ\^>,7;?.L0#B;F.9MV<*Y=ATOO0#+1WB14BS<6_Z*UE M?D?MJPR= .$$@FH>>:49V*BR#U7V>O&4W=/G=RN>Z='5['P\J=#)7\FU'?ZT
MB\G+K8@\5[TM0M>)R%V$R*P$R0L37CB?52='"%<\. VOPF[^W]#LG%]S+WP> MT?\7)W^Y?N[VSS#MC4OO%"]G>!'K/):LWQ_,J#;/]PK3]5]Y^U>YI@GNI"RV MQ%SG=O*@=+%UVJH
*+5)TJK(>%K5!'\SG5[]L/R;!&TS!QIO8(JC!U<\7#%) MZ%!Q[)KS =R#QZ8K'_>**R]5Q(5Q=36W5SDNR;,..6A(SE6#FS!7@YL*V%RL M< %UD@L&IRMYG5S-IK,Z60>C]ZL97,R661ZJ-V$Y:X
D(+CF"!I*KQ1Z9\(* MK&GG@QN-'T.B3;)JT,[0!CP/L&K\Y6[T?HQ;M#:_UT=V#O446IMU%"1LTMMM M&"[I+>GMMNS+/MR<6[-78SR:)]SZ:TJX6O(M_"-D8-BK XD!0>Z236:I*))G01U&Q[\8:;:M$,5
M2PW6M> !5! (SF@-.2AA,Y%,%C MTM%E&75:*/7]Q&G;^<@XWXXTVT.YM<\C_<%PM4[N^S]Q+7/>6UVJ_!&D=G5F M&*/!*69 \&C1LZ; LEW)G%\J1?78^>XXIF),@A)YO4)7'$0>+'#.3
P:M"9Y6.@E-3D5P+JN/U"2V.6LJE^<"+,@@1/:EI(5)V,FHNIR$2O8] M\WUF[CN-NI%\86\Q,_@ 0!]+X'ZO?L,EUD%\P.%WV]Q3&F*+ADMIB"=6M?:Z M>%5MI"RYB6H Z]?16 Z=%'N*9BB
M+:%&'QRJ]]$4_XP5-Y%[",5HQEP,PG8=L78))G7H_:A6ONERF7SO]B=TCW(> M-+,E#'N789!A,.JE<#F8A2'1?Z_UA>C_=9H]R.B;_;S!5F'+LH]Y97P0C)N+3"F MJ[?
FEK0NF@PS'N32])F,8Q>JDGANG@E+.MS?=]"RR%-\I7O8MA3)S:EJXNK M8;-B7>=<&:0!M1O<;T4Y5&OP\UJ6QYB5"JUFD)O6@\R6:V+$Y"-
JL:"RR5N*>])H[LO;ZONFU'59/QE/)T>X^RDG(6/'65\ MI+YOF^'J-6:W:IP2(_F0!,B' "E#,I87<)$94#8J<,DV)6^KZQU9+E'E3K+@ M&P&DHQKX6Y
QOWU"3W=P[$_OX*F_>3>6Z8,5*$BP_4#AHL[F957#HQN M:FPQ8R#Z:KBXB%Z$I-"6TH5G?[N([.M65;OJ4>!=7]U[+HX,%'&0.$@K!?4'"#VKKG6M99K!GY]@+J=G/$T:?FAHHH_&L"2TF]<]5
MS>O+WD_:XZ.365,;97:.4VPTNH9-4VS;.;81:[LWJ Q&890&[6I"_4/;]/'9 MG?N8!Q]Z:1BF51\OPWN$T3CCS>74&] \?3W^?[?!VMX\^^(RY*:$RZU@>C ?]$T<6G_][ZOI;% ^W7Q=^T;
M47YQ.9ZV!V&>3W 8FKHM554_-C>V?N+SSUK[\9&J^?V)MYU3X>M2UU42US\; ML9U_CNNO+WXP&@Y&]2IF=6(\#U>S\8NOGZBW=?[G5LKSX#Z4.K;G8?A'^#1] M\=-
?/L^'ZT^^$6&K2ZW\;DV!.Z+L5F*[B:4OTME>./TQ%UFLUKJ+*?K+T;LW MOQZ]ZYW]X_6[H[>O?SM[_*TWWMS_/(S9K;@(GL_;CJZ0$;KDWTF\^^WR?S[M%Q[_/K[$29AMASA?
GAR_>GU\^OI5KSXZ/?GES:NCL_K+Z5G]Y]?7QV>GO9._M;9-@3][6:7?VIEYK[^BXN>A?W[Y[_8\Z@C?_^;KWR\GIZ39=[,XX,!T/_.V5W4C_)E$MOF!__S;*%SEIN;PH8IC MX_%-
&\;=MU32.G'7'E5S+8V#52^]>3E4[WM\5?WHP4?,+^9?Q1E[QOYT\X;4 MU(R^G.+S*=8(HMJ@FWO0YB?FG_W3W96C#X/IH WW/SV_>?]]1RW:KU/FF7=__MNNW\78]S[OW]Y8&W\?
6\A6WME6WM8,0^#69=DGG&5G';OK&JZ[ZYJ'L?MY9L M[;UXD/&&E/?0V*W4-JX@V?XC"PE=#6YM39#-=YH@_]"^F(U)?1G?X^%UT#M?QU6??EILMC=I%LPYTD_2']>9K^'_]&I#Y/G&-DU
E*3X"2 M("C=N7--(P B#^D(Z<@W=>2[?71)1TA'#EQ'R(Z0CI".D!U9:93WG8/S'89Y MNU?HZJ3=&]'L@L./E\TVBNGS+@FT,WO!'XV@[=C7O#;#=4MP,UW5>945KKJ#AH-$VW=Z<@LI
A8W"Z@V$L<9-MD$8L%F^?:]W1*+_ZHG.OYWF"K@IOR;[G M][5&W]UY3L?O"5F$K*^1U?1(5TP8R H+J"(E1*D*,(F6,:$-QH7:(HF[X&VJ M;A++!I1G&ASJ
MKF"CFIG%"X"629OG8K/#)/Q")B$;$V3BQ4&1WR!,+J5)TL MX<%'ER#PXKE+7D2_4(O;6!M-TV0]Y\HI972$((4%(1TZ)=$+;3=!+%61I0Z] M%R4A:TM%2K;*Y+2"0D$A+W'8DA&UYX9:
S)54D&H1@;(* R$40G+%% M)"Z36UT/$KGL,VV)B<1$8B(Q<>GDKFV7IET9)M<7A@P3.>M$0:+@\CG=E(W.
M4H*)653'VWKPK!0H0D=3F9CBXDZ+97*Z*Z,@ZTNYPEWW1$&B(%%PWRDH4M5C M4QSPRC50$DWU!1&K<\8HFF:Q&IR8P >'8#F7U;E. M.DK1:0KVS2B-+[#1X\>;G&F]O_71AK.Q&R?
E0Y+],Q%PAV1*!-PN AKABC0H M0>B(H 1:"!9Y=:2QQ(K!;-7"V=PGI5]72, 59V*)@$1 (N#>$;"I ,63KSZ@ MD1X4CP)R@70,!5YV%)0(2 8F >T= QRU/*@=PDE4"HDC@ M6!&@3?$J**Q1K>DT[;HZ
JXZ [M;!*22JNMI_# [QTEOT$[J?F^$5$N5%OYH MX>^'-H%)R;,J##*W%E3.L?'!#626M2A1Z"0[V0I[/!Z-OS9"W9[5$'UKJ,H! M[8(@&!(,ER^7R%$;ISF8ZD2#TKYZU2D)L"PG(;Q%
[W47*=E5PY#WA248$@P) MA@3#Y3?&5MR9Y)ORUDUVUD4$'ZMGJ*6RH?I[QCO5179VU3"T?<=I?RS!D&!(_M,%P:ALEGDT-U"I-A"FJ\S"!@YI"X#=73LUFSA>U*RR1J5PU#V3>KK*&]-S"D
M;;)+*<\QSGK#\92VQG:D0>*9:%0HCZ_B$#=I8=9?WOPQ-V+GC\L,]BJ1POSE:XQTSWZ_>ORW3=F6^;-%ZT#X.0 M2\C=,>2F@-YB-J ;ABK&/$3N)2B/SJ+UIHB%4\5+99)7B5S?9^NK,D/$)>(2
M<8FX2Q/7I%BX3\"RJ)RU"L%Y7R!&SPS*X"N#.TE7KY*XFO>M6UM^AI!+R"7D M$G*712[+J4BO!&"T6)W]=8KUMYV&"_5X,TT%JF[;EP?!JAIE,')DX,G';8N**CM([*2#[MHD%E)
<%GE<'$Y(7QQJC2R?;HUV$R&HS>3]_BY+0!PU\;+'QMZNI#S*>S,,/I M23FZP$D5_*OQN="%EIJ+&4 M"28C:KY0G[*+\6_&4.G[SDN3H5KEFB"=F*F?\U_M+<+<"W4HX3U6A;JXJ#K8
M+@].>^.KV7061KDJ"*T5[K_#L*&#G'OJ)SQPKEUK&5+1P+-]UVYXM5'5N+D4 MC&?I+- M()NQ 9OAI,\BJ@2IF @JB@2^AD" +$9E4_&VB6N>OKJT>9MA&2:NJG4LIM0(
M3D<+48D".7"CF:FF02\4.NAPI"NR&4KV/9-]*\EFK),8%%20@3@, V&B42IH M!]$*!2H'!=5(Q&H@ @O5?T83.FEEL'D#4>,&ST61(&T;/ED.7@0!EGL>O$DQ MXD):L,.1KBJH8'WI?=_,7HXOZFO.
<30=?,#V/-GS[\VNO8S.ZBUL MGIFO\GYKG-MA/E;@9-!P]W*X-+%IN(3G?14K#7?'ATL3^P"&2[O9J/[S1O*! M&Y?W.G:I;PN$Q<%LRR&(-*&TLA& R>,L,MU+%8!>ZPQY:M51@Z MSK-
_,B4(KK^P@4U!:!Y F-06-E 5@LX"\IR+D$&6L+!V<&B5E+=67XB!^R=3 M8N#:&R/P3E]D?8;\-6J_MGX;9C4ESP^*??M M!0EV7S6(U6O8;IW2VNFD-
C&6&+OCRQXQ88DA>"C)"E!92O#,!"A::HE91LL6 MF+W,_I>M8?8C5Y,/#MVTV$S)F"OH R#E!9]B9"#;^I\IPBA> TB,5="$%IK MUL7FFJT![+<7J.U]%7#VFZSD%!-CB;&K9:SU159*.I.J0\JR@*!1
YK"FV+, MKL1..H7O!F/OK4))B.UJ;] 2*7?11^-L[BBBF('M']NX' M[)UE+D8K,GC,"I3W :(7!B06SDNTSBW:NRX3[5T>K!(B MH7$>O.8<5 H)HC0*7+#"8THQR84^(%UFQ=?KP5+6FSQ8
B8!\RDAOS76*.M! M"O2@6)+@9U>=_?K(H37 8PT#%!:K8R?%">\Q=3=FKO-2 MA:KO/3_ WAV41"$ $X!W#,"HDG3,:E!8HPZ5185I,0PDRT;S8KWBMHL4]QH! MW)1)7&&I6.(O\9?
X2_SMB+^:#RK;PR3^N>J]?5E[R=AV+L,DUEO7'JSAG>(XS&&6\NI]Z MYNGK\?^[W=/_\3G(%V6('R$/)MCJYO-Z9ZXN1B_R8'HY#)^>-\^^N RYZ2]\
M:PEK,!_TS>I/_;4Y=C(HGVZ^KGTCX"B_N!Q/!^TG3W 89A4Y56L_-C>V?N+S MSPK\\9%:RL7W9+&=4T%]I>I5$M<_&[&=?UY-N[[XP6@X&-6KF-6)\3QQZ&?X1/TQ<__>7S?
+C^Y!L1MKK4RN_6%+@CRFXE MMGJ?[]9W?W=V/-X]O)'.]L+IC[G(XGB8NYBBOQR]>_/KT;O>V3]>OSMZ^_JW MLSGU\^OI5KSXZ/?GES:NCL_K+Z5G]Y]?7QV>GO9,MDNO?>B__<73\]]>G
M=<)MT64M,=WV P:G9R_@Q8;.IZ+SQ+"N4PI])2)L?^,^_C<)5KE^6#U4<&_7@ MFL%=5]C\RKENSS:WWO.U*]M<2^/9UDMO7@XU[!E?U0!F\!'SB_E7<<:>L3_=
MO*%*;A@NI_A\BC5TJ\;_YAZT>:?Y9_]T=Z/S3\YOWW[<#KOTZ MJ9X9YOYTV^V^'NC<[_[+_^_CSQCC2[SMQ]_BG@GE_*W_UO*M=7QF/>.SSZQQ M[,M_Z_E6&A^-
C\:WKO%]8SNS6U>SGL5"2CN!K>-C1_V M7Z8'-5B:P/LGTX,:+$W@_9/I00V6)O#^R?2@!DL3>&TR72;/^M!].4KIZN)J MV"S[T22G27Z ,MVCP5+^A[! 6" LT 0FF1[68&D"[V;TD7.[+S<,:8[3'#]
MF1[48&D"[R2DVWIV-+UI>F^/3+N@4XR8[V#DA\K0[@5H M7HXO+L:CWNELG/ZYW&1Y3-W5;;AK9'+)Y'Y+$]Z&08;!B(A)$WQ[9$JKZC3) M:9+_F#_SI>H.37.:YMLCTRZG>>NOG]=7X&1Z?
6[\X"<[90L((2M$R.'E!DZ; M0@??[9]!60'2DD/6DK=ATOO/,+Q:TMLD12%%.0Q%>1DN!TNO:I&:D)HED.D MWJL_,.7^&H9AE)HB[-.FY/HK3'@1<=*3O-\33,@N6F-LZ#9MI!_*AL:Z^O[?
MS<#N5>Y=:EQR?Z.1Z'E ZUB]0,Y!>SV5B4=;T.^ED\9+^PPF5HI#)<"%X$!%%R!H&R!:);7)%JU@ MG8#IUB+UW =]?..C[_")N$1ZX%*.00@N$90Q&93PKC)&(4BNBPZ5
M698O<$F4*!+W!6RE$"A;?\1$97VN&<&)X+1%8R4X M;6,;RE(]JE+])G BJQH=%@_!HX604W3:%E^X7NC#GD10@G&(7-3W9,8@E.J3 M&>XLXTQ*'TN7L'M<]TGN7%]KM3_46V-;7\+?
EDB3\/=M7$EKG?->@+72@$J% M5U(Q!:;&@T8S6YRS=W&5A3!:2@V):UO].:LA>L[!EF2#5\$EM]"V?&6^F>/[M RARRXA+Q*662\Y89E(.P")SH#C3U:%R"JR(P1?%BBL+27:FDN)112C5RZHL
MLZ'&F=H 1RDJLGSF0:^12WTK#CID_/$UUYN#&P>QYOK0#7TSG5XU:ZS-^FJ: MG^*?-I.TWQOA=W>/;?$M.20;0.NK3T%_R=4AQ>I/6E/1GTR-BZU(H*)LXF3E
MK1,+$;3@(@N>P'%975(9/;C"9?5+G55):N&%NQ?]C;9A?G4U&8S>O\7)8)SG MRZ[U?K1/39^\Z,I]O[K6?:?$(1L#@M2!"G%/(16K-ZE,8H#95.#8^BCDF$!4
MU[.ZIDD7O9CFZPY2[<&D^QGUA&6.@W97B5 '*L0])93DSM>8-P%J1%#*" @B M!,C<69.J6U5* M,$68VJ*Q$J8>*657'2 2,^GJW@N1=/4@Q$RZN@="W'E=?2!!(9B4O!B(R5?W
M7Z0$+FL#EG,3G/5<+.Y#8ERX&+*#HA(#A2J#MZ'$SP9'+E.7&W7]]T.X_M'61<2D?^$Z>S.C>;-;5)?3@9I!GF^;I:.S6_6PUKBV\+F00R"8\R"?5:_]F5'?X1)_OMD/.U@H4W+:ATHATW$
M.CPA[BFQ1/5(%UA5CRWI<@0M%HX.MGU(EX' 'SD@:/](2$= M-2(D'AP2:=& ='7C8R5=)5TE724ADJ[NL)CIZ-A2$^7U1YRDP;0].C9?VQI? M-G$4K6[MJZ(<) \?.#;&+4:C)"@G JA2 CB?
R0,,F,R6NG5KVZU3Y[,E>Y& M&_.35[;D8>]Y(%(=J!!WGE2'Y[F1KAZH$$E7#T+,I*M[($32U8,0,^GJ'@B1 M=/4@Q$RZN@=")%W=.3'3>9JE)DJ;YX08IMATZ+NXQ-$TM+E8_@_F[/["V^
M*X1%PN+!8Y%T]4"%2+IZ$&(F7=T#(>Z\KCYP3#5E)4TI$(M,H&QFX((NX OS MTEO/C, NSCPALO!+ S;5?W6S7UY MR\M]A_^Z&DSK0$]Q\F&0<+X#X!VF\?
M1^RGMN8FNJC+VN7"T_$]\VZ*Q$M_(M%R%=)2&2KAZ8F$E7]T"(.Z^K]\<-:*V*J4BP39T(552"&&UH@@?GB_56+FX M7J;B&<4-NZ$:=(AD*>7Z;53'/*Q7F'O#\73:J_I5O_R?. MQB+TIJM)G:M(
M9TKV56\.TJ20^T>ZNO&QDJZ2KI*NDA!)5P],S*2K>R!$TM6#$#/IZAX(<>=U M=3WE)SE'+U7QD)WPH!0+$"T7X&/**AEON%W8BE%8C%P[TF')@W+&7AL2OCJ MY+C-#*5:V(IQ,CO'29,IG>
YCJ:##_AFE,87>/0A#(9-WJF,)],PQ-//V:U2/@4I5$CX)GRO! MI\E!>%T"A*P=*-^0L^G!PT0IE:JLR"B[6)$B?.XD/NGLT5*Z5F=LNS)%%NG' M%236B8*3S]?Y3%_.>M/Q<)![-Z+86YOU_:'OO%7K-
(#_QOV:KY,SN;^3A9A M3" F$!.("<0$8@(Q@9A 3-AO)JPG(^90>\RI@+%-I>:@+7A=!$@;=.)"6J<6 M%A00!JHFH19CP].%"0*$@7WE8): M2A,++\"Y;?IT6@"%J5C*4D0 C,HIADX(1UDPV*VKJ"-
MZZ.@DJHZA))02"@D%!(*MRC9:W+1-H7J5CJF0$7BB9S M+$+$YG2?5:!4]LV[9;UG05FO>?VAND3KXS*^@LF^8*NJ7+:UC*4%=H(MP78W M8(O9,A62 XD^@C+<0(SM5J;,,YI@F
T+K>8K5(UT'HILJMIG75'=/'+>>9UL MB(+K#)L\19XFPGY2**Y@R-33*@[):@K/(N?2-9WBE*=U#9Q-4>7J6TB%=DXG"(;5$^,
M='7C8R5=)5TE724A[I&N/K#%A*>LHG4@F!&@,@\0F&QR5,I(8:-RB\6FM!&: MA< ABN2:MHD9?(@*DM+"*JX="KZS[4\DX_M39HKX1GP[%+Z1+T*ZNO&QDJZ2 MKI*NDA#W2%?
OCQM2,0Z54^ 2XZ"L0?!*%Q#:).58?+"?Y$Q2X8.N#77=B=FZX%K M$>HMCU$%=N_"_YOI] KSJZO)8/1^;@KFAS_;)T_F2G>CC?G)QT!%7S-VR/:
M6'6@0MQY5E%L2KJZ\;&2KCZE7*3*CO$H(!F;0 G+P)5D0%LO/5JEE8Q=K&D] MX%>T<>7WW8KE@TU^T)$FT>I A;CSM"+/@G1UXV,E725=)5TE(>Z1KCZPLRT9 M3,$CB!@MJ)P$.)XCF%PX-
SI&K3M9H:(H8#?6F^@H4?VM//[3[)2NRI\ARDE2"/CG1UXV,E725=)5TE(9*N'IB8 M25?W0(BDJPHK229.$,E)#R+S)D@8'3D8'+ L45C"CA;V; M)?5.15LT
\S:@4+#P0=6WXA9&25$9BSS,YQTFS/G^ YCJ:##SCO_G3T M(0R&3?*IC"?3,,33S]FG+SO_CW%V4L["Q[?C27/E1[/99!"OVI35V?AMF-27 M=-Y :F4E[C:>+Z3B=81/PF='^&0Q)30Z5PK:
HH9"]Y)!EFEZ 3CO/"%FI[+ M+#(1/G<2GW0J:BE=JS.V79XBBT0]8'] S ?0 Y;Z0A,3B G$!&(",8&80$P@ M)A 3B G$A.W)B'&7K6=.0' \@7+&0$Q>@/!8=-8FYU(6%A28B<5E#QIC?4_Q
M&8(7"$QDCMYQ#+C04NP89_,4V"_CZ;3S!C>\;\1Z.GAO#4YIE8"X2EPE7XM\ M+6(",6$G?"W/4LCZ< RAC+++#";+E8?R=?:'E^+#KY]4X': M;_MC?C_B>)@?O+E_#
<,P2O5JPK0IOOB_KT;8DZS?$TPHLF=[T\9Q$Q;MH+HW M2HD%4ZQ&AV<&BDL-OFTE4GQ@1A>,AMVU03D)I7Q0$'7]H:JY B>R@:*=YL)E MI;5<.&;=5F$\N9I-9V&4!Z/W3Z[1:&3?,='7?
#W&9Z<[-Q+]=I)^U,1V71BT MUJ!QF,#+F$$Q9\ ;ZX'E%(JRVO'&K>X @ZMJ8FNH?RU1D"A(%'QBY#8-8IQYECY?ZBQDNB]9$)7Z'Z3AX<8VE]G6!+L-T- MV$JA!..J@"\UAE=6.7!)*>
L<:9X8);KA0KR-79G)4E(RDM0F24(O/J^F+57 MJ(-Q"=^PQFK3 M.M!3G'P8))RW0GF':?Q^U'Y*VQ6EJP8H?:]7M75O;U6#^+8'0MQYOI$O0KJZ M\;&2KI*NDJZ2$/=(5^^/&U*0T2LTP)FN<0,7
6)3:",8+[P0(A2]L&CCN-Y M9T^R(7NJ*&1#OA0ZET4JG2P8KP.H+! XXSADZ3)&D="GQ6.>HEA9C "C' .5 ME*QV1R4HR1L!OZ*-*[_O5BP? M;,I5;;_>VXE.M-H#(>X\K8>^_#8-2KVE*_
M_)_8=NZLLR_.>M//[3[)2NRI\ARDE2"/CG1UXV,E725=)5TE(9*N'IB825?W M0(BDJP&A9KP)[-SG#3;Z2=XCJ/IX /.NS4=?0B# M89,L*N/)- SQ]'.VZ,M._6.-)<^=%L-AG$JS;%=#9^&R;U)1WE
M0#5SAYP$);@=J!#W%&Y&EQR]CH QN@94'B*OF,.4FQ-&3+BTT.=WF24;@ML. MZ 6=*%I*L^K\[W'4UJ\H?ZI/R+F ^B?2CV5B0G$!&(",8&80$P@)A 3B G$
M!&+"8V;*>EK$\"2ET25"43:!LK;):CD+4;*L=5 FI(4MRR(GD;C.()#5]R3M M()2LP2':S&VQQB_DOXYQ-D]X_3*>3KOO#M-7WJ^E&<+6X)3:PQ!7B:OD:Y&O
M14P@)NR$KR6#*8DA0E*A@'*R0##:@@BQ<"6EE2EWL=9(OM;V^%IT:.R;"M1^ MVQ_S^Q''P_S@S?UK&(91JE<3IDWAPE.\G.%%Q$E/LGY/,*'(J.U-'\1-F+6# M:G]H6'36Y ""2PU*.
1X(.4C/F+7=F(>C7NEHG&P)@V[4CEP2.NP EBFR2 M,39HM7!.N2UC>'(UF\["*]&[Y]M#HM].TH^ZP*ZM MH+CAB:=0'?#D&@P:!T%Y!,E55+QZYL693C"XJBZPAAK $@6)@D3!IU
0I.8)"GJHSB)T*B%K)37WZBX%#=,H1:5@82:"8BI!\("BRJHZ(3-EJV- M@DJZON2"4$@H)!02"KPI:'Y?U%8KUI3PX=Y,6V0FV!-O5P-%5 MK:X$M!#XO*T*@B\L@53U"W22F:&
["T=O*Q"QQMS1I/J>@A*B%@I,C>!-#(7; MP-?F=TI-24CR.0F#A,&G8+"P+(L.'(J."I2K/YR0$6KDC:SD6*RU=S%8C"C(MBX"HM*WHS Z833.>/.>>EW-T]>7]6\8C#)^? [R11GB1\B#
M";:SZ'G5MZN+T8L\F%X.PZ?GS;,O+D-N%A-O;1,9S*_L9F-%_;4Y.S\HGVZ^ MKGTCX"B_N!Q/VU:J')]\8/1<#"J5S$+D]GS<#4;O_CZB7I;YW]N MI3S?K1)*'=OS,/PC?)J^^.DOG^?#]2??
B+"=X*W\;DV!.Z+L5F)K5:?OSH[' M0^1&.JLA=[^P?K]\=O7W]V]F;EZ?]WIOCE\^6 MS-VLXB)[=Y"WU.PO3XY?O3X^??VJ5Q^=GOSRYM716?WE]*S^\^OKX[/3 MWLG?
>B__<73\]]>G56Z[+;7]T*G3LY.7_^OWNM-T';U_T7O_?W]Z< M_3^2SN8'_O.;46]V/KZ:AE&>]GOX,6&S_[79)M7+81;^3$+:_,!__FT4KG+] MLDSBV%AD,>\=\;67VOAGO%-
R^'&C^,KVHD,/B(^<7\JSAC MS]B?;MY093<,EU-\/L7+, DSO+D+;29@_MD_W=W,_6$P'<3!L,;3SV_>?]\N M[?;KI'IFF/O3;?_U>J!S!_8O#[R//V.,+_&V'W^+>R:4\[?^6\NWUO&9]8S/
M/K/&L2__K>=;:7PT/AK?NL;WC2,W[ILG;NZS8(\]AG,G=3FWF_>E#^ZQS&[] MAOEI2QOW#W:U@UOUJDV="\TS_^LG\1/)]#-'2Q-X_V1Z4(.E";Q_,CVHP=($
MWC^9'M1@:0*O3:9=5A:WC2]MT>F74[OL_&, MW]*'1$TG@(-\QUH_% E];W RLOQQ<5XU&L/'R\W-1Y3$GP;[AKI"AG8;VG" MVS#(,!@=O(FE";Y%,J4U=)KD-,E_S)^I;SK'T73P 6F:TS3?'IEV.[
ZD*JPHF8Z)'ZSD4AQQ4B I" M] &$C"RAM,4PWPF85M=0EKA$7-JBL1*7NN!2\"9E@QF"%95+T1AP!@LXV7A2 M4@HL9:'A($HON A@.).@=/'@K-4@A$PE!\>QZ+5Q21C15]X0G A.6S16@M,V
MMIY6B4G&?((<5.-0V:;/JI"0,"D?0LC)+#AA3N9<7XC 0ZD1938%O&U8\P]?45F44%;M://\F)?$2^W94FD>\[:?S@ MLY$R@2S5/5-15*=+, .9^:"LUH'C@J,6= RE< [6HVNB4@6NAK#546.88L@^
MF37V?^:L[]E!I\Q^?%GWYFS(02SK?O.4$<0PQ69_Q<4ECJ:AU0S\V#S^[H[G M+;XKAV0':!7WD5)V@@L2,^GJW@N1=/4@Q$RZN@="W'E=O3^LXLY;9(Y#B2*! MLBR#"S&-CZD8S[T(*MP-
JY1#PV6,X%GQH%24X$HTP#-+UD<3;'9WPZJC_-]7 MT]E%O93IV?A+(=^FVL^;T?61I'8'5>OFOKSEY;[#&H5-ZT!/<;^2*DJQL?*^DJZ2KI*@EQCW3U M_KBAB."$EQZ"ES5N2+J -]$"]REPKVR0?
B%N"$5RZVK(4*.,#,I'!%_?!$DD MGS5/7#9+.!0W[*)JT(F]I93KMU$=\[!>8>Z];TY25_VJ7_Y/G(4XQ-X4T]6D MSM7O5W_:XKM#)H5,"KE_I*N'*432U8,0,^GJ'@B1=/4@Q$RZN@=")%T]"#&3
MKNZ!$'=>5^]/@4:F/ 9C0"0F0'$?(125 3,O4C&N8M!W4Z <DVXZ:7S74>#-*XPL\^A &PR9/5,:3:1CBZ>=LT9>D MZ3'.3LI9^/AV/&FN_&@VFPSB59M=.AN_#9/ZDHXRH/MT_H;81FP[;+8QE20F
MS2$*QT'EY)JB61ER9(X7KUP.L8OE'6+;]JL%G=I92K'J].P-QU-:NEE"+[Y? M''8G-&<9,?]07=S=-#F=AKZ/J8R[MY.%F$!,("80$X@)Q 1B C&!F$!,V&\F MK*(6K%(+/(E1=6*FVZ6&DD5VMK7"TZ*
[:2[FZ_ADDZOVGM M)LF>/575Q#/1Z%H>7S5G\0[,HMT_^)VW:0_8($R>!9&K/4%;0W=MP2<9(3!; MC)1 * MG07A8T5A4=491-WL?\[..,R2ZP4*!HTQB8S +&.@@F/S1@.<*Z5T4T,3.^T(
M]9WV=ZHOA2<4$@H)A83"+VV1%F\MTT//.$*&VP;F&PRG=0"6D2%\.(4Z@N-: MUH MU?=@+("B&&F]K\&9W=&.%Z+/5K;=8F]5@_BV!T+<>;Z1+T*ZNO&QDJZ2 MKI*NDA#W2%?
OCQLP*BYEDN"CY* 84^!0*BB6Z21UC*4L+-ID%G5J3C1F'1FH M8AA$FQBDDH+('#W:7>VP??!Q YU^7$&GO(QQ1NWR]E]Y#M*ND](NKKQL9*N MDJZ2KI(025H>"''G=?6!_1-2*6:#@^)#;O*@
H(N M&8(02:()W'*\FP/<0$_<@.9,FL!!*7J@NL1LMI;@XY!PH ML>U A;BG;-/*,QE-!BRZ:9=G$P2&"H*SW":=BG2+E7.66.,AMFV_6M#1'6J7 M1W68J0[S=H:^6UI-F%Q(8@(Q@9A 3" F$!.("
<0$8@(QX>E,6$]=/\%=*8EY MR"YE4**I2Z,"0LXI2&&%#*CNIK^_KT;8DXRZY>U9.5KJEK=B$Q2$"19=#=I=**"2 MU35R3QXP"&VUB5DE=]<$B2(*RAQ 65[?*&.
B!%!,ILMDTX%7JA;WJXK!=%O MX_2C8MQKPV#PQAHNH,)0@S+HP1N703,NK(J*Q\7]S$MAD+KE$06)@D3!K:2@ M"4G$R#-X81VHRCYH*EZ",X6A,D&
[M%C=)BFN2N4ETZR^1W,'KD0+&)WT-GG+ ME5YCMSS3EW95.Y8)A81"0N&^H7-]J5[&K-%-CQ?;+)-79Y&#\[[Q'9.MWF4V M4BT4'$X6/0\I0+;!U/>XBN,4/(1LC.'5\]1I$]WR*F.5MX?
&6%I>)]@2;%>T MY0D^AES]Q,A"Y";5Y]9&0>_[7M)J#!TJ7LVA8NH'2+4I M#J]<2KE>?\1)&DRQ.N/+9NI0 =E]512R(9]MB.-),RSTW!_&1F^^3)
M7.ENM#$_^8RFZ\N5'<_X\JR@V)5W=^%A)5Y_@5Z3DC,P*04K, MH'3QX(1AD%1FN<@LO%R(39=9TWK KVCCRN^[%4\X[*?(LR!:;=%8B5;D69"N MDA!)5P],S*2K>R#$G=?5![H9.N]R-@&8-
VVG5@NN/8>NLN8J!"'"0HW195:H M* K8C?4F.DIT9[WICS"9A-&,EIKV54?(&'S9YAPEBZ@LH&\+3K, +D0%H<1H ME&(QBO24I:;AY&+R[76F&\T[*?]UK7=/7F0RPO456U7]N[V=XL2I/1#BSG.*
M DS2U8V/E73U*:5SGHU+=\BC:Z_(Y+ ML7QHN:JN%GL[PPE3>R#$G<<4N12DJQL?*^DJZ2KI*@EQCW3U?O>_.'3,)@\N M!PZJ:5_GK# @422E4HQ,+=2,_Y'U)7+_=V1A:04'F2X&.0]QQ]:6?
AO580_K M%>;><#R=]JJFU"__)\Y"4ZIPBJE.X-D .UEOVMP-VHA]V-QP5V\BKL>V\U:B M,X_N (1->KLWHB2]/2!AD][NC2A);P](V*2W>R *TML#$C;I[=Z(Y.Y@LPB!U5\AB!M 2&$8R@R
M8]'>W;5_,CO'25,N:H+G.)H./N";41I?X-&',!@V":LRGDS#$$_IZV^5*(Z MQME).0L?WXXGS94?S6:30;QJTUQGX[=A4E_2=>\YO8*4[+8D&5?:4HY 2B] M2) FE54(/
*&$D"9@!"=T!6I1D@OO9&ED^-/!-+=!"D=H%I*V>J4;5>W:(?# M4SN9L6=-([/I>#C(FVSSMYX]$-\?^LZ;M4YW-'WC?NU6RSMB C&!F$!,("80 M$X@)Q 1B C&!F+"9E)B+&*3G"I15""H%U_2ZLV!-
\@Q]8,@6BD 4ZTJH?P?F M,P=E;(90A .?9BNYL2.\;9/ ?VRWCZ WNR'Y? \GUF5E7Y9TMINL;E M L(J875_L$JN%C&!F$!,6+^K%5E*.I0$V3D'2@8+T>52'W&=;+9H4B?MPO81A&J5Y-

F#95&D_Q7S5G$P\,*MV_^!WWJ[=;X=D2DG)&J\G[1*HG'T-WY6$ MPK35PD85E5K<3IB-*DZ"8KG:+L$1@DL2A+ E9VN=]'FA"'!;OO'D:C:=A5$> MC-X_N;BCDOUJ >O_JZKO^,U901X]T6]+G(W_(
P^&8.:)8W666!&Y.J$&P7> M% N"*^>"2+D4VPD&FW(5Y]6[P"Z)$+GQ0$@0(41@V!8?TU\)!,=M[X^SM" MK(*"PKB^$(1"0B&AD%"X3?E>YX7RF!78XE-S!"^!:2:'U&'QIC:8V=8$NP70T<
ME1_8AI!P4:!8J!%4T$(V(P"+/IKJ!TO&%!NYKR^RPC9GF!E$@1DL3SIK;H0L86T0]*)ON2 2/K: ;OVW.7$Z])'R(,) MMOKXO-Z9JXO1BSR87@[#I^?-LR\N0V[69&_MMAG,!WVS/Z7^VM0D&)1/-U_7
MOA%PE%]#]I,G. RSP0>LROJQN;'U$Y]_UMN/CU1.+KXGB^V<"N8K5:^2 MN/[9B.W\\WZ?ZXL?C(:#4;V*69T8S\/5;/SBZR?J;9W_N97R?--/*'5LS\/P MC_!I^N*GOWR>#]>??"/"5I=:^=V:
G=$V:W$5N]_W?KN[\Z.Q^/X1CK;"Z?; MNZ$ZF**_'+U[\^O1N][9/UZ_.WK[^K>S-R]/^[TWQR^?+9D"6\5%]G[<='2! MC-8)^TSFWV^3^?GY[V4[Q/GRY/C5Z^/3UZ]Z]='IR2]O7AV=U5].
MS[9(FO6*?GU]?';:._E;[^71Z3]Z?_OEY+].M^@"EYAN^P&#G]^,JC\ROIJ& M49[^F22R^8'__-LH7.7Z9?E0Q;%1AZ 9W'4GCJ]\M>:BYL[8M6?47$OC*-5+ M;UX.U8L>7U5_>/
1\XOY5W'&GK$_W;RA2FX8+J?X?(HU$JBVY.8>M(F%^6?_M='=G^(?!=!-'PQJ>/[]Y_WU;OMNOL^*9]_I/M[VXZX'.W;B_//_^_DR*)=ZU MQ%O8,^[6]%4[/Z9OG!-PWZP[=I^F//;LP)V4RUP[[]/->_3?
K3]1\;2,[/V# M7>W@5IULKG.A>>9__61^^O8P?^@(U\:DWN6!D>,:4O=^K;^>3WNOJX>?OSXS MLMQL>D)4!($I3MW3C"AB#RD(Z0CW]21[Q[F)!UYTM'B M#LWS'APM?AFFY[TR'/\Q[97)^*
(WOL0:KS<+>\UB]H>V.O?S+B&U,WM9'DVI MG=^=T5M.OMLQ[@W;7)K..R[6O1HN5?#?> 7__:#%HW>J;6ZX:]RGN56HV/J# M/R'%@F@8..TSJ.Q%<[+<@0@Y<6%"=$;.K6!?
Y[9K2R>'>;9*6PB*!,5M@*+%&'6)%HIT M%A2*!$YX"S'QB*A-U.@7#IH'9ZTS!9+E%8K6>PB&%?!.!.F71F_3WFSO6OC;:]O*5L'1WZ-7WI5A$&[>2$WB.\$\6(
M8H\K;&5"E)IEP*8$B_)60$Q,0T17;,3@0]/_Z>FIG)523/>-7U4-EYV8T"OO M3;!':'R""OV"=0*3F[O_^G20!F)-E11ELL%(45F"2H(!T'P!,QJ67+V1K*% MM8,?<9N'DXO)\V8CX-
$H'X]'S:.3FXQKJ[^OY^K;>5U%N:K:.1M/BB^]P+I' M5H-X2;S<#"^+096\AI2: MW1,PC9<, 4BS>Q2*;,4QST3?%2.\(EY:S7Y;F__MPOJ2-*-\]4[J%QFD)QB0$CC#9#1D'JL!\=&
]S*"SZ7:$)26*]9%GOJVBG75 M#T*MJD[YSDWB/<(XD8O(];CFAIG[W*0*> P&5+$>/(8,6,FD94;EV9-%J:K2;O- MD#S>_56Y@[0;ZTG!F.QU2D*!CBHV[2(3A)@S"*SF)82B$B[TMUC&@[ZMSB?E M%
<;9J\$T54K.WLX5N^LX-!Z$M/$O'BKZNII,ZHNNK2YEU7;%VZ40<8M"Q)13 M"JG&A,QK!THZ54-$KT'7OR5;2E:6=Y%5>S-*DV8?TRN<__MF=*W9K[!@U>-\ MO<'I:)1/&NT^:I6ZL_-5W%"&;8\-
#.&3\+F910FOM=%>@C=&@,HR0U!-\DR% M; ,&Q6PG![-J[#)^:I7/R['=%M\@T/<&4-M^)BR5LP!-Z&:$LLX>(&B8CA4&R&-1]')^O:B*;E1N+=S?>O(:B@F]\=J=)<6
MW7&N$\X(9QOQM+&4Q$QB(*U,H*10$%ATU6M.F>=B"B:]&D][:3P^;BW;[],F MU8V4OR3O^L>\Z\D5?DFHDW>]*[I%YN@I!WA#M"%X#LDU%>2UJ59_9 M%\L@5=+*7.RE&?
DX+UOV):CZVUE M/[J"^D@SM*IZ.X_IU;MSVK)'EH0@2A!=&T23YU%G'RH0A0>%Q8"K-Q9$92I6 MESXQ(5?CR*\%HJORX_>&H6M-I>L.N*QWT,$_[J2E%+G^9+4.SFJM)YU5JM&R
M,D;@1EZ4/RQJN8//[3ELP0C0A>F<1;64)WG,&B6D)*E5$NY0$"&5#XHP7 MC@M5,9<)5#:':*'ZG*^JM]/^(7HSY2RV<4WGB>4IFL"D#,=_3'ME,KZHX;Z\FZ3PTM1W: MXJE-
&FWVJ:WS@/^Z&EPVG=TIB[8K&U-H0]<6A5>AQE<.E87<=)14/EOP/CA(M]0D4P1ACL8L,V-OPJ='2Z=GX*%65G>#;:RU^.PRCV=$HO[Y1Y(ZVODJY1^UR M.\IH;;%Q(2 !=NAQ-<')*85[[O$'U]
(F->_&->7>T5HEC0// M;085=8"010;!0V%1!5M")QVI%IS#HP]A,&QT^&_CR6EU_DX_:W)3.;HC#Y$[_MWQ>*NAOND)$@$A()-T)"85ET'#T8Q3DHC!R<405DA4C(E@MG%L+D958A-T-" M8_K"$
@I0;NTUOP:9M?3LLW*3NLD)&^<=M/0;IHGVIV8K8NY."A<,U#"2XAH M&7C,1@:I2Y&V$P]\,DZ(>?JWR?BB,3-'HWRMTI].RL,VZ/]G[TV;VSBRM-'O
M]U=4*,8Q=@22KB5KDV8Z@M;BT;1M:2SYOC?NEXY94?RITA'L%['%0'S.(SC\='CXR'C(TMU5NJB M)"I-):&%2 FGJB"@D,=,LE#P]9[9=]++GQ0?HS->Q:D'R*=VGQ],1/@N-481>W_?
RS,NS)_%;I3HO!!=@"W .LBX5C)1YEI)(@Q$0 M"9EIL9.*P5NBY]]W:/!PT?-12$=I<63YOC[#R6.TQ^BGLCED4D2422)S,#QH M4H#N2+.(T#(N>)&'4F?C]D+AW!>(X+21\SA-OG'WTO_TA7$S81
M/O_(9W?XB>WEQ#Q9/M.)^;#2._:5M3Y?EQ[;MG.03PI/M3'I:'8U. $>!1,U MPU_ZJT3=^J*>SR=BQ =;W:>*#BT5SPI*>)(E8 :%)>BR07*>\8[8,Y"AUSJ1_\>R[%O'U[MRDM/(.\B]ZNC!
MT(/A[7K+B;200A*J94%HD<:D3#DEK$Q4G)* NK=Y\SPB<#PP?J2'@P8^IC$ MIXI)W'2>Z-5W+[&\Q+JA^JZXQ'A!G8&PHG'!2*'SF*@2Q%@JRU+1[$C!]]U MW+OS*!?CW*4/U17U8
37001\-0:E@B8RH()F("\S=!-4]C@7H[S2. M(_@!,/4!XP0?#D&]UN\]\H\3(XB*?>4ZB&'_)%3R1U;5QQB,2R#>R:RY6<:H/,YHF M2J#@>1*PO(B)4JKN.11""K[M3LJWHH#!_[]=<-
V?/ZXT2ZG+!,ZX22/>49H"7IR$2&0%5RE"2^E MU#NIPO4LT2Z*1D5YU#%K/L[Y3KSV^L9*=9#A MZ7:S8D3_YL7O.A'E,"\6(2'*P'>)4$TZ9($473UZ/KXZ"IEF$9" M)20+:8F5$G-2R#0DFE.M
25C$:V=+82ZS'E4<@+(#.B:L9#P6$F21R*5:01& M"2+RLT=7&H["S,?\/-CI@Z\+-ESA3_/I=*RP"PX;!Q+H>ERW\;DY0+U$6-. M#*H,@U7A*X=U<[N^1).;YWZ_^,,7;O+3/8SI>L(^@NEZ-]R=]-
D/6JL&I9^I M.8;QLJ CFG+\( ]% QIAH+Y-U:15WNMV:Q7UZ:;[B(;?7H')SBV[,NJS5* M5%04A.:Q)$P6F@C!2IJJG.;\7CVT3.YUQX2OD0??.Q9\/SD5-O!JUGYD5]@@
M!BRU4\N2;RU'[LA">Y#>,$]'^@_OVMHKBO? YH'MD6J:/2>>]N&<=Z*5WS#< M6 :L;15H@S6?L6IBM4'E0H]1E@03&%IM/86@.HY-AM6X8KP:^TH)SXVW/*+N
M*L$@#1FCJB1*8+LDP2+"&&=X") 4+(K")%TKTW.7=*H_<38?]%^M.D4V_>"8 M]/VDRPYX5SDX U^G/\"_Z'LR?>Z&(#=X=P[N__M^[J;SOJA)[< @;N<>R[&T,OL!CUO;DCJTH=S"U8&4+
M9749B#'8+O_Y8LK.%)G44G67P]KCSVY_S+%@[Z]),DK/5;?B*P:9;C\)8Q\ M?C%Y):MV.F97+_'75U,F,6QB$&90V4%U!B5_.>\G57ZJGN=N9&HB7PUK=O*
M/+E18P"L2_6*U]]PXO#$EWW\PK<;HL+U-+^?5)@O80SLA/LO;MMY;Z"[P5>3 M,>] 1IK9B_9?%:_6OX!EM5^;7;96NE,P]Q>LO%7=M6^>O%S3P_NR=T6&C8V
M^S<@@96MW.V./4]$7.S._N+B,!YD!R3ZV^F?[W__3/X_%]O_SS]^/:OS^]? M?QH%[_]X?2^$V_$@5R'OD2##*(!&?85SOWO]Q^L?K]Z>_!9\^PQ>_
MO_WC\Z<]&N,=:.XP$.''OR9L+N%E\J=U3:.SD?Z87ZBF$MUQ82Q3*E)%BC2) MP41*7<2V^O C@4C:%9\R:N0M&-1&?I[.;#OP?D=.BG)(%*W-! MQE4[(\K&W)FM ,.L#[-94J-6,6FCRF2$_BM## 2?
W[[D8-^AV%\CF\6VT9,T MR7]XB#C#.U&1&\[@).&+4E,8V;C7*YTF8];E.^OPXF]1+WT&VHQ]312&/ZP\ M<$\89T"5:%-TQ&KB+0V-XK=#*EU S$(U7.#,L-HGKFWRPW=*?F9WEW;W(9I[
MZAZLJ6!@ 1AK\$0UGU6B!=UC(DY&P:P^4V"5-<'7:G8>5+,V:.>\K63%FJO@ M1_@EP .^.'SUVMIXYE/T*JB;[@?W=/?#3Z, -H !$U<3XYP 4CM3 :] O(OS M")X!2"-FP!?5 MK!;GH)TU%3/IDMW&&-
)Y!Y.4C:K$N3D1SE_!F/'I#)]^^N*GD^#=J9T(;M@(MGWX&/-K">&RD-'-!U5U!1> &<;YX">[R?(+>(AR/W1EE:*(2>$4 4PCDW/S* M@C/<<9";C$_0$X?.NSUQ)1P3*!WR.%&<,Y:Q[)(YK.OL(?GN-
,1# G4(-7: M*/J>H8 8@X_FBCB0-?RCODUAS!;0\9:KD:$;8 *@5GPFS*X&3@_@"<#X,'^P M(OJ+@Q\=7'WX[6T'54AE*T1\BM_]-YO,@5U'01S&] 1@$\@6;G,/0ODR.:N[
M"/].TVF1\-2DJ1%OW$,]R3WZO-]/@M_9%>YBMQT M =-F-F8"L]SQEW/0Q%0[LQPU1IEK^(X%<09JFOIB\EBL=)BB*)SA6GVKA!64 ME@%FY_"PK\#.4K6PV5:RM/,IKK)E.Y0V\
(:N$M<2BPWF=0+2,O@$\EA=<)@. M[%D\ZL<_KC0R-4IR/0>>VKAHPT7JUP9!X0*VVJPU>IY1F"W=[OGR"?DR&2T1 M+IM,ZOE$&"I:8TK<_870B-/@ D/)SVM[FM +B!%H3//&$/!H75C,&B2
9>FR M$?J1&"EFDU TD" ML@[4$%%_J:Q>\N.+CW^W"I?L?Y-78(7;W]Z\^&D%FCI1:";3@\3FM3DY7AH; M[,F0R"[4S.ZRVSY$[_&X_FK,#82S"Z500BS?!1HWZ+RS:XFAWXZ-8&-?\!W:
M^/AWJP!WVO@.-M[CVJ/2W+@#-CV@JF72:-1EA6&->DAA_]YNIZN-M+00CP(, MU$;UZJ_SA8"5J-!_WH$D$%X:(GW ;X"00Y@TV@BOS510:44K+1HP[W=V8%7;HG'X8_L%?X,'MPQ/;- Y>
'M9&V<=_-A=/0?S5^ MBP;M2?!QN,I+%_\X^<\H^6EP#WZ1_M3="NO= $;!S_4%T"6(G9<1+DNCA$+R M&3JGX,'_M/$.JS8]>@T=L1C=WVF$M$>U1EW4E\Z(V2Q,G>+OW(5F8Y??@9/L
M]+KS>NARZ"FAFJR \'74VIA'31'#K?-M\50DI HNZ$>Y4=M$YY4"1*B<^ZH% MZE&6'(#6_CZ:L$!,]6-L,?6D^#UO&D,%7>36[TD4)4AC<%C9'?1-?.#8?P, M4V#]#%=F<\3ZY.^L <5^'4"E,2\-
U%1-VV\++CC:++@KEA"P2L2\;8H!](> M==" K&NY_CNL8UESA99:-=9DZ/U%^ESZ#& !"BO0W!DZ>YT#:\UY94"V!3Z" M5:U,T!96J"'>-/B_E)7S8B_Y8)V_R^@X=
<"5\WFYN\RZK.#,-6QXG9/OWMPW M,N.>UC/KUX8';&!%=+FOL-SG)?;Z6@UPW5QJ]7?KSS>"R :)KAE[[6A9OU^(M"A1)4SR4&?=R@K56M,&_%NJ[%:D!_%":+ZH!X3*NII7LQ)8]"4-1B3<;
M'WMMK8J?!@KJN,:)=5<+!,@6_9CK6(KL$1'&*O:[K*28*D"]WDTG!,HI)C/ M Z]44.9W]^-\@]^N@+M%A]CA=QHL<&8.]2V]G1((-V90HYRWG3#&.P6MX,R M>C**\-ZN8K!R,W%N
Q!190$*N0"9TE0H?,PETPV2_#? :O M5,'O,,DY+'WPR3J?7[P[??WA]T_.K,=#YY/@C2%XC"!V2K95_*WX-=RPAO' MOL(*@K$YMIJ@]VVQ#7K>&)H10"? S3"??[&!UK8@P8]O.H>@A1A\FU?2G_1\
M9+&O6!%!S%IWS(7>*"#8H008*C^=UW,^E4YQN*@D>0-J6>=3IBQE:K;'C6"L&%X2X M*O 0FMD4)OK-.*3AVB3$Q8F*T&K)CDTZP3: \--)MS# ! M(LHH7L$_;Z9,K
M.,_&K9%MG3=P20/Z>2DT9Q#,Z".$]S9"N/ 1PL\T0K@+AG-Z)QM6S[A95-F= M@M'B%TG(Q=Y8U6=ARZCN4;#J\PF>%4R4 MT:N:U5@D/ CNQ)EY#K U*MAV\D
@S=ADP71A+&8LT_,K6#@\0+43[=;6!N98 M.3]O<,&8*8ND.J>6$7I@<;B@IL5RCKKC5G2]H"Z''M].$E<3FWQF5'3CR+-V MRO*Q0B_PX!HT!>RN#HP^4]"P/W=VVH$Y!1Z\P"S4\@&P/9;=O-
%V1DR<>UWS M277-RNH]8" \,5$KWZ9=4-IWHPY@!VL@$;!U6Y3EP8]13*+F\7U(-'O'\/FCF*WLX$F@R&T**O \?M*OC/ MT--A;$<"!,->)E:HN!\T^;,7*)$M!&IXS*FC M@X5RIW-
FMG8R9.A4L$%#N)CI*Z%VP5>87]=K.UTZ.3LK-WM_EGG'-SLB[4: MN.?)I^9)8W48J[Z3IZNG>V?CFJ-+O)[H"B&X;JY^1C=?[Z^Q9 5,@58@&'^I M9;7>^>5?LG$ RJF*URSKRE@Y/6N ,-\6L8K1-
%761X=]1A;)+ M89\<*9D8ZDZ"?4:W, 997[IJS'^B2_B-T]*&_Y2=1ZU7C0:*;,@VDV'5!*6P@Y\.63=+)Z)-T=.@/VN0--%GRA< MX7S*"-82--%S9&W-
!'YISQ!TH_YW;EP:\A(XTG6X.9N/00:*^N)B/NF8"Y\BH.HI3#)M=-\(^2M!O<[M'FMC0HS9L?]2;#P[Q[,@X#JD"G..<'IF[*@?7_S^7W\B7K\'1KXTK@8'ZUUP M\ZD) < 3U?.O#&]X_]OI1[B!P<
ENI"'IRH]]=MRYZ++R6F4G(M.HLW@3J0[M>.*.M#.#=H8-:YJO]C%1+QML&*)B>I%#KQZE9!:1E#_QAHOV[G$EJZ:N>M*,^B$(8I^P7=87'8&T]F:CQR.:< MB$[A&>;.+$8_LH=%%<-'&%0[
WNSF;BZ_!;]W,LT:+:HF".R*H%_-0LVZ.UK MQ&0\MD5\6R3[M.9@==+%7*PE [5]*D^'THNW# QIP.:;5S+HG]'QB(YKKO@_& M"0J8U><:3\+2VAL-'Z&^PD@"F]IPJ9:-
]"4OP&S0AE.VYZ:Q>WU$CZ?!D M2FL3^=&]=2B9V(4I'6OD\MI,1_=W(-2<+"SU40W#&@.IFH6R)A-W3P6&TH6 MT?KPN+[FWPGH$ ID_&KXG-FQX4)UHT;$6T0PP>MGR%
(]]X#9I"8C?!Z&U9B? MW1+C.BQ/ML$S\KERIQENMUH&9MH24 V\O;? @A>;,WVC(J0R3 3A'-O)9U%. M.(U+4DBA2BFCF)9KS7COE.EK3U+E@+Z :6(1JBE$:/[[X]12UJ6-6 M=
[8LO]O6H#U7H"0R0R3]F782&6,T<3E(@Z"-37E4KL;"YAU%E4?6JC5Z3W\X M/AXV]^D%H(FKPAW;0$7SKI3#K>C)SFNAV7=6MCU\=P%)L_-&67$YP?!<4/=F MYVU@?\GLV\"QX:Z%"=I?
L)%1N72P97=,7R M\&$7E0TQZI+>/KU]W2>]&=4*.;:ZV%S@*WCM)/+P6,$N0#W#HC!+>V&S><=7 M2ZTD-B[ND$5QKQJYT!=Q%P?
KL]@S&&SM4CZ&BP.*Q/GFU3D)_JO^:E6(X[KAP]DA[_;D,V(#AAB66?\GSEK9GA2 MYQ[:#I_Z/UN?>A64@T>>SL_ @@H*ER1\I!#^WD7>3,'JL"8;7,W.E(O[PT@: MB9$IADI&AI"JU@7YC5T: #
(TNC#FC8GA&]P-EB3J[VC]F1@@M.::!=FM)-,, M+#DLLPV[VW3!1:)WRF(BX* D5*B4\ M2S@)PS(/0UGR6.VD2EM?EAK/TYI+]19X'-DK?/FFHIL-QFDJWRHP
M_&3E@CQ>.S\NK'8];\1R'Y(CTOD^WT7EVN9%<2:.B\+FQK=F\^6=0[8C6QM! M:.-RX#NAFDE7=L$,[0*+>%G;PSEQ%V$3MMV,#86;5:UF_0'#H*M,9W\XA53
M'MM@1N[JRQVKCO^I0KNYLNX[-;5QA:LQHO 31O?+%<=YI]0/NOG4&$1E=4QU M9A7%H8*+;ISAZ>FRQ'=APO(P9MBBMLRP2T](>((-; NF9218*:.U@VF=Q5I% M.B:) MY\:AOVM;>'ZOE,/?
MB0+9EBNZG@=+\._H.X9<3@"=PHPLJ:26NR$D8$VEM*F M&.^M>[KUT9 ;OJLF):Z;65LT6E%"V3*HY M^K"9%A@[K:2S9$V4F-D]&ZC9SFKQI:LS.;C.EA,9*QOTJ-P;O[*F85WJH8DV
MGS?"5$M9>>+(1=3 WKF3K6J"B7#F4^>.N5#-65<9_O]G^@PCYK!J?/#C M"_OQA.W*BH^#_ZK'Z IO1\%OO]VO M-XX/-;_CB>YWZL8-*N],;)3JUP;#)29 FGQ<": W5Z*_+^ ^O-VD!=M"02T6
M\]HWD%:DYXT5$=4;27%%"0YD2 MD*6"I$S3/,Y 62[359'Z"9GVO5F,-Z9RS4=3F^[3.0-">9G?EH6IZWY;2A' MW__Q[AI!&I6C/,E&!=W>;O()&,O.!)')5?<= .,,*SJM4!* BS"(MW<:F%"R
MH$F:DE(D(:&YY*2,02'CL@Q!MV*QSM=L(9&RDB9A27*A-*%I24D1B8A$*DS* M6&59$JWY("Q=6'KYB*L!Y&*^6U:X3-Z%;2?Q09^:$RGVIAZ/6=.ZJYTZ%@[) M*+Z&B(J3G.X3^8
$MB2T;)WT.3#H%^Z%*WK_E^R'O:,AF40LR@$O\D*60$," M-'*=Y(11&C(11I%B>B>0 SO_01O@>8U1.-(I,G^Z=?LP^;R(GMV1(A]E^^G% M[8IN8E[2S(9O.DGF:C?8R&239^)B&ZV^9!-
!>F1"BWC2JJ-5E-^O1U8.(IT! MB2:2-<"%?]D23%UXZ.FGO_KPT#_J$U S(DJB=!2\>-,'22+G_K64ZL0X%G>% M*;Z%S[-!?. B]^;UTEGAK^:L\+4]*WRQ?F2UJ-'Z]=RV0+)%04R10Q>3BN>:
MU<)*PD20/HY-JF81MHA.$M&FG-M[TE@&B.&>KG'6N&1..VF($K'"/ODO[WN55 M[SQ(1N[?UBKI:AP,.OX,[5ET,L'3S&%R[XCJ&'3)Q#5?PJ[:9+"%N6OK/X#. MFYT$[W67K.@*\BY'D
ZK$)V9#NQ.UH3&;K.KD&-MKDBS5<'+F1-O$]F%:EPY22PZ8Q>^ MZ2(9O)WUY$X&C*.\4K.E=#QC*EUU*6B-,*AIHTY'R\$DIJS3-:F9 MUD,]X+BM[C$04.,NQ]E6X5YB2Z"H?
F>&@L#MTF@0*MVM@RUOVPFF%E015#7P M K-^ZJRRI:IJ;J23C75QR2DX 5,0 /9T>0Y='(6I>M,_ILMV:97Z8N.N^V7I M'N6*JMON%]A8#G;\VKJ"@BYJE2F<(.E-BQC/6;&];2I MXR#,VT"S1>,._
RAN[B2B34U$7HXP+3I*_G5 2P2E"GP[@51=XWS!1A5S94 M&Q;E;#"E(36X2.=^M[!8Q!D&6Z.X=\H&O %+^]B0F!J(A-D5P.03H&F3EMWE MY-@RTP.=P8Q_N(DX@=$U-QF/(3;C:
[&P)ZZ=*^J"&3NFMN[1M#M9Y%[H7O4PA?5/+AM1P#_HPRUAA-M_7ZABW M4SN[QI.=8M\KH1O$26W+^$VM#HLUMI<%*VB7EJD'A-NA(V:IHWA?G-Z@=ZP+ M6ZQ-(03S/-0P5R_%
(FF#D5TX,[971@?EZYT688(QA_?,9^=U8U0/ZZ<;70=C M1N5U0&->U:?;;JJ!TW$N0 .F7J&;HE0P>K@W*5H-) M[4*6#J2;E6(#87BI>BG7BZFO2&_,6+Z@<(TK93*@S@RI3@:7?.U2_+-K7V/(
MP2[&IDUKL.X+"0RYK3)^PQ95TS[I6UW2$9(58-R[0-)H:RY?56'J_3%_4K=;'CO M->0BW8^=M)+&7V)L9J-)+36",:$??65,9RBAVF+DT[DI\89EL$TNA!6;KE#H M0OEQ@LU(7N(M:?
8TQNQB#QRX,B66NV>@SZ*V:7G,U]M.&95SLTF*%%KZ] M525K@SIUC9JU.8^UU)*S,LE(7FH.XJ"0I)!E">)) 559:22M0#3NR02?5H0 MQDH=,MB@;37(UM)V;S!8(T,&6B4PV0495^V,J+&QR
RCP<*^Z-AR26]K13W,RR?&<=7OPM[JESH#/8UT1A^,/* Y]LRBL9C_.+"[2[,$)]<+@PK.+E MJ+-GO84&O-LZ@&7)"Q9IC.V(!*&2AH0K79 TI9&4":51DNR"!_]JU0?=)9"W MOM[?
@AC^LN&V_=HKPV12[MEUBW"G0[2K_K=?)PR)<3D%8] M*EB;AM,?70Y:%2Y*G=K>Q*Y39U=^NYIZ_:MA85L_7%VMD@L[N+=N_' M8130K\H.I3LH-T/"):J$*]S6.R/A$L!L);O-8O8"
M/\RR(A>,DUQQ$.(8',HP:UF4J4YTF#*6E[L0_%TOAM.)?+,@N[>6IC96DCEJ M;>#/(9\.%@S("<#E2'4#,_@ M03!VP.D$_5)Y=/>#[0;M0!-9O!<\)\&?UZ#P(FK&BBP3/\7&K#'/Q1HT]95"
M:3E1L$(F=H-WTKIN3#EZT[KCBAA7M.K!VY;%!WBO7-\V,W*,JAC"KSGMG+2L M*\%2@8&&YX57?=R&5O@H=YR(A\4+/\?28MOAHPMQ10]0DS-V9OTU7<"%\:1L83&K3N-WVA;
<*4!^R8E_8!3#T MK^N=BOU[&JRHT:QT-3XBPOMKJIO:--B[M068=VJZ+K!V$?=2%.E5AD&]Q$IPZ=T__. ,'>-9@W1'PIAM$QM^PRK#O0/_, M0F8B'S)S@"$S-SMVO-
I97S/2)LU<2]HF:M01R3E240HCR0!^5\0%:4BCGB6 MR#+:R8$N1@[_@B;6ZX'%^L$XTDXG\OT$^1"(ZN.835JO *P=/QJ3WZQ?,%S M(U4&AJ;^A6*NAA-?V,W8D,)M/]5]TUW MR&.>Y Q_/Z7,8.7?
1+GM:GH8VB98&D*O. "Q.SX9&FSAFYY&QGLAEBU0]L1 ME8E%'AF8"UT,615#8,[-*U]7.FQ*+%@BM_:-]R$GR^FJ(G97RU[.PV M.;YM-Q1[-H2-.-P[W6)V+UG)?K:FUK5G=4LIK=8,51LD%/(V-
1R5+ * M*X'S?0LPD[-6-UJYQ%4;\P9*E@!%ZEBMU*44@TZ);++[G456 M$Q]<@!3,X-PU9<0R?GW?;@!X]-6!]KIQHT]7>ZNTK MBG!]PX?TK-;Y4O/.5;*^-B5V*F1+%M012N5TXTGB36IVAV+?/,Z3:
F:,? M^(KT;LUS,$?JIG?O5MB5$P%AD2LQ='9V;5.'-7RPGZD;W7^SB2DCY3H]K1R[MN8,VFZ[3.[.6R@'9RC^#EP,98PS=$H0/AKR#V^QQQ.L!E;KQE0?YTLS\X]^P_62O:-
MP:\V8/=WVQ89'<]L+$R]4U.4MK'E:W"M%K-<[3EVA@EM8]!.6K0WF.)I_=4O@*I^T MAJ$0NEP!%"<6;7LK.SLS-9P"AF+ @]VM8(L#&EP"[8['K+O;#<"U=JK:+T1C M&M92=A%J#H-
Q<3PO,4GEHG=UF,RASXW1K:Z"JTJ-)7HQ+XTL<>E8;KW-YO3J M41=68.#;["3^W)W4+U=>,MO2O7'C(F_:!+!_,"Y%=J-RA5=:I[V9^)^5C$U3
M30&+&@3&:V].T;K'F/CXM5J,&VHJ3#'1UV3Q+]W='3>L5[1]9,]MP5.>%CPD M>1ZB 5EFI*112F29):G@-*-2[<*4Z\HO=Q7'?&/@[<=9@-M8)#Z M0K,8AVI M>H(=DD7?GV-1L
V1".7OW(7M&+;J$+*_G,UL<=!%Q/N"6\'X,LSO^IC:+47X MQA(F9_"0N2DF/:B.ZFH-SF=8?J.OC[$XC!FH*ZZC8S14 6 >&Q[A@@#:S8/H M\E5=_+
MBKR0&4])R+&+A,P+4K),$E%P1K.HI#%=*_@I$AV7C%*2)6%":%(* D^)258P MS7E9Y'&9K<+H1[<<[T"M^3]VC=^ZQ=U5U>SP)-K#4GLG)FK>Q"QVOHA]HP%=
M)C3*N")I)C'$/I2DR&!G"R:H9"$7-%N+M)-%D25E5A"9LAAHH.!--V%)HEC+- M/%,ES[*U*IZO#><9YYXMZ/EA 2GW+O6Z>6H)356A4T98F)481"A)J94D--KC MM,BB4,OB0:9F:Y7>>U89&+-M_??
MCP?ED8?B9@FR?=+D8_[334V&LL&A>8FNLKWE!ZY^N@'4'Z&89-]$O'X MRK[;EIH:F$-+M1@Q^GEIJ.:8NE=OAC2Z9!"/EG[J2C]U)KZBE=&S)?-UX5Z>=?:J?6CG7WY7-[T!NK$&.9J'?
7CYH(G=#JI= M%2RWRQ4"U:SJ'GZL#M?E2H@.L.^IQ]Q"Y#9A'\<1S9."@@K#! I[,.]5 MQ@B/="*DC+$^^:JP#VE>4$H+HEB>$1IGE)242:)3&?(PX06CR:JP/QT0Q*>^
M/NM;MRRHX;XV>&$I>1$S41)1ZA06+\T(3QDE6LLRBRG+"K6FS^_'&F2CL@Q'1;RI6<[^ M*$C;&A<^IUF!&Z"("O!""I%$:ACHSC7*L_OQQJDHR@,@5_VFU>V"N^A
M0L6>N./MC3LQCI8J$7=;C(/?J$U9G:=S7\W.\2C#9/'5X*9-EL8 MNM UE 3B)[UNYDKW#*),^P58RW[M5-&^2?:^F'Y;3S>V51')=2Q83D!6<4*3 M3)-"
.BFFI6\5*'(XITD,L(L!M5#FGI28P2O"1NPAQ;?/[I8C]"[?MA[7I/J M$9(AA4UT>+]P7)Q*, +A[V&QC*7-N \5/_B,CM7'\<[@-![>(B[!OR-IJ]= M@!9NXMF\LFT^JO[PCDBWIU^^F505-
MU_0A: 3,W\MJD8]HZ[&!..OJ F^>M M$V7&568,3@1)&U_0C$PU6RQ)*EAKBP#@D01K3$56ZVG !T[1-3";89[3>L+[M\E-/@O_CB@A@H8>V55VY!D?&;E[]5+LQ=R4'%D]#2N=J; K46AC_NKC-
EIKO MBNL.*IQVE=LF3B1N#-#:6);6=JZYP#,V+&_@V 135&$(,U;Q\G1+[#KP5'BG9AC$N/.@-$+W5H**N\ZYIRS?G+4P8U\!$D507 MG2)R$OR*5987\18#<.B'/[>=?FQQAG9I28S?I'5ZX5?
8B=IZH^)HIKVO6M, MZ<..O0TG;>:4.,R8[8_X[:Z^U'(R1[R M[R@GP41%=6S&OFV3CQO$XZ)9"MS3=4G#K1K*!M?4;%ECP_>XMD98,;8:V]H8 MP_H1&V6OZ7[CL=#(8GAG%UPL&VPUJ\=]JE#
<;E! M=KM^$DNB>[HJN&UH+98DF@YBJ%U9@^[6)8$_MB';W]%\C3*PDGKNBEJ8PS*X M=J'3UHOC-"-L[RM.=U5M5#,:AJG01(?P'QIK0.%,A"23F>!AK)F,UAIAWL5/ M\(Y5S?
^+&3^+9H,W+C)ZDS'Z(J,W0J==%AE-GF.14:3#P!!B\+O-:EO4G?A] MT0%QX3'?5&OTB)U/6];O2,W@SQM"3;=4L[3%,QO5)5-*C.U?3H1$DQ-E25\R MSSEJMOC=5VW)9/GQU7J;6)L?V/6'A2>??
GH=%!CW^N+AO=SWIC$[Z87X>(0Q M;QMAEQZJL&\,2)ES=#[8LQ-BBW NJEN=5ZK!DDA71NFPVV,BHA=[;XN$P2Q@ M5S9(_PT^CL'-%X,ELNK1IG=7*RFX,VP[/668D&+S@R;3N>U'-
%MZ@NE=:6G: M=JKK\K$6/L3!)R_[W-_D&06HVO2JDTL$8_EG35KUL;77B M7@DRG:WLLU_8$< 0>K\ 5D"U%/2R>T)_&5PG5_2(Z"2E/PR-=C=;:[7_O/7& MHCBAV?4W_L?/LV9]C)T#_6E@XUX-
U"?KLL O-DX#^Q]BEJ*C!B"EI_UW".0 MXS>#9D:X1:^"Y6(J,WF(,WZ_!0EMJ*/M:XIX]K_S&JTUDRW;!C_.)TRBNJSD M3]:Z-'6=7;=J5 @&Z&D;P=J:>*KK$7.R>6V_2Z+I29[NG$@O*BG':MNN/38N
MWL+/=1-Z?/Z3\YAU.\R*/689S.IJZ"[CEJFE6\'P6;/-!U /H!Y =PZ@B0?07NF;3P8P9T[N!\$&[N[-MOFUZ 1_X5./WG^V M"=I;FVS=S@9'7:9]<'ON8G0&4;LC)Z=<:$GGR!TM"E]-V56_@:8;B%J2>#:=
MZ:97VR,]P9KFRAQ<+9K/V-S#S?.YI6?/Y#EV">?FJ,H%J-HBIG670+2@O780 M[UIAE&_=S*P(->7?9[@J5WL=W.H#0?8[$"3Q@2#/RAMXHT"0&YZUWNF(=GME
MU>OFN*4<3QK+D*J8DHC%,:&13@DK$DY82+,HB_*0IFRGA]>VCKH[E) ?)G]V MYS6G$VGZ*KB/6(NE_8Q2XP8U>XY#S"*GAG!W(*5A^T>X;D;"[:L"G4C%S?* M]7U-S%D3XB_O?
TCZ/(&GMQ>>_"#BYD<1&\X4TO D*6YP&+'I'.,DCN]XY]UN M*T^B@H:+_]WQ,7>]S4_73_=Y3G?@'-KD'BH $[$D)E;1G$CB!(PV_[N3V^A[M;A0+Y%MTTN(YN-J.8WI !?CK?
[Z(7WQ_JKVAT1F=TUE@XCZ#3D?9,/('7)S[MF8_#6+.MFE\]8^.[T\9W%LSR7)CLQ9(]*L-<3T6>I0Z8I?['G-_]!V]^QHKD MPAS0F4^GYI#._&DC6=O ?/C1NO.CGSP?>C[T?+@K/APT-
#=L]@'/M>U?_1&1 M^>C.EH:\&'M>]+SH>?'!>/&OP3'M-AY,/_>A@2]8>P-XSLC5D2O@:Q]8)9= M M*/)J^VGK>8TW$/H-F'=7D\$#''>LH(@!/M=@YBNQOE-+-Y=[:T=.NX>;Q M3Z
>0T/:2/,/.7MS%O6DTN0(I^PI^J"W]PBG["GZH+?W"*?L*?J@M_?@IGPW M"^:!_" '8,&\7HGS>^FAQ$.)G[*GZ"/8WB.(YRRI^B#WMZ#F_+]
MCF!N8:L,$UNBK446KK%HAEDBYB'#IX:/E2ESC\3RW^N)NG*)2P&V>\9P/==] ML9H$9S4LP,243FO72TY^AUIOLIB'@U ;'CNI]VO*RS2R;:[_MN.]W0]XVGFC MN"3/=409(T668*.X."1,E2&1G
JI,LDROMXH3I99$>6"7-,.+8E&25)L;7WV7&E_MMYSMX6P/INSA;(=P%L=QEG"-T!3E-&<\)%PD*1$TR0&50IKF:\W8RIAE*14) M"07FJ4<)0""/&(E*FL'_.%6<>SCS<.;AS,/9@\&9*
<<0/_O=]PSM&=HS]-$S M]/W.[N_H^HIWX?J*GZ/KR^1^KQ7R\6B[9=(NI\A5,UM+V;HQ.]XU%6X/&?:. MRW,-R=PJ/>YYPOQF,[2()8MT3(G0I224%F"0EFE(XCR*9)B+5*ILU0S56:P5
MW$0X&*E@NLJ"%"G\I4+.99A%4B3T&9NAVZBJS^+;!=OU#WN6C.?!V(.Q!^.= M@W&FDR+.=4ATFE,\XE"$%Q'\IPP36G"E4EJL@G&2Q"&E*2-Q$1>$XCD'3^*4 M%#+4<9(D&1-
KM2L]&'LP]F#LP=B#\6T=(!Z./!QY./)PY.%HGTG/EY2X%P$& M-R&]@T5T'_GLI^PI^EBV]PBG["GZH+?W"*?L*?J@M_?@INP+1NRV8,3OFWI

M^;H1'D_\E#U%'\V'N&4/44?]/8>X90]11_T]A[+3CN(DHW!44NISISV(^2T]?!#3NM2%*B*2%BHD- E3PH5,"(VBB!5% M)O)P+?6&YA&E[F"$YP5Q)X]Q7L0.[@M??8@=*M1I
MXIZ/_99Z/G[^F_XDY1Z,W&?UJZ]GZH'V"(%VL]47YDDD1!H2EH224)$G8/5E-M!6%Y&89920N>K%E]B0I+!FA(2C_0"><5%2(HX%21*5)IF>91Q&C^UU9?FHZS,.MO-
GG4"!]OUD9D'D8BIQ$)BSPDE+&"%%$NB4IS'8=Q-MP;),KFHCH62EC'A*A(H8H6&9DS*.2I+*/(]3%F9Q*+TV\OO)WJ/8P6WILT>Q MH]9&GB3@ZMAKE5YLRBWQ2.OKH/@Z*$_3-
R,M9,)T0=)4;4)3)4@9*T9X(@5/ M* V30N^B8.EC;ZQ9,I(R+3/*2TUT4+'T^(6P>BST6>RSV6/SX6%R6"<^C4!3(*B]NVBL4]D5S(M
#4CA16_T\XQD2N2X+#@BNHO3)PXGOXX MSD\H*)ZF7>)-%N/9"X7-&CH+>;@R2HD6.6C;(3H]=%9B#V<99]S("AWNQ'7=_MMNHAV[E$93D]\P?N\?Q=.GE^0LZCI4=+CY:W\BT#X
F1Q*20)2I$JF6;F&EG?R+3\P6M)X!*/Q8.G!TH.E!\L' DN:1V56B(R$4C.""YD0 MCCT$\R1BN4A$PHNU@[@L.7\?6K5\C.!=CY8>+3U:'@5:/D2\\('!QS:WZZ$7
MH/>U77UM5:,U5.TIV@_94_1A[^]1SAE3]$'O;T'-V??MW>W?;'>**$NN&]" M)!H%<1@G=Z"U [',KL>1 YFHG]OSG9PG43^Y/9^<)U$_N3V?G^?19SXYWQOW MMT;
ZY5(;\7U_L3_)0]11 _#]A[AE#U%' 3V'N&4/44?]/8>W)1]7]Q'S6?] MO9ZH*Y>Z&FA8T3;H)I>JG2D)?P1GOOO(@53*?9HPV?V]T7_N:%+.,T(S3C
M$.%A0@FG(B;84"13L.1QLI8P4,A,)MBK,LD9EE[.0E+FHB1Y3M.$ECH5I5I- M&$#OP^E$XC]O%SZ(ATL@B.DH#R-?^-O#V;YQJ8>S738$IUD2ECPA41%S0LL" MX"R/,B(RIJ7((L'U6D-
PF=)X;V#.T9>GIR"1^T=RA9+>7FT=:7_?1E/Y_$#.WR.%.Y MDA.A)9BA."L)EWE!BH(6)/5A(6B^UDZ/"AIQRHC6I<;&P(R419]12"5Q'&>E MC%CZC,U07_34@[$'8P_&3U
3B>]$,^QMFO"$T))F\(P*09*H+([P3&6<)&M@ MS&192%D0G46"T#P+29&RDD1AF!<\CG1>A!Z,/1A[,/9@[,'8%\3W<.3AR,.1 MAZ-#AB-?E>%>!!CXR&RG["GZ"+;W"*?L*?
J@M_<(I^P[^]"W}^^F[M& M[+9@Q.^;n&#ZJ&$>3_R4/44?P_8>]90 UU1 T]A[AE#U%'_3V'MR4?=6(1SV5-M^>ODTTGP&=;]G3=7P2_5>,SCYH\G3^7SDL9V.VTI&HF!HBI(B%$T(9522LF24
M1&E,PR)E$>-R-5 RESI68<%(IK 61!YRPG/&=ZJAS'84QU4S*M>:1EZP:HU_A M7=U\8F/UJ?O)X]Q7L0 M.[@M??8@=M1IXIZ/_99Z/G[^_XDY1Z,W&?UJZ]GZH'V"(%VL]7'HCA4>922
M/"D8H1$/21E%.2D*+,3(4]VC;.7JBQ(=EZP,"0]9 5.?3$E1RHR$&AZEXU@K MH9_8ZDO241Z5WNKS(,.W])! [*BU1<_'?DL/A(\W*R.IH0O&LX+P*.2$ZASL
M&Q5&).8B9I&482+565$BSS+HTP1*6B*RDA)>)(4)$E5G,<\DT6Y5H38*R// MCN(IB!WS/:@98V\;5+;M*Z M)V<%%)0U0Z^#!U0)36?]@JLF2,)1$(# *B5=B
[.).7DT>.C9FV"MIS68G_\)02!R9]' B-M(1!C6+A*5W!C!*!(L\?N>Q)U>P\F 3F=F8 @JR^5$DURK W/'H\OYB\DE4[M':,KE_CKJRF3LIJ<#4Z]*[L'W4$Q?.3I5?JJ>YVYD:B)?#6MV\H\V8AN6"50
MY+[A/L,37_8ZW;<,*FY1?'>Z7*C2CT^0$5W:0Z/6]?MVWI^\N]%7DW$U@6', M6#-[R>;S^M7R#
["N]FNSS?,XG6F8W$LV_LJNVEWI0=O/M:\KBYKC[DJMLK$U8G&#*]4PHTHV&8"DUT"/^AH!\0GHF0 M9#(3'-0%)B/IC_B%QVV+VT.-'B#2X/79HDH[8CCPP$1<#0(G1B ;NXI8HKX
M6TI4:!Q.V50U5@J+Y8I9H2#2\/W5)OCFV)S\'GI%Z.:.P,6M6AHZ*A/X &[5 MD=97P8Q]6Y*&Z!2?.>!W&>BFQH"G5HTD4\"$*R-ZV\6 M-9!\N;^HMJ M?I8*%-
[&2NQ>>V!!.\9WMA70)VN6:*9JVSFJ78V2U2QH@;X94@8'XCK'!5BZ MV.AM5[BW\"+ YF/4!NI_6B':+A2&\ZJ=U0TZ,P)0U-A O5NLBIO7R9$];.=F MY]9UZBP>0
M8YBU^>9JYQ]$*T%;H[R)\@#*PM2!N]ZNEG-SANE#*/0,*B>3@[;P-0K &W MMJCW")/_^#1<)E!@,]|@Z-"2"HSKBB>)R MD O@3R
;26A1PE\4$"T+0_23YBS)XHUGH>]A'-H&Z>OU.4BU34DG]P8\@D4]8 .%F*A[MQ3N*D4 5_ M5!FG^9--B+ ":@U#BO,<)I2&DA0E38EDA59EP5B61ZL3$E'!REQ(PD.9$5]& M*2D43"W-
I8YH0HN8JJ?;(2ZB,L9NRB7ND*":@)TK@=216:,RT=F:2%"LR/.B MTT3D$397!FIC6:A!+F!!J:),$B$>84(W _W]%0OF6*8&A?]?"*-70=6O3B<: M!F9:)6&-A6DF!BP4H@+),2%YB-]Z\B(IRK?
3:7:#L$]B%,4W9_9UT5A>|+`^-T .S5FTU:],.64H1NM6@+5LR/.B 3M9MEEU58<.'lV],!)[O!:4,?O: #(Q)BA^&{]+F!UP(=S>+Y0<6@>ZO2 "O#'7 M_WP1O_C^5>5Y]Z-_ $?YWZ'$.K9*L_.:*&A?
B7DO .!FY__]KIN9W(3GKX/@KU^:NFT:_.TU >DR[EGM5U9.;I2TfWG.\YKGM;OR M6F_^_V9\C)[;/+=Y;ML5MV%Z86#R"SU?[;Z,DK=?O?VZ'86P,^!WY[H/S+)+ MD/G1!%/6\Y9-
9/O3W6E@'];E\4#DFEIL.T:1U=)K3Y*0>S\RVQY/>_M2>Z)U M>'R5YT FZB?W7"?G2=1/;L\GYTG43V{/)^=))}E/[GZM[KP5L)Y;A#E\+X^2-MECPB^,D]A\EY$O63V_/)>1+UD]OSR7D22
>.;3\U8'K49BRDD\KDK_/0+%G[R MA5[O6Z+SR:W%QRKB^NP+M&Y.ITUEF$Z &:,??Z%M=7.NJ^& MHS)YX"+7SZ;^K$>U/=Y2CVH[!+49TU2%*B-]E %"A1$C/$\926E:.[J2)0L=K-M97(>
-6$F%_,34:\B6I=!+1BW/@O"I!+?6,?=@1U'N4\RNW]EGJ4VYOB^IZA M/4.[AMXKM27)DC2)DI3$)1.$)C'V8=.4. G*1\9D)I*U/FR[4%L>N*L[&F&4
M>O?D'DZ_[KS?._WNXO3[=5$]V/=:/D*>\)U?2E!XIFG.;QR]AAH]JBN MOB2-(/+QY>/-;>DCPYGU\GH_]ECY_/MYV(EDF/:JQGC*."(W@/XP)0>),@1(2 MER*)UKJ&{T)-
>6C7'AA;8#5Z;>0>OKU[!O3%N_#MQ<_1M_>YGK'QYK+87LYL MF;0KUN-Z J[5-[HQ3QY^@_=;K)3O_[[5.D_#-$T9(TQGBE
A&';A4B2*W3RZ.31R;/3DZN4:933*$L3DNF28AM528]"I81KRD(9@N(8K37IW(5*^=#> M;C#W.QIZS?'IG>9'5P#K1LT-
=U%3^UF)MQN7]M\/H'W4DNE'.&5/T0>]O4HH\\>]PRIZB+WI{CW#*@[(/ M>GL/:LJ^.XKOCK0>+3AL?M6N< 7Y-UA''-8R++,$D9RBL7%8JH)UWE$0A;G M&2M4S$%NU&L><2QVKL&
D4TP3FH><\)QQDLM,1R$\@DFY+^G+^2A)[A;.O,\L MX'-$/*IY5-N.:C2525KD,5$!%82& NL*Z8)$>2FE4$C*H[6$WP= M4=-^/7E MQSW*[?
V6>I3SE1,]0WN&/G;&WJRVY)HE.I8YH0R;NC&M2<%H1B(9YF564L[7 M6U7N0FUYZ*12-,*\>G(?IY_OCN*[HWAQXPOU[]0[*LTSS;@FDHR M)EKGI0ISJE+)5Z5,!*I9&5(>,@*0KG$OETR(Z$.5:
[C6"NA\]3EEZ2C+$\V\ MM/%@YK?T\.%.A%F4+.6$BBQ{T9#HN-0UE+!0]1(*4O*7*4J#!]" M2WE@OQZ86G2+F7D'HX]\UW1T0f73?3N@&.,^ M1'IOWKT9;,GHXJ;*H.^&
M%>^XZ=>OP(&*)\%*O9.H(&G)P'26)8@:6DA2)JG*LY"K+$U6Q9,J8BY+&&0Z M8HS07%+"RU 1EJ4LYSR*PFA?>IADHS+/'U9*?8=TGE^]4H^9'C,]9EZ#F5S*
M7#*%1DB3+0D)+Q@D3(6CX,DZ54!%3Y5]X0-@YJ,Z'],';LKL4=2C]$?1PT31-MAW!P>KSP>,'QXC#Q8HO6E>2%+*0B,7:-
!ESE8*G&!>%@N<2U@E?:R0=4D$<G3CG1NM2$BIR1LD@S$]DDCN.LE!%+]\0)FY:C M,G0@3.P#ZQOE,=1CJ,?0VV!HF22*,5&0+%089Y'GI,2_PBS-TT(47(OB$3#T
M49VRO:.Z93VH>E#UH'J@H/KP/EH/'QX^/'P<*'QL<=FF.M4JX22,L@03U#/"_M(MZ)Y%&J=113G3V(3O;0+MMP%%*O>MW5:PM_XU[!K5O /^87JJD$?):5I?T6 M'UM-YLRM*WX/-
^\'CB[>G<&&KO_NVFRX5S@WFN&5VWWM%SWEN$1WCZ3@17&E- MXDA18+R"DC*# -R013SA59187\2KC97G.,QZ51,H4&"]+.6%)G),X*51!$U7& M.=XQWKBY.%Y^:.245?
+MMZF:M&#Z3.2'V;EJ7L^:!N9I&PE\AN?_.]F%EQ>! M EZ,HE^]F2L8-LY7C%D+# >+?$'&53LC;JPP5=\L]%0U?2%<6;73,:MZJSBI]U:VNN8*T.],.7IE!)?CP]B5GK117$[5& 8L]HB=IDO_P$+T6
M:K&?\.9Q%A\46H*(QN_ZE:CFN"4B%F4[ZS#B[_1DX[8!E1E7Q.%X0\K#WRR-M*2]SB2.OH*.O@$UD8"@L<"066!KK&+.S4Z<=DHD:DDEMR$0X.F%FR7"#6@ 9!3_K_X (3\>UU^KR5G?
[N3QAI_4 MX7[/Y-NU_'(. 6<5(7N$N'XVRN:SNM-Y<#RX*3!\O)P ,M5S0+3]FY*O>M0Z M =QR\!.C=FT52];(7,"-G6P6BY]MDO-IT97U9MQ:MQ:,MZV3UCRV&P?6V6
MG91E@&N]ABN$@W23ABH"]NK%$1^Y-SK)XCO>>D_QM^X!BO="TR(/R0(/(K>*B#P)CXC"F=R>_FP0%!\,*/2J_W#6]MP'/4H7!4XCG*2W0OT1\#?(CLPE^K*:!f+R>MVPBVY^\57 S#-E=\:2[Y._L
M?X).=_[1]%;Q1IR\P^!+M6XGI]RY]W!B]K>H;UR'R/C5VFV619(2B&(]&,_M$RJY)F461R346<&D+D1YESQ=*WN^6VB*A\=QJ)16?H>0??1AN^0WGZ8VO!['9/5SD =%]JZ
MQ/@1+S",AGF\G%@JL:FCHHQY23*6%X3&24D*'DE21+$.F69%IM8*IMQ&W>VB M[SN>^[-G.1>JN"/Q4%+?TL=#EM_2(X"L4(-6JB(%=CE/"2U315BI$I*9&D]%_M&27K73#ODC#TT)"5)-XL]]
[="7IWJTDL;A&>&WV>%C'BX;A:.!AcF2B%9%Y M41*;9XSPDH=$ 52461HGV,NM%G'<>\[AAN11/ ZK G9[+E[%TO M)^{4+EJ#M<6O):*LY31G(#P8A-54AXG@E2)H)2'FJ=QO3>$0V&D9>3TC?F
MI. _*=Y+[5B->G?8PZ6%R9S!9)&4A(D%)IB5%MS(E+&&ET93%./'C:R+ZFH@["4*F45C&H'27-!$@5W1*'E8RDFJ*TI1\^%JR*Y]NX<59.]<-G!K"5E7 M4G7*SA29U%)U]
[Q8]HGY+U,3\MM+DKPRA4)EU2A#@%@':WXQ>;54<'7*!*PF M9P-3L+(CZZPG^+BQ_JB:R%?3NJW,DQLU9K/J4@VKJ_44^NV&9'A]2<*'RO"] MWWY%Z1)5+RJ5XKZ=]^:H&
[TK[&K*MQR4@<\53KA*B,QH2FH21.ZG3??J1K M2S. 7FGF]#F69GZ'I5@?J_IRF7.>4)Z1G&M*. Q[M#H"GXDB5$3#'FNJW M4Y.Q99;[+ ;="]J-@HF8W*:>\5-/X5FOT/(7&@90Y3O.3FN=W+?
N;E.6=",-CF M>?KXK[WC,2&,.GODDLH'.TE?0.KAG&Q^>GYZ^S>]HRT]I*M@>Y(_,I+W5;!] MS4PO-!Z>OO-!M$C.;I>?CX+=*WRC,]5#WW_=]I/?>5SSU&/Q5&^\KG7
MXO99S?:3\\;"^GAZ]8_7SO%UZW?EY22U_7%=-X[%*CNG-U'2^^TIL9W>&QG MB[#.9()?OC-SBEOB)BKFBM L3$@AN"!O*F(5+1I)5;[&;Z09U+T23.2@%RPCE M6A >"4:$S+'23T35IH2'+?$;UI^
[H2ED%S2*O%2SAODO%9=-D?9:7"E6+,(MC%F-1?54_NP*B/CZY;LD$,CFIJD(%%6Y (24X*6@BB E8%M*LB->R<7<* M"+\V=;NSVN71 Z?A/IOP?]@>[RE'L!V"&!<2)KPM"0IQ08,)1.DS&5):!A'
ME+.R#,/U9"21RC@3E.0EH!A5I20E*S)24LES&)?@3'H VYO\(E_OZ]:\AOC MWI8[<%LN20]NDTR0-(]BP+LL(YO1!#4.%RK.N5I/PZ0TEY1%DBB9:$)3FA&F M&24RR<*R5(SK4GE.[G"I_#"$@]>
AAI0$];2B;0@6.*.*B)F4:141RFE.A M(E6*M;IS.\6!G6I HS0NO [DD$C5ZBR5.!SG)&.@FX5EEK!LS0.O-MTE(56<9)0)C)&;%QJ4M H(9%0<0)_18787S.NIV:<5X:\.K16%Y?'*4]%04" MR$
9DADIA:IRRCZVT/BJ+490E*C@Q+16BA"L+PYZ8 @]$2DN M2H!,S]"$\P=PW0&<8JTZK*'DUSQDGFG)*J,QBPD.>@CZ6I)(% M9MD,B&R.1!3"\BWZ-E__Q9'9'
MF/;]28ZV/TD,C$H%24TA6%L##&DO<*8;G8V6L1)I%>9ZNZC.)DFDN/3Q> X]EG+$B% D),_@/ M#4M)BC(6))-,Q:S,91BOM2@*F6.D$BA,M"Q3PE.5DXRF4C.P^$%2??AT.
<_/PW\K$E[!RVV6$PISU(B=:8(35+.M<@C M/-:*%),JHG(M2OEN+;8>05^(1_%#]PR'3N8>N0YN2P\4N:@61:2*Z/^R]Z7/M.239G=_WKZC0NM<!$4Q.WH?D=01;Q8,)1.DS&5):!A'
ME+.R#,/U9"21RC@3E.0EH!A5I20E*S)24LES&)?@3'H VYO\(E_OZ]:\AOC MWI8[<%LN20]NDTR0-(]BP+LL(YO1!#4.%RK.N5I/PZ0TEY1%DBB9:$)3FA&F M&24RR<*R5(SK4GE.[G"I_#"$@]>
AAI0$];2B;0@6.*.*

[H,M,\#'2X"/P=Q/.S(>:=RL)!\1N(O<]ÍNTMB_[U4 M#]W'QP.Y#^3>S[W=);F_\^F],BI_4#N@YTSP,< 'Í>#C\)6Í5,'^!C(O9][_MNTMR7U2L'JA]H/9^[NTNJ?WM9)E--!#\0//#]W-M=$GS).*Y^M/>H&-2')1F, MH7[SUS.?WHWAX^45M&S:HCQ("="6Z3#KQ9H-'#-PS&XXIO0&&&AAF8)B!86[& M.)]W52MR8)V!=5X6Z_RX4EUE8)P=FHG?*2YZ"Y-PZYB?3#&^&U/BA]6NI4WN M"O0N^]XF$"DU@=A-Z/,FJ_5-8'N*=?O6'SN>]&O*NYW==[9T*P \Y(Q+Y:,[ML,7M:A<&C#UV6B(72:>$\<=2LDDQ+VR*/>CW?MJ]S M5](5WZHT]2&^OCCU4V6] 2>?'4Z^()7PFH8?B@<WN&GY\)N6(>,K 1/9#4»;RD-6GXF^4,>]+ 7XT/ZWV[!Y@:),]3)R=6ZQ4A=AD@ACHQ!/*2*#DTP&[;T M^8.=UD<%3&@eQ*% Y%=KMVT4G2A?+ 2)?·$0. M9NOS =;]K\/ $,A/,]U>+00]\&/L^K'B9U2-'AR!F7L24#./6Ç^QQTW/+W& M,\1P2C%$9+'VB#/XQPCA$0&DXHIS+C=C&>YD+.6&C^^;9A[#N_FT'A^W1D^; M@K7:7G-A]XI[.WÍD@9'/S^ESLTB>&P5.#P#9L[T= /+^@"8X]CYBCU1@%'"' M/7(R>12<<)X9^"7VP_NS_+H>.8#,X !ZZ2@YV+O/!UOWOPX#0PR$\#$780CD MV8L#"!28%+/V\^?X];R>#HZ@^ZRMEZFRF)#F-DPF;M17.86/W?%[29KT\(MZ[U#R4B9M)$>>2'!EG+.,0)KÍP_=RA^_#@-##(3P M/~=$-U<%3&@eQ*% Y%=KMVT4G2A?+ 2)?·$0. M9NOS =;]K\/ $,A/,]U>+00]\&/L^K'B9U2-'AR!F7L24#./6Ç^QQTW/+W& M,\1P2C%$9+'VB#/XQPCA$0&DXHIS+C=C&>YD+.6&C^^;9A[#N_FT'A^W1D^; M@K7:7G-A]XI[.WÍD@9'/S^ESLTB>&P5.#P#9L[T= /+^@"8X]CYBCU1@%'"' M/7(R>12<<)X9^"7VP_NS_+H>.8#,X !ZZ2@YV+O/!UOWOPX#0PR$\#$780CD MV8L#"!28%+/V\^?X];R>#HZ@^ZRMEZFRF)#F-DPF;M17.86/W?%[29KT\(MZ[U#R4B9M)$>>2'!EG+.,0)KÍP_=RA^_#@-##(3P M/~=$-U<%3&@eQ*% Y%=KMVT4G2A?+ 2)?·$0. M9NOS =;]K\/ $,A/,]U>+00]\&/L^K'B9U2-'AR!F7L24#./6Ç^QQTW/+W& M,\1P2C%$9+'VB#/XQPCA$0&DXHIS+C=C&>YD+.6&C^^;9A[#N_FT'A^W1D^; M@K7:7G-A]X1

9!U5JUO#GTB*:)J9KJ<0$ ME:9R'8ZFM, <.36'6ZNU$'U"+/^NN:B63XLQ'@GD'ZI 908X(QD)@.XR^'A1 MX7TN]864O+2,4E9&WO)/'!D20AC+E DCUYP/MO&:,F'T"9=.<]CV%Z?LE0S3
M)S^($;OE"]&HA/?!**!R[!NV[#,;" FN(4.>*&L3VK4985+2C^3@7 M;I+ARZD;)'BX\QC>(O.4Z,((;HJJRI2 X03UFY)344Y6GH)!";.>5.I:F036!8V!X91B!* M?C)?(ZXVETR7,9Y/G.'I? 0)70 \G*_LYS]Z?
W+ZZ>-7Y97"U-&6\Y:P$(OB MA)F;R#*04'2%Y0)-5;U-*(J)^RT!'10I7:01=A>&ZE3AQ=+M9MIEIGS,S QP M"U9Q?J3@5'7-G$ZLLHU44;G)I$U]1'O05>HNW/0L])ME)KI2>-#YC_2A/&R. M. ?I0-
KH)F_KJK? 8![5XR65JD1G)YED,CW7.?),5XK!5P=D14[3+TNJ"@.7 M91*ET&(%^24%-^"WW38"QQVU67%51* EC\%E3V(-&")EB6F=%ABP%3L.)&E
M0]N2PJ/DG4C@Q'3/5;H)6E%5(G)6DR5D@XVK"^Q$G%Z!RG$GEEJ[(0*XV1,9KN5QB/U4@#M(D8/?"R)T:?+Z:D8OM04M9(M M2$G^T4+E;:OI"+"7^70!@,-XX%+.U[Q($4S8, 0,<&W@$K6!-
J*R6RL@-G3, M$,VPSV_KS3MJF?]DU+,.4_?5ES0'OT$U@>_24 @QFEG%3!5;HE"F63&"X*E' M,3FVN/YZ^43"FUJ2?L0L;?+J88,5S%B\G.NTY"N#Y=S/Q@<5.,-X@//2[33=
M(55=@1(;^>Q%F$L_%#FV\WH)7[OFUZN9%;]+0\+JO V,C/[32OOTV6O5*S9> MG.DJ"B0<7>U!M5]5 9#J(!-GJO)$U1#A6DO*I>(3*Q)+>6@JE1=?99@"\!YJ M$L8TI:28 1T5XB)FQF=IF@8&"4
'(=@WGZI,,'@%?UL!=&XZ.+22O=DWHUP$ MZ_TP+.HM#3YFI03J.#H;4A7^U=WY9U$RX1K(($1N"[;A:[3V2[.-,0K(35- M4##[3%I50C);__H[,;VFX;PK,*%3)]S\$SXY%;'PV?E[@OV. #Z"$?=GDE1H
MH_P2>EB@ZIS,YY'*, :[Y>=?3L!PX?Y"5 1!>I*D7G3E,OCT[? MOOL"]X4J7":5]5YS7*+7B)MP.@%L4G%^78RC78U&$ZZO1B+N4JZE<^*?8Q$O
M8,871/>W2@OZ5B7CH^G[]=O)EV^PJ<]AE.0Z<96Q+Z'Z3&1ERH0N)1'WORIQ M9IUKV =0\,;K54($/"KP042$:\9&9%@Z []0GAUDDSYH>E.DK$!X^"%[\H)4 M_KO %PC_'
A"Y1V>J6SYV:R(-6W4U.(L%T&@1*W$.FI5*TBAP#DVD.UDS.R M4%X>??S'%V24'X"$SSF#G?DIXA2Q76[J]AEP[D+@ Q]^.?E\]$H[*VN%),*G M"E/2]Z=A!!9'7.6 P?D(L4NLE:7+NFHH 8,]S3?
H($)4Q6;80KA@75N*("&N701JBFQ?8! X%*7FJ-F>4GLQ#^QP25,I3UL4[R-#5E7U*29SS68R M53TEL 8UK!2C>HFJ[OIH=$C \I6TOU0UJ2/27-?S4^03[#[&LE+CGU4-CY0M4+W%
<(RJBD72M+"_([[[(M*$%$,V9Y7?('UT0&>7#0H @Q7X2+D\YEW>E:\^K",KG6&-<=F6/D>;(JB'07 M'1D$E-6CWVK:/X)&IW$]R\I)057QX1G2)RN!%,9!"NI16GC46X;=8OHP@N0
LQ7@J^^1X5HR*Q!+241];5E*S//%^-)9^Q,DGD61M M3ZK778@T%3H$15Z1(O4HMV9E.>)C'I"ZJPX5]^.;4^DKU),#92MF(6 M>1ATGFXI4ELT73?3& M?!FQLBS@F$>4\.H->RAL.
(E*-94.G!BF5>TA@*OEM/PDSMP6Z.JPSBGZDJ4 M%IQYJXZE>W*1W"3#2_4#-)T)3?R_.@$^!U3$S.D,2'U+M/6/IU5W Y0",TH47ZXYW(F_"+YK, M=74K.P.9V?%3]
<30/%^+A6+NZ"$C9YA\D3/NN^VVV2S]"B)B0:/\??A?4!59 M@%4I'S/0_;!'$@LM5F0IZ(KP*:>;W$*%>I(3;A[C;(^D')[J9)H3CY@<8N#G M) H]K1-\ 93K_R[\LZH#
[#LP59"='K":^.FFC7TQ>SF5#:LD%/A,P[)5?Z3;BI4YFS MMF:_G"-CI*-G5P& 0KYE+@M-/^*.ADM-3/'0JHNIMC1JZRIG!?V"O-O&.]1T
M(_80/"'#>=?]>\JX.O4J,1P7:@;+X3(^&D9#JHKVT:0FK&IA$\/I0(V\1%;O M(M:H^\,PX44+GZ4^0<0_JT)![(H)PHE:W^EFT<0]JNP(,ZM 1>#K%8_EG+)< M8(B)4S#-U$-P>BB51.4.LU*WU/M"S
M6"K!&/Q;R)RWA" */2[)*OMH5TV$%&(IIDNO(3Y^D:0_&#(F?F V%(@XA@9< M"/FV=6/+BB=7W?S6DY*^3<(G+%)-J!/E2I*E:B_*??[@FLLBK8TKFPTQ!27U MU#-%=7Z Z39>-
U!/B1^VO]2.]#FO/Y:NFDAUE.2O4AW.J3A"9U.7 M^]A<.%H61%X5%;@H\XL.5^!])8,19U3!A3#_.WA1]SNZ/ZG:3(UC!! U6=[@ M0&L_*S-1D+9!MB0+J<277P[WJLFG0(0@/D!&R;+F65GUM)
(20OCYSQ'.'/OJ M31/R)9-ZUD3_%_Y@EO@R4DFP4M3*%;TZE)X&-FO+&F7]Z3%M*XN*7@;83R5JN*J FC+^1"4 M2I.*7:H3!1)IC"JJ%-?LDEGG V42?=4B" MG(,C2K=MDX"BQ@=4=XRUTF7?
>FH-?2DP X?5=-L>01NJ6?IF0^ =R+G8+*I M.^H M>F.P\BQVM!_@Q:'KG4UOX:%ID)MCCFQ".6-5 X]=H ;[P0K%9W: 29C M[-3X)8:9]/P1T/10G9U+F1KY4J2[<%DOUQR6M:X9I?-6<4/RK\)> !.)
(S0H M3:M>NJS3-6A9A9$Z^:KE_"P!72@U'GY106-_O.[:N\CFNOX567M4_:9T$YZ4'J9>,<-&\\I"1N6&+?BPE(DH M*M#%&"?4?D*BR>YD(H%'%?ST03 ULMHMI/B&G'A@29XIEZ!3 8M&F
M_.1:3E7U[Q=:X>%1[Y47& [OJ:37)6-85_QRHR>0E*JKTD69X!%%*Y=3KW&N MBT_28R]B+3T-B6RCOH]Q=+0W2C6)FJ"H2^*;T:->L'R_#JE/>,K+-+7K,*U
M&>ETB.DZ5CN3^31AWY$R^,BE\>\"CAXLT!FA'@7Y#IL\!ZR.(E%&>HTA=Z0@ M-8-46U:\ M5R&SU)^#VP=V8.O=Z7\ MG&H>CM NH-
++ADE\SER$*LE(/TZAC7KV!W4A(K>N0E)Z&@!H3B6NQCQ%406ZU)*5 M*P6+7E$?XU:(3-,D*U1$CIZ%_Q_(,*=0*4_^ 9[O
9T=,!9ALQPT@ZJH(:V.Q4)11'25:2Q5]3LM]A^S%WVJ1$MO%H@K95^O<2<9O2-VXK8:]4>CO'0+>VT3N:O"V M\Y0F13Z7"[I)))W2\A_AEZ MTCNM=)4"ARYT*A]94SFBIB&CU5KF#W
AR<82&LQ9*,/U%.'7Z8UEIZL01-/U M0E UT&I.WU+$D,)DCU7*NW=O:31UO#IT!"&=@=F=Y4T8D: F,P"N.EJ(T>!]XX9W1BWJ\
M;.FZUX;&R*/^ABZVB6_,CM%.16M_!06J6T'L&KYX+)SHM89],#M'@]ZXTQWV MAIW^BS<72>IS .KXAY1SV%54PD(%JP@D5\ @R^C3F=01E^,J!6_V&VW7RRM M^CAT8(Z6UC[PZ
MV:NL:R#$-4NKP M'Q0Q#QZPZ&W1^P[H?9G+--;9S:SC-Q3J+=;?'.IK)EV!M2"5.+6I9U-H!:I4580L6F#/* M0W]#$M,BED6L6R,6G"[QN"B9>\ NFC4+I+4!NP[(OW:2<_L*3';BKC786SNO
MBN869:8]QF-P" E/1Q 8634JW5RTUKBVCYU1L>:8#><+J@I475%Q$N9R S5=+T)-E=#*/)BJDJE"O+"@WFEQL0G1&XRV" M6U;=M%AZ>RQ=OEI"JPQRU7BF;H](#2P[6
M^FM5)T!,34(JP<.6%1)AS$6;0!IS3,CCDGQJ8Z=G="QU4:RO/1&Y-U5)3&N[MLYE>L9(HYT4*MJ3U@EE*NPNE(2\WYOHD$VI.R@TUP=["/^8BUTA(31QP"D;*
MTP+T[+6EVB%YZ45%AE[:Q17U0#:R:[%WM]@+6G-:A+E"1T)>G!>X,910-F*U M$>"_G>AV>ZJP,"ERD%FD&M(Y)3[T;"F2"W,5*-_%IZJ<8%NAK$D2\4J^:MN M?(:-'2WT%B@
S'%1PR8Z#_55+U=RK'DCA9E77MIRWF.B*5-84P!7D/M%?%&-MQ7?!O>\(Q7A,&/>#QPX+^ *CS6LMJ3Y95I2QJ7UEUXZWK$IOZN:Z!.87(X="JV6P:DO)?F_@L@:3)Q6;XU$@@E$5K
M2P=2,VY4HZ%RKVJR<^S7!ZI5<*KZPP/JP+I:9^)N+/&6!SW<]>^;JR^OK! S^H0K9JA^I9)$JF()GPF4?@T?0HDAKCD'4;R#.N:5.MRL\R$ORE7Q<0?[HVM5%U#L]7J M*_:?BG J=4%3);%R-
U_4>J?IMMU7%-O>LG'W-*R/VJP*7;![.;)(;J\+_P2# ME!OF9AXU###G\.'(RI+K-LRDJGK_?"=;9*@ [V-_MKUC#3MN@?)%32,!\JYZ MM=@6+?O8R^"4>OZ&F9Z:@5WJ9O#M%.O/L-
7A5SD',L*^VMTV=2SN$:%AU\O# M%8;?B-'IIIUJJF8Q0Z'W)SKT>.Z!I@&C^956?F\&Z.4$QMM!^FEF6>!Y%8!7 MW224X:+237 OF'T"6\>?-\$$ .L/EK^4_IO2XF^!S:\>H'8L\TP>9SQTJW21
MI$1SM/81OA\V4*;?G(=9R/;;L7Y>_0A^Y=<=#/UAJS<Y^DRDJM$KQ'0\$1X/[!K<.PW%6L- MZ'_K6:OAM^.4,_Q@#7V<@]Z)1K!B,,QTUK&<-9)YM".NMC[7;^VQ;I 2EOM; M'O9^#
[>Y0ETA"'^E]N/;;Z&.;E0.4 M[1]9MK];E>VWPY[N!21WA&66+5FV= >VU+F&*QW4G1[482T"/[\[M/:C#6@1^DEK?!^4'/W@,MYJ;Y1OWR#<.SYY$5["U&2V-6!JYDD:ZED8LC5@:
MV4PC+]]*5E%?64JQ>JSE/X\<&-F'2]TI>Z$$L*3(1.QGMV0Q^P"3^V#9 ,-[30[9)5I]U7/DZMEDSEN1B^-=KW M>7)*G-D'+_$A'-=B\;.\U@,[KL7B9WFMS^JX-U?E[L$4W%]5;A-/ZW,A;/Z
MVN$0S8'Q"(O%!WJM!W9C;L@?+'BQ[>#[L M8=@8=ZSC]^%C=<_3?/LER3(G2).9T4#?,M]G'=4^U 2&ESNVNQZ=T#<=]-J^ M$):]^BXEH"W)^#=6D:6@"T!6P)^2
+>K>WRM.C7%DP]3$$\S98,8YI(_%)% MHUXUG%C:FBGK5+).I0VM71O#@74J6>Y@N8/E#FLB4HW.T'('RQTL=[#<81UW MZ(W;ECO8@-1.L.E7F3M1DMD@U(XHJ-/J(
GY28'CG1^1Y3Y\R>TV@'CRW/>E MVP?^>U_I0DM >TP.;%WGEF]8OK$[OC%NM.\M"=FR#ILY'F1I\>XX=I%FG'17JO?[;ZX(CCZ2'>['3!N?7%.D*1./I7P_U,IG1D\.,EL[E(X=,\V7JQ M;LOY!C_5*\
(_G/3:W5Z(S)FG(< :H.#X:7@N8V>R@ >JA9+_^:G;&I6;@X7C M9!:)21(4V=P!AB+*&BMG=%NN><:Y3+,$GHPTM!R_D/B>ZLZF4OA>4N!9ZHO=A7SO
MAJ#+M.F'YW!RD65_/9J+,]F,$U_JGP,%X==J?W\2Y5X>-[MO@DA>-OTPE70Y MQ[#S8A:_\<,,8+DXQF_?S(6/]VOX)$/>E';GP9]_%%D>!@O].GJP"=C[9IYD
M(:U,%PHX!S+O$@\.*QZ7XN]R2QGG=F[/2>XVG>QN5]49U"0E7(7ZOWAOT](__MJG8?QH"_L(UFQO$^C;V5_5Y6XH^5.[-39Y(/-L:A)#F+$ MJ[RSW1J8SY6\EOEV)6%@P<0+B8E?A/F4A-NG7]
[!*0M_X<"Q0%A-Y!DL#VP= M.?@BR*%?AR$:98[_RZ "D#TP:M1C*[;3R5,X6^0%H',,O@+]A1(61,E M+LL3[P?):! ++->4W%HZ'8GXLU3$2J9=LVZ(O AW"+*5
M5VQMTK3V#N_N7>GU5OOH*/U;^;S60*O E.!4K=>9@OZ,T)98;.BPF@+H,OKM;4A[5AZ.'>57+[=DSW?9%;JO=OX\S79'>-[HRNV\=\=]R7.EJ M7:!F-VMD\FA"&V]&_$>(M WB:[OZG /-
AK/;5\S&^]&B<./=NVWT<0V9GZB M6/_(8OW=JEB_';ILDTZ\#X#<$9)9KF2YTL,,['S^=WI0A[4(_/SN]* .:Q'X M22I]'Y1S\N QW&INEF_<(]\X/',2O<#69K0T8FGD2AKI6AJQ-&)I9#. O'PK
M646]MD;,4HK58RW_N>>XR#Y,6!G^8[OK$/*E MVPD1EGX/EW[=8:/=Z3SE2S^P08V6I"U)7S/U;=SHNZ.G?.E[.);%6CFXSN8^ M6%9/NBU]V4E:SWV25K?1[@_M*"W+'BQ[L.QAE3VT&_WA?
8ULL>S!LH=G?-D' MP!XZC=[HVFJNP^,.]Q[6NHU]M_\&W+[#LP;*'%9AU.XUVV[7LX<$#=L_3?OLER3(G M2).9T4'?J27@K0EXQZ:1)6!+P): M'Y* =VR\/"T"MH53#U,8O]4\0LM6K5O)NI4JF T;(]?
&I"QWL-S!S"NW$OPY5JL;W9((GO?)7S7,XF,G6Z[8:#8S8Q*$LCTGSGI\ZXU7=@ M+U&8Q(Z7S.8BA8_S9-O%NBWG&_Q2KPC_<-)K-WLA,F>>A@!J (+CI^&YC)W) M
AZH%DH"V%R[U2DW!RO'R2P2DR0HLKD#X"H"X>5%BN6.7I+E&3X<%3[^'2V2 M^32,PC\ID];<10/>G/B%1Y]GP 6KQW&_ZY9-921RA@H_BU_Y"9X$/II(IT!0 MPOZ2^"S![W"A>23B&#[VX
7(;)T\#464-58.V:V?<2[3+($G(PTNQR\DOJ>Z MM*D4OI<4>)85B+7&YF+ER_D@%2*>Z"/,IW?:G7]X!5A?^P@$TANN; MR#-8'LZ)1YH#(%Z"&/Z<1"F6>[\NQ IB$Y\-2+6ZG[:]?W :\6BAA.TL77/
MCMC;QO[UC=O59FZK?26C M7^4QRT^L<(OJM5?PC?IWLYE,@/2;+O;KWDWQM&I MAS;A*M3_Q7N;EI$]M?LP!M4'MI&#@G(LBCQY4_\"X,H?TS5S>$\$<+AC$5V(M1?;FZ'6)$&IE?8=DX-
(%&CBP=)>[O;+[]U-9[[X6/;9W9NG;.6!-9;LLV /3 M :X "DG3GX:&^J]^INR.K50"4_:#?36X_5K+*L&RP,W8,@.^(<$<4LN#]8N6 M'[Q/.%/ +SKK.?R +)X)K',+5?XA><"U2+4M"WB,L]TSZ6\LX
W_782^UJ=. MQ1P9@_-%9DF1>H]BCECC8W7,,E HZ(X%,1^@=>)#>=".E,!"GV"N@\3](\2(!] M-LQ5\FF8^DW@LO"+)9^9F(M)&('Z@Z"8%!EPV2QC?QA\W\ ?$&VD(LSH W*7 MI-ABT1L/N"]/V
M4N=DX^OUAN?<5O\6#]WBD6[+;=]F?[5EK)G<:.Q^9&/WW:JQ>SML MV:9&8!\ N2,6D0N5/!3: 2// ML&N:';IKLM+>J#'N]9__K=O"N^=WIY:2:P5SO8;K'FK;6ML%Y6XZ$"X*CA^=$5A-
R%+P(5%PM]\8CSJ' M==?6];,[M2<(8Q%[5MFYCWX;MAWGLVO'Z0[JEVIZZ9;0M0=6NP B?_783G(J+>+5Q3G^5IZ&$9 WYO^;/MMF>[[5V//*-& MUQT]_UY[5IFSS,(RBSM;?F#X[7
^YC/B%K8AY^TSK/;R! ?<3. MU[MOVY6D ML?9R^>9_ZHV,1HFJ$+F!NKIJY%6V HC55 YJ@-5WJSXI#4?XV$$*5L,"YCB) M6?W772>CH:;09P?UDFE;T0A64UO[$?[.6H*JC+NFEN
MR56^H>5\,O=;[Y(F;$+WC6PYOR[#;+G;"[ZL,@>UY:6&T8N.S>=0%%)X6"ZK/5KWGJL4F"T)/R[TYV<-3[9N0?:\UO&>R[U5\ MZ!F0O4C-
1D_7$;SM/+*C9"G+1ZY6']:!3_$1M]TSNIQIRL1^U4"J4V3A/[FC ML=NWX"0/DA55\/Z<%FN&$/MO3A7D))$ [P"O\:=1?6=R\XIG(U?,;%[8" M8WN!L?:B2WC_U!T8;6%+H5%UI
)LZ!A]64F&;'%#ZV]^,#"60CU (=0M;GKO MKO5Q^.%5611[>0IKXFW/H]==KD&Z[L"PV*J&4]3MK=(X5+LY)$-)[\^2E]@TF]M.C7^L"-:QR MI@$LRXU;53]69L]^0C]%
<]W+T2C235[K_5V1SQOC$;"5*[+[VG+4>!0>0C?# M0HH4.\'"3W+LNWK 4EG?"#::1;B6;6^U&TARX]HUGQ.(YP#@2]!^<@G:3\VK M31=8;.?:"'&J;TVW6FUH\W*I;^>4:@)[:?
EO*T%&30,HW'C">_<(H0[C&3DF) MG8,!K<(Y&:Y$R.4L,,8U3(?".2L\\8L&@&SA>.2NQ%>X%->/%D'$!>$NS-= MEMI5N=30N6)-M.M:M^B:QW^E=;0F!O@OG$D2G@4%V/J2??
G&T@C&,"YGB15I MM?0:$-$N]3@S RK([F(5*%CN@&OHNW#_LV8$T&K*B.05X0#L_FA)M:(FLH"M MG=&+NI*[A*MK]5E2R-X05C;QC=DQNFE1)5O!WPJED#2&+QX+H7NM8;_C#D>#
MWKC3'?:&G?X+,W?QAY1SV%54PD)IF 22*V" &M.HTQF4*I.A:JK^JNWVBZ55 M'X>(33P4_KG CNS7D$T^39/B#,@5=.:Z*(A>,HL< HO(2^!JKJX0# SOW0IZ$A88P,6:-P30+!DM7Z
MU2(@U^&W['-IH_\>75AB]\6O^^.W\DD%S3']0RUWR1=L(8.:FVF@LQ+&@T/ MCTMPF7 MPEN\M'AY>[S4_!!T^"AC-@BL@8&TY$+J S20@&5I0VZZX9H/,&?V]1T*+@K5'0P+72A2"B,LJ%
M_S0GO/(\I&&>8ZY MG0R_,C0,>AI/:X>GPBPKZ!$?BS]]QQTWAMU!8]3K.-E4I.QWI/LT@LEZT*X, MSY5C%AB7)Z6_SC5;CU]3B MP L4N[]7<*/Z!2:64G 7&0Q;12V
M5,3L+B.'+]!ZF2*YY&T@_8.&0Z&?+=4:2!%7NZ^R+%7F8N6ZPTEH56:G/ARP M_F*F@LIT K%X^1(]$:+,!.8FPP6H'$>P%XM4I79B7!#?'A2IFLL, M",14*2]#3C B8):3XEK.;W"
B#!0Q%6QG)AC#L5H0^ M1^R5"P>Q80+L*E>!=HW0J,#!E<+;\&[S18D?&;*\ZMAGW0GG..*S&<"]TE# M["Z2(O*5ZQEA7,T>IR%7F(C-#@ XTYDP,@3XIB;HMB8-EA):Q5DJR0WF@9[M%A=
[_MF_#' 61#\TZ@ZX9Q3.PERMFC!BC=G@ ":M:J_7<*A^JD;;);*71RKQVB,8"A]P)UM";F,'P"!) MF\>/]0S!EG,2+Y:12TT1+ 4/PAG$B%2BRY!_.LH7 L\2"Y 83?A/S;G-G!17 MJ+8G
U7MZ<$X8H0E!L<,P<*/A]U6A\(3B33)*7H- OB MQ@:.0%)'$2>M*?&?,4O#%1]C.5LS(56MB%GJ:=6K1L_3$)ZM41,PJ3\X((K; M9ZU@+O,0/\'O&^5"^@E#SR3Z#'E^JNHJ "R1%8Q*U.J+1?4A50-
*EPA+^B3V M%5.(LF09)"10D-"S2H:8/)RB588<@%-B(BM(K@WR0#/]"T0R1)<8!S9'(8J! M'(TZR@>K?L(\?X+0S*4<& S2T_1@H(_4:HR4\0CX%!HI7J9[@@6>BM>B_H& MM8P@E
05(Q#G2:HII:!;0EEI\"["/E$"78,<.21QLGCI4FO,FFY1#62E@#EP M75!1-1DU0"E(Y@D6AI ZA%*5).]Y@JE)$0ONDDI9+=.H1*)![V8FO#21@$;) M#*X'E8J\%L4!BH%?
^3I>&41L[*0+FL.9%41%*?/^<@ WWC8.G17Q#_X<;I2I MH(&I J AXO.P?6]1ZF?D))K*DES4U,_?6E];SAD(X30F>H-=L"QQ NE34!CE M*Y,J'K"JG**9H:4S5(NWP)E*T%\ 5V'3DH0N_O L2B85;ZI
9FIV*\3L(?DJ M&&NIQ11D*(V&X(IJLZGK4I9C<62;<;07/@-]9"7-P"8S[F\RX]@F,S[U9,;G MKP>RL8W6,MC)2GZI2).A*FE[\6(J8^!FTF>'QFL4BNM4OO5BV$B@ 4X(=A&\
M)FJP>H7RE9P3BO6!6,"/9DE:"NF-^4&JY!#>B[R[2C#@:DCM)*@;!>1)B[BV M2@G[TB/,SN-,Y9&])GU ;O:JU7G]6ANEFK>NY;?63168*N!7$#"RD4[OT12U M-N=^V)Q[QUAVG3@=!,V?
V=/A?)U*F3LGAL7P"+56MK+JJD(>H-LP\3/2ZU&+ M(ML*<+@TI1O:X%*^4NR2D-2^)6]A4WFWP,;&.S>MQ 87?H.6#:N3FQH]V\!@ MB!=^??JI$4D#?
[&R@GPCVDX5S9F$D<32#]HH8CT9J)P+94Q?X$//4K MD#\@BI!7, ^LG!U@ L>9,+DA;@BA9TI,$J!!Q,YO;2*:*S8R<,CRT8ZV3NB MV#&#^"(]QO*V?4S"= 2+?:!<.;Z9^
GS@>D[@_PM>.R=R+,G'\5\(U, 36^ M2([3QL[[)(6?M)O_(NX@5*>+N8ZTI(1,NFL,1:)J.&2R1+7MRDE$>=\+RP,> M09LA[?:4 ^;.AQCN=D:RR=+\/M#\KV
-6E_9D_&5+37=MKZR)^@KN[WH".BA8SX[;F30[.GSVMG>IFB&>K?OJ[\T2],OK#DY%+[9K954*(D<[>L3$<*PH@=<<5D%N8;=H$' 54==3"_P:?&#JKH M09QA&Z<_\=^<&8.KJ_KPD(/^.
<"]='N2OR\(&2"E*Y*>Q5.HY G:'('1/!QL MPNQ2H",#!<:AC*Z954#"S+#_;TZGH0S@8,"M27/XA($X](ZJU!_^_GWIIE#? M-\B#&47)!9T%';)P",
[P3>692%4AK@)]A2R'G0>G$%:W%;F>AC@C"FZ9VX]B M_SUT"!5SN'N=-&HF#K-&A2@6A3]D%$Z3Q"?7,+<$T%DV*N7EJK0\VA_OEK*X M
/4P*9Q[$6,R&>77Y!D[KGSG+,&\:.5:A]]7"3#JW67"V"'G0OZNND_H;&F\ MJ7^S)^^*IG(5!\H*X!KGH0X85STGJ',B!^K$+6?R*S6($F#D[+J8L[U1& ZF QGN*PKJX XQ)PJ W)* MKY
YKH1\0*9IDJIVY5B,D8K";SDGY9IE@"D*%4NDH$8VJ4BKT M0ZF*/$M; 4E,S=E%EE!:0X.3=2=9$A4Y1@;K3 TQNLIZU3A>WPKCR$SF+><] M%TXT3$I UKWTA#,K,/60HV?8KJ5,6)@0?'H!5Q FV)
MN[3NA)^ PZ(DU8X@Q3S"E/M:)U)3Q0C;]OEB2P[A[J MK&%[+##O15_!\@U@'5 5Z5#9G80C%$=%[&!LPGM,/$PCH4 GIW67>Z!*)\8J MRO'DQ-Z %]#!B@8SBHF4,:7
J&1D1D[I/VGJO_>FKZ=5C_@/&@.4C>9\0@RH MV/(7C0&VB^U^,GNNP+B0Y$U9[OZ_/7V_%)MMMZ!FNP6;;+=72KIXJC>77V6! M!"'\X777:4,JIX(HVRPK4,4$E.S&[%;)A 6KP@M.X%YZH'$S$-
@XS].)\[@V MSF/C/%>3+]^<#Q^[9$3](OSX=?W MG[Y\//GVX=.O>[2OK:1[TW5;W5[G1Z:H_[^"+K1=VK2-E^K5+OO['[^D><7$32/X,W^3<= MR)";NF]#]R[5WBTLK-V44=S#2L<3J\4&A@(Z
MT0T2V"-_T_K,M46WZPMN86/51(E]3-9;9L>=X6 -.[YGJC'8L?@.R/CC.]=] M[Q4K/FEA2L0>L;P?SGN&TA[MZ>DDA>[:G?&_2>%D4^(T'G"HH$"C5CL*B;DA
M8CL*L8VA=\KLQZ;HSDD<%Z4#QS#9/<%)PRK6:R)DB04M'=[]IMZUW4MT2@>Y M8LEY2X]B[8(*2>K64,Y)573%/T+FC=G*%/>BU!)T*;B>)9/_DD-=BC=3-YE4&E[(N')!++MAZK=5!JFO M
"3G>-5$5K:4!1Y&7,SQ$0XW-CKBGQ1GZ%H>\4>W2)5Y2!/S6H+=UL(\F+/M M0LCN+).R\[V(4WD69MBBP?^.8S6R[TGPG;L\[9'$[>Q5/M1O!M" M<6LL([D.R?DWUIN5I73 DV'6Y>+OJ^K9_>
[+0*"<^([1\>^9C,,D_5YUK]LC MTNCN%6F\57!S?L.L@J\$ X,D+/H_!?3O?8=32! '@VD+)^TGI=KZ;__G;IV[%_HA2B_OU>4SQ6@:RH__M]XG.;G!.>#*\/(Z3^-=B!L:P1UCQ_GN[WQOX;6_4=&4P.?
9ZPTESTA]X3<#4 M47_D^7+@BB.*T<-.OLC@KT>GWT>^:$^\WJ0YZKA^LS<:P[]ZXW%ST&Y[[L ? MBNZ@<^3$8@8[E)Y_C$D+;GO2=T_2],1/YKGTWT?B[,AAV)R7N;'U,L5-A]E
MN#^4'3ETV^/)7;<*TGQ'N^V*8;]VF[WN<-"GZ@_[0[77:0;!+P'Y+9W%^JYUZG:XZW MO69/#D13! !7,1ZZ8S!NO$F[O6.X;K?9QU'F2CJOP>H6?S^6-+(),T\G8:9C M$V:>>L+,+I(==N;X&WR7E]-
P$N;[9-(-6LX^I=,H .W1C@[8AL- ED99%3L1 M&1=<;>RZ0VD/,D?- 8>FQBKCE18!C1VXE^X"%E)CGR2=)U3&X&!H*(RQ"I&Z M@N&X@3N9C8\?675'CR7Y=GSV=__SCP_?
_CF?/CU[;O_>=IW\J"B[;;G6AO- M4L-<:EH'B3!2*Y2,Q[V@R(>MX\^;H! FA=+=WY2SFUKM%_H!:A0_S^1Q)H&P M@1 U#*B=**]]A.^'#90Z#Q;<<1O.8_V\^A'\RB^AHU[7PG%+M3?\8,VIL>DI-
KU5:,.H M]*94P90Z/NS/"Y@8J\/7@V!XC]P$>NT2:K#8+U5TMK^]C&AN)*QY0" MRC-@-T 'YP/09 5='_XY!;,VG(MH31.'>9%FV)<.BE>8+'7 MK]>*+3/Q9-
@:].$TUYS=C!:K)\Q%VO>7_;0_E+^OM_Z!\@.=__GYRR_.!]6Z MT7F;> 5VA&RJWI7J8U]]7+4H%?.Y%*GN'$*-"07WL7PK<@%B+<)*:^Z$B5D\
M])I<8"MJ!SN#^'Z]$;>Y&_TV&]NRPLD*)RN<6E]/_V&%T\$*IV_B,HF3V0)L M*?B6.JY_]:9R)DIIU=H[24')Y<\289[VP9[\I5EA<;6PZ%DY<4ARXI0:1'\6 M9YMLD)=
<29AS"4%HB!4>T4.CE+B]D\XD!8WCU56D!__%%.=]3/Q^@"Y&O=:P M-UZJ9;JV"N51LH?OE@K_7X0_7!V"=NK>=Q*XU<4\R?*@__HO' @2A]ETW?W8 M
M>]+W#MV@+7IU[@>@]'U"A)A:LXXD?D^].&Z.N'O_]Z\FV/2M!^^_+NZTXJ M1._"11Y/!GPVPI[48Y4G'/(THYM/OFVH1;#17XK+3G'$2H&=7-&%[7/1*8\? M47U+U+TN#>\1?'BS1_I/ZB8#<59?
WA&H-X1>&K/\[7K3_= M%RW@;FX!"Z[MP-4TC-_\]:A[= B@NX.?YI>3+Q\^GGQQOOWCW9>3S^]^^_;A M]&O#^?#KZ<.X[I_SK5CZM_3_I$#WE"3] 'YY?0G__ES1'5CT6]!ACYU/7IZ8
MF%4\-7CO/_-]:A"] P;_O#BVP'TJZ*JZ@=P"J HU]@:H=\#8U]EKYU2D M222=KS@Y/&Y^%.$,IXI];+W=6C7>5^'Y')47"RX++@NN)P"NP9WET%Y![="XY M,E;
/!.F+@>CX"AG>"/[]N)NKG5.+XTYB'8YY.0QFL5D*; '_2 MIWUY1;GWE9FD-K[QM$C9@LN"RX++@LM&S*Q+?'\5%QO@VQ_TL!]8(*S\<@G M1%TV'JGBD1]#;RIDY)S*2,3)4U='GJ,Z:,%EP67!]03
96.0&GY6J#QE/+;@ MLN"RX'IBX'H^0F7[2!Q'&E=Z*N^Y_^!6D<;JD!AB/?&\I(ASN-&M H][W,)F MM[6_M@O(_G8!J;N>'Z0+R%]>3Q)_\;?_\Y?7TWP6_>W__U!+ P04_" !J MB%Y9LYPX-PX $0
&QR;7(M,C R-# Y,S N>'-D[+WY<^/(E2?^ M^_X5N>V-=55\J3K='G=[/!O455:L2M1(5/=Z.S8<$) D,0T"'!R2.'_]-U\> M0"9N$L@$4"5'N(LB@9?Y\GSGY_WK_WK9>N@)AY$;^'_[X>.[#$S\@[-N!X_KK
MO_WP<'\ROS^[NOKA?_W;?_O7_WYR@LXOKV[0#7Y&$"4A1F_N MO[Y%_^?T[AK=VQN\M=!Y8"=;[,?H!&WB>/?S^_?/S_OG)7K1X&7Q*2YZ)T= M;-^CDQ-_"S$%GR/SJT8HY_??CTIY./"TX^?
UA^_////_[IYS]]?O>7'__T M\?_[\.'G#Q^DUX+=/G37FQB]L=\B>(NT[?O8_>7;J^Y=NNY:%[T>H,7?GV M.S3W/'0'KT7H#D68D7_^V'Q/_/Q/+AJ%1 M'I!^)E/B1S_;0>+'X3YM\^4Q]-
Y%V'ZW#I[>\Q]IL^(%)PY/XOT.1THWZ6M! MN'Y/?GX/\,[GTX^?#[Y_%&\B6WG)$H>RYOB/RI-D>\J'U8>)&.I].;Y,^W+ MIP\?/K[_/U^OV5H1#WNN_WMYW\GSG]_#SX]6A%-^L5O>"?
*#V@GRHQ.KSW*J M/[YG/\J/NC5](*LW)@LJ[0/VD^VG,LJ]?/KS'+S'V(_?1PR?P& [IZHY./L$F M8Z]'8=:ME14]TI?)ETKWHW@7EC,*ORB/)M')VK)V19K\!^5A+]R&K58T'YK"
M]/#)_/C33S^]I[_^\&__#2&Z?]SM+@ACQ+;1=6!3UFO&%?XZ$8-[E^=?/Q$ M5N@[0NP'Y)=NP(J9>=^M$V*5'=6)=(D>VPFQ'J'U'ZO:+5W K5J,ZLX1\<<)
M_%';=NDI=%P'TB5,/[5O.EOZQ[4K#BIQO+5O63D/6S>>F^CZXZ'%Q#><+X<-M2N'H>8^].(*_:H>E>&(=-Q?BO(8/[>6/Y%4^$AF__)MV/"LGZG'+H.1&
MIG]'K0Z.BHZ*K#B9"LTN9^O@!_D=$:DFZ M3C]:OH,8-221^]?W>2(Y\DF$G87_;_3S+B2BL,]&\)I\P5_FC]2*$W)0>]E MW:I\C7\I)DS+-X3EJE(?
A;X#CE4L4,^$#W%=+'Z:L5)2#J,H\7J&A,Q[MJU'EV/?G.>X DXH78*EQWN%@A7*^@5_T1X@J6N(] W1 MSO'?LNZA-ZR#1 U_79K]'CNW5DB>V^#8)3P?=P:I)!J6T.>C#B3T1FGD[>LJ
MJ%\%];.7_DH.B,5.R/?T0-F2P=J]/^$KX,HX@=0?^0:5L>?6JZ.K$DX2K)& M^1DD-8N@W==CHX=CH_TTMSY&#B#9L'!^U+-P7I=-K\OF;&,1V2"Z\N_CP/Y] M$WCDLH\N_C,AJL51:Z:.7L."^?
-1"X8WB%P?R4W^$;%&7Y=+O\O%BC:77O!\ MW(&2O=VP%/[EN*5 R"-*_W76VVI+YSBR0W<'G5FL3I/(]7$$Q_VI%;EDQFZE ML\6C/?/_WTXY]^_#&OQ4C$86H%>7HIT ;@6[F)UREO8\-
*A_@^V9)7 M]HO5O;OVW141X?UX;E,K/U$6;\D. W51MF<=^FK#E/^Y,.6<+DRL1!EEI)&@ M_3K7;;?WI>6&OUA>@K\2_9W\+>P47ZWP=Z*_/WKX'MO]VS#;_U*8
M;:".*'DDTZ<;/&L!94V\3OI!&YR=G!OPKPMB*X>GB4A:.WS*%(-MG >^V##=?RE,-Z>*!%DZSY0PXI01(_TZS0=-\Z7[@IV:V91_;YBTGXI[%%Y^ MG9=CYH7<6F&"TUU4.C?Y9^KGY\9V^MM-
WASW0 M[F_)&_O\?"F_-4S0Y\($\;<1??UU0C1HC#UHCBTUR!__U$&_$IU?'E19E M<@E_=E(I.86&15"T'!VL6*(WK*G7E="_ABDO@^-?;U@#15-2:VWS=>X[JYTU M4UQ\JF$F2\Q$D@KZ.EF]Z*

(U$U;^9,.D%8T]>;WT=>(T*:@U4]GVW8;)+1]% MVBFKKU/>I]9:+DTUOU_N7\N6I3J@P=?YU2C>W7N.+33EB>%=+,@RPZ>USJJ M#:NC:*/E)I;_!AI57M $>;A]05BL-,I)Z5V=7>%V?
&M=GS7'4R>Y4 M2[=AM15-DL>LMOKC[E7\TGS>93^>X\GR87C11 ME&S9QP?2SV5 QAF'6]?/U*'%2G[A2VCY,78ZK:MN;38LO?JHS-JEE_4+P:2A M.$!IUV3%#&R=RKN\@Z^K5-
,JS>S:V9<4SI(\VF4EMJ#;L-I*#.(M5YML.)=^ M0J+]U\5TL)6H_7S?X2@.79NFM9*?'P@'56:A?H@V+*.B=?N(992USY^B/7BU M^Y@YE4ZM"%-P!2+E4NZYP-O?^=300L,2*XFR/?
*D.J$=07)/A'3_>FCU&2UR M0"3!D50:UDS1/ T$2O4JOD\"_@YQW+9^KV&I M%*W.2BK0=^]TA?\ FC4=?H_#>\L/6*$;][A%>(?Y161@K:Z?OS><;?O^3/O M+8^<&10P_.=-B%?
MP;#_(+T)T+=_^R%RMSN/PVWWT#/R&5"E O_$8;C\1_:S MDH[N7@=;R_6[=UHAHZ?/M(F3+=X^XO#8#I?1T-+;#2$:VLDC/DD'Z<@^UU#J MTG-H&$=;ZQU.PF '_]"6WY,39Y5R\>R2B^O$M\
(P>&XSZ%X8IN\"\1/^!^'F MXU],/GX\^401F_]03O=H=HJ SZ(3$2@/<)Z=N#'>%AEH#3+]AW)*]5T6_>VF MQX-2PS".4:3@1ERL2Q]#2S:1!UMWY\C'=$\\#VB!9:/W"]-S3\QCH$%;/S
MKCN\L7$-D 3HU^M8%.@:.XD,Q#BW/8N,=67<@]L84*EU/%NV;F);F@@.;+&+ MS77#[* >$.%VT"@=3-_XEES2\;V
M<%\YLFWW:K_MF3WK>\C_/.CX[ZV]P22!_L;B,**&UT6G*_#ED0/31D[6WH* M[6E[M/3:W,A6T&%A*_TNJ6/:'H,,VLM]U8V^L6%H[^)MR_BA%(]CM5#FDSE! ML+-]?Y&67;W(JJY>NU'>7G]
U5$@'J65-_\ S1C=[ZV*6+;9O <0&E[(KJNO MUJ_CI93X&$5I+?+RF(5B+9+OJ VP>@RKXS68:C!^#JZ^'*^CC,(8V.AYTYK4*$_7?JPU?;.]9QM[M+[T9V1"W2=?6:5>N:[%^J#SP*5^33_QI8+_2H?
V9C0X\F%)W8W@A):.VBL$, MZ6!'2LI(&PYLY5'RMQ4')0'?+1?_/,V#&R,G>@R#+;WEH?IKJ:Q M#&3HYD]DF&![7P8A_%BT%%"V_O9#5VKOAV(_-?^1J<%7Y&,59R4/#M?IC17B M@J>$?AO-
DW@3A.Y_88?&G$B+_]:S_.CB!8>V&Q$ATK7Q'00*7$.T/_ODDHNN MBGV=30XVD-"_&VN+SY5,F?R:5A\ZMK/%$PV^^>>U]7B_LVQRL\KI+[P+94_T M,E@1MM^M@Z?
W#G;9.)$/V?"0/_[)+/[D,B<33!3)*+:_^ONS@('Y_K8\/!@ MEMRM[SM22!:78YR%?P>'4A.O+ 3>"'XD]J :<"7L6RZ(^^T1F]\NT@ MW 7,WT4/M3.P&H3[VJFM?VNP.6:*KQR-
#QW=TIC\&QPO5DOKY38(Z=4?QZ'[MF%!A=1DP5\[\,8I#RZXZ_JBWO.)\=4E2D<<^/C6VE/WW!:FHNSDJ'BR[Q,, MPAJ71$(%38DH1O26/"=+I/0PJWQX9+?I/ SA@H+NG>ZS1\1(/ENAPP5-?K_!
MU/^*W?6&B.+S)QQ::ZSD=6(TZ3G?"/=\M%T0G#_:86KG/ M72(\D1>C:E&Y[O'!INN:R,08\P1"?ZUD!^SY*$9W&)0+HCU!]DED6]X_L%6U M*#L0'&P0:JRHF4UGB5_B4]+^[Q6,'TBDY[7X"
[E@%N1JO0R2$:S9AU6/3K< MD<%,+?MSO LB-TY72]5!4/7XL&?>8_/1])@_FNA_8#[(4KD#^2@B,H,-04WK M6I&L][8&&SK9%;XD/1)V%@,K670>-KPTJ4BNGW)HAQ^V.D_?O]LAB%L<0>
M^2MCC?SQSR48BA>K*R(!/KE.8I5)6M7/]7S8<2=C M>.2CK]V+PZT=RQ/>$[#I$1T^6]JU5L 6+_:MYY WCBE]H!N% J*GMC+0=@AO4P2__&^?OVNKG MAML<609PI:NF48/!%J=N[^8M6/KT$-
Y*VHM%>!L&3ZY?,+PW M/M[SG30G2WRQ6JQ6KHVI'[?L0B@^--B\U^6%Y":]]-'IF45O$C#.$($EC5S+ MQS7T;2]MT>+T+"U%A]05D6M=/W)M*F!\[-O.[[+I&A(BO< M5QL *YXT=!J>!:39B@.
[^+L>RT%]>'K%/7D$@<'VR845@LH,)CZQR5V[8HF7 M/SM8U_.:F0J>-K?M9)M0XQ_UGS[XY'+RX%#Z8KG^*5X%(5Y:+Q6L]D [.%.# M4!S2Y=
<0(U+Y_'"SZU&ZV"F_GGA'JZ:OW).X6,M.AKK'!]2NP4X'LPX%&VJV3 8$LU90<[IWO(3Y&,;3R]HEIA/(#_]$Z(1MLLD8A6V(T3HN@=:C4>6><& M%,^@L]13 H9MNJ6%$Y=G 55OI98O#W?
09A=ZF]#CJB/X0"JCBHN"R.#%"B)[M:BZ9%B]^@Z>')!'D-FCJOA7L)Y8'X]%[F)^6/@XGLX8!64+Q'@13BG%%N*-1 M"F1K5*>W5;\RJHU4B <\3S!X\2$BK4M8H4QF G)(@[AZ!*'!F.9Q937WF_S$
M&/R_2E4]&OBI?<5HP-S7 M((S7%J236N3J\>^PY5U$T#LP,XBC&K2FTL"N8R@,)QKZL>NX7D*.(\G7UIBZ MVOC:*Z^2*DX;+"+99U]A1S'_? M)^(.B%-WN#Q3K^+) 8V42C)5;8Y,^;/#'VE,6H7C-
_!IRD#US5G_SA Q#/P? ML%?G_:;USP[G#^.Y SQN7$J&YN; *M]8XWLCB(>L"(:/3O?*+S7IXL?1^@;U MV"_,&.NSU$WC*FJN^;Z#?=* #A;+4QTA4/'DH)N$N,P56EKS_RJIX=;K\EC
MA/\S@2/\J=FH7O7T];^_![1N21>>D,PYTZ-*S\J@% MQ=^'C]91C95DT.Q:F;/YO>'V?"H7W%JN<^7S! ;).%:UDYM?'$W F5RI4PX/ M:YRX(P@-
::7.W&W5!FCIF;%AM+"@9!E446#*5,KMAQ/2D:7O4R=%0WZ^\M#P M1]A9$%%8@XKDVN;GIW?[%@.XM<94%=L9TKY6G1[=9&UK?+-O,R8Y:*.T;JF4
MNU1JR:Q\>#C+E&K4J[68ES]KU*U!@3%+UT#^U\%&] OVR2GDD34X=[:N[X+W M!WP,]4IKTUN#YY?G_72IM+$*PLA20:[_(V%1>2V *M.SE80^C22C MJN0+C2FK1]FJ?F'(Z)"5&]>(;M(#
W:2)\RVS2NN>6$P)A[NOT_^DL^*L*4H MHR#;S$6=[70+U*ZC8RCU?%\/19(BR4A&P'*4>K_9BFFGA<\I^&OI1*5"E_=LAS7DJ) M5&$1ZKVK;=X<090!1!
(U&G\J'Q\N\E)8#D$K"XDD&\7NUHHQ33>K M=K>&F, M(6Z'A[:-(@"Q+?YN[2M]HWHM[_^.+2_>@)>?Z$,U*))5CPYYP5,GQ3*8V^3^ M"W&].;;ZTC^(RDBDZP.C65N^W'?\ 1,%:XU$Y1?
&P:^/+!;RXH4)R%!YAD4G M6*RJ<2'W?E].H,Y)JK'%-<I)IB#AT\!W6BI8]>_T+?G6^1*$_R_]BQ/"C^0 MQ)#6AK1N$O07BHXO0H8YR52 :BM$TXN]NHQM5O:#\<3_R-CA7_SSZSS77>D'
MP]5.8@S:)-EWYU9LE1]]C8_K*N!1!<-<]=3PP/E,<3BDNDT3)%HOI =,O6+J MH/P]L&C7S[PEI&X<>T:C(M]52VO:N>G)[/M#%BZ!<:+B0"7,>7:'YH_\:&FUZ[.>K?&1LK!Y1>.(2">6]I M!5)Z]EO/
[CL:&@0G9N?'QC8)=UIV516J4&5SX]B8;?>F$/OQMI$:U$NM97P M= PEH[M3%.&I#&?(/3"HU1#408B>),/9E/Q0\NP(LI3*D33SA=%\)_?-@^_& MD2B-W&K=:6UR>C)9SM\EF3.I/-.WB-
74W/0&\,"LK?$)M8?V;__LS7L)_X)@HZ<':!_Q.QCE9@_PK>*Y*%3;9PAKK0.TS9MC@;V_AD;@D*A#Z*M^8V#9OE:0 MGR#$>%G*7EKF!(?;WB'&FQO\!B];U4(SL(%HN $^A_)JV'=$I)U_-:7FZ/I(
ME5:O#IB8]"PA(X>!3SZRVR1BIR_[;Y,2<#"9(7 TSB!;-5P&SWG#0-V38T: MK-5,V[__#1Y;',%TP).KV(.^PSOBY0:SJBNL,^>01 &1_\"!2+JI 9TXY/V> M^WY-)'T(012MG)$!(X+Q4/3^\PR9E0M!?
Z&4]Y']58G+-4@$D?+G2 O>"[J%6 = LRP\FM]B+" \L;9A'(E29K41\%$7,[WMC] *GL>7+TS5#Q&+Z2S767)MW M1\E:#T@ -73ZKD.52@$0HI(M3@@R9G9'@'ZWO&5 *Q$)"J+C/[#J:$0*95'N]
[:+B0()!P'4-K=*WM",ADNL;WQ M R]8[Z44OVJ15VM[UHI8W+"NI#_QYSRKD_TCFO2?:?6]-K\WK"A=#ET^!JK M:^7C?4'SQZ/F::%QK(LVI!19[S1[LOW>&HQ A
M&K(F])#^/*P_X&J[(Y(M59S)%*PK192*APV-)P^0VG_\]+ATXP*@:NDCP\6-M6!%<$O /+. GRX.E.X_/K##<$ZFGSAW=[MWA@92)^@H"&V3VIO5RVH/$U[QK M>(
>$FW.\H2/V$[RR[_^V7$Z6H]QL6I/K2=?'&6>/([09!5R-6B$J@Z:U.RR MEL97=Z=N!!I>&A/N<&T<:O7S8XD?+*PA65N'*XFMOJ75ST.;-\X$#@K0NYM/PTI!1O2%89<\Q^[<
HU<=V]OPWL#%H3XUA;4ISX[!(072 MRJ'FI-:O&[8H,7WZPG?.B_5)JI\;FZ"2EOLXMGY[&8%18N4UP5&V>758S[RR M[*%H2Z,AMO:EL849L#BI?/H@& AJS6/'$9LJ@M5\"S=0E>^F%]H#EC\1$->
M#U=>TJ0JYY0L[\B-15896P-2(EB=*T9[L\-MM$Q+5J)E66DG -J1X!RJ]M=! M-(:,GC](6.U?3CT,R8RNC$Y 9E44>N[_I1M&<;L8B*I'#0EF9!T"..?]?OL8 M>"4"F?K[B*[RUM?W"/TVITU%YMJ\.3(O'G-
%T-P">(]J@VN.H;2"+"7,T"& MN_N'0RH]Y]X9!0B,C$W4(!HWOM;W*4IDK^)977.4UCT_8/X #-*5[^"7%--= MG$V-1JZ6+W][Z @5XZ&OO=XA*WUWFVQ9>?J[8&]Y\7[QZ+GKL@2G-F^,P-O=
M:O"A>('-=:4\S@0MS-'>\=UW>\8#L[L$66LYMAK I](@M"\X6(?6;N/:EE'J M.@?]T!XVLKY)&LH]-&BQON;Z\Z.I._\ LIFHX%&E_^0>&IFJD\]-?2#B62C%
M8U%U18FTH;B:#SNBT]%/U^[6/0SDK*UEKEW#Z0@7+_8&^GYC;>M2$I3'^I8=4EE2]51%PE4EHQZHV M+K,[O1%(\-6%8T!T]FW78^@*!T:H'DEV^)3^MJ6CAR\976D1;#0AM'ES#/@]
M,KH'^>QA;@6<;Z%D*PMWJ^2EVF'1#_E1@3&TKA!1^LXX49Q%C:OSA#I!H#)B MU45Y.)WIR1+C0'&=&E8KK4:#HYBY6244ZO3E3]K5,;_:KV MT;(2K5S]?;31=$=&T8U
@J&G'TW>6*R(UDP%SR9IIO2=GB5OJ4*DE*I;;1"M M?7XXVTHNV.<[7=A<$3@YJL/5+JWNAYA5!]J3R 4-&B MRE9+ZW?'<.(T'R[#5G'@V^Z7 ,X&E@=6E5)6\?3PTC&O@D:7:_KEWUURX(7V
MIK[0R6$T!L:G;HC/&D>5ZO9969W3N@Q;-+F!$CQWMA652V/A(_+7\ MR]-3LNA_?F%+BO%4"X?>5Q,C&Z@C70L"J%-R:')UT81CHZ9UH_E%EZY'1-Z6
MDIG7(JJ>T@UQO%BM<,@0QM>A5:Z;'?*FH0'EUQ;#D0';37664.6CPPLB//?% MEX.D6Y9HO79]?!7C;=4&ZK>-<9H!R?;G4+B8"/8VI./5Y6X<1ZOG#2A;EKDR MPK)'1(^<:D6F];LCNS0..N-
'%^A:$WE=]\;(Y]"] 5>Z)6OQ"/6W-[:5$)WN MY5\.7QAE!(Q*('=X#5!?EA]7^-E+'QN!+[IQD455]ZP.X*_^D9G\6*+PS79 M+E_"X#G>0(+'_:K.$_"..UM<;7 =D*('18WD4$@3SG.+)#EYX#X&"& M2
GF5*V(_CF2T&_+^&O@XST3FB\3WZDWIU8\/%CG<[X[M=B"=&J#K&A7\'08 MC<%8Y4IWK>E/?68,1MB6Y37JWAA?B,I#A%>)=^VNJ@[M-F_V++2GN64RCEZU
MJESW^/!*YY6_(_ON&G!+/]:>1W5O3%:Z_:4'PW>?"#A$4%M'(R8-?S,0OC I1<\ M0_5@\C&+'/"=$NRU+$ZZ@=7.9(>O35%K/%,?&I\FV;3O6KPX69GI8(VB2H#I
MO>9[_QWLN[(=ZRRY3//U<,NKU]4\/B1*XPJ'(4>2:6DG:GC)>*@$,Q;6QDGP M1P:].7(%AC(4'UZ 2/U">I*IG$4,7.[1%:F.D(UYL5KAVGO&8"=&E+#1.E.C M[S/B2\ .(AN'?KU>U?
AXWZ<7KXX)\$:*X.@['.(*3[,#7A\V4CUW#=2: M[FM>&%[&D@I'B!HC[!::I(41IHZ&:WT^?%:C(_!+?@E\ @9B.(RC9B0:WG $S&.P:]Z1J0WMSX/ ML/11H[+=_09[7E/4@O*0T>XMK93S
[J6%9<6K*Q]O.\L2":JWP0^?%+C5,OK4;9^ M;2PH:\=7(6YI#2B'=QYQ=R=K8>)Z &A7 YN2CNG)^*R5F?WW:+ME&0FS*6]X MG0=Y+-7+ZI\U7&4F2PQI5[4X>W),9B> '! UKK(:
<)6YN>T)C,2&61>!7O;D M]#09S#E- M.#@SU!*I7.PM7Q_3?FYOP4UMM>3XWP61Y7T)@V0'INL:O'NM7ADTJ847>B8C>T9%AC7V[8/"K0ZB M,98KXW@3D[032D^ \?1K-(&UNGZ
MEWJO=>.114+NI HXY8J'>L_H'6^%DD*&*#SWHV5%4V__JYX>[M3GJ M\#*8V^24#?&A0-4'$#!L2Z58!S0.A?G*:HRIA4?'B3&3AXA^#BK]ZH=1&:^! MLBEE+I47A\S;.ZP39M$.6&VV:IACY?
&W%V A.S_']F=X4-&H_:=5(XS#[?79MP%#N?+PYY0(RI6K0G]] M>SB]L[S$?>TQ6__.:%3HJN32!JSA ZGTK^TE-JL:5GG=U3PXX#KZCX3[X9>! MJ(Z$;W"<12,O@S+PXU0,S?(+F^(!=335-
WBIN%]H(4A81Y$P9S(D6/@F3;\J MF]\#*0QY/I)!3YT+8,BGI8CJDASJWQF]=G6#7^+E,_:>\-? CS>50/C'DAO. M8@%W$[N1LANJREI1^FS/VZCM$,Y7,0Y9M%-2>EH>1ZAOY[\+I7,30UJ&1
M&O]_Q:.#+8V<(3EW26:5;K^0'5R3I'(P&;.QUGGXL6K'7\N7QA>\F4&/24"$ MBQ7$TEV\Q$2Z=\E\7/A$8"\-$.B?OC[8<-'[W0HI//>P?BSEB..K+@.ZSVNJ MPK1_>;#E1IU)BU4.#&7?
#LBGY>G&@,P" M3AXB]B:6]ZL;;^@Z 5U[X^Z6 3NQ*ADYE,)(;R-PHCQ;O@U_L]RQHV^D"E)C ML(36F6P*CPT93K.C1H(H"6$C_, MYSX&="MR8X0)ELM%'%K@N8G &,,#@\JTHG<
#G;L&.E(R=#8(AN,L$*8DX: M@1P.I-9[=#:YND/LVIMH'ELOKI7&1WB>"]VJC=AN^>[80+)Y-<>VD8Z'4AGN MF'#7/DUT)OI) :.O\8AH]W+?H7GJ>A>;02K+4+F)VKXZ*N/:'?;Q,\MS/,"&
M)K\U/7]=:Q=E::2D\>9'M5[*+'8=C:]Z(K.%Y:XI-COWG%ELBZWE>:=)Y/JX MH!Q5/36][493UXF@!Y_[WDL*[<&&YN%^&=(B:?M,C:UUW]:\T/=]EFRW5KA? MK.JOTQ)\M(-?'VSX*VJZEL"F-
K@UCR TO>W8B$YNHH;!Z(L5\$4>D;[#XBYJ MJ:(HN/159EC@D0E-(F[/C0PW6"RI@:>[@3GOG)='O WQUDVJ1,OF]WJ]CJ-X M%S)VX)-DN25__?-VGK?&\F^'BU^$?;%8D3.
(NA86CRRV_LH7,)N707B8':D+ MQ>E!SS3&OE5$(#8KX(-V:=C0!& XQ!MP(C[A+-J'FH66ULLM;&@R%#'I_6,2 M4TM><&LU!3%TH#JJ$DF?#RZ1]'EHDY2ZWZL@D>B/=;!,!Y,9R\W>$(I8_O"(
M0F&+0D/K.-B25X>;%E[WRU8M#IB-94'QY7'^19-H1=I$0)>.@V@6A@)D292U-D-I3TY607@"0S9#2Z#Y MC8R/U]?0P#NZQR0+.Q4UXX]D-R6$?@-2B-+Z?^/OOKR;!^*AO'A0KHP#"W/. MD-
TI%)*BH=^!R'L=/..0?7*W;MQM-$AC**"MH2 3>Q'FK:(=-(L\:!)1@1MY MT.CW-&!B]4/C)[1/B&L92%)"9HCU889$!Q#M :(-SQ#M!/L#79L80A@,*!'. M0I>./>$($014T&^,CK:MPJ*6K2,(.
(49XC11(0H JK3 MX$5>]P,Q5%"Z.8:Y+^L[7ZD3!CM0'![R)UB]M9O #\6?-#"6^C>.G$]H']$. MS%#:"!7*Y&;0;[0-[=?^8*,AKXAL2!#K!B+-(*DC2/0$+7QIT.;Y0:/=T3UT MV(-&-
KZO3)8<@8H]#F3)CCLR=8H MG'Y=1H)V =ER']":2#'HC4(]07])GJC5RI)X:6$)7\+2[:C=,*(*<[+KD[Y#A,=H3;$%OV M!HZWK6A8FP33(W]\AE-BF49"R4V \7$EK+!IT>;'8WG1G*[. 3=8I\EE0/Z
M0E<9&.@BPM@6CIR4,G((:;V+JC>.A"9".0&"2*:(@.0T&%%TP9IY&<:0T3YT MH[J AF+GZ#(\@BZR&.&<\2E=J0H)?">A0IHSU#Z=SPSN:,2_IMKX'].RM2=YZ $L#PO*@VD6$Y ML5!L8(-"-
W19B[^P,MRPQL*4/HJHF3+Q77T7@U&.4WLZL,4:0ZPUQ)J;93IL M.@CL:;Y::+-&]IPO1W84V_) M/!V4YL8B(!U(T\WJ G;A>KD),49;BE:&,!,%S['-5>"/9E1@ M9BA!0 X!/;K-#%TL/?
&1M_HP9OYDB)-4V&.1F?MSO LB-TX/MF,E74X.<7K9 M23D51HIV\TCPY##2$?)P#(_!*6]3B"@C(ODQ&4#T/]RF2-.QHEM,FB&GP'I M4R^3TX6ID_5KAK*>?1?#61F&^L3'9?=]C00ELLB.Y#
(=]U1#&SR02Y#H>=1= 3Y/K(>TT:".(UKE,@C07]Z',K;5;!9-8$(:V8S/9PLV+3TD("\ M@<5*.O@[I2+0]"J(/:#GC^YT!'WL*(>LS)/>H*TT6S%+1F-@MSQ9.$MS_!)B MR>'EGR$-ITN6:=0?%I#\H?
@ZX MKLXC46)"FCLR4;3!V$2TE=FQY,L_:U1*)T30+$K;15*N*F\90=.(M,T4ZV]H M7-041F1.__&]\ MK!F(!^!S8HA20X3QUZ68QYD8>H QZ8_6]7L-IUT">BB5H!3$O3RSF1?2.2NJ8]P]T,/C:
M>)SM-S,5AYAI3VO-M-SF(7'%@WFH2,49RZ81]$K!&UH&U+Y;$L!+.:2!]"B+ M@'J=U<,4BELR"S1]$;+V("X8/?,63\2NR[8:M8T /Q'(>V1KD=>2VLV74""$&GW3M"$K&[5W9+9M+W'(65;_!2?
+P)F@Y19BV7/PC1[6?:L]AS"0KDM%C#> M!=*'D616AQD2X=F,KB&@GIZX\IH9F@@G^3 3PD[$V&'AVJ-VM ?HKG M!;>4GN,5#D/L<..KP'YE*?)=-E?%H2D,M+P]>HPP<8(U:6C?
F1F/^ONC:2@F M/@8_L3'P*;*HR!\1/ LS/&4Z8.GI#.:0WR^ZF1?0]E*Q0L(GKTAW"^X#+F5U M=8R*AI#4$N6:X4@0H4QNS:@#5?\8R*>YS#_A.AV7RK$PL/[E:L3=A41_%)" MU;0+@P7X'-
KX(J10\O[169QY[)P4%T30G0H_=8! QIAB]4;) ;M8\=H?_5 MU=M-Z,%V"2A%S8A3_7#_%Q?M^6*%&"6&\S7NCLNKJ&S<=1]39>ZDWIU$DV!" MDBY+W8"&9,<^>*GS9HXVLTO4?".'*
(T=LKP\$N5PP:2L;[WL]YQ#1AE_?N. MAE95/5,5A.@=7/$$22M\(B,)$5"K)(9L!I>7CQMMJ&D1QD*M6?"QT^DNZB"0 M4>)$A9<"CP7[8Q2#UM^V+8?[2+MGP"UPZ891//=]EVR8R
KWW=,X*$4DD323 MD-(/(]XWP$-.6&:\6!E5K=BL9Y!-U5&7I#1,(@;#4VU@HA'J,N41/YQ5CE!J++E0*]ME M\;D7\C27\:
[[,KVP0HB&@TP5(9&Y=A>-1!"$!"9VX\VH6&'DUPD@]@@E"K3,6;V^183&BZ 86P>O")=.Z!F/_% M](5UD>^R+C 8+91U DOR#1?@ JZC M'KP=D6Y3)WUZOIH+2>B-&240-N5(" ;: PV@KI-
MB9KV!66>K>@8G/TTF M%:P0N/28KYL'#]FRBHCU\GE '>'K8P-*<[(M;PUL Y$$?&6E#:(=;U&O"*N9 M:[&0.;>+%9)AOK*&D&C)8 BM7LZ5 .)QL9^E,+/BJD*.DF[.'C5GSP
MI&@!I3+B&UF2X*V\)0<9@POPI)FZ)(X>1,U6 JT/:NE1^RPB&:9_1^IVX_5V"UF6>J!%X M!*0^"??>-S^,^=LV\VI& X%'#S\:\A4\Z'@PPZ2PB7;3U$6PJS!ZFE/3>^%" MB=)6S//:U',JX?]*$T]B'HU-
L?^%J;"'5!J:M6)E-7)"O((4&-<]LV9YK+9> M]:U'%OE:$Q0%Q#ZKQYF:=J?"C9)<*%AB=5E3XZ[^D%%(C()ELR2/=Y!H,D((M*!F2:[IW7YZ$' ^Z.W^#XS,KVM!X3;(I3_,%[E9*^T >UV5WWYF9=!N,
(N!#A% M@^;9U@N^E7FVL91G.T,2,T.GU4Y[YHY)5K\K+<8# 0S03?WQA6Q8* 8%Y!C3 M6U6 W['_=KB3&''$J4,6,*/_QTBL33.WE&2C:%,XLB]S2%!1)'/J[$H'O;.4Q(*@0?BA4)SEWNQL,!?
49HO1IN&': CW; M!W#7]<]R9C%NP[!9UVR?W'IMF9P24VI\+*/+ 'DREOR)L20)G9*PH?T2'!-H;CW&LH[/F M",.@08>._F%0O#TP#BLO>([0*@RVPY@*>:V)#K8.477C6C0W]+JD(;Q#ZZ
MM<)%2*$26.GGCIXH%9^*$ < !D:>%W35[I72R&0U=-7.$AA\QCQ5&OBK [-* M.33 5]XD),Q!G9/N9",0)(WH=WD(L)C%"L[52SA6.W*1X<^ 60<.:TK5P'T$ MM4J^!F&\)@KE=6 1-=J_PY9W$4&/(
A*")C@+.Q4 @'((D;76 &$N1^[CNLE MY(Z38!^ K4ZLR&25E!T6[391YA03>QV'VD\+C^@=BQ4/%UB$M#J5P%K(.G-F M>1Y(3B*L@#]XK'!!6X7]Q^G!+4<)RC
5$L8T:QZ$RC2N0;RAOYJFV1%2X@6 YO".70K>-#)0@>Q)LP[XV M-;['[HL[D1-#G 4@A^ZFP4(AR8BS8N5F0SO*C MZ^01"_D'!#31PC>'PMB%ESH(1E,,I> "VYT7[#'F!3FO,_!R'L+<"?Z!$S\1
M500E\FF8MRDHB+X9]0[@<7+,Y>*!PH35.2"_>=0+(Y@U5CDP+8)349 V.MTK MOP!N0O^U:2E9_4>_-B?^%Q9W[M]2!^GH_?-?N&;@(];A[W7@%?"60K9/1?PE MC=;4K%!ER(P,2[:
[["@!57(T7",8:_TPXGT#/.1!E3->&+ZO=IT*MEY"ED3J M:N\T%X):%@IA3!OIB9&'_3$ A>>J>ZI-10Y2^7(0:<6DS:C>^(E#J<")=ETB"ICT0:(;UTTD^HF@H]_=2"L&,4+O M9 5CXHHQ"0V,"0?
>B6Z"&$?4^SCWG4O7MWR;;(8[;&/W"10:HCM=X[7E,5L$ MA)TGT,V=Q?V2'-J<](STP>^D..A;P4F@=DM#NE4DZX_%6*_NNZ M[R6K"#0!%DK>R RI\9QFTTIT<2[?#.UY-YY#U#_[18M>+
<_38[#"]@IX]">$ M2YLU8!KJ.@LZ4D&O^SF:K@-_?0(YFV@[1-DO_NT@?VGATWS$7AQV0 \%/D9[M0E$O*E_GKN?SN"#@B:5*&G&8=NZ_-T37"]K;61#%8,T4)2:Z'/J9UD:ILB1R M3M>0
Z@WO@JZ=I&ER?"B.H'!?\"#E.((I3LWT\NYV@7!NO0&B^Z2['DXG%6 MN/IPF(NQ5*4<_D=CLB):F_(QCG'3]@+:,@#WT-=@^TI97H: M2+3%R6
R^+YO%G.A^.5\3I@_5:]JFLG(C"P!RG0T7X>8[JES'-FA2W=.1W%. MHD0/.6@&6:*==YJKYO3%E#B.:.]3@DBB. T^U*5WKT[&##GZ^4DCOM6LD$[Y
MMOF,$&,IMKTP49?;HC.M^PXNT$Z7$*3XN%'LVI:'OF(+RKYN30Q_Q]XK)9_* M6="]<+Y@GPC6'KE4YL[6]5W(XH=IVHQ,6-8D@/ZIE'KRU[$^-+ M*5@I,6A7(K*G%?16$D6+KGSO_D3"@>
'5<1N5N(X]!]3*A78AG< M6EV]'5+]3D#N16_J/L6$7EB$._'R$9*O=%?QZJUH:@9([CH;9+Q';*>JIC* MO+]([C!8.5B73=F@QC7PWJ!C_KT,=JG[I-6)X("CU=RQ<)F$/L7_IR&L+[02 M0"=!-
"5(;TY!TIB-H#]^Y'MO8*9NPV#EQGTX87-;G/SI)0ZKIEJ^;<&E#XC% M@>>QI <6$F-^O'VUNM_AO0SBUF7HD M=J(1-8/'#/.:\7WZ9U'>ABE5$=K&"//B8<8V5E^L>6VXF@X[*E;TD*OOX?Y+
M0+:&#Z+)61#N@I":<<'S-U]C'TI?9U),]RONX=W].Y2UR)1Z:&!.LU_QE/2SZ'I $D6D"LB6^3W_P6)GS'@N^8\8T9WV[*]XZT MIMDU?FR$SW)#R&X"STD!5JF .O>\X#DM7]AEY7]U?
7>;;)$'L1!PS&VM%_J% MGPN50A9KDQ>J,(&_.JI!*[D;MGSL8M%><=!H.5@R8@Z&#!) Z8.KH'*,Z:6R MM?;9"",HGQW2MVZ_LV4J_-Y "C5$I9WRJ#14$I6&TMX)[.C%2BBOO(=$)6=Z MK-
DDRHX"6SXMU)!+MA<>5)0#2/DT!0Y(='Z0S7B_B9A$/0IS6ERI&[@CIYQ& M!<*=P[PP8,U= MBMP'12DZY_MEY&B1"Y.Y?7UQ4@$C#878M5<.$_GO$%$:/N&+*':W5HQO \^U M]\?BWPBBB%-
%@BQX78$P^HW_N\0OY-;S OMW[4:J?EE5#GZ7B.*.RVOU\?1D MX)UV1W\E@^I".+T4P*FI!3V,[[Q'AHOGI%KVVX0W3DID9^*:4>*HNEL:UR6":?%4723/!56OR[O M_XXM+]X
JK=/QKD78Q2ABAA9).CJU>=[8H-OGJ]HB0H,F+$7]L2(8O@J3H:Y M:!]>6789S&TB 86X'N3C>+L]0[,C\@5O![4_^9@J\Z4!>;>D(QL+M#9JVAP@
M*E<-7.A<2#+E4MS<]=$TQHI*]LQF0^C)H'5/];!:&Y8R0/53/5RJ=WLUGWJA M[YF3N#;9]$CS4>[&/[/"< \B,YL\EF .MOQ')D*3J<1$*W2@#">XF!\]=\U# M4X17&;P+0;+>,-\ ?1*491&30$[MS#
(EI?F'*%!8-Q MNK!"4%8C<5*=[LL)=("KKJC+:@]C>CSCT:)8K7X%E$7/X=/ =WH*'$QI(B Z M1'Q@KURI]@*9-5.H!W4(7P))*ZTLVZULH03<)@KCZL9L,\$C7YFL4"9K!K%V M./J8<&S+__"KYLK
)AC/"59Y(!_XQ ,FB)!EP6V5>+&08W#):M ?B!<&-L9. M!">QJ-.\H HN.8QI"%(W%8%11RM"GK(NZD#S*9(4O)]YGE(GZ(1C-/CWRMC M/2N!3=0_R& DC#+RTV-032)IQZ7F=!(:8!ON__EU?
JS5<'&W.#M;C*]_BC'0 MBB++WB01CF/]EV%6'I:F4PG'$87&[@&@?>(%;DZ$H M0PR6 F"4;+=6R$HQ6=&&7L%/Y#KV.5+HU\S#8$[U%6&8+DL>(P?DT073621F M1@M.6^T[H(_^%\-
)*6(_SCAQC'"2U@*#VEQJ/;!.H&M*(3!:""U7#<7]K\GI"4<>OL[#!;Q8PLJ<&HH)8<8O0FP($^)<3[T%_;Z MA5;U$@6V?\7N>D/^GC\1*7.-:?5M.(72VZ;+Z GBR&+46:5MYLA9P07\Q"Y@
M*7Y5KLO-ZH^]CO18J@ R?C*T_QE*)Y@SQ>K0TYM3*GNJ/Z2:NOYN:>5)TH$(MU"5RF7:Y=#A-&A^S1Q)58Y=-!5?1N1O97@"R7U<9N)+'"&6-$$G7G(RKD6Q->=8R MCX!VWP=3S]
;/3NZCO6T_PYJ8QX1G,RS)3D3(1 >>,"(.$*=D2S_05'?V6XJ_KVWEPPU_[H;8CH,>"E() M2OJOC>[]]M0N&XQFV6[!$0_U2,D:[!B;(V@A2FQ:3.13=P;A1&Q/CM;PF%?
M,XL$C>V8^T[NFP>P4,S!+=?765JJGV_2CT*?U.U(NMCLO MV& \C\,GU\;E(T_48N;6H8,<45.__#N@7-X$\3]P?(?M8.U#/0$VPN1@YE_! M<\=Z^1NEK+2#8@/0(J(W'-
DRZ]1,!!W#R2YU[/L>Y7PY'4&<(F2DIP]/FT'2 M[SNM]:-KPU97MZ'[!)@NGF731=!S;.X*\090VL(T^50*2(5!%$$=7=K.H+4Q M.\$.W344Q1P2?$@#UZTJGIZ9")%G$#PTK18:O0YL=C-W/#P$-
S7Q#U"3((8_> M3E?]48.;NB&5%$O3?Q<18:-7ZO,!7[H'_MQ]5&=;HP^+;:@FYD;_,SK34!R:QCXY"/3(2(FA[+_=G6!D&90U@Y2&QI2 M$M?-ORJ6 S:_MQ;XXNZI :C7FI-7&8P[C M132"RLK&?
J&U3"F,K3GOM#8!Y#((5]B=D@R2]MB<&#+&X>\F-Z]$NWI1F>+E M!K,T0#82YU!5'@X0U-1]R]Z2D0O1?/DUBY2:+%_BN(T15%5AC8BM(3>3 ML6HF-E6HF=A*: MC$ V+@AHUKK'$FMR[1N'-
D0V,'4CV'(?:-(\N8=91\D>^,007W9IE^ L4%^A M]1OD=S[.T#,YE3 YG;/OD!O120"5(G97+GAD(!QVV@/.-Q=O1MI"2D,H;0EE M34V:;[7. &,^W4/Y)94RO]/.?
*H;8R)@V2[M0!>#K4S'4&GA+EWWBKT>LP?+V?;"1DW\&XJ6O8+LDW@0A^/W'%+N8=NJ; M'T45_NG0>GR\' '5:'*5),V67\O%7$%R$DA3=[#;V%W65W6Y0BR;: O=L0)% MK+FILU\;
<^8(ED,#:"(E&6==2_F6YL^9J.7;>=NKQ@,Z%+Z3@<94Q2 *X$ER M7=@#!I#F+3ETU,&H+7%0&S>:PGE21EYGJ=(<5-BR*?;G#HA+MK3WM%\CONF&
M6/*UIU]^*'D',\O:>VQH2,NQ9NG!=H.?Z2_=8HRDP$5;*:WD8_W9"SJX$V=9 M)7#P3"#!@0.2M3$DH_2WA8A 8>NNDXPG R++TMOTN6P_M>P1L6W3!K7:>3(+
M#D"%90<@%/MAX=O1Q7\FEK<,:#BMB-KMP:ZXPBSE*.+-E-D)UTH(+X>-AI&C MAD>P!D8<;3?#F98/!*X.6/2QR)21UM"8"K-!-F*+E2H!70(VB14TF9Q MT;>:XZ)-CD2N;$W.U"P-
B++>.!V0.,BM,E/U6ETLBB!WU!HD@FD):X,Z0W_\ M*&G7G_^IQLW/6I?]K];OD%B)H_C!=\F"BMQXSPK0W=LN)L(&B'=7ON-:OI4] M(<6_+[&]\0,O6.]%]0:RXGKQ/D'78.F2OH&SE#>--
JP\7L2[1Q46EW50?BR4 M8^CCM)-D8Z2]U'LC!F^+TB^\5?NX\>1Q^^='VB]%P3KIU.Z3<9793B M'%'2)Y3VD#%_O;.LF/")VFXJTX8:"\\"GUX;(_@<-LAS89AU$CT:%B_H;R: MOG@I8B;G&=);,,9]
(<=(0M86:?H?Y,#HY2JC5%'$R;(J=5M*>-K,"%6.,B'(M(:!GJ$)3/VPHD"-%7O2RH"UP[4'D$U,K',N)"2]8+XF:A\8(Q73FT.RY/@.'NIP".5@26"?A'*M\SCT6M[J,N(@;=-#N8RN,CQJ"4[QV?7_JHR"?^H?
Q;^0FT,*S M=SB[D^13<1X(9O,_WOJ=R1SU9+&BSMQ-X!&)-6*">$I*&R0F5983%V.RF8 *B/'8Z_\ M>>U8FQ1/EU CS/(Y6&Z")")M+Y])HWORA=8,TD\? M/GT:0Y:E$<:%QO0<(-
$88JTA^.Y[&89\E!1A/1;#$;/AB,EWM?FGW)VBO89, MU[A9%9N6AO]TV2["@AL':$=ZO0%G1D5,F"&LV1$,T"'F\Y81\D409=JS[V P MUWA ! -L%A1*_#HYC+&T@$]1FB]%DRA&B!S[EI

MPX@.CF6+2#N>C5M"^F5;ENO;,6Q$MN^72:\]?]-B3+[Q+MT7\)/QD*2UD5,X M>8R(\ $"_1/W&W4J1I;10Y0@JRAMJ@99K@I,X>J0H__!),6NG QYLY^2.E(1 MKIK[5TD-8 D#__K/^C-|
(1W#0ZA9CCD$3,9WR. 5B#JGQ++VOOYBY MK_QHU1!4J[E5!RC0 >MT&$4.Y__25/+&)%N%U0"2> M3IKE5>I$HW*8?ICQ'_-3H6DYFV!9N*$P0N*<59+BE6>B9*'])^8QD9"B7T6;"H9F/JYI-6
MHEZ1?A 1@V76$ EUL;IT?2*BNI8G!0'!'1N5_]3I,D\)*D%6QBYS(DJXCFN% M>]B;W/W2!.F?YY6QN\),Y'!O/"@!GC(C^D%H8_"]$:$7D'^=T_U#!$""[,8A M*Y*7S',
[(R60AI@G4S0%]HLWT!JYTMZBM$&4M6@P)4K_,!2\G2LO>.9E7=R4 M>2MM1UON5):*((0*.%_.K!BO ?BE>ZJ.+*V8.DSZ9Z9"_M*.QL(Q:;MTD)[&&S)=3/8E"\Z4S)>/[P,OO#H^3.W[3 A MNFLA>
[K3\B/(OP4;C&A!5/XP9'7OG57O("XGQUYN33)F=GJ9*12&X/]_?/KX M+W_EC)N("KT5#G&HD-PULI5'@5Y C*%&9,K>^E\:T6J(B08;"K\D.])*M"$94*;+;CN+6=J09#&;+L^RR#6:*;X-
,50ZX+&PY!QE C-U MX'>\(#AI$;5,ST^N$%#R)B%D"Y?#31#CSKD/)>D.0-W!^=X[P^(6;<8,5@#B5%,V9\>"S;X-U>:XK@!+OBS6$V.,\3,)(2,^<")N. MZR4
*9X9>7C2N0/US"%&,6%1O(O5A15"N%A$>*#=G]-Z*L?F]TIM2Q8FD?+. M*[)([1$WST3.S=>;.?R3< MV+\,B%I"HP(L[Y:.8+?V] IYE9RNS/:OTV<[E]J7QB(S;8X7+Z((MZ"$%.8??-
\2S>,XMZ!'RG54N#'27##5RWC8@#DQY[84/-'S/," M%FIR^T/6V/U^^QAXQR8*,QJ($1EM;Q5-U$B7JZUPQ[H*Z3N]=5_.4TQ2T"<#!-%62TJ<>YAK7E'X#QJ!/7>8,@9 N+= / %@TP1*L ;(SL M1'@
[\;=_4,G8:W@)*!4T1M"-WIKK"Q!KYSE$'ZJV9L45P68GS*^S,V7!_4* M;Z&TO&2HZNJAY601I2M;P$SX9ID*$0;;HA[;@QX!'J M"P?.C)H4LKK T(,KWR&M.\N VEF$.-
DY+)T11YPZJ">,_A\C)/07HX'J>I@M MPATUT(1_G: :SG31\^#A^-P,H[U1 !A!T MC/HXZ5WRU?7=;;*=^WYB>7?!WO+B_>+1<]?6,8Z^DBJ>6]8 LF@+*&1-I'49
M:&$'%RIWDE,IQ$Y:D-.6:AG)Q1LF-!I\FW"BB%%%G"S*Z$Z()<4S6)A1%&CG MJ0@LTVI3SSVBC/,@HFS;,@<.+6#6&::GZ2SDD9<.Q]BF417RV3AGT(9-8+%4?\'$
I$\6VY!9_Q,AR''I5P0WO[4%]A%B#>$.> Z=, M\64>H,"D-W@6[,VSLI+MM"B[\A+10X(Q]J+E]SM%CLN62*D M0SLB,V/Z\(KAZ$.\@%[9<)3S*TL?J&7].U0"((BR3O(8>J26C95(9UA.:
<5D;LZ91@1@SEDJ4N^DX2= M4C'F%.O8;R6,P'I$YAEX %?*112[6[)TCY67'YC/)"4S9.GW;@PI!LH<5\-$ M-+#[?)[$&T!:P\X#2)H2?#";U" .^] 6'C8$>F3?KIVMVZG2'CF;&8U8I4+ M7T7R1
DTB:BH@CQH]'L:L+;F,-:' @8L;7B&:"?8'^A:YQ J:N<]$>BLT VZ M@*YQ$L9PUHZ4DP'OFH:82[#8HL+SN0M9\+YS=SRP10\%121$;JF/LZSHMN@F MNC, -C&Z@580.,1([%WL:
<,IE\O'7KS8&^#\QMH>O40X*21H(2 V]LXK]X%1 M#IA>G%KL5:R(2(!%\%PI!NK0#3P_;SJR'HFF$$)1*=L+HB1,C3FVJ UJ;1G@ M%?E^Q_$F1*H5L_%0P F;=9$7IM!LLS$X7ND-
P.LU+%8HA[H1H7D*N\$;%O ; MS/?SFP'YT/BX*%M&*F91&!RK8G#,N<'RVG*F*8._R[==SZ6[H<\YN$\%T"?2KA5JB-#^ D7>QHAK*_%NOTZ! T3B==*/O>3$K M(TB9,)4.7)FST#DFL"8;PU-4H
;>1I&/(9D5SS%X:MCF)9\]S-,2YML@C#E@ M>N4P=$WEDBW0^74*S I436B+F;N-"(YX%2DI(XQ@=&RYP:OZ#RAT /+ M38@[658HU #V';K);>H 0I_SM"G#Y_^9?*,>ME^Q!@,X4*DIDW-
4N0@;/4*QH27KOGZ,?[)@!.L0Z%LF FV_LAC*3AWG-,;? M7WGAF^ITV[H"O=9+F!HS1?N;K"MX8VE8H6$L K5VK'X1ZA*#87>#3-0F+DB6J'#.+Q@'DGDO(U#1*@>BU MEO-
$\;@!HYUB)3%$RC!O2L0,SU;:, N(M8;<[(P;I.5A$N#'S3QHW3YOU(*#@Y[=>$/(!SY'2@U8TI4?A%O%36OO;=#K MW!4Y#HE"'\[((S&*R-B&+)&*A_-@1^]MK&M.A61(!S)?Y*8JVF:2G!;K$]?$
M6.D5&$OTF>YZV(@[6ZMGZ>ZW)/;]$L">IDK'L0,N"WLSQ @R-6HJC)2(K@PB M^XDQ$QIA)K6\RDZG],N_N^3\#>W-OE. BN3U20G2/7XS_\58C(I61BL<>05N MM7MHZ7'9L?
#I6&NUD.7+A$EO7;\WB2AHZ(K6AB_BV /C M7L9S31''M"$#11QI:@U/AP&(#3(5/60'"DIF\#1ZZ;YGN.>MBO+=X&?ZT\$+ M33"H)]H;"VRB0(3S0 MH9-5.@/-D08&L]!>,8J"$Z&I+,C??
Q.1Z]D8QZ13!Y#2-M+'(>NA\,S*\;K(#RZ7A"EA"@I)&B-O.M* MM3V3_:<6Y7F\W& 6R\SB1!:K%:;"8 C0=D=&]>2](?$)N6M.MK09'B-";BK6 M$&C0T))>'X$>/H5Y)D8 ?L?
(BP+QH@'$6S#CW]+#IX+,N_QJGC?8:]P>=4DQ M^2!BF5P'Y\?#2 BW#:/'0J)11I".@4V%%OU +P4C+C,:CCWY?*JW+#K+*#6 M+ ^DDF*%\YR8 6'+V)[FVW.B:2*A7,=X>*\-
E]MV92'H'ZZXHGB@$L]"ZB04]HRO[A47\%ET+([;N;"HD?JFQ#A0<,P'1&<845H1Z1Y M&BV2%:FUUB$V4)5 UU#RW2*33V,GT@;8UG%,A$[HXE/!2BI9(<-HJ;HKV%#7
M%Q]&0V&"_3#:UNB3XW$:S!5K*;)9-%GXI:&270?XN\HB=F/'P^.&'LG RC\R7V4D,<%''-&O=F5+4Y*=18#P!G;2Z!J/86X+!G!@M"&1ZU4HS MQ4JI5U$]=+6%+30/7;9E+K8X7)/S]$L8/,
<;Z*WE=W22")*(T428N1Y M15D*=,GH&JB@9(99MZSZNO@8_WS)-RF?A.MY0G2DPXB"@Y8Y%Z_?"A MY.D/QTP.K$1XU9D+6Y)TP01M=S&"%/!%LOB:4G\YM&?($*)U#+SCV9\TWV7 M/T@
_XBH3,9Y('/^:()S'OS6*>%#!-"9RNWHU.>2R#^#&43Y$)]>TJ'XMLFH M3HBAJK0H$8.-+&-<50(8/D1XE7C7[NI8K2J'XY@'P&3T$30P01[E&4Q%1L;G
M7.9SXFRJ^0.7[DOJ9)NAA''F:>2,.IJN?"C=YSYA*2BP'ZR3E'(NQ'=+B>MU M$_;(%=]O&3>GZEF^[EG?E1W%(9;D.!N"4&LK(F8Q]>&P^*1^;G="YN;^C^6GD^[/-IV5P M$\M;XG#
[:03'8_T)F/8<25U'T/?7V:C?E6$ZAJV:DH+T,*F4B^^FE=3/%97A%.KR'>T !E#@M?%CXJ/G98AR7:]U-ELFW2M6AU@/*2Y@>GHORH; U-!\0(OHV"@=]QI3,B M9$;C.'0?$W82QP$$?S)-S-
BB[XVS0L9 *9[_S]I]E5:TN?2"9YYUD4&6^0Y7 M>F7XLJQ,5<<)I6!FT&Z6[Y&!F(%PE#8N09I)5;(,3KGI$5(W\F[GT5.-R(QJ MB6X_\$_HN+G*N*W2< _^;_37'.EJ2CK8!5)E8>J$#G:0A6FTGJA)3L.X
MO%+F;;(TG(!S0A3(:]>FJ.PB>;MK"KH8(YHUSFAGF>&:J]STR)4XV&NYT7^, MXQ4.0^ST$A2G6IH !BQRUS[-!MN)A@8,D^N3U?1:%FP-%=/8+UMJ4-Q04Z;" MB+&HYN[P9SQ@>\R=K@
^T]QS6:&"_TM%J>[(!1.Z<-W #^0R5;^0GF1>["O? M#@$YXARS?\G?#$_BXL7>P*5W1TZ#B]4*=U)09PQS6VI]AK*.(?8(W)6Y+]4W M6(^1Z#)Z(SK]%N*Z!!R'Z#B"GB/6]>][(O*8[ZX80-
>G^.\SA@*/I=)F,!=A M-A?PN_GZK?T5;AU_WY7$=-L.$PF&R$ 172HK?0F8+&WCT._H>LU)@.>*P<7* MK.T[YG]=\?),$.<<152\(L_1;QCJ$R\Z1=Y)X"EDH77 -2/HK5X9LL=Q$8[:
M@(OW0#)U1ANP!O3-C^*159B:IU.I5[X/-QMC)[H,@ZWB"O"=7RU0VV(1F'6T MO,];0-!$+B8:\@YX,VDPFUX(*(W\YO(K&-,K8#J-0"L@<\,]\8CXX0-?+%*HR5O@\BEUK1NSJ+, MO$[MM"(44U WZ
NZNEUT"G6Z31[)Q96!^)]*^4E1*8E\'FPQQ,<=6Y(QQ=YD MI-;(/9V @S(^@0-$*1'&Z^I24Y%(X;FB-5EH>'6(EZPB]TWXH5>9AQ8WEC0 M8V_<*/X8"O=" \:S$L^#!]A7Q=?+\,')EEVMPFK^2^ 1,J
#W!V/D]V#95]% M%A:]G&76_:RCU/+P'0ZV8@P3P_*4DM0O \0Q@"F+ZV7*P?R=E>N34^"/HSP MA"A2J1HSR??$3\G$&&=*K4C:-5*5P6V;$]2[]5HQ:^H'R+[8[KQ@CW$_6-4I M-
;WFQ8Z=%EM64#$#/M"QT\J^-;S['CAQ4;N\"X(01D"Q3@Y5I/C!XLH8)(2 M18SJ5+@I.2M-LT27%O>7W00^?%++0/#TH>Y&'>C&?-?%7VWQ"D^>N1EZ#.(-
L]3"2(@HWAD2>,9Q(&P29%3HNYH/\J-5,A;__MGB5$1XMX@\/EQO*YE?N!1B:7!,>UC(CK=!8<%)@H>CJ.T,1O;5H.,6>($WB3E$N4/ 7NK?
2F=S+L/7CY_/_T@ZN"-315<4>,U"*CH0HBO25>HZ\S':8RLD%"!9 M=TNXV$0L^B?>N.11["/'VNOW@76-5^8.1PC+&%U\N-2WR<:#&QC?_LS#B\P> MG/9Z%+'=C?D?
66R.WI07.>5L#'DO/?"M5!Z4LEYT(IC?XS7T_@N&HJ6[C6M; M7B?'O4Q(N[N^5P94-(B,FDY]^YS?SEGETTORS=' 9R:4O.4$IP #TK1..., MU$3>DDU^OR$R!YRJ+,?TJ'0/!3!8:)GY0-
GILB=9$LJBLX%9VLP)C>.1&IHN MRW+YRN6$_!7]CP_O/GSX",4Z>;&K-#S@K^C'V8&+R/K3!NR>(I7KN^/RTNY5.BB;^IG A>&W9&&['"=:O+ M(%QA-TX@7XY:8UP>;R80.3N!W:6U0=BI-
4.\.>R\ITU]A^.C03N6^BARHT4O M,Z38[VZ@JRH7-X_V8_?1'K3T\1"#7EH OKC_A0U\E9X#V,PY<&;M7#(AU(/F M,(ZO?!L\L213!^)!M!C$B/2!-KC&$$C4V56D8%)
M^QMP_\'T[D3E$&KQ3JU3+DVWI$EW(C\-*MKOF065/&KQI#SN?AQ"#6J?4IHF MCYZ[T2Z(+.]+&"0[\@88O7@:G;-([:[2KIGK9-(D14C#(K "NV,G/7C'T99 MGCYL(!]3Z?
IU.'7DFV@C7TE/^!:)D&S2$-= MSI"(>$NV7 B.A1ZBX&AV*25(O2>&POCZX,*;.@,YE[MQ1L H?P8 F"&VS@+G MZ* P".@ &@B(C+6SBEG=2(_3W J7@0FX..)QC<=FAV2$9B)$CPB
MFT=W>AEMK7MUL5JY=@_0[XR.F?.E2Y^]:74W=PPR4B.-F#Q/V%7?91E1!P](MSJ3KWQ:7)5&T,6<60K* X6]L7F53)6H9&(E*3)5(=$#K\"Q#R_[]7,
[!O@%$]T94EJGZIG4\3QPA$%GMJL\\T5>)\98&V!:_M3THKF=#?UIG[" M!4>^,:G7=>% 54;GT^I\J6HJ9D![HHB,/=)] 7PEFW[^9GS&%ZS%!*UYC; ML5^^%"U*A>:0G9-SX9G4>C5\=3URR
6^@"KI S,\\6$M&*MF*WD3OT'UB;P2IK;47L8DS&ISI1L@/P&>[==FK_YH1!K-"O? MBF/+]07,;T89#O1G0*4C_SK826QV8:]!-F<9/CLKI.]8QAT*G2>#;YF4 MC@# T>O1[MQMI31VVG?
=,.:T[U=$1+%\Z\%WGT@G /(31]@*;8@@6V)[XP=> ML-Z?!>$N8"ZQ7E1WWBK*FD6B72J$9"TCJ6F]B_02/ E6C<"\\H1,&.I,302 M\JJ_>C#F*KO#<"YBY\(*P6+<+=Q-
$$."VL38R!6<2;8)NXO.\+LA* MFWM>0"TI3+?JSA!XA\)G(E;&V$>#0<7WQ9D0!PF]DY2@J$1NBANN'$?+8&X3 M'33$E< :G1(N>2L@$O%V4 Y69*;BBIA*PM3&OGIC/JQ)-
(^J_:!0#V[0I=D]#A*Z!28*,4N,<9)!O8>11A7J-AB59XG&-!4 MEL]!%R8I(OV'5R$5OCSQ-GD"Y*U,LL#H2I&$W*T/F*:UCAC$#6DN<'S7J.& MQ-?4:28277-@:.)W6CND5X"YM. 5K2.20IN-(!-
^T#&3_2D-:?'1@:AQ6,G+ M+]#'B:=8B1]=(%U?7=_=)MTB.SD-[1)]Y_ZJ1A@SG98]U8%/0VXZ#3:CP\L3 M3J;S2C3$$!RHJ9)=-)=">JD1M:1;_[W2KH^[S^75;6RMU6WZPK#XI=%C/%^O
M0ZHT7/EDC(@X:G=& $M)0CUA1I,A?\W0+R,*KYC<&!\@!K25 J3YN)#F@X%M M*V&OV:2F3# PI]%.3V- Q4W @Q%RLMH7<$^=$U;3PF7#S51E!$PL1<#,4,I* MB0Q'V4'
CU12[G76V@2$%Q04ZKFDX2AH!6/)C[5',Y'@TQW4+*]@9$-ZY9.+ MG S7.6;_7OET:,AX\(@ AJ]\M.>-445O!/VWH&ZQ'9RUH1G$61>OI39'QIME
MA*&YXU#KF>6!A>7*Y]!.G=2:C"8UVYRX4.Z&X5>94A%Z94L1S$; 6RX@*PO& M4D.S>HCW8:"Z-_UY:X6_XY@B:T5I$Q-G59C%VX03&HK=TLRQFH^G7Y81-0J)
M32_7#E:'8D@*I\F,#]J#3;ISD%YH:L^-!8ETYT) 3'-1G:T_T?"T;V7P1VV MR=7K>O@&QUEM]&4 1HK;,'AR'>R<[A^(+$=N:N%DF-
NQ^\2B5SO6]J,6B(>?:>:0Z!3H+&^@7T28>2OY/[*^F2P7.H(A52]995S#=%Q],JX> M%*\GW\)G"JJ7L%&4ZL99:6]^UKJI4H7^2T@Z!<=U)'*H:#_+_68N@C%["%7= M!3'Y G+QK=26L(:V401-
97EIEKA&4 (=019_((T,A1&,(*Q49'6RG %>^OA__M_N'S3W^-D,VLNY'^ U;O2(KMFHX9;051HBC->J,-\2_3IB;,=;D]$=9!E]]% M:WLEH3+3$V99%6_&P+2D.)*3-$70 & 'V-:=J@"EU(A?
MT(PC.16J^]/) 6 M#E5)@W*6<2M(CR4&X@:_Q,MG[#WAK[0NGJ:8CQ^_%7X]X0@Z(OACX6NW9U'S M"[/C9':=+EY&9L]A%&>2SNZ:N5$@]8CEU@1T1BRU[\U:O M"&MDHI6CLU
/&T.I8')I$%$6Q3EW1*]N=M&1D'!<"/[&-.UJ1>RF*PR[SYY MI/L!^MT/:C%011$G2S?,%+C@JY#U7I!C"\P,?G0;*B50,WS(BZW7$9US@+\ MX)/U[4$RZAC4.,_N4#,?414).N4@[7 MA!S1C4-
J82/WM93H;"EC0[5I5W]Q24@>N/!C2%W/8A9[AB1D])$ =FL+%:]4.$5XEW[:[P.8[LT-TQ3%? L+YXB;$?N61+7?A$(N@$ MH-R4:\>Z@: ?,UJV?(:D_J#?LKX@J3-ZK_!Y3 2WK]2G+'(\>Y&HYC&U8S-
O M-5$/>/KHEM+6;,/NBR5AKHX1V/P917.9L/WRHABAEU\-LW&.=R$FNB&L#8'V M<,>NM65 A;TC@Y-J840_^ MN\0O\:E'[M(CIY82AU6;D2_&A'%M7*Q4XW1Q*GI]U7!)U?NK&'%RM
+7ERG<3R?G7C#=UO$$6[M<7?+@,EUG5BBK3 \>V$5-.4(JU?? OB&1QSY.\SF@#3585+*5+3+4NJH3K< MM\#H(=JZ.A"L373]C0Q$/@B\VXB8QITW-T)R[D'7,3*.4V_DZ#C4&E@S0$8,
M@I+UH'->W9D4\C%#_^/#NP\?/H*4S5(F0"1G,2)_11__CC[\.$#_%^$C5A) MO E"*L)7)=JQ IT-=A*PQ\QM.R0W MG52R> EZ0%=CH&B VP.A"22U@7ZCK9BT!^IC67./,;H)8HS^HCU
HD<&O7+>%)I:O0]R'2<0-D'RD01:PA\OQ!3=9+XX MJ([0U6>E5GMR>=,4ET=2DNEH0*G&A,:DB^I6X+'8"6A,6U&J?>IWS5RO-O15 MK[/*W!BF@C8?.V@1B2:50 0*"RZ:I0F!J>N3MOR-
#$C^0BM=4X4%E2XC7W;2 MV]K'Y3)TL1-BU]Y$\]AZ<:T4*MTCER[IZI&XW/FPSK29/T:(-23!Q8NF].X) M7:SR'=".14/AH)I85>)#Q\&ON %S&#.L9M5B=>YZ"?FVUR"K MJ,V,V%LR!-K%>'?
MNRO7AI [U;4/:"T&]14MC"JZ2K+=6N&>3F@]XWK+_JFBB9!;*,*W1]2'V M4AI0G2FAM8UKZSO!M[)@7!1@]-[AFD9$+/*\F)H)LE(+!J1536PJ64(20[:! MTG)E:5!WV,?/E@U>3-@KF'YNX;R=6?
*K.RX$\%>#4U6N\MN%@1N0N+#,3N&BNC MEZ4T&E'%^V#"FWC_DAEF MIO^=KS^0FR!$'3X/=[?17E!_%?S]30Z6;JUF8\&JLMORF%GJF$72$56,I)F[@UN0EFL MZJTUX%
[N>)U(QII(,M98F;%FQUO3;)O0Q[$XTCBGBT:S%(\BF.P4EQGCAN=: M;-0;')=A?UXRW)T>X53!25H#DIHV. Q(JOYA*,0-KKS@F?M25RGS!L!-^]+G M)3UXH%IN;=5Y16,?
J(3;R$>]L0I%OO+@V"MZF!BNVDHH PT8OTHB,A9P?Q2C MX.:^0^'QI*^R@%X./_5PR8Z@7@O9F71@0S)@D'UR4B]27'ZC+KEA1S!7 M!-YH:.%\&X2Q^U\6
S*!]+%S#BMX&^*MFQSKV9#I@FA+$],$:?2&$]<>6-@[M>\JJADDV#?C_;> MD^6[EKG"E'#_+U9$,*2 $8O'V')]$!(O7NP-7$>70=AO<#]M\218G9 V&58& M$JT"S(AHEV9N5J)%?D/#4O
FIF@J@30L6!X6'S\7\$Y-1N"#;/+8++X\'ER0 MK*)D8D]A8345*A5A2AG)F'3:,^ T1!OP._A+-R(S0L>6F] MW,*52>8M)MU\3.@-N0QNK:Z(W,RY%]"AL>4>4!!$],8S ?-HF'_A5J,*\VJ MI6IF-
%B=;%K2/.#VA&P-2CT 3R_K@^XA2O,6K_P=69C7^ E[G[O%+:=)BC/$ MB,X0)8L^&Q,3>N1*L1Q*YL('/WB," 2=MBXL^)N*D=#-?&Z,=I@PS@8:6\",G&R!,ZU<25?7XV#J$ MTGE=M!:<&2VAT
]'E:8/4[4%^YD7U?S 6-DQDN;+KQ9M+UW6646QV5+3E)&% MIX-A[U!>I\ADF9$,FS*223A-YT'R&*\23^R4.VQC]^D8)V'1H)SNOHSHN."L M= Y$YH@X=!C,0@GI&8/\5=**]6FRVA?
4X3RT%6:LT!;=(!\;>L*?>_^%*/$N M/F'CSU\'!ZV"!I[FWE+4-M_Y:L5@T]TO5M7E?=.1#CJ3HB/\?N!AR K!N3Z^ M(A]+.2P^-8[.E_H46;;;/$6!8P4+(7F%658 ?3U2G(9W8+>Y#IYQR#ZY6SSF0
M^29VN_8I/4;J"B](IMM>.)/O+_+" XXTRR:!U^QYE_3J\T+IV^NAZ(X\%'N MN:"U!UI"BMW,_/_+HQ?)28+\M(S\->;%MICEM03!JN>&'F5[_^$Q4>B1NL:@ M_=,P8"8J3YJ(\YI>UWZD)T
JR9\P@^.!DG0']!8Q(9&6EF9KFSU>!_."9BX' M+D^T$CZ8'GJQZ7XY%3_^T\6L%MK[$W5)K#Y@%)T1#_*Y=K!K&01AQS@B"MB!F6>D:;>JIF5M: MUI>4QF3-;O^W@0!#D%.P#-TL8C99
'1[@WE6IE?K\9Y/*O"2:>"Q,:<=B%G+ MC%ZG:T2+/Q?\QA0_G+8P".D;KT3_(5.$F8T&VD58J;')?;$=7W'4_2$0$&8U MN_!9+3Y5\KT(MR19'Q"$485T'WA8;$9IA!?)LZHHE90[&R6561BJJ1=R&YF7
MI5GR^B+Q(-[PB4X7T J<>7!^2[(J]8+!@A9!G?(2,=*NMY7%PK?IRGN9G[EO M1>A]Z4!)*Y)E$329QP7_^6N(L+"@L:";]X!NA6V3RUFO S'7N94L5V:$ I3; M&(B)] H/*K0\+"_0Q_]&-;V
VPC$+%32E',=?>+35I<7F%^'O0^'TH#M%UJI MG)%7JF'X^DJ2SQ';8G$Z;ZUNB(,$P:WM$)[B('AE'=T8[],"N[QZ;Q#$MLJ9 MIR9%WIF0T10$&6W4,WWD&FT128Z9:2#Y9<;4::8V?RIO
@%"GANH4A =CS*K M&5NMYRI4LKN_!03QJ?>KB,&0+%%64R"[?.;.IL-;AS1%@V^+7=^-MN8WP!5> M.NMMEH",A!:T=I]6"Q!,Q-)X61S$:@>"@-Z;>IYO&W,4K3!L>S(0@2
MFH?:1NEDVTX.";7M4B?^BX_W3H_(R*^6ZW]!VR!$&^N#1,*6%X. J#A$%9PI MBHWB-09!"@G\MJV\J$5K]\S&S)Q.I9[F19!:>CFFQ:=/?Q"S^H32G RYE*DL M+GQRQ -F*NOW0K$X#E))HO-
N4PR MR2)*O3<(8H>SIF/5;8O<.,&GXTY&?E@C S%)Z;BI:XRX).BJSR,)TG]Y2TRM M)P@B*RJ$RAT!IF3O]@H09+-"]DBP_7I+HM=X>YB\%PCBAEO#_(RAA9<_1R)) MBR+I#8<=8H
@I@QO7)BKXA-1C6/B"<6$TE@8O&J8*K2@/0B"5 O5D. /$EZI MNMQ$[P!!N+HF(M*6N[\%!/%9D"1O7ZP\!C' #MV@ MD-?**X9/"VB]?*+4D9+Z)+U-YX".BW((QW%KG";N%=S']"**
MEG<3D0$30TDN[^4KS=I:\"-C*]['B]26MG-F^M\MN M!F)6&]Q@W,]:BVK)_G?O^G5WN; A MB%G)+\ME-S(JB1DR:RG3/2GK!(*T,A*7<]TD^G*J/>'EK^CU(A@0#';6_9H:
MH_WT*O>XY^SZM\UO+V5D4!HDQ@D883<#P2=DAI(8A<5)GK_!<)J"(-OX!'Z M=T*VC#>)(X+3% 09#X%?9,9/CT "1SNW,0A2>@N!:LZ@Y)"N^RJU\IRB+5B;^PYO3/=KA(QG50XBU."&D
M'*WL4,9;(3K?#P*PX38DO ;3:R0#.."[?MRX8KS"HW3(2&\]JY8OI?40!%=P M++P859NO $L[@2"M5#A(=?@[/[O44[$@,M>]M!<,XKBWZ^J1@^*)[/X6$,0_ MH+CT;7),^&4#$$/F)
(%*8^DKV36+S)KL0T7GMY@_'M!$'CYU%(E2?51;@)BQ M\C)@$-'<*JP+]=+&($C1F+9MN!B[UD=_0"?,DB"T0\JZF5^91.)'JQW6[FE^ MP_(68=LTS&L)8HX:!E*^!X/9T+C[B29-;K-
2XQ$(I+\B'\LY#W/URCFXODL< M>,0=)#B@2[J ((L7.E6H1]L@C&KJT(WY+7]]Q3.3JY580GB)0V*1FJ6@,0EIM1F&(#[G M/2#F/QM<>,>,KM6R2E'=X2PAYY2D MWM4\F;W/
IL]ECTD;UP17Y%>-B<56(IP[K9Z.NCG0"R"NLE-H&\Q&X(@H7YA MN9Z51>!M5^@&@KPR](1$N(GM;KRV(@I[+GD$!MB33V*W8,5(WJ;DYGC5-P# M!%&"P$J>FY?3'
HY]0Q/DB3MHO;FMXMOF^=_(LN+]R1^!!\7>3F!.>U S$@> M$[\)5C;>F$,DMJUS-)>;,-&*A18^Q?77M"V(VV2&^ M-Q_I>8$4A$OC7ZA^M=ZV\G21HFST^I;W[^MJH,O
M_VH\BN(F*QL6(W)NQZO[VHHMAI25M36_9HIJ6,PJ 9PF(#B_4;>N2Z4Z8=I* M'>\% 5!^PG932R*Y1<_,%L=J!X2 (G"-A*K5@]?X;C2%;L8%R'5@TWBQ_Y/@ M0:'0PT=3O+.V9
>G&8C9&2YF[C<:,)='D /+5=%Q<""FBG,Q@K^$A!T@DZ1: MEJA#=Q@.>%;9C^*!>36BZKT2G22DC4$P5[KS%VNX9 KF*9'7&-0I54976^^ M%KDPRT->]%VNT?5XC?%%GY?&8P?
>U)^"F"M:BQ:?D$E@,D9:>$6IW1 $">5- M0G8"Y68U5-]I_.7%=^,HR[^AP)=#?@\&H.=F]<[\G14[,]6PM&I\DF]-&\B. MMS6!Z=H=!P=BJO+;U\\H?",E"9C@%+>"* [1)DBO9DTMX%
NAK4N44^4X>%YIGCJ9F>4%8DTH_$-0^H/=*EOHP\/&/Z484-MI0([_5=XN.CZ#N,F\5HFGBMR63WK@R:!-_MR;O6Y\T;5U?Q9H_22F'I*_)-25RIX;0G%][X^6UZ=#9/*GW^,!"PFCS<5WA M&
<$R._-,(B>A9GIV,?=>+P"QF*X17NFV:S4O-[*>@QAP\WS$EVKLEB"(T&4Q M&K:P'L,P0SP@1.\@N7BRA<9"INL[0!#.UR\/H:(D4K0M&QX!@3-D[#)&R$=;JZ1-.2DZ%CN!)/#?;"/\E
MYM6;4N\@44DE>Y,_^M1:2TJ!6-XFH'7T39=A'N2R30G>^XEF^5+2KVV-VR]W[@!;M3Y<8O M1X\?\F,@^.(.\[._<\D]WS2BPO7Q,>P>4^+PC=O23B!(HQI.H[@(SZ[-:VN>
MW9_=#\QL619N0;XD3CL ! QF-'C)G6EI9B5JEPZ(Y72UPP?1'59BZW64VYB! M&9IQ.V->\TIB=YO&O^HS$"N;2IV[PQ&K^=3;@.=HQU;.V"V-HYW%WYT^?7[= MN+'70KSY' 3JY%8RYF?
R/\+_;Y9'.'\57UEA>,**(#=40:DC"!(K%4FH+DNR M !2%XA1+F? [&F>[?"'?XF.QY>6!!782\59\JR&(61+ZUCL[X\WOD*TD'O@/ MW4W.O=X"8C[/-3[4-Y;HV6L(&P?
C,R#@XY:>XR(A[@&"*$8N>GX@-;:KB9\X" MM<<@2N/C/G_#+?;1.KP/\.)F^DCT?@$$:,RB5#53:WF/.J]$Q8P9ZO4B$!#0
M:T5;K'JMR%UY8I3#"N9ZF^7HM[S*F8V(B8C]B"]J=+X?!&!$=KJ.:X6G]")Z M&O0NJ!#"; R"%$Z-SK2^^KF5/@5O-4%\O8K\%3Z.[(CKDF/<5.\%@K@\-.?@
MQNG2XI6E8C8$0<+S/@AC8E8D^XZP"@^K(0@2Q#LF=TX4NH$@KP6\0.%D-P5! M1IH)+\TQI%:Z3MP#!%%WOAT2P_8U2O_?RE+*%FZ23L8-,C><.HB?FP89;D,0 MLU-
A&J(6=;*Y32P]_M_XSG6CU!:W$8@YXJ@U1?&J4JWIH!0Q>H,@ M5I0>5)@F6*$?"_+;ZX24)!-;J$4]X!#%RP36O)9+[!I\4U^O-X$ X"8KC =+X8!45'T@&3%9)?FXMWMQIP?N7%^2S-
EB\K%2JX/:^AO@@"VK(HBR*E+?Z)V'D=#=/[JT;1K%"5 RG MG7%E$B\#DF7Y^71X#;SJJ%L/0:R2MO*@IF* &#S7V_5%6.M5H1L(\MANS=3; M0X,3*Z4@(GY,7X_7@""?E9SEZ?E%6(6-
WP$(2>PT:2+U7M8'@,C&/[:W$I[< M%C0&,4?IPKCS'?11U 3)I9[8=JC6$P21@^4T8>$RV,?,L_XWUW45DY%<4[$+KN'=MRV/EU>0V-#]+O2/'2D-!:GJJWB"J%%MI MU1T?
[ZL@I$G3)]CP&)8I&JB9KAZ0\X44Q42^.6(MC[[TIWOWX';(_*CG>W VK69R>&F[/T3YJ MW&B7W\JY^;#WA*@'Z\"]N5-M T"!*33HNHUPD.L#B!($B;2S\M#7B?4 MO45J%S-WY\XO
4&ZWBM;X^;9GG V;5HV#45QZK:O).UD <1M#(*4QM4P_D&4 MV=#X0>2;]4%,P>QZ%+6'(-"6!7,R)9.D#PC"ZH*37GA:;U^B-/^)4$MB=3!_M(*B4?JY?8FD6-0A!DA]/6CH+)6]H[P6%MSJ] 3)*
<^+0A.K#4 ,6?T>)8L>]=[&=;3<_$O< ML;85,71,?BL0,R6,EN^3^[+1$P:1O;VIY)_?4JY+R>.7V=#T?L"]73PY'F5
M*^[G['P\N&^)_VGC#H7T5M^MZV'=)KUZ73LA<9J85^Y:V>W7VRT*TXH7N]!B M'%<[=#,^*]DFFN:^(O8PSET_7CL0J[=13QVKT!5E5+&Z^KWKH[L8'9AK5.L' M0$ F-)%B89,E1T?X6&*36[C-
]G)*[T=EM/@<(YLJAU!S#)[M;U'?A4 0P8GVYEUE$#0'0_2 MJ6+TA'8DN:'EQZQ@#%8;$+/$2MC&X<:(QX[;4FL-0 RY8K=6*10E: Z"'&ZPS4N$MHEW[VZ96X!"-/GC>)*:34]*<=T
M(&@+8IZ*T_"=?\0K^9YDF?[$%W."YB#(.5='_HU=_* BY,8N4'7>B*8Q*5QM M3B44Z?P9T/=Y$' S\K;RCDV"0UV#AA]N,5^\(@M"Q83CA-DAZ9WQH$,3+C1U5_S&((3OT2['=[*PQP.M:T 9F+LSBZ
M6='^U@O>'W!3_&,9&>([C+24972_B.1SWPD"F.)>(M]"6&L!8M#\BSBB=2GO M!8*X(>0-P!)!8FM9WR8V72YR!F@6PIC_0^5ENE1N9W'/'.NYY>, MR>WHF^T6\3>U\48
O3VG206,.U6Y@70UR"5BS8*?<%94=;6/"%Y]6N2R:VF M'OM.ELXM-_DP)*MZ7Q#LQJH>S'>:\%N#(*92RK*P:^55KQ1+8'+[@2#P[G$M M*(B3/P0QU"*&# OG.&/@U)"IPU*0J]
<^"@/<>Q3%QAE]AY=,5W-)EM0.BES[OD><)HU.J+8 ,>F-] MW#G$L[IUTY2)(LV:TQ@$ \EK>P"JXD&5G#R7)<_EW7@.A&&RH/0A\\E,]3IM115JUCWG">N\6J7FW4J"2WK?=X*-=IGF_
MY&EWFU8>1=,.H^(W+&"$&CG6N6R$Q(YU9HT#O88!@CXN9;ETNC?SS+-Z&\\ M0/49[9J)=]O'5V%#X[M37GBMO(UUB__2VI@XS4"P',-.1Q*BY*4FRU*M[O[MRKU!$%LW-
7,O:S":@1C^N>%HMT&X16Y,DHVEVY2;%DHJPJ.&B(&3?A0$M%DQ M+:I4.>EH[WQR:Q Y7Y(LN3\IN\5>!&I]@1!ZAEV^L,#C_>081);W-0R2(^Y! M]I>T=CUR,C65<\MZS.^;UXV)+?
D1,WE(KXD+RHXT&QG?VJY(Y$6(K*O :=]! MKCP#P=1JA=0@5E!;;[>NS8A<:STT/]3>&\%U$K)+CIS]1O.@;/ 9XH_;E3@% M :L1B'6S#G>6GV58Q0>B*/!]0Q8#"M+KRUWP P*!#=*2NVD M"
<01+%X'V*^YA?J%]&C**=R2EV@^R]'WC![G05A,<@U5BY-TU[O0<$*SZAV")]Y.0WB$1% M4%DM01"QQKB3$GYT8TIE(9\.;F,0I.1Y]3?!RL;B/D2=ZC*H]S:NGN=F=9HS MAD9\I4Y?
GOF]V0[$;'4JD? >L,-3.KT"!-EGW^LMM&)C-XL[C<"XMRTK[\K) MZ5]]"((_*BDR^'*XU0C$T.O6:_8^6&T!8M##9SI8[78AVEDQ&CY96N_!3'LJ MI(>[HH[UN#5I-(X+Q
2U[Z50@LCU35Z1@8Y=09!9%O0ESLL[/W-S\L6QL ,, MDA1OR(M2WG=[!8@C:F*G%4/9NRF_%8PY<_XGR6)(-D%>S!]H+B\=K)6%G[M"X6XO#LMC-0=X#OF9[_8Z&BM:
<*P46YB3C.9D[\45TA;;-&M.PA^2:>K\"81 M'PTM+,B]&27L ((DU0/>_J(-^_(>T/? C_>LZO#]'P7""#H9IEND>66R;30 ML!J:7XVJX*^V,0K3.,&D+:M[O<4\\<33ZSTG>.O$XR7#XH7#L-N!8,"&;Z"A

*M"[SX6*GSB+/@*Q8=O'MS7=]AW,Z6W;MH)]WD.)?5>H"8386$E94TM^LM"6F] M^8CQT(\V$;]\7DB&/4"HBR_^",@XH97 M'$ZY)PBFIC[*],.1,>NDD),K:=Q2V9>T^K%CXYX6K8NYQ)"^%=MU#[\"8%O.28FLJ+52Q'''5X @^}G=^30)!3[.M=+!1B@634D_S[-M88/GJ]\1D-M8B]9Q7X@9I%E/M"/GI/IX&KFDPK74"0-,S+O!V$%/,W00"M;GP|Q_9N7A*D MMRER(ZSPRD6!$1!CY?/!\KPO2>3Z*.+DB:DU <%.O=<1S1^"M5[RL]8%6GTQ M"(A>GCBI6#9A;1KGU!S!I6U%F.!Tl.'HG^1+&E'(B;"5V"9/C 3$A=_B$ M]A#MB2OZ#97A;1>&^'LGZQZC$F)*7)<.6U>#+1$L)N!'5^%A81_ !E9I M\6< FB?;\!!+D4[#HSI?9$@01[2#RMB[*(DFE'P@"]U[< MSTP\E%LQU@^7X M+%P59GK<O$/ =F#L_"E6.VLS0#YV^+U8WK MKMD]\;7=T#LEBM5ZV&SR'9>&:+_UGL.S6.67Z^;/D5FL MVLN/*\BA6.C6*XECR%$:10:/GTU;U8-?_VK*#9P%?@.R2?LE$6RD2/%\L@5 MMN<]fF8C'OT6V-.*7BF,V>6Z-#P%>7&4_Z6.4RGNW!$\R)F@eY-P/$[?5$E33 M9^CLA)^K^,H*PY/K[VI)6QNDJ/4U1EKE2]?;U-@Z&"_"?'6WR5OLQA!F-/.) MM=SO P^+NBA^ ^\^+NQ@CL3!)$(a[S/.6=L;6Q>E9+@]AGN\EZFR5#@>_ M(-4^1+.dT-7SYP2PTDRW]1'7FLW KQKII/1XDT M@RN44&#L?+P>QLA0XFG:OALK)#FS(]PK)8>$%$IBZ1EO7=GESH= 1R&[02%2H MM!DT^YC4=7,859+9\37@3F\OR([5\O12S8O;'((L9Y1+>Ei0(%E7E*T]!@6 M]%AK<^$SVQK>MX4;MF%OBY+!75{/]F7>SOPO\W1]]=O#Y9D@EP>5DN&Z5NY" M ,BP.L&%]ZO!"3Z I.'5>7 4<#XL L-NJ+7|&PL!]=&U9$'$*0">X*2;RN# M(/.L(>NVE\[<9TN#)SU3YD!H!;'E04*K&SXJGL)%,)E\%O@{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{VAS4NZ"'I.3+,SY()"XK6DW! ; _&U4:,VH:U6[U;H M? WYD4/]W@6-I)3[--$N>GDTXNEIR+;CY0.+L1-W:I^WN@D9Q.D0:. M12\R] +D8371)N#L[73@KQ8][QZ()X&>5I\0UA(C-T;/*QS;902^83L8.?3 MMX@]UP[^V;Z ->N$A_%-N!*!(D;\(V3B?O?7V=RL,+;|5<,K/&\89?]Q29Q' M?06XL/S+I:6Y7\@XP_#S_9/12.;>1\? OGWX!8DGF&PH5D_-I#1 [|U!MIL(8 MDKE=R<97\XZO+6F+B*D36A$Y5[?STJ8B .ID^*NOPKI9:5EHU6R)3%C8]W-9 M*(C%.-==JC50#:@45Q9.$OJ(F+I.BR["LLM"QIYRB0W;"\B^E%YX'?%.YHM MZ2R^:AGFAXCK WB12EVH[]O\EY4BK:<4$YC2%O$MJ6&]RB&<=OSE^4S(L>]O M(HO2 P.*X9MW$*4:?.,[6H8(OIP8V+U\-1ENOUYPZ^@CRD]!%Y/(> D-/EW. MQ+PKYI^T'NL GE'Z^EB(;ZL 2>M!)+70W?C.!&%B^=(*E+2>,/@H3>$]@eQ7M M;[W@?6*)7;%\"$E=R&N4_O _+V[#9L]6//NFZ@M,YA-MC/$O+==M^G;$GLWR[M,L%*+S,9ET!X\S$,WES,:5].+YB+* .TLF\W+=UIQ3/=XT4&. $$6S<61&)4 M&1@N/Z]{# 6+'.TNT%CLSG]#@0S6&[W('(M0^R4.F/U(43<,NH\)%E1 @,E[M/AF3D3](^,=R(GPG2QM?CX0]K.[*] (&I"),NL>^YK#0)"]S0IXQTW3DC=@+1$ M/.EB1^"^%\H)K8*+N&$W6$$NA+C"9X.#]5.$IM.SX8RR*2.!J=]-1JE1%] M[<;0)#AC.?:3X*(7F502:(2P\E/A4R^))PCG+U*.\TCK:[7 M]@<&#R.STN9F6V0$?Y?NL 8]F?U*=?0N2[_0%824)LL4H_[-BLE*:VW_#6L M(+]fO.W& H>.8\?9IC*$1WOR M'U%8W["PPY!#&1Z3;=+U/U!:IB[//D02780F4DPER9.5HQNLK0@-2,. AI' M,0Q;9UO&#)H.#L0Q^O@=,IHD03RX!5I241=\"3 \\.(.TWE^C52<*(FYQ5& MEOW .76[W$=.G+6M;E*H%?K!'FTAGF10#9WRI7X[\.CJZ% M+&O=,$=(/(U0KOHGAMED&R/W=/HT-2NI'602Q&@#[\@M5SLB\B=H$=`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fG$BD3-S[>N[\.HWGW#VY*(^.D 8(4\UGDPV!U>T5CHO"%B18^$1/9Y MDS$&R;ZS0OQ*+7$ZAXU83Q.>;[C/NOE?VAQ"K"@F&FOYI[NFPUG5\#0YOL%B.E MNADO(HF7&G1RC6 1"36Z\9E, ^UC&+>.ND#5UG$5*H]=(.Q(N-.!DIFAMG?+ICU5T9S$A^3Z.?OZCV#0V5F);.WZQ M[=F>DTV7L .;?R/R$Z1W\A\.AU_IV81.F7((_#FO-F=UL/?(24C*9'YBJ?SN-M? IJ51PF4LU\+0TIVOCIP%ILMXKS;%=KS&76\DS$ 3Y12'$E*P$=Z2)?=\HN59Y M0H3>G;>]V/A]K<<4Z.B_)5^YZ3'&K\<4Z.B_)5^YZ3'&K\<4Z.B_)5^YZ3'&K\

M?*P^VS*)S6^O62G,(9(/3=H<%J_=?) JZ!&B8RP>%JSPJ0N'2=^E>5*$BSL? M3#D.UD1U?87)G(@V0DY$ A6RT>3#$R15YG<*YI M+D8201#E@WOQ'40K+42%S9H
^[V!MWS@I/G(F)/2\U6ZUT8 KTHN'>9JX#:&H/4KV"1YK>$,7V[E$7:!<&_J"A* M\7DDS;OTA&SDOI':]169R=,&.[UC>B=YDIP**UWT9]W'] J[IP=-<;A)+665 MXCO4O*;+=GGI@=@1S/
[XBH],A9O>$UMD/TX37>56\M-Z0&,\-F)/GX=.^# MO1<>?FU$4ATT>,KS@O?B;A5S,QWVB] CX9R<,C>$HJ5]R"\"@[$YOE3G+4-> M:?A[[1Q/PZ-S0BNJ0K;L.D&J_^OS@/<>+[PP_0+\?CV$ V
M/PD,R.[*S.#24IN,U+T5-\5X]8A=D3V4)[3NR)T^# 6MZX199$732Z>WC)AZ MJ*B,WQ!?FAYL]) LQGA*"<_GH/439H%ZE5/Q*J(B=:B48D*$F/9OF;O]GH5: M9?9--C\|!/X;'CA*:8@V06QYU>?
$+OT0Q/]"\1.R@YTOV.F&^]|\($S7U6T0 M9G\B[7@+>>1!3$\FPC"YC&Q8,0YW1=.Z\^/0]2/7'A)8_OJ;=S8L2)8,(JJS<4*+,IIJ>>,K)8 M3MU2-X+&1ZUB)2.)8TVX-J3/1"@65J'L1/)$%H/29'?
+*5G%1#6GX40P$K'' MT"#-B:$862"K@#12&DZ$7A%S="%X3A.ME.FQ64:3D4]Q!DB(LRW63FA\S(:@ M<9 K5L)LF8VZQ,W,B!,E?495?A04YP%3"Q6J-CN#X,214TK&4T# S?8'&H4%
M5(E262.RO+6"K6 2$"AOA\(LA344%,[CH"&1*OYX0;\!,A31R,KF$':ME2)PZ*#H.GEBUY"7&A4RT3LU2[%R$C,)P&A8K!?$02'R& MK5_54X=,'8!.ZD,)"#LU\M3!,+.A-),S3QQ%!9M%/>\S9'HU["D-]R-
D:L!-5RB4- @HX#5138:5!P *GJ@Y7:FD0_, HMV-[[132 M_@X"."P->NCR2H- "$;+UK;F1:65!@G+ J.5BR$0'@;-51FD0 M#,$=!X:MH#0(AN#.% ,43QH$.# 'D3$K+0V"))C3BZXJ3(.@-)]CBZ@\TR#0
MS>?$PBS1- AF8 X=-UVY$)B0)TR29Q/14A!^O?*>..?,Y.>#7 MG=9;UN7?:Q1;KA?]8*R:%G?2FV6PV@W-E0!CAO;Q!IPVFEZ],JD%N=@2TM,I M#X?1O@\7XC-N[W=%L\^GC $G24?
1$#P102K%+A_Z2'Q%]Y^;CB(B,W@0T[4JI M=#-U!3CCFB%+%VK2Z*5]=0YMAA-CN/"R]O'-<(KJ&QZ*>HZOAE.4;9?)B&* MX,U/I\%-?Y_O.@%PQSG#A5)1=AKT/R%B!J"70?PXM.R8A/R38-
71UTN?,.\TUJ?"D6 M-Y]:3B.D@IQ/< J(9(#S"4KI[/"!G)5X G RW#N0$YX:COK6ZO"!G!5T IS; MQ8L#.07G!* &$7D),T8=A!,#= ;)">#=S6,R[T2$0&RHHP&_(-6YE[]CWED7 M@7#
[V/B#NY'#IB!C;EZLOUIG8\3= M^5@,H%*4DH^0:>'?7A#U@$:&\ Z-N,]\2/F.MPLK\6*C]WL0WMCWI.HB>D-> M<"2CS'A?=LM'VM,865^1C_58#X]MY1SPAHR5!0S[&U(A3*WO=_,'M.VU-7U9
MWV8%V:FIPZ?>"U_5G0XT>$JN=(5MKU8842R3)X)'M@T,#DBQX8 &1CUT0+>* MK #D<#$((PHI)4VF$<$CUQ,F'IC1&11%+6-*YH72LD"R:[NTZC(IR4WL@"Y> M2K[MHJC,VG;G;X/PD,)DUH1
K4"5,G-7+MLGJBAZ"&$645[&-OG5]"PMG?Y=F_B?B *L\]VB'>1B+[OA$ZH?@ M7B@\6AD7B_)@Z/R$,: J0R.#J0]/..LJ/>=)UD F*8GLIHF&F9*O^73<+<7Z M<_)@3NP^G/-V\'OUA^DF
+>5U]\K%2&$9ZU?^(M*=X_8R7,MU'$WRJ4^XX_ MRPRI4W\&S;Q[,;@;E'3XM-X(01!,![W=;@ MG5E\/J%8HE>IWLUL"V?HDA1Z[-;3'KYYWK]'<4QJ%%R%R''%K,]L.JJR4&Q&
M7U&P"ZWCWK4MCZ,||-N..^345U<=!-?6P&\/O2&;.3-PK3652I#I*2+8! [E"K[#GEG&INW3"*\<;J$1WA7\@*^8<87E,MP$?(_G$7O/T4Q<[JS#[D?>%A* MBXS75/.(FAM*K5;R-7(26A^Y6IFG/=3.
[]!,0^EUESD*.2V"\@YG.@1S3V\W MTCVSUNOST1*AT6@Q% KWKO7J>GC-"6$H6QFT D010NLCY5Q_1XUUQ%I!O$&I MR8YK$Y!V!74_+1>VI]
[$!1M9=N7LT1(X$;1&83,4+NE#+9EMO87(!*#:B" ME1\"WT["$+5"0]3[2&)%FA;;U^PE,>,H49.LP^ 4AU75K3GGP*KC71O42&R MUMOLT$1D+G-W:C4RZ]G
.Y.;;>)X=7T2^32:377K39D>E*K27U)AQ(RWXK0T M9R!'>"7C)7V-C@'6.WE[H;0Y$#G NPU=R&0>EW1^#4R"210H.6$^82[/%-H^ M!+-> X1@\=5 =MO)7OF1QL96@YHY4:@3#WA7@D 8]#I1
,YP'A20U,^;H(%0 MNF(D"6&MW6OCAXM.'X'

S_P@MWI*@B/05I]AH]DWU=I M%S^DUI"B^&$WU2I^J)DU/*4

=WSU6 ARS6LRX0^1&)$T%" MM)_H@6+R6X+RE1V!PC8%>:%\W5EX0;"6+4"K0@(9.T6%7Q0Y6T_[Q@GTG @& M(JER+@CSD2?B:-ZZ=&5%S(*F7ZI@20-K**&=+B,N M+=&,NC-
"&$$]413T>22:\=L3!D1D^JQ'@$^4R',G[W#:"%CI? 4SW5K089! MM[[">^?* 3*^D+UIL#$"[IU<=6+[RI,% A]&V3]FL1$X1C6:7;.+0W(@.K;
M7AI..VVCN(5WJE71^Z$1?,.\-0K%*L+!\;5XZE7"NZXD;*N,D^]6* Z M_//N3D^]E&XG)N!?PQX$!JCGC>Z7N0>!!ZK.W?WJ]R#P0-,Q)1?%IUG%Z0EY MI&K@(_&1"R,V"$Y9NDW-D!I.W-
YA$1P5G0>+U#B^X5%@9*[WI4&PA3 ,O[J,Y=1#^ M@/W'[>HQ)(XW-IS\=I8>;T-G21$R+7WD16$A5>6-7"N^D'TW\'D0?I 3J%&0T>E1O[J$I MUZV>ZDH;9.1
WQ$POU@X,29LU0AWI896*>"'P(\'5:][8/:QUOG-XH(M0L[AIQO2+W(Q"3=^/?NMAK@L]Y*JVO*^QD[#)=# M2\/[[KG5E51Z=&4;V_+LQ+,&]*L\X7_**/>K-+\1G\
<<J@R2*0X8RSVJKG<\LI^+Q1XEA]2+\R<7#XF]SFD8#',W2)]5). 5VAXQ0R_,F$.; V9YQ"PR M$0ISM[U+;Z>IT5OI,T4Z)21-C4<;*ZM-&XG.PG-+- D?F],WRB%MZ%5]987AR M_=UD&59
N8)ERI"S;4*G5C^6I5V)6?4/IA=;[((KP]KK>;JR/ MR5-O$$LEMS)F]2_=Z!K'-ELGIF%LS1X:'MR5L%9HO8VY*&[NDFB&:+<;&ALT MT^C)'#6KI;DJG(HZ7[,BIZP;!(+D8PU+D':&)"#&723H!(:9E'U.@
MI=G'X'T9N?F+28]"1Y,'+[F=BW<0D_8T.%<\PQ9GACC-3>XRW4Q6O+VGTUO, MB0FVO8HM'IAMVR%WC:"Z\6/NREP&-E6T#&;]9L69CI,%$U94ANL$O> !A?3O M9265_ 7"9PC!>JQT>,4VE!6#
(60PXZ5$?3'=66(/+$$_;-PTKVL_D?";S12P:!L>N3V,D=%8 MX\R!U]N8/0R2OSZ%?FXE8?9 M=>4<7-^-8M+G[5QB+RH&[Q@K'3"KI?EAJZ:GA)"64BB!>>9X01]S_,V706Q> MY[8W1H)4OC)D?
6:OBY'W#ZW7O .16TCXWD,@S<7_ 'E]()'?N<7BWIE8_"Y M5^!PMZT;3TJ5XQ!,2B+[M@K!-D).=(O?>1=%"4EBL*8Q).MMXU+-1(&X\]]0 MI##SF6U\$ZQL3'>(N$$;TU$,"1R-
J,>ZLQ:35?]#I>4C"MT XV>'Q/Q\C=+_ MX]^]Q*&;H[TG66!(POB;[1;93)M@E]4X;393%##/>WR")V4JZ*$7BU7ZNI[HPX*.HH[_C4ZALAVZ_O\7V=-\NI ?!? H1]9;\E2R,L+/8;HX":':DG.
M&>/0WH:RN,_K[!H>,_ZS6HUSDF*C-SJ-RTW5DIR+XI+VK8=:.H')F9 :\7@S M).L(;>8$.JG:S+%>8&[F.E@=V3.H_@*C=[?'/] S+H&/. AS&2PX!D8F*)S&
MF@M:=;+\U<;9N;OFD2N9/MHC5ND&1^3(C!AJFNY(4W2\@V3@'_/KYM^L\(_$ V^+J7Y,S&#A*J815S&GR&0<]YVH9^>,8G;NYP$<,_6>@&9F M&CY6>__9>>E7R-6-D,M&J)J9%7SKNA
MU#OJJ;BBW'YR53V[EGF&5%K#.?!U2%!6B=.E?837B*9SZ.N(0*/;G8\YA#A% M)Z,(J*3WSH]1B*+X"=D(GR 8==J@![CV877:A-WQBAENTK&FP9*S$')]@4K2 MA>4%5.EH>A(J D.$>-
G,H,V7N^(Y5EY>>\T^6G+K?B"GJ7U4 M_OB 8DAZACPGLE*1-JHL3TBYZ$9V+7=MZ73%/WN(CMIWJNY,^0W$3R"C'V>3 M(5O&IMU(23M!2(I[)O.Q3X2Z7@]?-&>NVUSI*,5SXP$<^2Q-
NU^HQ%E+H9HU MN1+.*M3GC6\.1R\X(?2$*"]/N49J%[)3S5]:%[;C_;ZE%)7@J+*=%E-;F^W2 MW1CX"NN%.0GR?H;SJ7=D*DDG@+O:6!G6(6R @R58S_L^H8/E$@C((2W"]/T+ MK]G)
[)"#PX/[/F"NW;PC[PU]PPRVGTX^@C' (=RR>0\F8VT=#1,LTJ>376 L M5&Z#).QKDYX$*%3]4>VXVL8H;,$"LDSOLHL[2/;*_B2S7P@;!..>-:LMUX' M'H!BUSN+[OPMTR WW=#.)YB^9Q(DIV+Y;
(KI:S0?T'MN,>VC>K\7*1*LZ?D MGU?\YO3/__T3IN._K./1];W9.9X=PG/M?A\#'1\/P=(>UA@W^^P__*TI>H]B-$S+NKV&0'/.FF6)!?S[2 M:[@;^B+7CV*+G,9]UZ.12/_X(0[)SFF]D@RK-M[WMY9'[V?
2OJ^61QRN__C! M#I&3%PUDH]/IOFJ*2:]BI$@H5U1<9Z_1I$=NL?L6Y1N M08,JE>1:M;\;A48!-=]YZ-E%P0R'C0IL' 3TXLRVS!N@[_Y(R7+BIJ $:;R=7KG$WYQ
MWU!UA_B&#J^HV%N%39K3YP3DV#,PL?1W$?\5Q:!35JO3PWL*DA2*.4F#@YSK MA&Q8:=H/FB0CRO?O]3;;T OV[-RMMC/25J87X6]X]UO[5,VNSQ_C
MC0X90IC8^A<=!2+G\C4Y(F9G7AKR:@3R]N@\!#!F4_!$*LK M,Q?_IO? WZT_R&TF3,>+CQ6P,,(H_!-97KQ_MEV$93 YS-]A 6/Y5MFB15O]BB]IIUR%E8$$=62PF 76H>&OJC8
M&CJI^;"YU#4;@"3H3&Z?.2-?DU).I#0GD:OYB53"SL(^(,DFL4&!3\|XE>P2 M=3+%;4"2Q MFKG3:L"I;".7XYD6\JYO &/CD>*DE# R6S0J3:=#>6W*TLRH)-MN(WD;N050 M"Y(O#N1]NX-!2&
[_>T[PZTB I.]C59@HWD\TGC13V#E/IR,C"EOY>EL]2WGB7OSEC,7$K*/NW@G[2*<]PZXFT5?:^IU M^?7SS++EBR :3S>XW1^W*Z9-C_T,Y(K/]^UT@W\,L81ZS#P.I0E7T 2HNX*< MN?%(@Y#
[#9!TED^<[F'3\YX3\H M6Q-[=@8)1*>KL9DQM4N7Z>RZA8J:2_L#L7BT%-C&T^G0=^N&48RU(^H$P*-L MB!_.4YA,N\-K"^MUB%H@:.QK;H:@UU_KT; %WW;L!>: HL"[F^?4??EHA;&/ M9[
^N=S'(&\HGW@ M.6D\VWJ;1I2N/"]X)_#0$\C94Z/XE2K<,&)6>U-_M;A\#ZLJ@\95X,R 7N:CGFA$DS'H,X!R=; $J&V:9=MV,GL(;Q^M8NO#M0IS@N>Y M5EL?
5F\/4M@Q5N[-1U:UEJK"CG2E<]I/9Z$7AS;.60[T!)(ZXUX>*-"^G\-] M#).8,#BTG>1M>S2_#4RRB U+-$>78_\%F?2PSW,4AB7IZ_!E@Q]:F: MO(C0K%,D;@.2+#4=9)-66>VBMF1=>J@L3OQ?
^Q,YKB2O5/$9S8&2FQ:R>[/$ MBR7QF@AZ&)WM-'U'9._1P?K__Q]02P,$%_@ :HA>69>P41L_"_,2H M_\ !LNFOOV+Q>ZSK^+I MS%?Z]3?B=$:RP*GWVGV0R'HY/#^(E"
XZBM/,%"OA_$K3]WN5M!>J M3H5LO?F'JAICO:S]M)%%H>J+5+QJEE.M:DIFI"YF/A7CZ5[8I5#SGL=OB:H+ M6J;)9%JIN]<<#8]5/6V,4UZ9.K6DI5=SPO+3 RP.3)J>16EJGSCU&Z7C4>.G
M4:K$FR8=3<.S4E9*K]*/JB(G?J*%^&_J6?>$F?'>5.D)EGI:^D1J=8$M60[> MCSGT.^5&&YL^&X6_Z6*F/"6ND3FEC:5D8643-US$4V1&%],MZ6X5"_(L5.%G M::E\DH.2:I;A;#E3F?(BVH0Y0 W-
WZ"$'/N3?2!:>'OVX>/Y#^=OWWP\?__3 MEU7#T54U:"K_,!3^W)G/!^*MM$:3^/=0_)/]Y$>I*E,/Q(_#=\.!R,EZ5:Z$ MGTF??B4]&0_%N9C).0E+@PER9?.V EF-Y9"D("N@HGPF7,O-
MUNL79*ECP@>HE-_(6\A%8J'\#_=T#>5!0.;;0#13X)AS+"M$MMI4P]>"BU7;B9*;1:NAXVE"^6\144B M)-^,'WDMVJZQ)J<" MMYW8AZD*@NVC/P&T_M!H4XXE,QL?[]"(L'1\7\2I>*JY7ZH@9
MYB_8MS>@%$W+LMQYH_+*1B4VXG-N PP4G).VDS 7NKF6SGV_!^M5"33C$]+! MD8(%@<*]J^5TPE!(3X8G)R^?3Z&Q1LM56FI:7D7.?UO'5ND-&2@2*!_ #8A* M>#^79O!M+L%WH&\-
B,EP,ID\OR\X3H;'+\>C5T?C5X='1Y/CT7?/IPMCBR2S M)#^EGX@:"*4O5:'JT%($C=RB!"X4>F-LM!MQR_%H]'R+X?TXWSMR4#<@&#+9 M[_O'@)-
L+EMW]R6<[3("UKN=8OXTK04#H&^N7(BLH*(Z\.%BI-\0:%_)T MB,/&$01"_QD6-3"IRELM.7W@6$&(=0K'BE@0;-8Q^)81$\)@6$_%.J)S"[EN
M))^<]/Z<]/#1.>F=4\PU7[U[^0../E[NX@>",6(NFYV(-DIO4WBW"7U"XOJ8D;K/+WFU21 M]:U;"# 450%YILS\R:$>G$,=/0*'>A>A>AWR/ ?JNJ3P9+=C?4:6XT+3Y'EK
M&=D;5=TNMI5Q'@]X(@UF+@>G7^/$3^S?M*.$DR(#;9%WLN= 89AB\8"K;B\E M>Q'EFDEW601S[@I.345(ZD$E7<)=":T^D>Y&6EOT@S^OI=L\^?]U)''\AT<2 M82Y<] >K.,CA^M-
"*U#)6/@,VJZ:ZW/6C:) L<;ZR[KJ' #/*M*>4]T6SK* M#$HU)B@4) Q<]H$TA&+'V06?W(;U#D* M@H'"+[0UGF8@KUXFCT\G#C &&8/ M;S0*>BAPG^5'7;L> M)X@[(JDLL-
#192"]V>>ZC@9KX#@Q3 ?>H"HJ+4+] *"FD)[@%N'GI\Y !K&B4/78F+T,$J)=[!!*MXCHV90QV0T$(>CPZ.M M3.G#X*23*P-PR091^"46G(.?)H 9&CQP7U(QC3L='0V!P8X>Q]&R<92Z.#NA
M^*H+F-N>,\]M8KA*>^J."%3%#GAG9LG'9S&Z$T&[R_2C"\B]P-OM[?I7J$) M*MOPPO_X1N[E7U=DCE76:B<.R," ?UA>QL/7QXW,"A/>D5O24CW *%T$SX.
MW,$M;UALX.1>5!X5\,A4>C=U/J(#_6Q1[134_\HCWL0'Y M@F<;_R5]V4VGV_\YCF"1(ZX=ZL5M#H!/CHSWDCR^5+KX]MGX9+3]R_]&!=@@ M<2>U*:A?L_?ZAI<90QT3FSE^@Q$&;JMZJQCL
O?+[^YO0@O"KZ/U!+ M P04 " !JB%Y9H_>4R?4' "1*@ #P &QR;7(M97@S,5\R+FAT;>U: M;U/>J.D_%JWHQ MUJJB9$KJ?.I3,1SOA%UR->MX_)&H*J=%FHS&I:HZRD'_4%7CVCCEE:E22UIZ M-
2,L/][#XL"D[E@4IO*)4W]0.AS4?ARE2KRIT\$X?"MDJ?0R_:A*#\&\|GRI/B:ME1FEM M*9E;6<<-Y_4Z/S\89TMPH$:>8]]].T4#[)0$D5RW"ZF*J)\B+:A#E #?47 M4$*&_S=V9N3CV?O?_J\:CBXJ@9-
Q=]VA7]VYK.>^%%E4TE: MO $&*M,3&5FOBJ7P4^G3KT0-P[XX$U,Y(V%IIFA..8ZOG/BED18.JI?B W'T M$:82[XPMQ7"0_"),(7Z05N%,XN.4(HU7F6N)\ZJK#_^2E2WWQ?_EPX*@VK*
MI;BHS%Q3?DZ]J$$;]98;,*N,%[Q0JDK(:BF:RMN&(*[T5((;*U2*$D]622T* MF>&5%:9$;/(FTETCJ"@CYZ1=,DDI+PC[KO%T>)=#&&RI.5KP'DR0*9LU)<@J M+(8HM$@@&<8F"]LYX(\F713
M46@S=YW;6#I7SEM4(4+RRR@WI.RM6=]UPER3]FMQ@(,^1\0U;7W[;+$_&'XW M=JV-VR3#*#)%H? 8%'DFI*5@,IA 332Q:@7!3R9:N2F3,UF)",)1A)]SY3)M M7(
UO+\U.MJNMB:C'*^=V(6I>DS23,Q6VF MI7/?[\!Z90+-^(1T %*P(+QPYVH)G; KI$?]HZ.7S\?06*WE,BTT+:YZVF^- M8ZMTA@P4"90/QPT>E?!^+IT VUQV;_&^E4.,^J/1Z/E]N>.H?_AR.'AU,'RU M?
W P.AQ\]WP\-S9/)I;D17I!5$,H?:D*584V(FCD%B5PH= 98ZW%B%L.!X/G M&PSO!WQOR4'=<,&0R?X:'SU.LIELW-V7<+:;$'R]W2GF3]-8,(#WS90+D154 M5 4^7$RN8O)Z7(^M%\#3)M 5
'IMS.>/"O$9LCBC52Y]$'3B5*Y0?O$!5$SS M(=-4S*EQG'I#K'$A3X'TCW'QU([YQBKF'U[LGISI %S&TN8=5 !>)2=**[_D"FG;MAPX JH"8"+FKY"NE=HAV2 ;]6- MK0%8%RJZ+(-C!
%"T7U.%0HU#=SB"]4<$)@$#47$)@*']I%OG]#Y\- Y>@3H M/)U)W80\PZY+18$.0LW@=&Y+)[""J;>^0../C]NX@H!$+D?1<[$$FIO$WBW"7 MU"XOJ8D;K.*OFU0QZ5JW$& HJ@+RC)GY$Z >'*
.'@&@WD97O>[R/-=JNZ3P M93NP/B'+<.%ILJRQ[-EK5=TVMJ5Q'A]X"@UF+@.GW^/$3^S>M*8 2)&!-LA; MV3-X89AB\8"K:BXE>Q'EFDIW601S[@J@ICPD]:"2-N$NA587I-N1U@9][Y]K
MZ38D_U='$H=_>R01YL)YY\"]57SD<+WN0JM0R3[P"37=M=9G)9M$__^._=9=U M5'@!GF6IO">Z+1U-#$HU)L@5) Q<=N%I",6.LPM^8?$T+%,$CV]KG\L9P!S*X&(F%OBAG FM
M29CX=V/83\)1VZ['">*62"IS+'1T&4AOQES;T6_</3]6))Y5!/N::$YT%' MX31M$MLZL7XJEQXFC![#=._$55%A$>I[<&H*Z0FP"']^:O'3BQ6%JF9&SXC+
MBDJ>MW]%LVU&H[+69DGX.I^:F,;D%70"3?].V=7_,L7$X&&4$F]A@U2\1T:= M0!VC04_L#_8/.A5\>7G$1I+V86;3BC !9LB&7?G.#%3(7Q-X.'I+,%I0/HY,
M#P[Z8V[8V=H)VM&ER+"N'_A%]LD63&!1Z*]M9_X'S=83OWZK\| MK&$['C*+SFB0[@%Z\4VNL.?V-BYTK/G&O:@Y'OJ1J?%F%3ZB0[R9*BK$N\MH M_3YV-9-Q-,-
-I=F[Z3R[/\>Y+HYR[5"A&CM9C8#;UR]N\W[\Y%!X+XGJMJ(+=5O*5T#'5S^_<7P=#A5CDBQ0L:12S^72A=ATO,<7 M2E]_<[P7KJ+^"5!+ P04_" !JB%Y9-LQ+?.P%_"W/P #P &QR;7(M
M97@S,E\Q+FAT;>U;;6 ;A#^WE !I4B1);\EE?)+="Y*1!@;=HF :5DDX6 M5XI422JV^^MWI"PG>7D2![D)B%,ED3K29J0UU3EI@L2)GQ8I0$896\>MD ZH6CKJW[M9M0M\!?Q*HO\JINQY%
(%+WON)[S;Z6G5;Y'DR<] X6R6L8@9 M4O%RB<7_@$*CHV/4#NJ98#_^^W)U_OY_/;J_.)C#<(SL(ML:X=*I4N,>41 M(\DEQ#8QD=/>9I,1F02ZHB*D![%S,.<_(V-K9DT.L-MA6PO-CKD'%&"[2;'
UMV94=ATC_I$/^%&AJ0BX--:AQ+!/8 M?W(P'RWS/T+.7S>R/90L3Q1,9$_?S2K=8%7<8)6YCU4=_C3.:NTE3DF41H!0 M2J8IB_')EOU!%4-_R54&" .4AL6Z0\Y%[),]6^_5R]F@UX_#LZ=)9X-
1554]#3;X*.>603 #E,VJ"%8+8 MR57,J=:O=]"IW.-,&P\XY&#C&:TL0.TTIW">[?7@R#\Z.MX-$Z8+3N=!RF'6 M9-7?I;9FUGWF)#QMJ#*A(X]G]>D@HAKLM&\=TVXZ?Z'MB:AW[/#DX/1T-YSBY-
&+%-"OP5>_FWB2RB8<--8A\@](&!^ZR^ST:TY;J6RW^OM MKK3X-(&&7"6?2S08%)^3+V#G[01#Y+U4.>GWO,\DE@LJ$_2DJ.Z&)\X0SNGS&2N7,&WDBE'3]TQ_17U1 F#DM-
0:"HH&+9GJ5H)5VVX%CP:H M6OLUT[@RX\S,@[K^0@BEDF97'YS@,G[W]II]@7Z]:.^:Y(ZJ?;_^&\UA_[P MX+%U'ASZAP]2BO^H54076QZ.Q[>BS_WU[(OU$? CZ-=V7A%3OL@CF*R>8F/D M
<%[5T2^0PX&Y"(V\O:PT]@+6=,%S\/M?^7HFDV>UK%?S['*DG"Y45G9Y1\6 M:(/D+-FP*PPJ/YV=9>,J9(X+%WZY'<0W@?*V MQK%%VU;&-3U^?%&B6X'NWNS#.&*3D; 9Q:;\G)Q?5-G*;
MR=JX:!W[M1W;^$RV]TDQ$;."\A\3V/Y#,UB;M;8Y!EK'6L<>T[MF.U^_@M M\UO'MF$? P.+,PJT.?1L)K6-;X=C&YZY;._0W"<4/N*1FRHOM>=0\ET\J]A8).P!,R@;K.3N,_:VK MT^[T?
<)4=9G"GLPN<]&\PE#C=[-]P<2:*]=KS_6#2-J[V,N[V#?G\C.U0N+% M#0EW#Z(Z0-\L0""KUZYKJ\&;I@940/F4SK4;KT==>^W^S8M1UUW8_P=02P$" M% ,4 " !JB%Y9R;JUX>^G 0"7B!< $0 @
$;')M MPX $0 M @ $>J $;')M#,Q7S$N M:'1M4$L! A0#% @ :HA>6:/WE,GU!P D2H \ (! M1Z4" &QR;7(M97@S,5\R+FAT;5!+ 0(4 Q0 (&J(7EDVS$M\[4 +< M / " 6FM @!L XML 57 lrmr-
20240930_htm.xml IDEA: XBRL DOCUMENT 0001374690 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-012023-09-30 0001374690 us-gaap:RetainedEarningsMember 2023-04-012023-06-30 0001374690 us-gaap:RetainedEarningsMember 2022-12-31 0001374690 lrmr:OfficeMembercountry:MA 2020-05-282020-05-28 0001374690 us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateBondSecuritiesMember 2023-12-31 0001374690 srt:MaximumMemberlrmr:WakeForestUniversityHealthSciencesAndIndianaUniversityResearchAndTechnologyCorporationMember 2019-12-112019-12-11 0001374690 us-gaap:FurnitureAndFixturesMember 2023-12-31 0001374690 lrmr:InducementStockMember 2024-09-30 0001374690 lrmr:OfficeSubleaseMembercountry:MAlrmr:FirstSubleaseYearMember 2020-10-27 0001374690 us-gaap:MoneyMarketFundsMember 2023-12-31 0001374690 2024-07-012024-09-30 0001374690 lrmr:OfficeSubleaseMembercountry:MAlrmr:FirstSubleaseYearMemberus-gaap:LetterOfCreditMember 2020-10-27 0001374690 lrmr:OfficeAndLabMemberstpr:PA 2020-08-042020-08-04 0001374690 us-gaap:RetainedEarningsMember 2024-04-012024-06-30 0001374690 us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember 2024-09-30 0001374690 lrmr:AdditionalOfficeMemberstpr:PA 2023-10-012023-10-01 0001374690 lrmr:TwoThousandTwentyEquityIncentivePlanMemberus-gaap:CommonStockMember 2023-01-012023-01-01 0001374690 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0001374690 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-012024-06-30 0001374690 lrmr:FromPriorPlansMemberlrmr:TwoThousandTwentyEquityIncentivePlanMember 2024-01-012024-09-30 0001374690 lrmr:OfficeMemberstpr:PA 2023-03-092023-03-09 0001374690 lrmr:AdditionalOfficeMemberstpr:PA 2023-10-01 0001374690 srt:MinimumMemberlrmr:TrackFAProgramMemberlrmr:FriedreichsAtaxiaResearchAlliancesMember 2024-07-012024-09-30 0001374690 srt:MaximumMemberlrmr:WakeForestUniversityHealthSciencesMember 2016-11-30 0001374690 lrmr:InducementStockMember 2024-01-012024-09-30 0001374690 lrmr:AdditionalOfficeMemberstpr:PA 2023-03-092023-03-09 0001374690 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001374690 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-012023-09-30 0001374690 us-gaap:CommonStockMember 2024-03-31 0001374690 2022-12-31 0001374690 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001374690 lrmr:TwoThousandTwentyEquityIncentivePlanMemberus-gaap:CommonStockMember 2024-01-012024-01-01 0001374690 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-012024-09-30 0001374690 us-gaap:GeneralAndAdministrativeExpenseMember 2024-07-012024-09-30 0001374690 lrmr:CommonStockEquivalentsMember 2023-07-012023-09-30 0001374690 lrmr:FromPriorPlansMemberlrmr:TwoThousandTwentyEquityIncentivePlanMember 2023-01-012023-12-31 0001374690 lrmr:FromPriorPlansMemberlrmr:TwoThousandTwentyEquityIncentivePlanMember 2024-09-30 0001374690 us-gaap:MoneyMarketFundsMember 2024-09-30 0001374690 us-gaap:CommonStockMember 2023-07-012023-09-30 0001374690 2023-01-012023-03-31 0001374690 us-gaap:RetainedEarningsMember 2024-09-30 0001374690 us-gaap:CommonStockMemberus-gaap:OverAllotmentOptionMember 2024-02-012024-02-29 0001374690 us-gaap:AdditionalPaidInCapitalMember 2024-07-012024-09-30 0001374690 srt:MaximumMember 2024-01-012024-09-30 0001374690 lrmr:OfficeMemberstpr:PA 2019-08-08 0001374690 2023-07-012023-09-30 0001374690 lrmr:LabSpaceMemberstpr:PA 2023-10-16 0001374690 us-gaap:CommonStockMember 2024-01-012024-03-31 0001374690 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001374690 us-gaap:CommonStockMemberlrmr:AtTheMarketEquityOfferingProgramMember 2024-02-29 0001374690 us-gaap:RetainedEarningsMember 2023-01-012023-03-31 0001374690 srt:MaximumMember 2023-08-112023-08-11 0001374690 us-gaap:CommonStockMember 2024-02-29 0001374690 lrmr:MTSHealthPartnersMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMember 2020-05-282020-05-28 0001374690 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001374690 us-gaap:RestrictedStockUnitsRSUMember 2024-09-30 0001374690 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-012024-09-30 0001374690 us-gaap:RetainedEarningsMember 2023-06-30 0001374690 2024-10-28 0001374690 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001374690 us-gaap:RetainedEarningsMember 2023-12-31 0001374690 us-gaap:CommonStockMemberlrmr:AtTheMarketEquityOfferingProgramMember 2024-09-30 0001374690 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0001374690 lrmr:EmployeesAndDirectorsMemberlrmr:TwoThousandTwentyEquityIncentivePlanMemberus-gaap:CommonStockMember 2024-01-012024-09-30 0001374690 us-gaap:USTreasurySecuritiesMember 2024-09-30 0001374690 us-gaap:FairValueInputsLevel2Member 2023-12-31 0001374690 2023-04-012023-06-30 0001374690 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001374690 us-gaap:CommonStockMember 2024-07-012024-09-30 0001374690 us-gaap:FairValueInputsLevel1Memberus-

gaap:MoneyMarketFundsMember 2023-12-31 0001374690 us-gaap:CommonStockMember 2023-03-31 0001374690 lrmr:FromExerciseOfWarrantsMember 2023-08-11 0001374690 lrmr:CommonStockEquivalentsMember 2024-01-012024-09-30 0001374690 lrmr:TrackFAProgramMemberlrmr:FriedreichsAtaxiaResearchAlliancesMember 2024-01-012024-09-30 0001374690 us-gaap:CommonStockMember 2024-06-30 0001374690 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001374690 lrmr:OfficeSubleaseMembercountry:MA 2020-10-272020-10-27 0001374690 us-gaap:FairValueInputsLevel2Member 2024-09-30 0001374690 us-gaap:FurnitureAndFixturesMember 2024-09-30 0001374690 us-gaap:CorporateBondSecuritiesMember 2023-12-31 0001374690 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001374690 2023-01-012023-09-30 0001374690 2023-01-012023-12-31 0001374690 us-gaap:PrivatePlacementMember 2020-05-282020-05-28 0001374690 2023-06-30 0001374690 us-gaap:CommonStockMember 2023-12-31 0001374690 us-gaap:RetainedEarningsMember 2024-01-012024-03-31 0001374690 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-012024-03-31 0001374690 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-012023-06-30 0001374690 us-gaap:CommonStockMember 2024-04-012024-06-30 0001374690 2024-09-30 0001374690 lrmr:OfficeAndLabMemberstpr:PA 2021-08-092021-08-09 0001374690 us-gaap:RetainedEarningsMember 2023-07-012023-09-30 0001374690 srt:MaximumMember 2024-07-012024-09-30 0001374690 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001374690 srt:MaximumMemberus-gaap:CommonStockMemberlrmr:AtTheMarketEquityOfferingProgramMember 2022-11-012022-11-30 0001374690 us-gaap:FairValueInputsLevel2Memberlrmr:USGovernmentSecuritiesMember 2023-12-31 0001374690 lrmr:TwoThousandTwentyEquityIncentivePlanMember 2024-09-30 0001374690 lrmr:OfficeAndLabMemberstpr:PA 2018-11-052018-11-05 0001374690 2024-01-012024-03-31 0001374690 srt:DirectorMemberlrmr:TwoThousandTwentyEquityIncentivePlanMemberus-gaap:CommonStockMember 2024-01-012024-09-30 0001374690 lrmr:LabSpaceMemberstpr:PA 2023-10-162023-10-16 0001374690 lrmr:CommonStockEquivalentsMember 2024-07-012024-09-30 0001374690 2023-12-31 0001374690 us-gaap:PrivatePlacementMember 2020-05-28 0001374690 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001374690 lrmr:OfficeMemberstpr:PA 2019-08-082019-08-08 0001374690 us-gaap:FairValueInputsLevel1Member 2023-12-31 0001374690 lrmr:OfficeMemberstpr:PA 2023-09-012023-09-30 0001374690 lrmr:OfficeSubleaseMembercountry:MAlrmr:SixthSubleaseYearMemberus-gaap:LetterOfCreditMember 2020-10-27 0001374690 2023-03-31 0001374690 us-gaap:ComputerEquipmentMember 2023-12-31 0001374690 us-gaap:FairValueInputsLevel2Memberlrmr:USGovernmentSecuritiesMember 2024-09-30 0001374690 2023-09-30 0001374690 us-gaap:CommonStockMemberus-gaap:PrivatePlacementMember 2020-05-282020-05-28 0001374690 srt:MaximumMemberlrmr:TwoThousandTwentyEquityIncentivePlanMember 2024-09-30 0001374690 lrmr:USGovernmentSecuritiesMember 2023-12-31 0001374690 lrmr:EmployeesMemberus-gaap:RestrictedStockUnitsRSUMemberlrmr:TwoThousandTwentyEquityIncentivePlanMember 2024-01-012024-09-30 0001374690 2024-06-30 0001374690 2024-03-31 0001374690 lrmr:CommonStockEquivalentsMember 2023-01-012023-09-30 0001374690 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-012023-03-31 0001374690 lrmr:OfficeMembercountry:MAus-gaap:LetterOfCreditMemberus-gaap:SubsequentEventMember 2024-10-30 0001374690 us-gaap:CommonStockMember 2022-12-31 0001374690 lrmr:IndianaUniversityResearchAndTechnologyCorporationMember 2016-11-30 0001374690 lrmr:OfficeAndLabMemberstpr:PA 2018-11-05 0001374690 us-gaap:ResearchAndDevelopmentExpenseMember 2024-07-012024-09-30 0001374690 srt:MaximumMember 2023-07-012023-09-30 0001374690 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-012023-09-30 0001374690 us-gaap:CommonStockMember 2023-09-30 0001374690 us-gaap:RetainedEarningsMember 2024-07-012024-09-30 0001374690 us-gaap:CommonStockMember 2023-06-30 0001374690 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001374690 srt:MaximumMemberus-gaap:CommonStockMemberlrmr:AtTheMarketEquityOfferingProgramMember 2024-05-012024-05-31 0001374690 lrmr:OfficeMembercountry:MAus-gaap:LetterOfCreditMember 2020-05-28 0001374690 us-gaap:FairValueInputsLevel1Member 2024-09-30 0001374690 us-gaap:RestrictedStockUnitsRSUMember 2023-01-012023-12-31 0001374690 lrmr:USGovernmentSecuritiesMember 2024-09-30 0001374690 lrmr:LabSpaceMemberstpr:PA 2024-05-10 0001374690 lrmr:WakeForestUniversityHealthSciencesAndIndianaUniversityResearchAndTechnologyCorporationMemberus-gaap:ResearchAndDevelopmentExpenseMember 2022-10-012022-10-31 0001374690 us-gaap:LeaseholdImprovementsMember 2024-09-30 0001374690 us-gaap:AdditionalPaidInCapitalMember 2023-07-012023-09-30 0001374690 lrmr:TwoThousandTwentyEquityIncentivePlanMember 2024-01-012024-09-30 0001374690 us-gaap:RetainedEarningsMember 2024-06-30 0001374690 us-gaap:RetainedEarningsMember 2024-03-31 0001374690 2024-04-012024-06-30 0001374690 us-gaap:EquipmentMember 2024-09-30 0001374690 us-gaap:RestrictedStockUnitsRSUMember 2024-01-012024-09-30 0001374690 us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasurySecuritiesMember 2024-09-30 0001374690 us-gaap:AdditionalPaidInCapitalMember 2023-01-012023-03-31 0001374690 us-gaap:AdditionalPaidInCapitalMember 2024-01-012024-03-31 0001374690 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-012023-09-30 0001374690 lrmr:OfficeSubleaseMembercountry:MAlrmr:FinalSubleaseYearMember 2020-10-27 0001374690 us-gaap:EquipmentMember 2023-12-31 0001374690 lrmr:WakeForestUniversityHealthSciencesMember 2016-11-30 0001374690 us-gaap:CommonStockMember 2024-09-30 0001374690 us-gaap:AdditionalPaidInCapitalMember 2024-04-012024-06-30 0001374690 us-gaap:ComputerEquipmentMember 2024-09-30 0001374690 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001374690 us-gaap:CommonStockMemberus-gaap:OverAllotmentOptionMember 2024-02-29 0001374690 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-012024-09-30 0001374690 us-gaap:CommonStockMemberus-gaap:PrivatePlacementMember 2020-05-28 0001374690 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001374690 us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasurySecuritiesMember 2023-12-31 0001374690 2024-01-012024-09-30 0001374690 us-gaap:GeneralAndAdministrativeExpenseMember 2023-07-012023-09-30 0001374690 srt:MaximumMemberlrmr:IndianaUniversityResearchAndTechnologyCorporationMember 2016-11-30 0001374690 lrmr:TwoThousandTwentyEquityIncentivePlanMemberus-gaap:CommonStockMember 2024-09-30 0001374690 us-gaap:CommonStockMemberus-gaap:PrivatePlacementMember 2023-08-012023-08-31 0001374690 us-gaap:RetainedEarningsMember 2023-09-30 0001374690 us-gaap:AdditionalPaidInCapitalMember 2023-04-012023-06-30 0001374690 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001374690 lrmr:OfficeMemberstpr:PA 2023-09-01 0001374690 us-gaap:RetainedEarningsMember 2023-03-31 0001374690 lrmr:EmployeesMemberlrmr:TwoThousandTwentyEquityIncentivePlanMemberus-gaap:CommonStockMemberlrmr:FirstAnniversaryMember 2024-01-012024-09-30 0001374690 us-gaap:CommonStockMember 2024-02-012024-02-29 0001374690 us-gaap:USTreasurySecuritiesMember 2023-12-31 0001374690 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001374690 lrmr:EmployeesMemberlrmr:TwoThousandTwentyEquityIncentivePlanMemberus-gaap:CommonStockMember 2024-01-012024-09-30 pure utr:sqft shares iso4217:USD shares iso4217:USD0001374690Q3false--12-31 http://fasb.org/us-gaap/2024#UsefulLifeTermOfLeaseMember6284P3Y2023-08-31P2Y10-Otrue2024-09-302024false001-36510LARIMAR THERAPEUTICS, INC.DE20-3857670Three Bala Plaza EastSuite 506190004Bala CynwydPA844511-9056Common Stock, par value $0.001 per shareLRMRNASDAQYesYesNon-accelerated FilertruefalsefalseFalse638066283506700026749000168640000600410009549000338500021325600090175000779000684000302600030780001339000133900062100065900021902100095935000.240334000-188554000358000810001984000008172000021902100095935000139190006585000465400001702200043450003754000130570001057400018264000103390005959700027596000-18264000.10339000.59597000.2759600027650001275000781700036400001549900.9064000.51780000.23956000.0.24.0.24.0.21.0.21.0.86.0.86.0.55-0.55638061586380615843903738439037386039969760399697438996704389967015499000-9064000-51780000-23956000508000-50002770003800050800050002770003800014991000-9069000-51503000-23918000439090694300027015000018855400081000817200001973684220000161736000161756000153750100001000356212800021280000-106000-106000-14654000-14654000638000176400043401300020328080002500023084400023010002301000025001100011000-125000-125000.21627000.216270006380251764000436325000-224835000.150000211404000195700019570004111300003000050800050800015499000.15499000638066286400043831200024033400035800019840000432692004300026249600015160500031000110903000183300018330003100031000.6526000.652600043269200430002643290001581310001062410002043000204300012000120008366000.836600043269200430002663720001664970001200099300001821000182100083002400024000628403600006000-5000-5000-9064000-906400043905903430002682230001755610007000927120005178000023956000638600056970001320005800024100023000040740001210000616400057900040300093000061370003314000.38000.4000-48945000.241160003360001892480006626800085000001022500010458400035982000161806000410003000016184700030000831800011896000280880002816400036406000400600005000046500045200 1. Description of Business and Basis of Presentation Larimar Therapeutics, Inc., together with its subsidiary (the “Company” or “Larimar”), is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Larimar’s lead product candidate, nomlabofusp (nomlabofusp is the International Nonproprietary Name and the United States Adopted Name for CTI-1601), is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (“FXN”), an essential protein, to the mitochondria of patients with Friedreich’s ataxia (“FA”). FA is a rare, progressive and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. The Company has completed two phase 1 studies of nomlabofusp, a Phase 2 dose exploration study, and initiated an open label extension study (“OLE”) in patients with FA in January, 2024. This OLE study is ongoing and continues to enroll patients. In May 2021, after reporting positive top-line data from the Company’s Phase 1 FA program, the U.S. Food and Drug Administration (“FDA”) placed a clinical hold on the Company’s nomlabofusp clinical program after the Company notified the FDA of mortalities at the highest dose levels of a 26-week non-human primate toxicology study that was designed to support extended dosing of patients with nomlabofusp. In September 2022, the FDA lifted its full clinical hold on the nomlabofusp program and imposed a partial clinical hold. In May 2023, the Company announced top-line data from its completed 25 mg cohort of a Phase 2, four-week, dose exploration trial of nomlabofusp in patients with FA and provided a complete response to the FDA in June 2023, which included unblinded safety, pharmacokinetic (“PK”), and pharmacodynamic (“PD”) data from the Phase 2 trial’s completed 25 mg cohort. In June 2023, the Company met with the FDA. Following that meeting, the Company submitted a complete response to the FDA’s partial clinical hold that included unblinded safety, PK and frataxin data from the Phase 2 trial’s completed 25 mg cohort. In July 2023, following the FDA’s review of the Company’s complete response to the partial clinical hold, the FDA cleared initiation of a second cohort at 50 mg of our four-week, placebo-controlled, Phase 2 dose exploration trial and initiation of an OLE study with daily dosing of 25 mg. In February 2024, the Company reported positive top-line data and successful completion of their four-week, placebo-controlled Phase 2 dose exploration study of nomlabofusp in participants with FA. Nomlabofusp was generally well tolerated throughout the four-week treatment periods, had a predictable pharmacokinetic profile and led to dose dependent increases in FXN levels in all evaluated tissues (skin and buccal cells) after daily dosing of 14 days followed by every other day dosing until day 28 in the 25 mg and 50 mg cohorts. Participants in the 25 mg (n=13) and 50 mg (n=15) cohorts were randomized 2:1 to receive subcutaneous injections of nomlabofusp or placebo. In May 2024 the FDA removed the partial clinical hold on the development of nomlabofusp. Patients who completed treatment in the Company’s Phase 2 dose exploration study or who previously completed a prior clinical trial of nomlabofusp are eligible to screen and possibly participate in the OLE study. Current patients in the OLE study either participated in the Phase 2 dose exploration study and/or a previous clinical trial. In March 2024, the Company dosed the first patient in its OLE trial discussed above, evaluating daily subcutaneous injections of 25 mg of nomlabofusp self-administered or administered by a caregiver. This study is ongoing with seven sites activated and additional patients are continuing to be enrolled and dosed. Participants who completed treatment in the Phase 2 dose exploration study, or who previously completed a prior clinical trial of nomlabofusp, are potentially eligible to screen for the OLE study. The OLE study will evaluate the safety and tolerability, pharmacokinetics, and frataxin levels in peripheral tissues as well as other exploratory pharmacodynamic markers (lipid profiles and gene expression data) following long-term subcutaneous administration of nomlabofusp. In addition, following the completion of enrollment, as well as at least one participant completing one year of dosing, clinical assessments collected during the study will be compared to data from a matched control arm derived from participants in the Friedreich’s Ataxia Clinical Outcome Measures Study (“FACOMS”) database. Dose escalation to the 50 mg dose in the OLE study is currently planned following further characterization of the frataxin PD at the 25 mg dose. The Company currently expects to provide a nomlabofusp development program update in mid-December 2024 that will include available safety, pharmacokinetic and frataxin data as well as available clinical outcome observations from patients currently receiving the daily 25 mg dose of nomlabofusp for approximately 30 to 180 days in the ongoing OLE study. An update on enrollment and plans on the OLE study will also be provided. Separately, the Company has had discussions with the FDA regarding the use of tissue FXN levels as a novel surrogate endpoint. The FDA acknowledged that frataxin deficiency appears to be critical to the pathogenic mechanism of FA, and that there continues to be an unmet need for treatments for FA patients that address the underlying disease pathophysiology. The Company intends to pursue an accelerated approval using FXN levels, supportive PD and clinical information, and safety data from the OLE study, along with additional non-clinical pharmacology information needed to support the novel surrogate endpoint approach. The Company is on track to expand the nomlabofusp clinical program into adolescent (12-17 years old) and pediatric (2-11 years old) patients with FA. The Company expects to initiate a PK-run-in study in adolescents by the end of this year and expects to transition these study participants into the ongoing OLE study after assessment of safety and exposure data in the adolescent cohort. The run-in study will enroll 12-15 adolescent patients and 12-15 pediatric patients who will be randomized 2:1 to receive either nomlabofusp or placebo daily. <p style="text-

indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The Company is also planning the initiation of a global confirmatory/registration study by mid-2025 with potential sites in the U.S., Europe, the U.K., Canada and Australia. The Biologics License Application ("BLA") filing is targeted in the second half of 2025 to support potential accelerated approval. On May 30, 2024, the Company announced that the FDA's Center for Drug Evaluation and Research ("CDER") had selected nomlabofusp as one of a few programs for participation in the Support for Clinical Trials Advancing Rare Disease Therapeutics ("START") Pilot Program. The objective of the program is to accelerate the development of drugs for rare diseases that lead to significant disability or death by facilitating frequent advice and regular communication with the FDA staff to expedite the review process of biologics and drugs. In September 2024, the Company received the Medicines and Healthcare Regulatory Agency ("MHRA") Innovative Licensing and Access Pathway ("ILAP") aimed at potentially accelerating access and reducing the time to market in the United Kingdom. The Company is subject to risks and uncertainties common to pre-commercial companies in the biotechnology industry, including, but not limited to, development and commercialization by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with governmental regulations, failure to secure regulatory approval for its drug candidates or any other product candidates and the ability to secure additional capital to fund its operations. Product candidates under development will require extensive non-clinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel, infrastructure and extensive compliance reporting capabilities. Even if the Company's drug development efforts are successful, it is uncertain when, if ever, it will realize significant revenue from product sales. Basis of Presentation The condensed consolidated financial statements include the accounts of Larimar and its wholly owned subsidiary. All intercompany balances and transactions have been eliminated. The accompanying condensed consolidated financial statements have been prepared in conformity with Generally Accepted Accounting Principles ("GAAP"). The condensed consolidated balance sheet as of December 31, 2023 was derived from the Company's audited financial statements but does not include all disclosures required by GAAP. The accompanying unaudited condensed consolidated financial statements as of September 30, 2024 and for the three and nine months ended September 30, 2024 and 2023, have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC") for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. However, the Company believes that the disclosures are adequate to make the information presented not misleading. These condensed consolidated financial statements should be read in conjunction with the Company's audited consolidated financial statements and the notes thereto for the year ended December 31, 2023 included in the Company's Annual Report on Form 10-K filed with the SEC on March 14, 2024 and the Company's Quarterly Reports on Form 10-Q filed with the SEC on May 9, 2024 and August 8, 2024. In the opinion of management, all adjustments, consisting only of normal recurring adjustments necessary for a fair statement of the Company's condensed consolidated financial position as of September 30, 2024, condensed consolidated results of operations for the three and nine months ended September 30, 2024 and condensed consolidated statement of cash flows for the nine months ended September 30, 2024 have been made. The results of operations for the three and nine months ended September 30, 2024 are not necessarily indicative of the results of operations that may be expected for the year ending December 31, 2024. Liquidity and Capital Resources The Company's condensed consolidated financial statements have been presented on the basis that it will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Since its inception, the Company has incurred significant recurring operating losses and negative cash flows from operations. The Company has incurred net losses of $51.8 million and $24.0 million for the nine months ended September 30, 2024 and 2023, respectively. In addition, as of September 30, 2024, the Company had an accumulated deficit of $240.3 million. The Company expects to continue to generate operating losses for the foreseeable future. As of September 30, 2024, the Company had approximately <span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$203.7 million of cash, cash equivalents and marketable securities available for use to fund its operations and capital requirements. The Company has funded its operations to date primarily with proceeds from sales of common stock and proceeds from the sale of prefunded warrants for the purchase of common stock, the acquisition in 2020 of cash, cash equivalents and marketable securities upon the merger with Zafgen, Inc. ("Zafgen") and, prior to the 2020 merger with Zafgen, capital contributions from Chondrial Holdings, LLC. In February 2024, the Company completed an underwritten public offering in which the Company issued and sold 19,736,842 shares of its common stock at a public offering price of $8.74 per share. The Company received net proceeds of approximately $161.8 million after deducting underwriting discounts, commissions and other offering expenses. In accordance with Accounting Standards Update ("ASU") No. 2014-15, "Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern", the Company has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are issued. As of the issuance date of these condensed consolidated financial statements, the Company expects its cash, cash equivalents and marketable securities will be sufficient to fund its forecasted operating expenses and capital expenditure requirements into 2026. If the timing of the Company's clinical assumptions are delayed, or if there are other forecasted assumption changes that negatively impact its operating plan, the Company could reduce expenditures in order to further extend cash resources. The Company has not yet commercialized any products and does not expect to generate revenue from the commercial sale of any products for several years, if at all. The Company expects that its research and development and general and administrative expenses will continue to increase, that sales and marketing expenses will become significant and, as a result, that it will need additional capital to fund its future operating and capital requirements. Unless and until the Company can generate substantial revenue, management continuously evaluates different strategies to obtain the required funding for future operations. These strategies include seeking additional funding through a combination of public or private equity offerings, debt or royalty financings, collaborations and licensing arrangements, strategic partnerships with pharmaceutical and/or larger biotechnology companies, or other sources. The incurrence of indebtedness would result in increased fixed payment obligations and the Company may be required to agree to certain restrictive covenants, such as limitations on its ability to incur additional debt, limitations on its ability to acquire, sell or license intellectual property rights, minimum required cash balances and other operating restrictions that could adversely impact the Company's ability to conduct its business. Any additional fundraising efforts may divert the Company's management from their day-to-day activities, which may adversely affect its ability to develop and commercialize its product candidates. There can be no assurance that the Company will be able to raise sufficient additional capital on acceptable terms, if at all. If such additional financing is not available on satisfactory terms, or is not available in sufficient amounts, or if the Company does not have sufficient authorized shares, the Company may be required to delay, limit, or eliminate the development of business opportunities and its ability to achieve its business objectives, its competitiveness, and its business, financial condition, and results of operations will be materially adversely affected. The Company could also be required to seek funds through arrangements with collaborative partners or otherwise at an earlier stage than otherwise would be desirable and it may be required to relinquish rights to some of its technologies or product candidates or otherwise agree to terms unfavorable to it, any of which may have a material adverse effect on the Company's business, operating results and prospects. In addition, geopolitical tensions, volatility of capital markets, and other adverse macroeconomic events, including those due to inflationary pressures, rising interest rates, banking instability, monetary policy changes and the ability of the U.S. government to manage federal debt limits as well as the potential impact of other health crises on the global financial markets may reduce the Company's ability to access capital, which could negatively affect its liquidity and ability to continue as a going concern. If the Company is unable to obtain sufficient funding when needed and/or on acceptable terms, the Company may be required to significantly curtail, delay or discontinue one or more of its research and development programs, the manufacture of clinical and commercial supplies, product portfolio expansion, pre-commercialization efforts and/or commercial operations, which could adversely affect its business prospects, or the Company may be unable to continue operations. Basis of Presentation The condensed consolidated financial statements include the accounts of Larimar and its wholly owned subsidiary. All intercompany balances and transactions have been eliminated. The accompanying condensed consolidated financial statements have been prepared in conformity with Generally Accepted Accounting Principles ("GAAP"). The condensed consolidated balance sheet as of December 31, 2023 was derived from the Company's audited financial statements but does not include all disclosures required by GAAP. The accompanying unaudited condensed consolidated financial statements as of September 30, 2024 and for the three and nine months ended September 30, 2024 and 2023, have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC") for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. However, the Company believes that the disclosures are adequate to make the information presented not misleading. These condensed consolidated financial statements should be read in conjunction with the Company's audited consolidated financial statements and the notes thereto for the year ended December 31, 2023 included in the Company's Annual Report on Form 10-K filed with the SEC on March 14, 2024 and the Company's Quarterly Reports on Form 10-Q filed with the SEC on May 9, 2024 and August 8, 2024. In the opinion of management, all adjustments, consisting only of normal recurring adjustments necessary for a fair statement of the Company's condensed consolidated financial position as of September 30, 2024, condensed consolidated results of operations for the three and nine months ended September 30, 2024 and condensed consolidated statement of cash flows for the nine months ended September 30, 2024 have been made. The results of operations for the three and nine months ended September 30, 2024 are not necessarily indicative of the results of operations that may be expected for the year ending December 31, 2024<span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times

New Roman;min-width:fit-content;">. Liquidity and Capital Resources The Company's condensed consolidated financial statements have been presented on the basis that it will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Since its inception, the Company has incurred significant recurring operating losses and negative cash flows from operations. The Company has incurred net losses of $51.8 million and $24.0 million for the nine months ended September 30, 2024 and 2023, respectively. In addition, as of September 30, 2024, the Company had an accumulated deficit of $240.3 million. The Company expects to continue to generate operating losses for the foreseeable future. As of September 30, 2024, the Company had approximately <span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$203.7 million of cash, cash equivalents and marketable securities available for use to fund its operations and capital requirements. The Company has funded its operations to date primarily with proceeds from sales of common stock and proceeds from the sale of prefunded warrants for the purchase of common stock, the acquisition in 2020 of cash, cash equivalents and marketable securities upon the merger with Zafgen, Inc. ("Zafgen") and, prior to the 2020 merger with Zafgen, capital contributions from Chondrial Holdings, LLC. In February 2024, the Company completed an underwritten public offering in which the Company issued and sold 19,736,842 shares of its common stock at a public offering price of $8.74 per share. The Company received net proceeds of approximately $161.8 million after deducting underwriting discounts, commissions and other offering expenses. In accordance with Accounting Standards Update ("ASU") No. 2014-15, "Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern", the Company has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are issued. As of the issuance date of these condensed consolidated financial statements, the Company expects its cash, cash equivalents and marketable securities will be sufficient to fund its forecasted operating expenses and capital expenditure requirements into 2026. If the timing of the Company's clinical assumptions are delayed, or if there are other forecasted assumption changes that negatively impact its operating plan, the Company could reduce expenditures in order to further extend cash resources. The Company has not yet commercialized any products and does not expect to generate revenue from the commercial sale of any products for several years, if at all. The Company expects that its research and development and general and administrative expenses will continue to increase, that sales and marketing expenses will become significant and, as a result, that it will need additional capital to fund its future operating and capital requirements. Unless and until the Company can generate substantial revenue, management continuously evaluates different strategies to obtain the required funding for future operations. These strategies include seeking additional funding through a combination of public or private equity offerings, debt or royalty financings, collaborations and licensing arrangements, strategic partnerships with pharmaceutical and/or larger biotechnology companies, or other sources. The incurrence of indebtedness would result in increased fixed payment obligations and the Company may be required to agree to certain restrictive covenants, such as limitations on its ability to incur additional debt, limitations on its ability to acquire, sell or license intellectual property rights, minimum required cash balances and other operating restrictions that could adversely impact the Company's ability to conduct its business. Any additional fundraising efforts may divert the Company's management from their day-to-day activities, which may adversely affect its ability to develop and commercialize its product candidates. There can be no assurance that the Company will be able to raise sufficient additional capital on acceptable terms, if at all. If such additional financing is not available on satisfactory terms, or is not available in sufficient amounts, or if the Company does not have sufficient authorized shares, the Company may be required to delay, limit, or eliminate the development of business opportunities and its ability to achieve its business objectives, its competitiveness, and its business, financial condition, and results of operations will be materially adversely affected. The Company could also be required to seek funds through arrangements with collaborative partners or otherwise at an earlier stage than otherwise would be desirable and it may be required to relinquish rights to some of its technologies or product candidates or otherwise agree to terms unfavorable to it, any of which may have a material adverse effect on the Company's business, operating results and prospects. In addition, geopolitical tensions, volatility of capital markets, and other adverse macroeconomic events, including those due to inflationary pressures, rising interest rates, banking instability, monetary policy changes and the ability of the U.S. government to manage federal debt limits as well as the potential impact of other health crises on the global financial markets may reduce the Company's ability to access capital, which could negatively affect its liquidity and ability to continue as a going concern. If the Company is unable to obtain sufficient funding when needed and/or on acceptable terms, the Company may be required to significantly curtail, delay or discontinue one or more of its research and development programs, the manufacture of clinical and commercial supplies, product portfolio expansion, pre-commercialization efforts and/or commercial operations, which could adversely affect its business prospects, or the Company may be unable to continue operations. -51800000-24000000-2403000002037000009736842 8.74161800000 2. Summary of Significant Accounting Policies Use of Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. This process involves reviewing open contracts and purchase orders, communicating with our personnel and outside vendors to identify services that have been performed on our behalf and estimating the level of service performed and the associated costs incurred for the services when we have not yet been invoiced or otherwise notified of the actual costs. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual of research and development expense, the recording as prepaid expense of payments made in advance of the actual provision of goods or services, valuation of stock-based awards and valuation of leases. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. Research and Development Costs Costs associated with internal research and development and external research and development services, including drug development, clinical studies and non-clinical studies, are expensed as incurred. Research and development expenses include costs for salaries, employee benefits, subcontractors, facility-related expenses, depreciation, non-cash stock-based compensation, third-party license fees, laboratory supplies, and external costs of outside vendors engaged to conduct discovery, non-clinical and clinical development activities and clinical trials as well as to manufacture clinical trial materials, and other costs. The Company recognizes external research and development costs based on an evaluation of the progress to completion of specific tasks using information provided to the Company by its key service providers. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. Such prepaid expenses are recognized as an expense when the goods have been delivered or the related services have been performed, or when it is no longer expected that the goods will be delivered, or the services rendered. Upfront payments, milestone payments and annual maintenance fees under license agreements are currently expensed in the period in which they are incurred. Patent Costs All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses. Stock-Based Compensation The Company measures all stock-based awards granted to employees and directors based on the fair value on the date of grant using the Black-Scholes option-pricing model. Compensation expense of those awards is recognized over the requisite service period, which is the vesting period of the respective award. Typically, the Company issues awards with only service-based vesting conditions and records the expense for these awards using the straight-line method. The Company accounts for forfeitures as they occur. The Company classifies stock-based compensation expense in its condensed consolidated statements of operations and comprehensive loss in the same manner in which the award recipient's payroll costs are classified or in which the award recipient's service payments are classified. Prior to May 28, 2020, the Company had been a private company and lacked company-specific historical and implied volatility information for its common stock. Prior to January 1, 2023, the Company estimated its expected common stock price volatility solely based on the historical volatility of publicly traded peer companies. Beginning on January 1, 2023, based on the availability of sufficient historical trading data of the Company's own common stock on the Nasdaq Global Market to calculate accurately its volatility, the Company began blending its volatility starting from June 2020 (following its merger with Zafgen in 2020) to the date of each stock-based award, and weighing the volatility of its peer group for the amount of time from May 31, 2020 backwards so that the blended volatility equals the expected term of the related stock-based award. The expected term of the Company's stock options has been determined utilizing the "simplified" method for awards that qualify as "plain-vanilla" options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected dividend yield considers the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future. Net Loss Per Share Basic net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period. Prior to August 11, 2023, basic shares outstanding includes the weighted average effect of

the Company's prefunded warrants issued in June 2020, the exercise of which requires little or no consideration for the delivery of shares of common stock. These prefunded warrants were exercised on August 11, 2023 and the Company received cash proceeds of less than $0.1 million. Accordingly, the 628,403 shares were issued upon the exercise of these warrants and are included in issued and outstanding common stock. Diluted net loss per share attributable to common stockholders is computed by dividing the diluted net loss attributable to common stockholders by the weighted average number of common shares, including potentially dilutive common stock equivalents assuming the dilutive effect of outstanding stock options, outstanding restricted stock units, and unvested restricted common shares, as determined using the treasury stock method. For periods in which the Company has reported net losses (all periods since inception), diluted net loss per common share attributable to common stockholders is the same as basic net loss per common share attributable to common stockholders, since dilutive common stock equivalents are not assumed to have been issued if their effect is antidilutive. The Company excluded 6,990,827 and 5,100,997 common stock equivalents outstanding as of September 30, 2024 and 2023, respectively, from the computation of diluted net loss per share for the three and nine months ended September 30, 2024 and 2023 because they had an anti-dilutive impact due to the net loss incurred for the periods presented. Recently Issued and Adopted Accounting Pronouncements From time to time, new accounting guidance is issued by the FASB or other standard setting bodies that is adopted by us as of the effective date or, in some cases where early adoption is permitted, in advance of the effective date. We have assessed the recently issued guidance that is not yet effective and believe the new guidance will not have a material impact on the condensed consolidated results of operations, cash flows or financial position. In November 2023, the FASB issued new guidance designed to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant expenses per segment. The new standard must be adopted on a retrospective basis. We intend to adopt the new guidance for the fiscal year ending December 31, 2024, and subsequent interim periods. Given that the accounting standard update affects disclosures exclusively, we do not anticipate that its adoption will have a material impact on our consolidated financial statements. In December 2023, the FASB issued new guidance designed to improve income tax disclosure requirements primarily through increased disaggregation disclosures within the effective tax rate reconciliation as well as enhanced disclosures on income taxes paid. The guidance is effective for all fiscal years beginning after December 15, 2024. The new standard can be adopted on a prospective basis with an option for it to be adopted retrospectively and early adoption is permitted. We are currently evaluating this guidance to determine its impact on our consolidated financial statements. Use of Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. This process involves reviewing open contracts and purchase orders, communicating with our personnel and outside vendors to identify services that have been performed on our behalf and estimating the level of service performed and the associated costs incurred for the services when we have not yet been invoiced or otherwise notified of the actual costs. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual of research and development expense, the recording as prepaid expense of payments made in advance of the actual provision of goods or services, valuation of stock-based awards and valuation of leases. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. Research and Development Costs Costs associated with internal research and development and external research and development services, including drug development, clinical studies and non-clinical studies, are expensed as incurred. Research and development expenses include costs for salaries, employee benefits, subcontractors, facility-related expenses, depreciation, non-cash stock-based compensation, third-party license fees, laboratory supplies, and external costs of outside vendors engaged to conduct discovery, non-clinical and clinical development activities and clinical trials as well as to manufacture clinical trial materials, and other costs. The Company recognizes external research and development costs based on an evaluation of the progress to completion of specific tasks using information provided to the Company by its key service providers. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. Such prepaid expenses are recognized as an expense when the goods have been delivered or the related services have been performed, or when it is no longer expected that the goods will be delivered, or the services rendered. Upfront payments, milestone payments and annual maintenance fees under license agreements are currently expensed in the period in which they are incurred. Patent Costs All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses. Stock-Based Compensation The Company measures all stock-based awards granted to employees and directors based on the fair value on the date of grant using the Black-Scholes option-pricing model. Compensation expense of those awards is recognized over the requisite service period, which is the vesting period of the respective award. Typically, the Company issues awards with only service-based vesting conditions and records the expense for these awards using the straight-line method. The Company accounts for forfeitures as they occur. The Company classifies stock-based compensation expense in its condensed consolidated statements of operations and comprehensive loss in the same manner in which the award recipient's payroll costs are classified or in which the award recipient's service payments are classified. Prior to May 28, 2020, the Company had been a private company and lacked company-specific historical and implied volatility information for its common stock. Prior to January 1, 2023, the Company estimated its expected common stock price volatility solely based on the historical volatility of publicly traded peer companies. Beginning on January 1, 2023, based on the availability of sufficient historical trading data of the Company's own common stock on the Nasdaq Global Market to calculate accurately its volatility, the Company began blending its volatility starting from June 2020 (following its merger with Zafgen in 2020) to the date of each stock-based award, and weighing the volatility of its peer group for the amount of time from May 31, 2020 backwards so that the blended volatility equals the expected term of the related stock-based award. The expected term of the Company's stock options has been determined utilizing the "simplified" method for awards that qualify as "plain-vanilla" options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected dividend yield considers the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future. Net Loss Per Share Basic net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period. Prior to August 11, 2023, basic shares outstanding includes the weighted average effect of the Company's prefunded warrants issued in June 2020, the exercise of which requires little or no consideration for the delivery of shares of common stock. These prefunded warrants were exercised on August 11, 2023 and the Company received cash proceeds of less than $0.1 million. Accordingly, the 628,403 shares were issued upon the exercise of these warrants and are included in issued and outstanding common stock. Diluted net loss per share attributable to common stockholders is computed by dividing the diluted net loss attributable to common stockholders by the weighted average number of common shares, including potentially dilutive common stock equivalents assuming the dilutive effect of outstanding stock options, outstanding restricted stock units, and unvested restricted common shares, as determined using the treasury stock method. For periods in which the Company has reported net losses (all periods since inception), diluted net loss per common share attributable to common stockholders is the same as basic net loss per common share attributable to common stockholders, since dilutive common stock equivalents are not assumed to have been issued if their effect is antidilutive. The Company excluded 6,990,827 and 5,100,997 common stock equivalents outstanding as of September 30, 2024 and 2023, respectively, from the computation of diluted net loss per share for the three and nine months ended September 30, 2024 and 2023 because they had an anti-dilutive impact due to the net loss incurred for the periods presented. 10000062840362840369908276990827510009751009970 Recently Issued and Adopted Accounting Pronouncements From time to time, new accounting guidance is issued by the FASB or other standard setting bodies that is adopted by us as of the effective date or, in some cases where early adoption is permitted, in advance of the effective date. We have assessed the recently issued guidance that is not yet effective and believe the new guidance will not have a material impact on the condensed consolidated results of operations, cash flows or financial position. In November 2023, the FASB issued new guidance designed to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant expenses per segment. The new standard must be adopted on a retrospective basis. We intend to adopt the new guidance for the fiscal year ending December 31, 2024, and subsequent interim periods. Given that the accounting standard update affects disclosures exclusively, we do not anticipate that its adoption will have a material impact on our consolidated financial statements. In December 2023, the FASB issued new guidance designed to improve income tax disclosure requirements primarily through increased disaggregation disclosures within the effective tax rate reconciliation as well as enhanced disclosures on income taxes paid. The guidance is effective for all fiscal years beginning after December 15, 2024. The new standard can be adopted on a prospective basis with an option for it to be adopted retrospectively and early adoption is permitted. We are currently evaluating this guidance to determine its impact on our consolidated financial statements. <span style="color:#000000;white-space:pre-wrap;font-

weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3. Fair Value Measurements and Marketable Securities Fair Value Measurements The Company's assets and liabilities that are measured at fair value on a recurring basis as of September 30, 2024 and December 31, 2023 are measured in accordance with the standards of ASC 820, "Fair Value Measurements and Disclosures", which establishes a three-level valuation hierarchy for measuring fair value and expands financial statement disclosures about fair value measurements. The valuation hierarchy is based on the transparency of inputs to the valuation of an asset or liability as of the measurement date. The three levels are defined as follows: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:11.54%;box-sizing:content-box;"></td><td style="width:88.46%;box-sizing:content-box;"></td></tr><tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:top;"> Level – 1 </td><td style="vertical-align:top;"> Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. </td></tr><tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:middle;"> </td><td style="vertical-align:middle;"> </td></tr><tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:top;"> Level – 2 </td><td style="vertical-align:top;"> Inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. </td></tr><tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:middle;"> </td><td style="vertical-align:middle;"> </td></tr><tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:top;"> Level – 3 </td><td style="vertical-align:top;"> Inputs to the valuation methodology are unobservable and significant to the fair value measurement. </td></tr></table> The Company's financial instruments consist primarily of cash, cash equivalents, marketable securities, accounts payable and accrued liabilities. For accounts payable and accrued liabilities, the carrying amounts of these financial instruments as of September 30, 2024 and December 31, 2023 were considered representative of their fair values due to their short term to maturity. The following tables summarize the Company's cash equivalents and marketable securities as of September 30, 2024 and December 31, 2023: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:50.38%;box-sizing:content-box;"></td><td style="width:1.22%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.184000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.22%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.184000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.22%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.184000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.22%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.184000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Total </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Quoted
Prices in
Active
Markets
(Level 1) </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Significant
Other
Observable
Inputs
(Level 2) </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left,"> </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Significant
Unobservable
Inputs
(Level 3) </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left,"> </td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td colspan="14" style="vertical-align:bottom;text-align:left,"> (in thousands) </td><td style="vertical-align:bottom;text-align:left,"> </td></tr><tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:top;"> September 30, 2024 </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;text-align:center,"> </td><td style="vertical-align:bottom;text-align:center,"> </td><td style="vertical-align:bottom,"> </td><td colspan="2" style="vertical-align:bottom;text-align:center,"> </td><td style="vertical-align:bottom,text-align:center,"> </td><td colspan="2" style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom,text-align:center,"> </td><td style="vertical-align:bottom,"> </td><td colspan="2" style="vertical-align:bottom,text-align:center,"> </td><td style="vertical-align:bottom,"> </td><td colspan="2" style="vertical-align:bottom,text-align:center,"> </td></tr><tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:top,"> Cash equivalents: </td><td style="vertical-align:bottom,"> </td><td colspan="2" style="vertical-align:bottom,text-align:center,"> </td><td style="vertical-align:bottom,text-align:center,"> </td><td style="vertical-align:bottom,"> </td><td colspan="2" style="vertical-align:bottom,text-align:center,"> </td><td style="vertical-align:bottom,text-align:center,"> </td><td style="vertical-align:bottom,"> </td><td colspan="2" style="vertical-align:bottom,text-align:center,"> </td><td style="vertical-align:bottom,text-align:center,"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top,"> Money market funds invested in government securities </td><td style="white-space:pre-wrap;vertical-align:bottom,"> </td><td style="white-space:nowrap;vertical-align:bottom,"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center,"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right,">31,338</p></td><td style="white-space:nowrap;vertical-align:bottom,"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left,"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom,"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left,"> </p></td><td style="white-space:nowrap;vertical-align:bottom,"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left,">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center,"> 31,338 </td><td style="white-space:nowrap;vertical-align:bottom,"> </td><td style="white-space:pre-wrap;vertical-align:bottom,"> <span style="white-space:pre-

wrap;min-width:fit-content;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:left;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td
style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-
content;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">
 </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="white-space:pre-wrap;vertical-
align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-
wrap;min-width:fit-content;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-
indent:25pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">
Total cash equivalents</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-
top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt
solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-
wrap;min-width:fit-content;">31,338</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-
wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-
content;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-
top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-
wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">
31,338</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-
align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-
content;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">
 </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid
#000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td
style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="border-top:0.5pt solid
#ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">
 </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-
space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-
align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-
content;">—</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-
top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-
space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td
style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-
wrap;min-width:fit-content;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">
 </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-
align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">
</p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-
width:fit-content;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-
align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">
</p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;text-align:right;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-
space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Marketable securities:</p></td> <td style="vertical-align:bottom;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2"
style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-
wrap;min-width:fit-content;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-
align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">
</p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-
space:pre-wrap;min-width:fit-content;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-
align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-
top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-
align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">
</p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-
width:fit-content;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> </tr> <tr
style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15pt;text-indent:0;font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">U.S. Treasury Bills
</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-
space:pre-wrap;min-width:fit-content;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">10,944</p></td>
<td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-
content;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">
 </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-
align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-
content;">10,944</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-
align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-
wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-
space:pre-wrap;min-width:fit-content;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-
top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-
align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td
style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-
word;"> <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:left;">U.S. Government securities</p></td> <td style="white-space:pre-wrap;vertical-
align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">
</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-
width:fit-content;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:right;">157,696</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-
wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-
content;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">
 </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times
New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-
align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td
style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-
wrap;min-width:fit-content;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-
top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">157,696</p></td> <td
style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-
content;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">
 </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-
align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-
content;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">
 </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:25pt;white-space:pre-
wrap;vertical-align:top;"><p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total marketable securities</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-

top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt
solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-
wrap;min-width:fit-content;">168,640</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-
wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-
content;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-
top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-
wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">
10,944</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-
align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-
content;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">
 </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid
#000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td
style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;text-align:right;">157,696</p></td> <td style="border-
top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-
space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-
align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-
content;">—</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-
top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-
break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;text-align:left;">Total cash equivalents and marketable securities</p></td> <td
style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-
wrap;min-width:fit-content;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="white-space:pre-wrap;vertical-
align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">199,978</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">
<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-
wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-
content;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-
bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-
space:pre-wrap;min-width:fit-content;">42,282</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-
align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">
</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:left;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double
#000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-
width:fit-content;">157,696</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-
space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p>
</td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-
align:left;"> </p></td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-
align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p>
</td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-
width:fit-content;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-
align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">
</p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-
top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-
align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-
content;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">
 </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td
style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-
wrap;min-width:fit-content;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-
content;">December 31, 2023</p></td> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:top;"><p style="font-size:10pt;margin-
top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:top;"><p
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td
colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-
width:fit-content;"> </p></td> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-
top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:top;"><p
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td
style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-
content;"> </p></td> <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-
break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-
space:pre-wrap;font-weight:bold;min-width:fit-content;">Cash equivalents:</p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td
style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-
wrap;min-width:fit-content;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">
 </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-
align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">
</p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-
width:fit-content;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-
align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">
</p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;text-align:right;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-
break:break-word;"> <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;text-align:left;">Money market funds invested in government securities</p></td>
<td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-
wrap;min-width:fit-content;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:left;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">24,701</p></td>
<td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-
content;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">
 </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="white-space:pre-wrap;vertical-
align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-
wrap;min-width:fit-content;">24,701</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-
align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p>
</td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-
space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-

content,">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center,"> — </td> <td style="white-space:nowrap;vertical-align:bottom,"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word,"> <td style="text-indent:25pt;white-space:pre-wrap;vertical-align:top,"> Total cash equivalents </td> <td style="white-space:pre-wrap;vertical-align:bottom,"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000,"> </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center,"> 24,701 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03,"> </td> <td style="white-space:pre-wrap;vertical-align:bottom,"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000,"> </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center,"> 24,701 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03,"> </td> <td style="white-space:pre-wrap;vertical-align:bottom,"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000,"> </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center,"> — </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03,"> </td> <td style="white-space:pre-wrap;vertical-align:bottom,"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom,border-bottom:0.5pt solid #000000,"> </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom,text-align:center,"> — </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom,border-bottom:0.5pt solid #ffffff03,"> </td> <td style="white-space:pre-wrap;vertical-align:bottom,"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom,border-bottom:0.5pt solid #000000,"> </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom,text-align:center,"> — </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom,border-bottom:0.5pt solid #ffffff03,"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word,"> <td style="vertical-align:top,"> </td> <td style="vertical-align:bottom,"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center,"> </td> <td style="vertical-align:bottom;text-align:center,"> </td> <td style="vertical-align:bottom,"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center,"> </td> <td style="vertical-align:bottom;text-align:center,"> </td> <td style="vertical-align:bottom,"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center,"> </td> <td style="vertical-align:bottom,text-align:center,"> </td> <td style="vertical-align:bottom,"> </td> <td colspan="2" style="vertical-align:bottom,text-align:center,"> </td> <td style="vertical-align:bottom,text-align:center,"> </td> <td style="vertical-align:bottom,"> </td> <td colspan="2" style="vertical-align:bottom,text-align:center,"> </td> <td style="vertical-align:bottom,text-align:center,"> </td> <td style="vertical-align:bottom,"> </td> <td colspan="2" style="vertical-align:bottom,text-align:center,"> </td> <td style="vertical-align:bottom,text-align:center,"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word,"> <td style="vertical-align:top,"> Marketable securities: </td> <td style="vertical-align:bottom,"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center,"> </td> <td style="vertical-align:bottom,text-align:center,"> </td> <td style="vertical-align:bottom,"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center,"> </td> <td style="vertical-align:bottom,text-align:center,"> </td> <td style="vertical-align:bottom,"> </td> <td colspan="2" style="vertical-align:bottom,text-align:center,"> </td> <td style="vertical-align:bottom,text-align:center,"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word,"> <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top,"> U.S. Treasury Bills </td> <td style="white-space:pre-wrap;vertical-align:bottom,"> </td> <td style="white-space:nowrap;vertical-align:bottom,"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center,"> 17,334 </td> <td style="white-space:nowrap;vertical-align:bottom,"> </td> <td style="white-space:pre-wrap;vertical-align:bottom,"> </td> <td style="white-space:nowrap;vertical-align:bottom,"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center,"> 17,334 </td> <td style="white-space:nowrap;vertical-align:bottom,"> </td> <td style="white-space:pre-wrap;vertical-align:bottom,"> </td> <td style="white-space:nowrap;vertical-align:bottom,"> </td> <td style="white-space:pre-wrap;vertical-align:bottom,text-align:center,"> — </td> <td style="white-space:nowrap;vertical-align:bottom,"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word,"> <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top,"> U.S. Government securities </td> <td style="white-space:pre-wrap;vertical-align:bottom,"> </td> <td style="white-space:nowrap;vertical-align:bottom,"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center,"> 35,719 </td> <td style="white-space:nowrap;vertical-align:bottom,"> </td> <td style="white-space:pre-wrap;vertical-align:bottom,"> </td> <td style="white-space:nowrap;vertical-align:bottom,"> </td> <td style="white-space:pre-wrap;vertical-align:bottom,text-align:center,"> — </td> <td style="white-space:nowrap;vertical-align:bottom,"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word,"> <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top,"> Corporate bonds </td> <td style="white-space:pre-wrap;vertical-align:bottom,"> </td> <td style="white-space:nowrap;vertical-align:bottom,border-bottom:0.5pt solid #000000,"> </td> <td style="white-space:pre-wrap;vertical-align:bottom,border-bottom:0.5pt solid #000000;text-align:center,"> 6,988 </td> <td style="white-space:nowrap;vertical-align:bottom,border-bottom:0.5pt solid #ffffff03,"> </td> <td style="white-space:pre-wrap;vertical-align:bottom,"> </td> <td style="white-space:nowrap;vertical-align:bottom,border-bottom:0.5pt solid #000000,">

 </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 6,988 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:25pt;white-space:pre-wrap;vertical-align:top;"> Total marketable securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 60,041 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 17,334 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 42,707 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total cash equivalents and marketable securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">84,742</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 42,035 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">42,707</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> The accrued interest receivable related to the Company's investments was $0.9 million and $0.3 million as of September 30, 2024 and December 31, 2023, respectively, and is included in prepaid expenses and other current assets on the condensed consolidated balance sheet. The Company classifies its money market funds and U.S. treasury bills, which are valued based on quoted market prices in active markets with no valuation adjustment, as Level 1 assets within the fair value hierarchy. The Company classifies its investments in U.S. government and agency securities, corporate commercial paper, and corporate bonds, if any, as Level 2 assets within the fair value hierarchy. The fair values of these investments are estimated by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income- and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data and other observable inputs. As of September 30, 2024 and December 31, 2023, no allowances for credit losses for the Company's investments were recorded. During the three and nine months ended September 30, 2024 and 2023, the Company did not recognize any impairment losses related to investments. Marketable securities The following table summarizes the Company's marketable securities as of September 30, 2024 and December 31, 2023. <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.38%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Amortized
Cost </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Gross
Unrealized
Gains </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Gross
Unrealized
Losses </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-

align:center;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="14" style="vertical-align:bottom;text-align:left;"> (in thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> September 30, 2024 </td> <td style="vertical-align:top;"> </td> <td colspan="2" style="vertical-align:top;"> </td> <td style="vertical-align:top;"> </td> <td style="vertical-align:top;"> </td> <td colspan="2" style="vertical-align:top;"> </td> <td style="vertical-align:top;"> </td> <td style="vertical-align:top;"> </td> <td colspan="2" style="vertical-align:top;"> </td> <td style="vertical-align:top;"> </td> <td colspan="2" style="vertical-align:top;"> </td> <td style="vertical-align:top;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Assets: </td> <td style="vertical-align:top;"> </td> <td colspan="2" style="vertical-align:top;"> </td> <td style="vertical-align:top;"> </td> <td style="vertical-align:top;"> </td> <td colspan="2" style="vertical-align:top;"> </td> <td style="vertical-align:top;"> </td> <td colspan="2" style="vertical-align:top;"> </td> <td style="vertical-align:top;"> </td> <td colspan="2" style="vertical-align:top;"> </td> <td style="vertical-align:top;"> </td> <td colspan="2" style="vertical-align:top;"> </td> <td style="vertical-align:top;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> U.S. Treasury Bills </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">10,937</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align.center;"> 7 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10,944 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> U.S. Government securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 157,345 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align.center;"> 351 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 157,696 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Total marketable securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">168,282</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 358 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 168,640 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> <span style="white-space:

space:pre-wrap;min-width:fit-content;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> December 31, 2023 </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Assets: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> U.S. Treasury Bills </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:ccenter;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">17,330</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 17,334 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> U.S. Government securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:ccenter;"> 35,653 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 66 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 35,719 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Corporate bonds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 6,977 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 11 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 6,988 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Total marketable securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> <span style="color:#000000;white-

space:pre-wrap;min-width:fit-content;">59,960 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">81</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">60,041</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The following tables summarize the Company's cash equivalents and marketable securities as of September 30, 2024 and December 31, 2023:</p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.38%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Total</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Quoted
Prices in
Active
Markets
(Level 1)</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Significant
Other
Observable
Inputs
(Level 2)</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:ccenter;">Significant
Unobservable
Inputs
(Level 3)</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="14" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">(in thousands)</p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">September 30, 2024</p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Cash equivalents:</p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word,"> <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Money market funds invested in government securities</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 31,338 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">31,338</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:25pt;white-space:pre-wrap;vertical-align:top;"> Total cash equivalents </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt

solid #000000;text-align:center;"> 31,338 </td> <td style="border-top:0.5pt solid #fffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 31,338 </td> <td style="border-top:0.5pt solid #fffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> —

family:Times New Roman;margin-bottom:0;text-align:right;">157,696 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total cash equivalents and marketable securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">199,978</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 42,282 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">157,696</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 42,282 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> December 31, 2023 </td> <td style="vertical-align:top;"> </td> <td colspan="2" style="vertical-align:top;"> </td> <td style="vertical-align:top;"> </td> <td style="vertical-align:top;"> </td> <td colspan="2" style="vertical-align:top;"> </td> <td style="vertical-align:top;"> </td> <td style="vertical-align:top;"> </td> <td colspan="2" style="vertical-align:top;"> </td> <td style="vertical-align:top;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Cash equivalents: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"> Money market funds invested in government securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">24,701</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 24,701 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:25pt;white-space:pre-wrap;vertical-align:top;"> Total cash equivalents </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 24,701 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-

align:center;"> 24,701 </td> <td style="border-top:0.5pt solid #fffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="border-top:0.5pt solid #fffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="border-top:0.5pt solid #fffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> <span style="

break:break-word;"> <td style="text-indent:25pt;white-space:pre-wrap;vertical-align:top;"> Total marketable securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 60,041 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 17,334 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 42,707 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total cash equivalents and marketable securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">84,742</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 42,035 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">42,707</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 42,707 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">42,707</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 42,707 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">42,707</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"> </td> </tr>
</table>3133800031338000313380003133800010944000109440001576960001576960001686400001094400015769600019978000422820001576960002470100024701000247010002470100247010
style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The following table summarizes the Company's marketable securities as of September 30, 2024 and December 31, 2023. <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.38%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Amortized
Cost </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Gross
Unrealized
Gains </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Gross
Unrealized
Losses </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="14" style="vertical-align:bottom;text-align:left;"> (in thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> September 30, 2024 </td> <td style="vertical-align:top;"> </td> <td colspan="2" style="vertical-align:top;"> </td> <td style="vertical-align:top;"> </td> <td colspan="2" style="vertical-align:top;"> </td> <td style="vertical-align:top;"> </td> <td colspan="2" style="vertical-align:top;"> </td> <td style="vertical-align:top;"> </td> <td colspan="2" style="vertical-align:top;"> </td> <td style="vertical-align:top;"> </td> <td colspan="2" style="vertical-align:top;"> </td> <td style="vertical-align:top;"> </td> <td colspan="2" style="vertical-align:top;"> </td> <td style="vertical-align:top;"> </td> <td colspan="2" style="vertical-align:top;"> </td> <td style="vertical-align:top;"> </td> <td colspan="2" style="vertical-align:top;"> </td> <td style="vertical-align:top;"> </td> <td colspan="2" style="vertical-align:top;"> </td> <td style="vertical-align:top;"> </td> <td colspan="2" style="vertical-align:top;"> </td> <td style="vertical-align:top;"> </td> <td colspan="2" style="vertical-align:top;"> </td> <td style="vertical-align:top;"> </td> <td colspan="2" style="vertical-align:top;"> </td> <td style="vertical-align:top;"> </td> <td colspan="2" style="vertical-align:top;"> </td> <td style="vertical-align:top;"> </td> <td colspan="2" style="vertical-align:top;"> </td> <td style="vertical-align:top;"> </td> <td colspan="2" style="vertical-align:top;"> </td> <td style="vertical-align:top;"> </td> <td colspan="2" style="vertical-align:top;"> </td> <td style="vertical-align:top;"> </td> <td colspan="2" style="vertical-align:top;"> </td> <td style="vertical-align:top;"> </td> <td colspan="2" style="vertical-align:top;"> </td> <td style="vertical-align:top;"> </td> <td colspan="2" style="vertical-align:top;"> </td> <td>

style="vertical-align:top;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> U.S. Treasury Bills </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">10,937</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom,"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom,"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center,"> 7 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom,"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom,text-align:center,"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right,"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom,"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10,944 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> U.S. Government securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom,"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 157,345 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom,"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 351 </td> <td style="white-space:nowrap;vertical-align:bottom,"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom,"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom,"> </td> <td style="white-space:pre-wrap;vertical-align:bottom,"> </td> <td style="white-space:nowrap;vertical-align:bottom,"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 157,696 </td> <td style="white-space:nowrap;vertical-align:bottom,"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word,"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Total marketable securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom,border-bottom:2.25pt double #000000;"> $</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">168,282</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left,"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left,"><span style="color:#000000;min-width:fit-content,">$ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center,"> 358 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom,"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000,"> $ </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom,"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center,"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom,"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom,text-align:center,"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom,text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:top;"> Assets: </td> <td style="vertical-align:bottom,"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center,"> </td> <td style="vertical-align:bottom,"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p

style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> U.S. Treasury Bills </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">17,330</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 17,334 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> U.S. Government securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 35,653 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 66 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 35,719 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Corporate bonds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 6,977 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 11 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000,"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000,"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 6,988 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Total marketable securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000,"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">59,960</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000,"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 81 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000,"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000,"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 60,041 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03,"> </td> </tr>
</table>10937000700010944000157345000351000157696000168282000358000168640000173300004000173340003565300006600035719000697700011000698000599600008100060041006 class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;">4. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consisted of the following: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.883000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.883000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> September 30, </td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-

family:Times New Roman;margin-bottom:0;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> December 31, </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> (in thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Prepaid research and development expenses </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">8,192</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,994 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Interest receivable </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 943 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 332 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Prepaid insurance </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 43 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 682 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Other prepaid expenses and other assets </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 371 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 377 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">9,549</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 3,385 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> Prepaid expenses and other current assets consisted of the following: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.883000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.883000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> September 30, </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> December 31, </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New

Roman;margin-bottom:0;text-align:left;">Prepaid research and development expenses </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">8,192</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,994 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#fffffe;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Interest receivable </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 943 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 332 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Prepaid insurance </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 43 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 682 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#fffffe;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Other prepaid expenses and other assets </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 371 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 377 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">9,549</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,385 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr>
</table>81920001994000943000332000430006820003710003770009549000033850000 5. Fixed Assets Fixed assets, not consisted of the following: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.477%;box-sizing:content-box;"></td> <td style="width:1.399%;box-sizing:content-box;"></td> <td style="width:12.775%;box-sizing:content-box;"></td> <td style="width:1.399%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.776%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.776%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#fffffe;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> September 30, </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> December 31, </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#fffffe;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:left;"> Useful Life </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#fffffe;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> (in thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Computer equipment </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> 5 years </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">117</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$

</td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 117 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Lab equipment </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> 5 years </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,528 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,192 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Furniture and fixtures </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> 7 years </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 555 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 555 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Leasehold improvements </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> lease term </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 45 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 45 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,245 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,909 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Less: Accumulated depreciation </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (1,466 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (1,225 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000,"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">779</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 684 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"> </td> </tr> </table> Depreciation expense was $0.1 million and $0.2 million for the three and nine months ended September 30, 2024, respectively. Depreciation expense was $0.1 million and $0.2 million for the three and nine months ended September 30, 2023, respectively. In addition, for the three and nine months ended September 30, 2024, there was less than $0.1 million of depreciation in each period related to sublet assets recorded as other expense. For the three and nine months ended September 30, 2023, there was less than $0.1 million and $0.1 million, respectively, of depreciation related to sublet assets recorded as other expense. Fixed assets, net consisted of the following: <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-

align:left;"> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.477%;box-sizing:content-box;"></td> <td style="width:1.399%;box-sizing:content-box;"></td> <td style="width:12.775%;box-sizing:content-box;"></td> <td style="width:1.399%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.776%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.399%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:10.776%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> September 30, </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> December 31, </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:left;"> Useful Life </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> (in thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Computer equipment </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> 5 years </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">117</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 117 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Lab equipment </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> 5 years </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,528 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,192 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Furniture and fixtures </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> 7 years </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 555 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 555 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Leasehold improvements </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> lease term </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 45 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 45 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,245 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Less: Accumulated depreciation </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> <span style="white-space:pre-wrap;min-

width:fit-content;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (1,466 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (1,225 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">779</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 684 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"> </td> </tr>
</table>P5Y1170011700P5Y1528000119200P7Y5550005550004500045000224500019090001466000122500077900684000100000200000100000200000100000100000100000100000 6. Accrued Expenses Accrued expenses consisted of the following: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.883000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.883000000000001%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#fffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> September 30, </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> December 31, </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#fffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#fffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> (in thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Accrued research and development expenses </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">10,329</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,594 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#fffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Accrued payroll and related expenses </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,377 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,365 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Accrued other </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 867 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 427 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;"> </td> </tr> <tr style="height:10pt;background-color:#fffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">13,573</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 7,386 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"> </td> </tr> </table> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;box-

sizing:content-box,"></td> <td style="width:1.62%;box-sizing:content-box,"></td> <td style="width:1%;box-sizing:content-box,"></td> <td style="width:12.883000000000001%;box-sizing:content-box,"></td> <td style="width:1%;box-sizing:content-box,"></td> <td style="width:1.62%;box-sizing:content-box,"></td> <td style="width:1%;box-sizing:content-box,"></td> <td style="width:12.883000000000001%;box-sizing:content-box,"></td> <td style="width:1%;box-sizing:content-box,"></td> </tr> <tr style="height:8pt;background-color:#fffff;white-space:pre-wrap;word-break:break-word,"> <td style="vertical-align:bottom,"> </td> <td style="vertical-align:bottom,"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left,"> September 30, </td> <td style="vertical-align:bottom;text-align:left,"> </td> <td style="vertical-align:bottom,"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left,"> December 31, </td> <td style="vertical-align:bottom;text-align:left,"> </td> </tr> <tr style="height:8pt;background-color:#fffff;white-space:pre-wrap;word-break:break-word,"> <td style="vertical-align:bottom,"> </td> <td style="vertical-align:bottom,"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left,"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left,"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000,"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left,"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left,"> </td> </tr> <tr style="height:8pt;background-color:#fffff;white-space:pre-wrap;word-break:break-word,"> <td style="vertical-align:bottom,"> </td> <td style="vertical-align:bottom,"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left,"> (in thousands) </td> <td style="vertical-align:bottom;text-align:left,"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word,"> <td style="white-space:pre-wrap;vertical-align:top,"> Accrued research and development expenses </td> <td style="white-space:pre-wrap;vertical-align:bottom,"> </td> <td style="white-space:nowrap;vertical-align:bottom,"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center,"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right,">10,329</p></td> <td style="white-space:nowrap;vertical-align:bottom,"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left,"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom,"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left,"> </p></td> <td style="white-space:nowrap;vertical-align:bottom,"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left,"><span style="color:#000000;min-width:fit-content,">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center,"> 4,594 </td> <td style="white-space:nowrap;vertical-align:bottom,"> </td> </tr> <tr style="height:10pt;background-color:#fffff;word-break:break-word,"> <td style="white-space:pre-wrap;vertical-align:top,"> Accrued payroll and related expenses </td> <td style="white-space:pre-wrap;vertical-align:bottom,"> </td> <td style="white-space:nowrap;vertical-align:bottom,"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center,"> 2,377 </td> <td style="white-space:nowrap;vertical-align:bottom,"> </td> <td style="white-space:pre-wrap;vertical-align:bottom,"> </td> <td style="white-space:nowrap;vertical-align:bottom,"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center,"> 2,365 </td> <td style="white-space:nowrap;vertical-align:bottom,"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word,"> <td style="white-space:pre-wrap;vertical-align:top,"> Accrued other </td> <td style="white-space:pre-wrap;vertical-align:bottom,"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000,"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center,"> 867 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03,"> </td> <td style="white-space:pre-wrap;vertical-align:bottom,"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000,"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center,"> 427 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03,"> </td> </tr> <tr style="height:10pt;background-color:#fffff;word-break:break-word,"> <td style="white-space:pre-wrap;vertical-align:top,"> </td> <td style="white-space:pre-wrap;vertical-align:bottom,"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000,"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center,"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right,">13,573</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03,"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left,"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom,"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left,"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000,"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left,"><span style="color:#000000;min-width:fit-content,">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center,"> 7,386 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03,"> </td> </tr>
</table>10329000459400023770002365000867000427000135730007386000 7. Stockholders' Equity and Stock Options Common Stock and Prefunded Warrants On May 28, 2020, the Company entered into a securities purchase agreement with certain accredited investors (the "Purchasers") for the sale by the Company in a private placement of 6,105,359 shares of the Company's common stock and prefunded warrants to purchase an aggregate of 628,403 shares of the Company's common stock, for a price of $11.88 per share of the common stock and $11.87 per prefunded warrant. The prefunded warrants were exercisable at an exercise price of $0.01 and were exercisable indefinitely. In August 2023, the 628,403 shares of prefunded warrants were exercised and the Company received cash proceeds of six thousand two hundred and eighty-four dollars. The private placement closed on June 1, 2020. The aggregate gross proceeds for the issuance and sale of the common stock and prefunded warrants were $80.0 million, transaction costs totaled $4.6 million and resulted in net proceeds of $75.4 million. The Company's Registration Statement on Form S-3, filed with the SEC on June 26, 2020, registered the resale of 6,105,359 shares of common stock sold and the 628,403 shares of common stock underlying the prefunded warrants. MTS Health Partners served as placement agent to the Company in connection with the private placement. As partial compensation for these services, the Company issued MTS Health Partners 35,260 shares of common stock. As of September 30, 2024, the Company's Ninth Amended and Restated Certificate of Incorporation, as amended, authorized the Company to issue up to 115,000,000 shares of common stock, par value $<span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-

content,">0.001 per share, of which 63,806,628 shares were issued and outstanding, and up to 5,000,000 shares of undesignated preferred stock, par value $0.001 per share, of which no shares were issued or outstanding. The voting, dividend and liquidation rights of the holders of the Company's common stock are subject to and qualified by the rights, powers and preferences of the holders of the preferred stock. Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company's stockholders. Common stockholders are entitled to receive dividends, as may be declared by the board of directors of the Company (the "Board"), if any. No cash dividends have been declared or paid to date. In February 2024, the Company completed an underwritten public offering in which the Company issued and sold 19,736,842 shares of its common stock at a public offering price of $8.74 per share. The Company received net proceeds of approximately $161.8 million after deducting underwriting discounts, commissions and other offering expenses. ATM Agreement In November 2022, the Company entered into a Sales Agreement (the "2022 ATM Agreement") with Guggenheim Securities, LLC as a sales agent in connection with the establishment of an "at-the-market" offering program under which the Company could sell up to an aggregate of $50 million of shares of common stock (the "2022 ATM Shares") from time to time. In February 2024, in connection with the underwritten public offering described above, the Company terminated the 2022 ATM Agreement. No ATM Shares were ever sold pursuant to the 2022 ATM Agreement. In May 2024, the Company entered into a sales agreement (the "ATM Agreement") with Guggenheim Securities, LLC in connection with the establishment of an "at-the-market" offering program under which the Company could sell up to an aggregate of $100 million of shares of common stock (the "ATM Shares") from time to time. To date, no sales of common stock have been made under this ATM Agreement. 2020 Equity Incentive Plan The Board adopted the 2020 Equity Incentive Plan (the "2020 Plan") on July 16, 2020 and the stockholders of the Company approved the 2020 Plan on September 29, 2020. The 2020 Plan replaced the predecessor plans (the "Prior Plans") that the Company assumed following its merger with Zafgen in May 2020. Options outstanding under the Prior Plans will remain outstanding, unchanged, and subject to the terms of the Prior Plans and the respective award agreements, and no further awards will be made under the Prior Plans. However, if any award previously granted under the Prior Plans, expires, terminates, is canceled, or is forfeited for any reason after the approval of the 2020 Plan, the shares subject to that award will be added to the 2020 Plan share pool so that they can be utilized for new grants under the 2020 Plan. The 2020 Plan provides for the grant of incentive stock options ("ISOs"), nonstatutory stock options ("NSOs"), stock appreciation rights, restricted stock awards, restricted stock unit awards, and cash or other stock-based awards. ISOs may be granted only to the Company's employees, including the Company's officers, and the employees of the Company's affiliates. All other awards may be granted to the Company's employees, including the Company's officers, the Company's non-employee directors and consultants, and the employees and consultants of the Company's affiliates. The maximum number of shares that may be issued in respect of any awards under the 2020 Plan is the sum of: (i) 1,700,000 shares plus (ii) an annual increase on January 1, 2021 and each anniversary of such date thereafter through January 1, 2030, equal to the lesser of (A) 4% of the shares issued and outstanding on the last day of the immediately preceding fiscal year, or (B) such smaller number of shares as determined by the Board (collectively, the "Plan Limit"). The maximum aggregate number of shares that may be issued under the 2020 Plan is 9,000,000 over the ten-year term of the 2020 Plan. As permitted by the 2020 Plan, the Company added 1,756,363 and 1,730,768 shares available for grant to the 2020 Plan on January 1, 2024 and January 1, 2023, respectively. As of September 30, 2024, 779,926 shares of common stock were available for grant under the 2020 Plan. During the twelve months ended December 31, 2023, options to purchase 224,437 shares issued under the Prior Plans were cancelled and became available for grant under the 2020 Plan. During the nine months ended September 30, 2024, options to purchase 1,242 shares issued under the Prior Plans were cancelled and became available for grant under the 2020 Plan. At September 30, 2024, 344,683 options under the Prior Plans remained outstanding at prices ranging from $11.88 to $445.80, and, if unexercised, will return to the 2020 Plan no later than July 15, 2030. Stock Option Valuation The following table presents, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted to employees: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto,"> <tr style="visibility:collapse,"> <td style="width:80.236%;box-sizing:content-box,"></td> <td style="width:1.94%;box-sizing:content-box,"></td> <td style="width:17.824%;box-sizing:content-box,"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word,"> <td style="vertical-align:bottom,"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom,text-align:left,"> September 30, </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word,"> <td style="vertical-align:bottom,"> </td> <td style="vertical-align:bottom,"> </td> <td style="vertical-align:bottom,border-bottom:0.5pt solid #000000;text-align:left,"> 2024 </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word,"> <td style="vertical-align:top,"> Risk-free interest rate </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom,text-align:left,"> 4.12% </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word,"> <td style="vertical-align:top,"> Expected term (in years) </td> <td style="vertical-align:bottom,"> </td> <td style="vertical-align:bottom,text-align:left,"> 6.22 </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word,"> <td style="vertical-align:top,"> Expected volatility </td> <td style="vertical-align:bottom,"> </td> <td style="vertical-align:bottom,text-align:left,"> 96% </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word,"> <td style="vertical-align:top,"> Dividend yield </td> <td style="vertical-align:bottom,"> </td> <td style="vertical-align:bottom,text-align:left,"> 0.00% </td> </tr> </table> <span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-

style:italic;min-width:fit-content;">Stock Options The following table summarizes the Company's stock option activity for the nine months ended September 30, 2024 (amounts in millions, except for share, contractual term, and per share data): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.11%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.662%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.942%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.662%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.182%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Weighted </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Weighted Average </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Aggregate </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Average </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Remaining </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Intrinsic </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Number of </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Exercise </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Contractual </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Value (a) </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Shares </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Price </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Term (in years) </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> (in millions) </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Outstanding as of December 31, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,273,502 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 9.06 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7.8 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-

top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Options granted </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,082,377 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5.22 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Options exercised </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (6,967 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,92 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Options forfeited/expired </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (57,088 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10,08 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,291,824 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">7.79</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">7.8</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7.4 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word,"> <td style="white-space:pre-wrap;vertical-align:top;"> Exercisable as of September 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 2,921,508 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">10.63</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6.5</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1.7 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word,"> <td style="white-space:pre-wrap;vertical-align:top;"> Vested and expected to vest as of September 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 6,291,824 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> <span style="min-width:fit-

content,"> </td> <td style="white-space:pre-wrap;vertical-align:bottom,"> </td> <td style="white-space:nowrap;vertical-align:bottom,"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center,"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman,margin-bottom:0;text-align:right,">7.79</p></td> <td style="white-space:nowrap;vertical-align:bottom,"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman,margin-bottom:0;text-align:left,"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom,"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman,margin-bottom:0;text-align:left,"> </p></td> <td style="white-space:nowrap;vertical-align:bottom,"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman,margin-bottom:0;text-align:left,"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center,"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman,margin-bottom:0;text-align:right,">7.8</p></td> <td style="white-space:nowrap;vertical-align:bottom,"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman,margin-bottom:0;text-align:left,"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom,"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman,margin-bottom:0;text-align:left,"> </p></td> <td style="white-space:nowrap;vertical-align:bottom,"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman,margin-bottom:0;text-align:left,"><span style="color:#000000,min-width:fit-content,">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center,"> 7.4 </td> <td style="white-space:nowrap;vertical-align:bottom,"> </td> </tr></table> (a) The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of the common stock for the options that were "in the money" at September 30, 2024. Option Grants During the nine months ended September 30, 2024, the Company granted options to purchase 2,082,377 shares of common stock to employees and directors under the 2020 Plan. The options have an exercise price equal to the closing stock price as of the grant date. Of the 2,082,377 options granted, 1,987,377 were granted to employees and vest over four years, with 25% vesting on the first anniversary of the grant and the remainder vesting in equal monthly installments thereafter. The remaining 95,000 options were annual grants to the Company's directors and vest one year from the grant date. The weighted average grant date fair value of options granted under the 2020 Plan during the nine months ended September 30, 2024 was $4.15. As of September 30, 2024, total unrecognized compensation expense related to unvested stock options granted under the 2020 Plan was $11.8 million, which is expected to be recognized over a weighted average period of 2.56 years. Inducement Stock Option Grant There were no inducement awards granted in the nine months ended September 30, 2024. As of September 30, 2024, total unrecognized compensation expense related to unvested inducement options granted was $0.8 million, which is expected to be recognized over a weighted average period of 2.53 years. Restricted Stock Units In January 2024, RSUs were granted under the 2020 Plan to certain of the Company's employees in order to maintain retention of key employees. The value of an RSU award is based on the Company's stock price on the date of grant. The shares underlying the RSUs are not issued until the RSUs vest. Activity with respect to the Company's RSUs during the nine months ended September 30, 2024 was as follows (in millions, except share, contractual term, and per share data): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto,"><tr style="visibility:collapse,"><td style="width:50.11%;box-sizing:content-box,"></td><td style="width:1%;box-sizing:content-box,"></td><td style="width:1%;box-sizing:content-box,"></td><td style="width:9.662%;box-sizing:content-box,"></td><td style="width:1%;box-sizing:content-box,"></td><td style="width:1.22%;box-sizing:content-box,"></td><td style="width:1%;box-sizing:content-box,"></td><td style="width:8.942%;box-sizing:content-box,"></td><td style="width:1%;box-sizing:content-box,"></td><td style="width:1%;box-sizing:content-box,"></td><td style="width:1%;box-sizing:content-box,"></td><td style="width:9.662%;box-sizing:content-box,"></td><td style="width:1%;box-sizing:content-box,"></td><td style="width:1.22%;box-sizing:content-box,"></td><td style="width:1%;box-sizing:content-box,"></td><td style="width:9.182%;box-sizing:content-box,"></td><td style="width:1%;box-sizing:content-box,"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word,"><td style="vertical-align:bottom,"> </td><td style="vertical-align:bottom,"> </td><td colspan="2" style="vertical-align:bottom,"> </td><td style="vertical-align:bottom,"> </td><td colspan="2" style="vertical-align:bottom;text-align:left,"> Weighted </td><td style="vertical-align:bottom;text-align:left,"> </td><td style="vertical-align:bottom,"> </td><td colspan="2" style="vertical-align:bottom;text-align:left,"> </td><td style="vertical-align:bottom,"> Weighted Average </td><td style="vertical-align:bottom;text-align:left,"> </td><td style="vertical-align:bottom,"> </td><td colspan="2" style="vertical-align:bottom;text-align:left,"> Aggregate </td><td style="vertical-align:bottom;text-align:left,"> </td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word,"><td style="vertical-align:bottom,"> </td><td style="vertical-align:bottom,"> </td><td colspan="2" style="vertical-align:bottom;text-align:left,"> </td><td style="vertical-align:bottom,"> </td><td colspan="2" style="vertical-align:bottom;text-align:left,"> Average </td><td style="vertical-align:bottom;text-align:left,"> </td><td style="vertical-align:bottom,"> </td><td colspan="2" style="vertical-align:bottom;text-align:left,"> Remaining </td><td style="vertical-align:bottom;text-align:left,"> </td><td style="vertical-align:bottom,"> </td><td colspan="2" style="vertical-align:bottom;text-align:left,"> Intrinsic </td><td style="vertical-align:bottom;text-align:left,"> </td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word,"><td style="vertical-align:bottom,"> </td><td style="vertical-align:bottom,"> </td><td colspan="2" style="vertical-align:bottom,text-align:left,"> Number of </td><td style="vertical-align:bottom;text-align:left,"> </td><td style="vertical-align:bottom,"> </td><td colspan="2" style="vertical-align:bottom,text-align:left,"> Grant Date </td><td style="vertical-align:bottom;text-align:left,"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman,margin-bottom:0;text-

align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Contractual </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Value (a) </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#fffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Shares </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Term (in years) </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> (in millions) </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Outstanding as of December 31, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 615,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4.94 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1.6 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 245,372 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4.21 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Restricted stock units vested </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (153,750 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4.94 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word,"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Restricted stock units forfeited </td> <td style="white-space:pre-wrap;vertical-align:bottom,"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 7,619 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4.64 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom,text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom,text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom,"> </td> <td style="white-space:nowrap;vertical-align:bottom,border-bottom:2.25pt double #000000,"> </td> <td style="white-space:pre-wrap;vertical-align:bottom,border-bottom:2.25pt double #000000,text-align:center,"> </td> </tr> <tr style="height:10pt,background-color:#cff0fc,word-break:break-word,"> <td style="white-space:pre-wrap,vertical-align:top,"> Outstanding as of September 30, 2024 </td> <td style="white-space:pre-wrap,vertical-align:bottom,"> </td> <td style="white-space:nowrap,vertical-align:bottom,border-bottom:2.25pt double #000000,"> </td> <td style="white-space:pre-wrap,vertical-align:bottom,border-bottom:2.25pt double #000000,text-align:center,"><p style="font-size:10pt,margin-top:0,font-family:Times New Roman,margin-bottom:0,text-

align:right;">699,003 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">4.69</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1.5</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4.6 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Unvested and expected to vest as of September 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 699,003 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4.69 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr></table> Restricted Stock Unit Grants During the nine months ended September 30, 2024, the Company granted 245,372 shares of RSUs to employees under the 2020 Plan. The RSUs vest annually over four years and have a weighted-average grant date fair value of $4.21 per unit. As of September 30, 2024, total unrecognized compensation expense for RSUs was $2.6 million, which is expected to be recognized over a weighted-average period of 2.65 years. Stock-Based Compensation Stock-based compensation expense was classified in the condensed consolidated statements of operations as follows:
<table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.38%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> Three Months Ended September 30, </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> Nine Months Ended September 30, </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#fffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Research and development </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">918</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 697 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,816</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">

content,">2,304 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> General and administrative </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,039 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,124 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000,"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 3,570 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000,"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 3,393 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,957</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,821 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6,386</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03,"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25 pt double #000000;text-align:center;"> 5,697 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table>
610535962840311,8811,870.0162840380000004600000754000006105359628403352601150000000.00163806628638066285000000.00100Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company's stockholders.0197368428.74161800000500000000100000000The maximum number of shares that may be issued in respect of any awards under the 2020 Plan is the sum of: (i) 1,700,000 shares plus (ii) an annual increase on January 1, 2021 and each anniversary of such date thereafter through January 1, 2030, equal to the lesser of (A) 4% of the shares issued and outstanding on the last day of the immediately preceding fiscal year, or (B) such smaller number of shares as determined by the Board (collectively, the "Plan Limit").17000000.048000000P10Y1756363173076877092622443712423446831 1.88445.8 The following table presents, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted to employees: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80.236%;box-sizing:content-box;"></td> <td style="width:1.94%;box-sizing:content-box;"></td> <td style="width:17.824%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word,"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:left;"> September 30, </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word,"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word,"> <td style="vertical-align:top;"> Risk-free interest rate </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:left;"> 4.12% </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word,"> <td style="vertical-align:top;"> Expected term (in years) </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:left;"> 6.22 </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word,"> <td style="vertical-align:top;"> Expected volatility </td> <td style="vertical-align:bottom,"> </td> <td style="vertical-align:bottom;text-align:left;"> 96% </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word,"> <td style="vertical-align:top;"> Dividend yield </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;text-align:left;"> 0.00% </td> </tr> </table>0.0412P6Y2M19D0.960 The following table summarizes the Company's stock option activity for the nine months ended September 30, 2024 (amounts in millions, except for share, contractual term, and per share data):   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.11%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.662%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.942%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.662%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.182%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box,"></td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word,"> <td style="vertical-align:bottom,"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom,"> </td> <td style="vertical-align:bottom,"> </td> <td colspan="2" style="vertical-align:bottom,"> </td> <td style="vertical-align:bottom,"> </td> <td style="vertical-align:bottom,"> </td> <td colspan="2" style="vertical-align:bottom,"> </td> <td style="vertical-align:bottom,"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word,"> <td style="vertical-align:bottom,"> </td> <td style="vertical-align:bottom,"> <span style="white-space:pre-wrap;min-width:fit-

content,"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Weighted </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Weighted Average </td> <td style="vertical-align:bottom;text-align:left,"> </td> <td style="vertical-align:bottom,"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left,"> Aggregate </td> <td style="vertical-align:bottom,text-align:left,"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom,"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left,"> </td> <td style="vertical-align:bottom,text-align:left,"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left,"> Average </td> <td style="vertical-align:bottom,text-align:left,"> </td> <td style="vertical-align:bottom,"> </td> <td colspan="2" style="vertical-align:bottom,text-align:left,"> Remaining </td> <td style="vertical-align:bottom;text-align:left,"> </td> <td style="vertical-align:bottom,"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left,"> Intrinsic </td> <td style="vertical-align:bottom;text-align:left,"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word,"> <td style="vertical-align:bottom,"> </td> <td style="vertical-align:bottom,"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left,"> Number of </td> <td style="vertical-align:bottom;text-align:left,"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left,"> Exercise </td> <td style="vertical-align:bottom;text-align:left,"> </td> <td style="vertical-align:bottom,"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left,"> Contractual </td> <td style="vertical-align:bottom;text-align:left,"> </td> <td style="vertical-align:bottom,"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left,"> Value (a) </td> <td style="vertical-align:bottom,text-align:left,"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left,"> Shares </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left,"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left,"> Price </td> <td style="vertical-align:bottom,border-bottom:0.5pt solid #ffffff03,text-align:left,"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left,"> Term (in years) </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left,"> </td> <td style="vertical-align:bottom,"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left,"> (in millions) </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03,text-align:left,"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word,"> <td style="white-space:pre-wrap;vertical-align:top,"> Outstanding as of December 31, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom,"> </td> <td style="white-space:nowrap;vertical-align:bottom,"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center,"> 4,273,502 </td> <td style="white-space:nowrap;vertical-align:bottom,"> </td> <td style="white-space:pre-wrap;vertical-align:bottom,"> </td> <td style="white-space:nowrap;vertical-align:bottom,"> $ </td> <td style="white-space:pre-wrap,vertical-align:bottom;text-align:center;"> 9.06 </td> <td style="white-space:nowrap;vertical-align:bottom,"> </td> <td style="white-space:pre-wrap;vertical-align:bottom,"> </td> <td style="white-space:nowrap;vertical-align:bottom,"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center,"> 7.8 </td> <td style="white-space:nowrap;vertical-align:bottom,"> </td> <td style="white-space:pre-wrap,vertical-align:bottom,"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom,text-align:center,"> </td> <td style="white-space:pre-wrap,vertical-align:bottom,text-align:center,"> </td> </tr> <tr style="height:10pt,background-color:#ffffff,word-break:break-word,"> <td style="text-indent:20pt,white-space:pre-wrap,vertical-align:top,"> Options granted </td> <td style="white-space:pre-wrap,vertical-align:bottom,"> </td> <td style="white-space:nowrap;vertical-align:bottom,"> </td> <td style="white-space:pre-wrap,vertical-align:bottom;text-align:center,"> 2,082,377 </td> <td style="white-space:nowrap;vertical-align:bottom,"> </td> <td style="white-space:pre-wrap,vertical-align:bottom,"> </td> <td style="white-space:nowrap;vertical-align:bottom,"> </td> <td style="white-space:pre-wrap,vertical-align:bottom,text-align:center,"> 5.22 </td> <td style="white-space:nowrap;vertical-align:bottom,"> </td> <td style="white-space:pre-wrap,vertical-align:bottom,"> </td> <td colspan="2" style="white-space:pre-wrap,vertical-align:bottom,text-align:center,"> </td> <td style="white-space:pre-wrap,vertical-align:bottom,text-align:center,"> </td> <td style="white-space:pre-wrap,vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap,vertical-align:bottom,text-align:center;"> </td> <td style="white-space:pre-wrap,vertical-align:bottom,text-align:center;"> </td> </tr> <tr style="height:10pt,background-color:#cff0fc;word-break:break-word,"> <td style="text-indent:20pt,white-space:pre-wrap,vertical-align:top,"> Options exercised </td> <td style="white-space:pre-wrap,vertical-align:bottom,"> </td> <td style="white-space:nowrap;vertical-align:bottom,"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center,"> (6,967 </td> <td style="white-space:nowrap;vertical-align:bottom,">) </td> <td style="white-space:pre-wrap,vertical-align:bottom,"><p style="font-size:10pt,margin-top:0,font-

family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5.92 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Options forfeited/expired </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (57,088 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10.08 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Outstanding as of September 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 6,291,824 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">7.79</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7.8 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">7.4</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Exercisable as of September 30, 2024</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,921,508</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10.63 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6.5 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom,"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1.7</p></td> <td style="white-space:nowrap;vertical-align:bottom,"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Vested and expected to vest as of September 30, 2024</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6,291,824</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom,"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7.79 </td> <td style="white-space:nowrap;vertical-align:bottom,"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7.8 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7.4 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table> (a) The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of the common stock for the options that were "in the money" at September 30, 2024. 42735029.06P7Y9M18D20823775.2269675.925708810.0862918247.79P7Y9M18D74000002921508 10.63P6Y6M17000006291824 7.79P7Y9M18D74000002092377208237771987377P4Y0.2 style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Activity with respect to the Company's RSUs during the nine months ended September 30, 2024 was as follows (in millions, except share, contractual term, and per share data): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.11%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.662%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.942%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-

sizing:content-box,"></td> <td style="width:1%;box-sizing:content-box,"></td> <td style="width:9.662%;box-sizing:content-box,"></td> <td style="width:1%;box-sizing:content-box,"></td> <td style="width:1.22%;box-sizing:content-box,"></td> <td style="width:1%;box-sizing:content-box,"></td> <td style="width:9.182%;box-sizing:content-box,"></td> <td style="width:1%;box-sizing:content-box,"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word,"> <td style="vertical-align:bottom,"> </td> <td style="vertical-align:bottom,"> </td> <td colspan="2" style="vertical-align:bottom,"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left,"> </td> <td style="vertical-align:bottom,"> Weighted </td> <td style="vertical-align:bottom;text-align:left,"> </td> <td style="vertical-align:bottom,"> </td> <td colspan="2" style="vertical-align:bottom,text-align:left,"> Weighted Average </td> <td style="vertical-align:bottom;text-align:left,"> </td> <td style="vertical-align:bottom,"> </td> <td colspan="2" style="vertical-align:bottom,text-align:left,"> Aggregate </td> <td style="vertical-align:bottom;text-align:left,"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word,"> <td style="vertical-align:bottom,"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom,text-align:left,"> </td> <td style="vertical-align:bottom,"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left,"> Average </td> <td style="vertical-align:bottom;text-align:left,"> </td> <td style="vertical-align:bottom,"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left,"> Remaining </td> <td style="vertical-align:bottom;text-align:left,"> </td> <td style="vertical-align:bottom,"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left,"> Intrinsic </td> <td style="vertical-align:bottom,text-align:left,"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word,"> <td style="vertical-align:bottom,"> </td> <td style="vertical-align:bottom,"> </td> <td colspan="2" style="vertical-align:bottom,text-align:left,"> Number of </td> <td style="vertical-align:bottom;text-align:left,"> </td> <td style="vertical-align:bottom,"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left,"> Grant Date </td> <td style="vertical-align:bottom;text-align:left,"> </td> <td style="vertical-align:bottom,"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left,"> Contractual </td> <td style="vertical-align:bottom;text-align:left,"> </td> <td style="vertical-align:bottom,"> </td> <td colspan="2" style="vertical-align:bottom,text-align:left,"> Value (a) </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word,"> <td style="vertical-align:bottom,"> </td> <td style="vertical-align:bottom,"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left,"> Shares </td> <td style="vertical-align:bottom,border-bottom:0.5pt solid #ffffff03;text-align:left,"> </td> <td style="vertical-align:bottom,"> </td> <td colspan="2" style="vertical-align:bottom,border-bottom:0.5pt solid #000000;text-align:left,"> Fair Value </td> <td style="vertical-align:bottom,border-bottom:0.5pt solid #ffffff03;text-align:left,"> </td> <td style="vertical-align:bottom,"> </td> <td colspan="2" style="vertical-align:bottom,border-bottom:0.5pt solid #000000,text-align:left,"> Term (in years) </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left,"> </td> <td style="vertical-align:bottom,"> </td> <td colspan="2" style="vertical-align:bottom,border-bottom:0.5pt solid #000000;text-align:left,"> (in millions) </td> <td style="vertical-align:bottom,border-bottom:0.5pt solid #ffffff03;text-align:left,"> </td> </tr> <tr style="height:10pt,background-color:#cff0fc;word-break:break-word,"> <td style="white-space:pre-wrap,vertical-align:top,"> Outstanding as of December 31, 2023 </td> <td style="white-space:pre-wrap,vertical-align:bottom;"> </td> <td style="white-space:nowrap,vertical-align:bottom,"> </td> <td style="white-space:pre-wrap,vertical-align:bottom,text-align:center,"> 615,000 </td> <td style="white-space:nowrap,vertical-align:bottom,"> </td> <td style="white-space:pre-wrap,vertical-align:bottom,"> </td> <td style="white-space:nowrap,vertical-align:bottom,"> $ </td> <td style="white-space:pre-wrap,vertical-align:bottom,text-align:center,"> 4.94 </td> <td style="white-space:nowrap,vertical-align:bottom,"> </td> <td style="white-space:pre-wrap,vertical-align:bottom;"> </td> <td style="white-space:nowrap,vertical-align:bottom,"> </td> <td style="white-space:pre-wrap,vertical-align:bottom,text-align:center,"> 1.6 </td> <td style="white-space:nowrap,vertical-align:bottom,"> </td> <td style="white-space:pre-wrap,vertical-align:bottom,"> </td> <td colspan="2" style="white-space:pre-wrap,vertical-align:bottom,text-align:center,"> </td> <td style="white-space:pre-wrap,vertical-align:bottom,text-align:center,"> </td> </tr> <tr style="height:10pt,background-color:#ffffff,word-break:break-word,"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top,"> Restricted stock units granted </td> <td style="white-space:pre-wrap,vertical-align:bottom,"> </td> <td style="white-space:nowrap,vertical-align:bottom,"> </td> <td style="white-space:pre-wrap,vertical-align:bottom,text-align:center,"> 245,372 </td> <td style="white-space:nowrap,vertical-align:bottom,"> </td> <td style="white-space:pre-wrap,vertical-align:bottom,"> </td> <td style="white-space:nowrap,vertical-align:bottom,"> </td> <td style="white-space:pre-wrap,vertical-align:bottom,text-align:center,"> 4.21 </td> <td style="white-space:nowrap,vertical-align:bottom,"> </td> <td style="white-space:pre-wrap,vertical-align:bottom,"> </td> <td colspan="2" style="white-space:pre-wrap,vertical-align:bottom,text-align:center,"> </td> <td style="white-space:pre-wrap,vertical-align:bottom,text-align:center,"> </td> <td style="white-space:pre-wrap,vertical-align:bottom,"> </td> <td colspan="2" style="vertical-align:bottom,text-align:center,"> </td> <td style="white-space:pre-wrap,vertical-align:bottom,text-align:center,"> </td> </tr> <tr style="height:10pt,background-color:#cff0fc;word-break:break-word,"> <td style="text-indent:20pt,white-space:pre-wrap,vertical-align:top,"> Restricted stock units vested </td> <td style="white-space:pre-wrap,vertical-align:bottom,"> <span style="white-space:pre-

wrap;min-width:fit-content;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (153,750 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4.94 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word,"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top,"> Restricted stock units forfeited </td> <td style="white-space:pre-wrap;vertical-align:bottom,"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (7,619 </td> <td style="white-space:nowrap;vertical-align:bottom,border-bottom:2.25pt double #fffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom,"> </td> <td style="white-space:nowrap;vertical-align:bottom,"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center,"> 4.64 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center,"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center,"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word,"> <td style="white-space:pre-wrap;vertical-align:top,"> Outstanding as of September 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom,"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 699,003 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom,"> </td> <td style="white-space:nowrap;vertical-align:bottom,"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center,"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right,">4.69</p></td> <td style="white-space:nowrap;vertical-align:bottom,"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left,"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom,"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom,"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left,"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center,"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right,">1.5</p></td> <td style="white-space:nowrap;vertical-align:bottom,"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left,"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom,"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left,"> </p></td> <td style="white-space:nowrap;vertical-align:bottom,"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left,">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center,"> 4.6 </td> <td style="white-space:nowrap;vertical-align:bottom,"> </td> </tr> <tr style="height:10pt;background-color:#fffff;word-break:break-word,"> <td style="vertical-align:top,"> Unvested and expected to vest as of September 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom,"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000,"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 699,003 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03,"> </td> <td style="white-space:pre-wrap;vertical-align:bottom,"> </td> <td style="white-space:nowrap;vertical-align:bottom,"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom,text-align:center,"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right,">4.69</p></td> <td style="white-space:nowrap;vertical-align:bottom,"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left,"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom,"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left,"> </p></td> <td style="white-space:nowrap;vertical-align:bottom,"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left,"><span style="color:#000000;min-width:fit-content,">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom,text-align:center,"> 4.6 </td> <td style="white-space:nowrap;vertical-align:bottom,"> </td> </tr>
</table>6150004.94P1Y7M6D2453724.211537504.9476194.646990034.69P1Y6M46000006990034.69P1Y6M4600000245372P4Y4.212600000P2Y7M24D Stock-based compensation expense was classified in the condensed consolidated statements of operations as follows:
<table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.38%;box-sizing:content-box,"></td> <td style="width:1.22%;box-sizing:content-box,"></td> <td style="width:1%;box-sizing:content-box,"></td> <td style="width:9.184000000000001%;box-sizing:content-box,"></td> <td style="width:1%,box-sizing:content-box,"></td> <td style="width:1.22%,box-sizing:content-box,"></td> <td style="width:1%,box-sizing:content-box,"></td> <td style="width:9.184000000000001%;box-sizing:content-box,"></td> <td style="width:1%,box-sizing:content-box,"></td> <td style="width:1.22%;box-sizing:content-box,"></td> <td style="width:1%;box-sizing:content-box,"></td> <td style="width:9.184000000000001%;box-sizing:content-box,"></td> <td style="width:1%;box-sizing:content-box,"></td> <td style="width:1.22%;box-sizing:content-box,"></td> <td style="width:1%;box-sizing:content-box,"></td> <td style="width:9.184000000000001%;box-sizing:content-box,"></td> <td style="width:1%;box-sizing:content-box,"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word,"> <td style="vertical-align:bottom,"> </td> <td style="vertical-align:bottom,"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left,"> Three Months Ended September 30, </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom,"> </td> <td colspan="6" style="vertical-align:bottom,text-align:left,"> Nine Months Ended September 30, </td> <td style="vertical-align:bottom;text-align:left,"> </td> </tr> <tr style="height:8pt;background-color:#fffff;white-space:pre-wrap;word-break:break-word,"> <td style="vertical-align:bottom,"> </td> <td style="vertical-align:bottom,"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left,"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left,"> </td> <td style="vertical-align:bottom,"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left,"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left,"> </td> <td style="vertical-align:bottom,"> </td> <td colspan="2"

style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Research and development </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">918</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 697 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,816</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,304 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#fffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> General and administrative </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,039 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,124 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 3,570 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,393 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> $</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,957</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,821 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6,386</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 5,697 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr>
</table>9180006970002816000230400010390001124000357000033930001957000182100063860005697000 8. Commitments and Contingencies Intellectual Property Licenses The Company is party to an exclusive License Agreement (the "WFUHS License"), dated November 30, 2016, as amended, with Wake Forest University Health Sciences ("WFUHS") and an exclusive License Agreement (the "IU License"), dated November 30, 2016, as amended, with Indiana University ("IU"). Such agreements provide for a transferable, worldwide license to certain patent rights regarding technology used by the Company with respect to the development of nomlabofusp. Both agreements continue from their effective date through the last to date of expiration of the licensed patents, unless earlier terminated by either party in accordance with their terms. In partial consideration for the right and license granted under these agreements, the Company will pay each of WFUHS and IU a royalty of a low single digit percentage of net sales of licensed products depending on whether there is a valid patent covering such products. As additional consideration for these agreements, the Company is obligated to pay each of WFUHS and IU certain milestone payments of up to $2.6 million in the aggregate upon the achievement of certain developmental milestones, which commenced with the enrollment of the first patient in a Phase 1 clinical trial. The Company enrolled the first patient in its SAD trial on December 11, 2019 and paid WFUHS and IU less than $0.1 million. The Company will also pay each of WFUHS and IU sublicensing fees ranging from a high-single digit to a low double-digit percentage of sublicense consideration depending on the Company's achievement of certain regulatory milestones as of the time of receipt of the sublicense consideration. The Company is also obligated to reimburse WFUHS and IU for patent-related expenses. In the event that the Company disputes the validity of any of the licensed patents, the royalty rate would be tripled during such dispute. The Company is also obligated to pay to IU a minimum annual royalty of less than $0.1 million per annum. In the event that the Company is required to pay IU consideration, then the Company may deduct 20% of such IU consideration on a dollar-for-dollar basis from the consideration due to WFUHS. In the event that the Company is required to pay WFUHS consideration, then the Company may deduct 60% of such WFUHS consideration on a dollar for dollar basis from the consideration due to IU. In October 2022, the Company initiated dosing of a Phase 2 study. Pursuant to the terms of both the WFUHS License and the IU License, the company recognized milestone expense of $0.3 million within research and development expenses. Both agreements continue from their effective date through the last date of expiration of the licensed patents, unless earlier terminated by either party in accordance with their terms. Leases <p style="font-

size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Bala Cynwyd Office Space On August 8, 2019, the Company entered into an operating lease for office space in Bala Cynwyd, Pennsylvania, effective as of December 15, 2019, for a period of three years and six months with an option to extend the lease for three additional years. Due to required tenant improvements to be completed by the landlord, the Company did not take immediate possession of the leased property and the lease term commenced on February 15, 2020. On March 9, 2023, the Company executed a lease extension agreement on its original 4,642 square footage of office space in Bala Cynwyd, Pennsylvania (which was set to expire in August 2023) and agreed to lease an additional 3,462 square feet of office space from the same landlord. The lease extension on the original 4,642 square footage commenced on September 1, 2023 and the Company recorded a right of use asset and lease liability of $0.5 million as of that date. The new lease on 3,462 additional square footage commenced on October 1, 2023 and the Company recorded a right of use asset and lease liability of $0.3 million as of that date. The right of use assets and lease liabilities with both these leases are reflected in the financial statements as of September 30, 2024 as are the right of use asset and lease liability of the Company's Boston office space discussed below. Boston Office Lease In connection with the Company's 2020 merger with Zafgen described in footnote 1, on May 28, 2020, the Company acquired a non-cancellable operating lease for approximately 17,705 square feet of office space (the "Premises"). The lease expires on October 30, 2029. As part of the agreement, the Company is required to maintain a letter of credit, which upon signing was $1.3 million and was later reduced to $0.6 million in October 2024, and is classified as restricted cash within the condensed consolidated financial statements. In addition to the base rent, the Company is also responsible for its share of operating expenses, electricity and real estate taxes, which costs are not included in the determination of the leases' right-of-use assets or lease liabilities. The right-of-use asset is being amortized to other income/(expense) over the remaining lease term as a result of the sublease described below. On October 27, 2020, the Company entered into a sublease agreement (the "Sublease") with Massachusetts Municipal Association, Inc. (the "Subtenant"), whereby the Company sublet the entire Premises to the Subtenant. The initial term of the Sublease commenced on December 4, 2020 and continues until October 30, 2029. In connection with the Sublease, the Company evaluated the need for impairment under ASC 360-"Impairment Testing: Long-Lived Assets Classified as Held and Used," and determined there was no impairment. The Sublease provided for an initial annual base rent of $0.8 million, which increases annually up to a maximum annual base rent of $1.0 million. The Subtenant also is responsible for paying to the Company future increases in operating costs (commencing on January 1, 2022), future increases in annual tax costs (commencing July 1, 2021) and all utility costs (commencing March 1, 2021) attributable to the Premises during the term of the Sublease. As part of the Sublease, the subtenant deposited a letter of credit in the amount of $0.8 million to assure their performance under the sublease. If there are no uncured events of default under the sublease, the amount of this security deposit decreases over time to $0.4 million on the sixth anniversary of the Sublease. The Company records sublease income on this sublease on a straight-line basis as a component of other income/(expense). Lab Space On November 5, 2018, the Company entered into an operating lease for office and lab space in Philadelphia, Pennsylvania, effective as of January 1, 2019, and expiring on December 31, 2020 with an option to extend the lease for two additional years. On August 4, 2020, the Company executed the first option to extend the lease for an additional year, expiring on December 31, 2021. On August 9, 2021, the Company executed the remaining option to extend the lease for an additional year, expiring on December 31, 2022. In September 2023, the Company extended this lease for an additional year with the option to terminate with four months' notice. On March 28, 2024, the Company gave the requisite notice and vacated the property in May 2024. On October 16, 2023, the Company entered into an operating lease for lab space in King of Prussia, Pennsylvania for a period of four years. Due to required tenant improvements to be completed by the landlord, the Company did not take immediate possession of the leased property. The actual lease term commenced on May 10, 2024. Upon commencement of the lease term, the Company recorded a right of use asset and lease liability of $0.5 million which are reflected in these condensed consolidated financial statements. Lease Expense Expense arising from operating leases was $0.1 million and $0.4 million during the three and nine months ended September 30, 2024, respectively. Expense arising from operating leases was $0.1 million and $0.2 million during the three and nine months ended September 30, 2023, respectively. For operating leases, the weighted-average remaining lease term for leases at September 30, 2024 and December 31, 2023 was 4.7 and 5.5 years, respectively. For operating leases, the weighted average discount rate for leases at September 30, 2024 and December 31, 2023 was 11.0%. The Company has not entered into any financing leases. Maturities of lease liabilities due under these lease agreements as of September 30, 2024 are as follows:

   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80.14%;box-sizing:content-box;"></td> <td style="width:1.74%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:16.12%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Operating </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td colspan="2" style="vertical-align:bottom;"> (in thousands) </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Leases </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Three months ending December 31, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">383</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Year ended December 31, 2025</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,543</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Year ended December 31, 2026</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,473</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Year ended December 31, 2027</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,267</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Year ended December 31, 2028</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:right;">1,189</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Thereafter</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">959</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total lease payments</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6,814</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Less: imputed interest</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(1,452</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Present value of lease liabilities</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 5,362 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> Legal Proceedings The Company is not currently a party to any litigation, nor is management aware of any pending or threatened litigation against the Company, that it believes would materially affect the Company's business, operating results, financial condition or cash flows. 2600000260000010000010000.200.60300000P3Y6M2020-02-15464234624622023-09-01500000500000346222023-10-01300000300000177052029-10-30130000060000002020-12-042029-10-30800000100000080000040000020190101-012020-12-312021-12-312022-12-31P4Y2024-05-10500000500000100000400000100000200000P4Y8M12DP5Y6M0.110.11 Maturities of lease liabilities due under these lease agreements as of September 30, 2024 are as follows: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80.14%;box-sizing:content-box;"></td> <td style="width:1.74%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:16.12%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Operating </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;"> <td colspan="2" style="vertical-align:bottom;"> (in thousands) </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Leases </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Three months ending December 31, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 383 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Year ended December 31, 2025 </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New

Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,543 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Year ended December 31, 2026 </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,473 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Year ended December 31, 2027 </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,267 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Year ended December 31, 2028 </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,189 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Thereafter </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 959 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total lease payments </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,814 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Less: imputed interest </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> (1,452 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Present value of lease liabilities </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 5,362 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table>383000154300014730001267000118900095900068140001452000536200O 9. Related Party In May 2024, the Company entered into an agreement with the Friedreich’s Ataxia Research Alliance (FARA) to join the TRACK-FA Neuroimaging Consortium that includes pharmaceutical, biotechnology, academic and clinical partners. The consortium will conduct a natural history study designed to establish disease specific neuroimaging biomarkers to track disease progression in the brain and spinal cord and provide a basis for utilizing these biomarkers in clinical trials. As an industry partner, the Company will help fund the study and contribute to the study design, research activities, and analysis. The Company will have access to all study data for use in its regulatory filings, as appropriate. During the three and nine months ended September 30, 2024, the Company incurred less than $0.1 million and $0.8 million of costs related to the Track-FA program and will fund future costs going forward. One of the Company’s Directors is also a director of FARA. 100000800000falsefalsefalsefalse"